

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number  
**WO 01/77171 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K 14/705**
- (21) International Application Number: **PCT/US01/10872**
- (22) International Filing Date: **3 April 2001 (03.04.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
60/194,731 5 April 2000 (05.04.2000) US  
60/222,121 28 July 2000 (28.07.2000) US
- (71) Applicant: **ZYMOGENETICS, INC.** [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).
- (72) Inventors: **SPRECHER, Cindy, A.**; 8207 39th Avenue NE, Seattle, WA 98115 (US). **NOVAK, Julia, E.**; 10699 Battle Point Drive Northeast, Bainbridge Island, WA 98110 (US). **WEST, James, W.**; 7539 19th NE, Seattle, WA 98115 (US). **PRESNELL, Scott, R.**; 2902 N. Puget Sound Avenue, Tacoma, WA 98407 (US). **HOLLY, Richard, D.**; 12539 10th Avenue N.W., Seattle, WA 98177 (US). **NELSON, Andrew, J.**; 1829 Northeast 170th Street, Shoreline, WA 98155 (US).
- (74) Agent: **JOHNSON, Jennifer, K.**; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 01/77171 A2**

(54) Title: **SOLUBLE ZALPHA11 CYTOKINE RECEPTORS**

(57) **Abstract:** Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalp $\alpha$ 11 receptors that may be used as novel cytokine antagonist, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalp $\alpha$ 11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalp $\alpha$ 11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Description

5

## SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

## BACKGROUND OF THE INVENTION

Hormones and polypeptide growth factors control proliferation and differentiation of cells of multicellular organisms. These diffusable molecules allow  
10 cells to communicate with each other and act in concert to form cells and organs, and to repair damaged tissue. Examples of hormones and growth factors include the steroid hormones (e.g. estrogen, testosterone), parathyroid hormone, follicle stimulating hormone, the interleukins, platelet derived growth factor (PDGF), epidermal growth factor (EGF), granulocyte-macrophage colony stimulating factor (GM-CSF),  
15 erythropoietin (EPO) and calcitonin.

Hormones and growth factors influence cellular metabolism by binding to receptors. Receptors may be integral membrane proteins that are linked to signaling pathways within the cell, such as second messenger systems. Other classes of receptors are soluble molecules, such as the transcription factors. Of particular interest are  
20 receptors for cytokines, molecules that promote the proliferation and/or differentiation of cells. Examples of cytokines include erythropoietin (EPO), which stimulates the development of red blood cells; thrombopoietin (TPO), which stimulates development of cells of the megakaryocyte lineage; and granulocyte-colony stimulating factor (G-CSF), which stimulates development of neutrophils. These cytokines are useful in  
25 restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer.

The demonstrated *in vivo* activities of these cytokines illustrate the enormous clinical potential of, and need for, other cytokines, cytokine agonists, and cytokine antagonists or binding partners. The present invention addresses these needs  
30 by providing a new cytokine antagonist or binding partner, a soluble hematopoietic cytokine receptor, as well as related compositions and methods.

The present invention provides such polypeptides for these and other uses that should be apparent to those skilled in the art from the teachings herein.

## DESCRIPTION OF THE INVENTION

5           Within one aspect, the present invention provides an isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:6, and wherein the soluble receptor polypeptide encoded by the polynucleotide sequence binds a ligand comprising a polypeptide of SEQ ID NO:10 or  
10   SEQ ID NO:47, or antagonizes the ligand activity. In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a homodimeric receptor complex.

          Within another aspect, the present invention provides an isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of  
15   amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex. In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or  
20   multimeric receptor complex further comprising a soluble Class I cytokine receptor.

          In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha$ ' receptor polypeptide (SEQ ID  
25   NO:82). In another embodiment, the isolated polynucleotide is as disclosed above, wherein the polypeptide further comprises a WSXWS motif as shown in SEQ ID NO:13.

          Within another aspect, the present invention provides an isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of  
30   amino acid residues as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric

receptor complex. In one embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded by the polynucleotide further comprises a soluble Class I cytokine receptor. In another embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide encoded  
5 by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82). In another embodiment, the isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide is encoded by the polynucleotide as shown in SEQ ID NO:7. In another embodiment, the  
10 isolated polynucleotide is as disclosed above, wherein the soluble receptor polypeptide further comprises an affinity tag.

Within a second aspect, the present invention provides an expression vector comprising the following operably linked elements: (a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid  
15 sequence as shown in SEQ ID NO:6; and a transcription terminator; and (b) a second transcription promoter; a second DNA segment encoding a soluble Class I cytokine receptor polypeptide; and a transcription terminator; and wherein the first and second DNA segments are contained within a single expression vector or are contained within independent expression vectors. In one embodiment, the expression vector disclosed  
20 above further comprises a secretory signal sequence operably linked to the first and second DNA segments. In another embodiment, the expression vector is as disclosed above, wherein the second DNA segment encodes a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82).

25 Within a third aspect, the present invention provides a cultured cell comprising an expression vector as disclosed above, wherein the cell expresses the polypeptides encoded by the DNA segments. In one embodiment, the cultured cell comprising an expression vector is as disclosed above, wherein the first and second DNA segments are located on independent expression vectors and are co-transfected  
30 into the cell, and cell expresses the polypeptides encoded by the DNA segments. In another embodiment, the cultured cell comprising an expression vector is as disclosed



above, wherein the cell expresses a heterodimeric or multimeric soluble receptor polypeptide encoded by the DNA segments. In another embodiment, the cultured cell comprising an expression vector is as disclosed above, wherein the cell secretes a soluble receptor polypeptide heterodimer or multimeric complex. In another  
5 embodiment, the cultured cell comprising an expression vector is as disclosed above, wherein the cell secretes a soluble receptor polypeptide heterodimer or multimeric complex that binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

Within another aspect, the present invention provides a DNA construct  
10 encoding a fusion protein comprising: a first DNA segment encoding a polypeptide having a sequence of amino acid residues as shown in SEQ ID NO:6; and at least one other DNA segment encoding a soluble Class I cytokine receptor polypeptide, wherein the first and other DNA segments are connected in-frame; and wherein the first and other DNA segments encode the fusion protein. In one embodiment, the DNA  
15 construct encodes a fusion protein as disclosed above, wherein at least one other DNA segment encodes a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82).

Within another aspect, the present invention provides an expression vector comprising the following operably linked elements: a transcription promoter; a  
20 DNA construct encoding a fusion protein as disclosed above; and a transcription terminator, wherein the promoter is operably linked to the DNA construct, and the DNA construct is operably linked to the transcription terminator.

Within another aspect, the present invention provides a cultured cell comprising an expression vector as disclosed above, wherein the cell expresses a  
25 polypeptide encoded by the DNA construct.

Within another aspect, the present invention provides a method of producing a fusion protein comprising: culturing a cell as disclosed above; and isolating the polypeptide produced by the cell.

Within another aspect, the present invention provides an isolated soluble  
30 receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:6, and wherein the soluble

receptor polypeptide binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity. In one embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide forms a homodimeric receptor complex.

5                Within another aspect, the present invention provides an isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex. In one embodiment, the isolated polypeptide is as disclosed above, wherein the soluble  
10 receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I cytokine receptor. In another embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID  
15 NO:82). In another embodiment, the isolated polypeptide is as disclosed above, wherein the polypeptide further comprises a WSXWS motif as shown in SEQ ID NO:13.

                Within another aspect, the present invention provides an isolated soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID  
20 NO:6, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex. In one embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I cytokine receptor. In another embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide  
25 forms a heterodimeric or multimeric receptor complex comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82). In another embodiment, the isolated polypeptide is as disclosed above, wherein the soluble receptor polypeptide further comprises an affinity tag, chemical moiety, toxin, or label.

30                Within another aspect, the present invention provides an isolated heterodimeric or multimeric soluble receptor complex comprising soluble receptor

subunits, wherein at least one of soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6. In one embodiment, the isolated heterodimeric or multimeric soluble receptor complex disclosed above further comprises a soluble Class I cytokine receptor polypeptide. In  
5 another embodiment, the isolated heterodimeric or multimeric soluble receptor complex disclosed above further comprises a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82).

Within another aspect, the present invention provides a method of producing a soluble receptor polypeptide that form a heterodimeric or multimeric  
10 complex comprising: culturing a cell as disclosed above; and isolating the soluble receptor polypeptides produced by the cell.

Within another aspect, the present invention provides a method of producing an antibody to a soluble receptor polypeptide comprising: inoculating an animal with a soluble receptor polypeptide complex selected from the group consisting  
15 of: (a) a polypeptide comprising a homodimeric soluble receptor complex comprising SEQ ID NO:6; (b) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6; (b) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble Class I cytokine receptor polypeptide; (c) a  
20 polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4); (d) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82); and wherein the  
25 polypeptide complex elicits an immune response in the animal to produce the antibody; and isolating the antibody from the animal.

Within another aspect, the present invention provides an antibody produced by the method as disclosed above, which specifically binds to a homodimeric, heterodimeric or multimeric receptor complex comprising a soluble receptor  
30 polypeptide comprising SEQ ID NO:6. In one embodiment the antibody disclosed above is a monoclonal antibody.

Within another aspect, the present invention provides an antibody which specifically binds to a homodimeric, heterodimeric or multimeric receptor complex as disclosed above.

Within another aspect, the present invention provides a method for  
5 inhibiting a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or  
antagonizing the ligand activity-induced proliferation of hematopoietic cells and  
hematopoietic cell progenitors comprising culturing bone marrow or peripheral blood  
cells with a composition comprising an amount of soluble receptor comprising SEQ ID  
10 NO:6 sufficient to reduce proliferation of the hematopoietic cells in the bone marrow or  
peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in  
the absence of soluble receptor. In one embodiment the method is as disclosed above,  
wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.  
In another embodiment the method is as disclosed above, wherein the lymphoid cells  
are NK cells or cytotoxic T cells.

15 Within another aspect, the present invention provides a method of  
reducing proliferation of neoplastic B or T cells comprising administering to a mammal  
with a B or T cell neoplasm an amount of a composition of soluble receptor comprising  
SEQ ID NO:6 sufficient to reduce proliferation of the neoplastic B or T cells.

Within another aspect, the present invention provides a method of  
20 suppressing an immune response in a mammal exposed to an antigen or pathogen  
comprising: (1) determining a level of an antigen- or pathogen-specific antibody; (2)  
administering a composition of soluble receptor polypeptide comprising SEQ ID NO:6  
in an acceptable pharmaceutical vehicle; (3) determining a post administration level of  
antigen- or pathogen-specific antibody; (4) comparing the level of antibody in step (1)  
25 to the level of antibody in step (3), wherein a lack of increase or a decrease in antibody  
level is indicative of suppressing an immune response.

These and other aspects of the invention will become evident upon  
reference to the following detailed description of the invention.

Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:

The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A (Nilsson et al., EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67:31, 1988), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952-4, 1985), substance P, Flag™ peptide (Hopp et al., Biotechnology 6:1204-10, 1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and Purification 2: 95-107, 1991. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of  $<10^9 \text{ M}^{-1}$ .

The term "complements of a polynucleotide molecule" is a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

5           The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

10           The term "expression vector" is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal,  
15 etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

          The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within  
20 genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of  
25 associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985).

          An "isolated" polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other  
30 polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e. greater than 95% pure, more preferably

greater than 99% pure. When used in this context, the term "isolated" does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

The term "operably linked", when referring to DNA segments, indicates  
5 that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.

The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different  
10 species. Sequence differences among orthologs are the result of speciation.

"Paralogs" are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example,  $\alpha$ -globin,  $\beta$ -globin, and myoglobin are paralogs of each other.

A "polynucleotide" is a single- or double-stranded polymer of  
15 deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe  
20 polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all  
25 nucleotides within a double-stranded polynucleotide molecule may not be paired.

A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides".

"Probes and/or primers" as used herein can be RNA or DNA. DNA can  
30 be either cDNA or genomic DNA. Polynucleotide probes and primers are single or double-stranded DNA or RNA, generally synthetic oligonucleotides, but may be

generated from cloned cDNA or genomic sequences or its complements. Analytical probes will generally be at least 20 nucleotides in length, although somewhat shorter probes (14-17 nucleotides) can be used. PCR primers are at least 5 nucleotides in length, preferably 15 or more nt, more preferably 20-30 nt. Short polynucleotides can be used when a small region of the gene is targeted for analysis. For gross analysis of genes, a polynucleotide probe may comprise an entire exon or more. Probes can be labeled to provide a detectable signal, such as with an enzyme, biotin, a radionuclide, fluorophore, chemiluminescer, paramagnetic particle and the like, which are commercially available from many sources, such as Molecular Probes, Inc., Eugene, OR, and Amersham Corp., Arlington Heights, IL, using techniques that are well known in the art.

The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

The term "receptor" is used herein to denote a cell-associated protein, or a polypeptide subunit of such a protein, that binds to a bioactive molecule (the "ligand") and mediates the effect of the ligand on the cell. Binding of ligand to receptor results in a conformational change in the receptor (and, in some cases, receptor multimerization, i.e., association of identical or different receptor subunits) that causes interactions between the effector domain(s) and other molecule(s) in the cell. These interactions in turn lead to alterations in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, cell proliferation, increases in cyclic AMP production, mobilization



of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. Cell-surface cytokine receptors are characterized by a multi-domain structure as discussed in more detail below. These receptors are anchored in the cell membrane by a transmembrane domain characterized  
5 by a sequence of hydrophobic amino acid residues (typically about 21-25 residues), which is commonly flanked by positively charged residues (Lys or Arg). In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor,  
10 erythropoietin receptor and IL-6 receptor). The term "receptor polypeptide" is used to denote complete receptor polypeptide chains and portions thereof, including isolated functional domains (e.g., ligand-binding domains).

A "secretory signal sequence" is a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs  
15 the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger peptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

A "soluble receptor" is a receptor polypeptide that is not bound to a cell membrane. Soluble receptors are most commonly ligand-binding receptor polypeptides  
20 that lack transmembrane and cytoplasmic domains. Soluble receptors can comprise additional amino acid residues, such as affinity tags that provide for purification of the polypeptide or provide sites for attachment of the polypeptide to a substrate, or immunoglobulin constant region sequences. Many cell-surface receptors have naturally occurring, soluble counterparts that are produced by proteolysis. Soluble receptor  
25 polypeptides are said to be substantially free of transmembrane and intracellular polypeptide segments when they lack sufficient portions of these segments to provide membrane anchoring or signal transduction, respectively.

The term "splice variant" is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of  
30 alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs

transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene.

Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to  $\pm 10\%$ .

All references cited herein are incorporated by reference in their entirety.

The present invention is based in part upon the discovery of a novel heterodimeric soluble receptor protein having the structure of a class I cytokine receptor. The heterodimeric soluble receptor includes at least one  $\alpha$ 1 soluble receptor subunit, disclosed in the commonly owned US Patent application No. 09/404,641. A second soluble receptor polypeptide included in the heterodimeric soluble receptor belongs to the receptor subfamily that includes the IL-2  $\gamma$ -common receptor (IL-2R $\gamma$ , or  $\gamma_c$ ), IL-2 receptor  $\beta$ -subunit, and the  $\beta$ -common receptor (i.e., IL-3, IL-5, IL-13, IL-15 and GM-CSF receptor  $\beta$ -subunits), IL-13 $\alpha$ , IL-13 $\alpha'$ , IL-15 receptor subunits, and the like. The soluble human and mouse  $\alpha$ 1 receptor (IL-21R) monomer and homodimer was shown to antagonize of the activity of the natural ligand for the  $\alpha$ 1 receptor,  $\alpha$ 1 Ligand (IL-21) (Parrish-Novak, J. et al., Nature 408:57-63, 2000). The  $\alpha$ 1 Ligand is disclosed in the commonly owned US Patent application No. 09/522,217. According to the present invention, a heterodimeric soluble  $\alpha$ 1 receptor, as exemplified by a preferred embodiment of a soluble  $\alpha$ 1 receptor + soluble IL-2R $\gamma$  receptor heterodimer ( $\alpha$ 1/IL-2R $\gamma$ ), was shown to act as a potent antagonist of the  $\alpha$ 1 Ligand. As disclosed in the examples herein, the preferred  $\alpha$ 1/IL-2R $\gamma$  heterodimer was a more effective antagonist  $\alpha$ 1 Ligand activity, and hence more superior antagonist, than a  $\alpha$ 1 homodimer or monomer.

Moreover, also contemplated by the present invention are homodimeric and monomeric  $\alpha$ 1-comprising soluble receptors; as well as homodimeric, heterodimeric, and multimeric  $\alpha$ 1-comprising receptors that are capable of

intracellular signaling. Such receptors can comprise at least one an extracellular domain of a  $\alpha$ 1 receptor, and an intracellular domain from  $\alpha$ 1 or another class I cytokine receptor. The additional heterodimeric or multimeric subunit can comprise the extracellular domain from IL-2R $\gamma$  receptor (e.g., SEQ ID NO:4), IL-13 $\alpha$  (also known as IL-13RA2; SEQ ID NO:84), IL-13 $\alpha'$  (also known as IL-13RA1; SEQ ID NO:82), IL-15 (SEQ ID NO:86) receptor, or other class I receptor, and an intracellular domain from  $\alpha$ 1 or another class I cytokine receptor.

The nucleotide sequence of a representative  $\alpha$ 1-encoding DNA is described in SEQ ID NO:1 (from nucleotide 1 to 1614), and its deduced 538 amino acid sequence is described in SEQ ID NO:2. In its entirety, the  $\alpha$ 1 polypeptide (SEQ ID NO:2) represents a full-length polypeptide segment (residue 1 (Met) to residue 538 (Ser) of SEQ ID NO:2). The domains and structural features of the  $\alpha$ 1 polypeptide are further described below.

Analysis of the  $\alpha$ 1 polypeptide encoded by the DNA sequence of SEQ ID NO:1 revealed an open reading frame encoding 538 amino acids (SEQ ID NO:2) comprising a predicted secretory signal peptide of 19 amino acid residues (residue 1 (Met) to residue 19 (Gly) of SEQ ID NO:2), and a mature polypeptide of 519 amino acids (residue 20 (Cys) to residue 538 (Ser) of SEQ ID NO:2). In addition to the WSXWS motif (SEQ ID NO:13) corresponding to residues 214 to 218 of SEQ ID NO:2, the receptor comprises a cytokine-binding domain of approximately 200 amino acid residues (residues 20 (Cys) to 237 (His) of SEQ ID NO:2); a domain linker (residues 120 (Pro) to 123 (Pro) of SEQ ID NO:2); a penultimate strand region (residues 192 (Lys) to 202 (Ala) of SEQ ID NO:2); a transmembrane domain (residues 238 (Leu) to 255 (Leu) of SEQ ID NO:2); complete intracellular signaling domain (residues 256 (Lys) to 538 (Ser) of SEQ ID NO:2) which contains a "Box I" signaling site (residues 267 (Ile) to 273 (Pro) of SEQ ID NO:2), and a "Box II" signaling site (residues 301 (Leu) to 304 (Gly) of SEQ ID NO:2). Moreover, there is a STAT3 binding site (YXXQ) located near the C-terminus from residues 519 (Tyr) to 522 (Gln) of SEQ ID NO:2. Those skilled in the art will recognize that these domain boundaries are approximate, and are based on alignments with known proteins and predictions of protein folding. In addition to these domains, conserved receptor features in the

encoded receptor include (as shown in SEQ ID NO:2) a conserved Trp residue at position 138, and a conserved Arg residue at position 201. Moreover the  $\alpha$ 11 contains conserved Cys residues typical of class I cytokine receptors, shown in residues 25, 35, 65, and 81 of SEQ ID NO:2, and corresponding regions of SEQ ID NO:6 and  
5 SEQ ID NO:69 described below. The corresponding polynucleotides encoding the  $\alpha$ 11 polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NO:1. The human  $\alpha$ 11 soluble receptor polypeptide, comprising residues 20 (Cys) to 237 (His) of SEQ ID NO:2, is shown in SEQ ID NO:6, and the corresponding polynucleotide sequence for the human  $\alpha$ 11 soluble  
10 receptor polypeptide is shown in SEQ ID NO:5.

SEQ ID NO:3 is a polynucleotide sequence comprising a fragment of the human IL-2R $\gamma$  receptor that encodes a soluble 232 amino acid soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4). Those skilled in the art will recognize that these domain boundaries for the IL-2R $\gamma$  receptor extracellular domain are approximate, and other  
15 soluble IL-2R $\gamma$  receptor polypeptides, such as those including an IL-2R $\gamma$  receptor polypeptide secretory signal sequence or additional IL-2R $\gamma$  receptor polypeptide amino acids in the extracellular domain, are encompassed within the scope of the present invention.

A variant form of the human  $\alpha$ 11 polypeptide was identified  
20 (WIPO publication No. WO 00/27822 shown as SEQ ID NO:3 and SEQ ID NO:4 therein) and is shown in the DNA sequence of SEQ ID NO:64; and corresponding polypeptide sequence shown in (SEQ ID NO:65). This particular alternative  $\alpha$ 11 receptor polypeptide contains 568 amino acids, and comprises a predicted secretory signal peptide of 20 amino acid residues (residue 1 (Met) to residue 20 (Gly) of SEQ ID  
25 NO:65), and a mature polypeptide of 548 amino acids (residue 21 (Met) to residue 568 (Ser) of SEQ ID NO:65). In addition to the WSXWS motif (SEQ ID NO:13) corresponding to residues 244 to 248 of SEQ ID NO:65, the receptor comprises a cytokine-binding domain of approximately 200 amino acid residues (residues 21 (Met) to 267 (His) of SEQ ID NO:65); no domain linker; a penultimate strand region  
30 (residues 222 (Lys) to 232 (Ala) of SEQ ID NO:65); a transmembrane domain (residues 268 (Leu) to 285 (Leu) of SEQ ID NO:65); complete intracellular signaling domain

(residues 286 (Lys) to 568 (Ser) of SEQ ID NO:65) which contains a "Box I" signaling site (residues 297 (Ile) to 303 (Pro) of SEQ ID NO:65), and a "Box II" signaling site (residues 331 (Leu) to 334 (Gly) of SEQ ID NO:65). Moreover, there is a STAT3 binding site (YXXQ) located near the C-terminus from residues 549 (Tyr) to 552 (Gln) of SEQ ID NO:65. Those skilled in the art will recognize that these domain boundaries are approximate, and are based on alignments with known proteins and predictions of protein folding. In addition to these domains, conserved receptor features in the encoded receptor include (as shown in SEQ ID NO:65) a conserved Trp residue at position 168, and a conserved Arg residue at position 231. The corresponding polynucleotides encoding the zalpha11 polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NO:64. This particular human zalpha11 soluble receptor variant polypeptide, comprising residues 21 (Met) to 267 (His) of SEQ ID NO:65 (SEQ ID NO:69) and the corresponding polynucleotide sequence for this particular human zalpha11 soluble receptor polypeptide is shown in SEQ ID NO:68. This variant form of the human zalpha11 receptor is included in the heterodimeric and multimeric zalpha11 receptor complexes of the present invention, disclosed herein.

In addition, other variant forms of zalpha11 receptor are contemplated by the present invention, wherein the extracellular domain of the variant form disclosed above (e.g., 21 (Met) to 267 (His) of SEQ ID NO:65, or SEQ ID NO:69) comprises a domain linker comprising the amino acids PAPP (SEQ ID NO:70) inserted between amino acid 161 (Ser) and 162 (Arg) of SEQ ID NO:65, or the corresponding region of SEQ ID NO:69. A preferred domain linker comprises a sequence of amino acids from preferably 4 to 14 amino acids long, most preferably 14 amino acids long, wherein aside from the PAPP (SEQ ID NO:70) motif sequence any amino acid may be present. For example, a representative linker-containing variant zalpha11 soluble receptor is shown in SEQ ID NO:71. Moreover, other variant zalpha11 sequences can include, in reference to SEQ ID NO:65 a Gly at position 162 rather than an Arg, or the same Arg to Gly substitution in the corresponding region of SEQ ID NO:69 or SEQ ID NO:71, or other variant of SEQ ID NO:65 or SEQ ID NO:69 containing a domain linker as described above. Corresponding DNA sequences that encode such variants can be

readily determined by one of skill in the art upon using the information present in Table 1 and Table 2.

The zalpha11 Ligand is a "short-helix" form secreted four-helical bundle cytokine. The zalpha11 Ligand polynucleotide sequence is shown in SEQ ID NO:9 and  
5 corresponding amino acid sequence shown in SEQ ID NO:10. The secretory signal sequence comprises amino acid residues 1 (Met) to 31 (Gly), and the mature polypeptide comprises amino acid residues 32 (Gln) to 162 (Ser) (as shown in SEQ ID NO:10). In general, cytokines are predicted to have a four-alpha helix structure, with helices A, C and D being most important in ligand-receptor interactions, and are more  
10 highly conserved among members of the family. Referring to the human zalpha11 Ligand amino acid sequence shown in SEQ ID NO:10, alignment of human zalpha11 Ligand, human IL-15, human IL-4, and human GM-CSF amino acid sequences it is predicted that zalpha11 Ligand helix A is defined by amino acid residues 41-56; helix B by amino acid residues 69-84; helix C by amino acid residues 92-105; and helix D by  
15 amino acid residues 135-148; as shown in SEQ ID NO:10. Structural analysis suggests that the A/B loop is long, the B/C loop is short and the C/D loop is parallel long. Conserved cysteine residues within zalpha11 Ligand correspond to amino acid residues 71, 78, 122 and 125 of SEQ ID NO:10. Consistent cysteine placement is further confirmation of the four-helical-bundle structure. Also highly conserved in the family  
20 comprising IL-15, IL-2, IL-4, GM-CSF and zalpha11 Ligand is the Glu-Phe-Leu sequence as shown in SEQ ID NO:10 at residues 136-138.

Further analysis of zalpha11 Ligand based on multiple alignments of known cytokines predicts that amino acid residues 44, 47 and 135 (as shown in SEQ ID NO:10) play an important role in zalpha11 Ligand binding to its cognate receptor.  
25 Based on comparison between sequences of human and murine zalpha11 Ligand well-conserved residues were found in the regions predicted to encode alpha helices A and D. The corresponding polynucleotides encoding the zalpha11 Ligand polypeptide regions, domains, motifs, residues and sequences described herein are as shown in SEQ ID NO:9. The murine zalpha11 Ligand is shown in SEQ ID NO:46, and corresponding  
30 polypeptide sequence shown in SEQ ID NO:47.

The activity of molecules of the present invention can be measured using a variety of assays that measure proliferation of and/or binding to cells expressing the zalpha11 receptor. Of particular interest are changes in zalpha11 Ligand-dependent cells. A suitable cell line was engineered to be zalpha11 Ligand-dependent that  
5 comprises an IL-3-dependent BaF3 cell line (Palacios and Steinmetz, Cell 41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986). Moreover, other suitable cell lines to be engineered to be zalpha11 Ligand-dependent include FDC-P1 (Hapel et al., Blood 64: 786-790, 1984); and MO7e (Kiss et al., Leukemia 7: 235-240, 1993). Growth factor-dependent cell lines can be established according to published  
10 methods (e.g. Greenberger et al., Leukemia Res. 8: 363-375, 1984; Dexter et al., in Baum et al. Eds., Experimental Hematology Today, 8th Ann. Mtg. Int. Soc. Exp. Hematol. 1979, 145-156, 1980).

Zalpha11 Ligand stimulates proliferation, activation, differentiation and/or induction or inhibition of specialized cell function of cells involved homeostasis  
15 of hematopoiesis and immune function. In particular, zalpha11 Ligand polypeptides stimulate proliferation, activation, differentiation, induction or inhibition of specialized cell functions of cells of the hematopoietic lineages, including, but not limited to, T cells, B cells, NK cells, dendritic cells, monocytes, and macrophages, as well as epithelial cells. Proliferation and/or differentiation of hematopoietic cells can be  
20 measured *in vitro* using cultured cells or *in vivo* by administering zalpha11 Ligand to the appropriate animal model. Assays measuring cell proliferation or differentiation are well known in the art and described herein. For example, assays measuring proliferation include such assays as chemosensitivity to neutral red dye (Cavanaugh et al., Investigational New Drugs 8:347-354, 1990, incorporated herein by reference),  
25 incorporation of radiolabeled nucleotides (Cook et al., Analytical Biochem. 179:1-7, 1989, incorporated herein by reference), incorporation of 5-bromo-2'-deoxyuridine (BrdU) in the DNA of proliferating cells (Porstmann et al., J. Immunol. Methods 82:169-179, 1985, incorporated herein by reference), and use of tetrazolium salts (Mosmann, J. Immunol. Methods 65:55-63, 1983; Alley et al., Cancer Res. 48:589-601,  
30 1988; Marshall et al., Growth Reg. 5:69-84, 1995; and Scudiero et al., Cancer Res. 48:4827-4833, 1988; all incorporated herein by reference). Assays measuring

differentiation include, for example, measuring cell-surface markers associated with stage-specific expression of a tissue, enzymatic activity, functional activity or morphological changes (Watt, FASEB, 5:281-284, 1991; Francis, Differentiation 57:63-75, 1994; Raes, Adv. Anim. Cell Biol. Technol. Bioprocesses, 161-171, 1989; all incorporated herein by reference). Conversely, these assays can be used in a competition to assess the antagonist or zalpha11 Ligand binding activity of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  receptors of the present invention. Moreover, the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  receptors of the present invention can be used as an antagonist or Ligand binding agent to modulate the immune system and hematopoietic activities of the zalpha11 Ligand.

Zalpha11 Ligand was isolated from tissue known to have important immunological function and which contain cells that play a role in the immune system. Zalpha11 Ligand is expressed in CD3+ selected, activated peripheral blood cells, and it has been shown that zalpha11 Ligand expression increases after T cell activation. Moreover, results of experiments described in commonly owned US Patent application No. 09/522,217, and the Examples section herein, demonstrate that zalpha11 Ligand has an effect on the growth/expansion and/or differentiated state of NK cells or NK progenitors. Additional evidence demonstrates that zalpha11 Ligand affects proliferation and/or differentiation of T cells and B cells *in vivo*. Factors that both stimulate proliferation of hematopoietic progenitors and activate mature cells are generally known. NK cells are responsive to IL-2 alone, but proliferation and activation generally require additional growth factors. For example, it has been shown that IL-7 and Steel Factor (c-kit ligand) were required for colony formation of NK progenitors. IL-15 + IL-2 in combination with IL-7 and Steel Factor was more effective (Mrózek et al., Blood 87:2632-2640, 1996). However, unidentified cytokines may be necessary for proliferation of specific subsets of NK cells and/or NK progenitors (Robertson et. al., Blood 76:2451-2438, 1990). A composition comprising zalpha11 Ligand and IL-15 stimulates NK progenitors and NK cells, with evidence that this composition is more potent than previously described factors and combinations of factors. Such



compositions can further comprise kit ligand or stem cell factor. Thus, the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  receptors of the present invention can be used as an antagonist or Ligand binding agent to decrease the activity of the zalpha11 Ligand on NK cells.

5           Moreover, the tissue distribution of a receptor for a given cytokine offers a strong indication of the potential sites of action of that cytokine. Northern analysis of zalpha11 receptor revealed transcripts in human spleen, thymus, lymph node, bone marrow, and peripheral blood leukocytes. Specific cell types were identified as expressing zalpha11 receptors, and strong signals were seen in a mixed lymphocyte  
10   reaction (MLR) and in the Burkitt's lymphoma Raji. The two monocytic cell lines, THP-1 (Tsuchiya et al., Int. J. Cancer 26:171-176, 1980) and U937 (Sundstrom et al., Int. J. Cancer 17:565-577, 1976), were negative. Zalpha11 receptor is expressed at relatively high levels in the MLR, in which peripheral blood mononuclear cells (PBMNC) from two individuals are mixed, resulting in mutual activation. Detection of  
15   high levels of transcript in the MLR but not in resting T or B cell populations suggests that zalpha11 receptor expression may be induced in one or more cell types during activation. Activation of isolated populations of T and B cells can be artificially achieved by stimulating cells with PMA and Ionomycin. When sorted cells were subjected to these activation conditions, levels of zalpha11 receptor transcript increased  
20   in both cell types, supporting a role for this receptor and zalpha11 Ligand in immune responses, especially in autocrine and paracrine T and B cell expansions during activation. Zalpha11 Ligand may also play a role in the expansion of more primitive progenitors involved in lymphopoiesis. Thus, the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  receptors of the  
25   present invention can be used as an antagonist or Ligand binding agent to modulate the lymphopoietic activities of the zalpha11 Ligand.

          Zalpha11 receptor was found to be present at low levels in resting T and B cells, and was upregulated during activation in both cell types. Interestingly, the B  
cells also down-regulate the message more quickly than do T cells, suggesting that  
30   amplitude of signal and timing of quenching of signal are important for the appropriate regulation of B cell responses.

In addition, a large proportion of intestinal lamina propria cells show positive hybridization signals with zalpha11 receptor. This tissue consists of a mixed population of lymphoid cells, including activated CD4+ T cells and activated B cells. Immune dysfunction, in particular chronic activation of the mucosal immune response, plays an important role in the etiology of Crohn's disease and inflammatory bowel disease (IBD); abnormal response to and/or production of proinflammatory cytokines is also a suspected factor (Braegger et al., Annals Allergy 72:135-141, 1994; Sartor RB Am. J. Gastroenterol. 92:5S-11S, 1997). The zalpha11 Ligand in concert with IL-15 expands NK cells from bone marrow progenitors and augments NK cell effector function. Zalpha11 Ligand also co-stimulates mature B cells stimulated with anti-CD40 antibodies, but inhibits B cell proliferation to signals through IgM. Zalpha11 Ligand enhances T cell proliferation in concert with a signal through the T cell receptor, and over expression in transgenic mice leads to lymphopenia and an expansion of monocytes and granulocytes. These pleiotropic effects of zalpha11 Ligand suggest that molecules that antagonize or bind zalpha11 Ligand, such as the molecules of the present invention, can provide therapeutic utility for a wide range of diseases arising from defects in the immune system, including (but not limited to) systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), myasthenia gravis, Crohn's Disease, IBD, and diabetes. It is important to note that these diseases are the result of a complex network of immune dysfunction (SLE, for example, is the manifestation of defects in both T and B cells), and that immune cells are dependent upon interaction with one another to elicit a potent immune response. Therefore, zalpha11 Ligand (or an antagonist of the Ligand, such a molecule of the present invention) that can be used to manipulate more than one type of immune cell is an attractive therapeutic candidate for intervention at multiple stages of disease.

Similarly, the tissue distribution of the mRNA corresponding to IL-2R $\gamma$  receptor cDNA shows expression in hematopoietic and lymphoid cells including CD4+ T-cells, CD8+ T-cells, CD20+ B-cells, CD56+ NK cells, CD14+ monocytes, as well as granulocytes. IL-2R $\gamma$  receptor cDNA is generally not found in other cell types, including epithelial cells and fibroblast cells. The expression pattern of this receptor correlates with the activities of the zalpha11 Ligand and the localization of the zalpha11

receptor. Moreover, antibodies to the IL-2R $\gamma$  receptor decrease or ablate the effect of zalpha11 Ligand in B-cells and BaF3/zalpha11 receptor cells, demonstrating that the zalpha11 receptor and IL-2R $\gamma$  receptor can heterodimerize *in vivo* and *in vitro*.

The zalpha11 Ligand both promotes expansion of NK cell populations  
5 from bone marrow and regulates the proliferation of mature T and B cells in response to activating stimuli. The zalpha11 Ligand acts through a receptor complex that includes at least one zalpha11 receptor subunit and the  $\gamma_c$  subunit of IL2R, even though the cytoplasmic domain of zalpha11 receptor is capable of transducing signal in a homodimeric configuration (commonly owned US Patent application No. 09/522,217).  
10 IL4R $\alpha$  is also capable of signaling as a homodimer (Kammer, W. et al., J. Biol. Chem. 271:23634-23637, 1996), although the true functional IL4 receptor complex is a IL4R $\alpha$ / $\gamma_c$  heterodimer. Signaling in BaF3/zalpha11 receptor could have resulted from interactions of the human zalpha11 receptor with endogenous murine  $\gamma_c$ , and Examples herein show that antibodies to the  $\gamma_c$  subunit decrease zalpha11 Ligand signaling in  
15 these cells.

Moreover, the IL2 receptor has been studied in detail and is composed of an  $\alpha$ - $\beta$ - $\gamma_c$  heterotrimer. The  $\beta$  and  $\gamma_c$  subunits are both essential for signal transduction and are members of the hematopoietin receptor superfamily (Cosman, D., Cytokine 5:95-106, 1993), whereas the  $\alpha$  subunit appears to primarily be involved in high-affinity  
20 binding conversion and is structurally distinct from the hematopoietin receptor family. The  $\gamma_c$  subunit has been shown to participate in forming the receptors for IL4, IL7, IL9, and IL15, in addition to IL2 (for review, see Sugamura, K., et al., Annu. Rev. Immunol. 14:179-205, 1996), and null mutations in the  $\gamma_c$  gene have been shown to cause X-linked severe combined immunodeficiency (X-SCID) (Noguchi, M. et al., Cell 73:147-  
25 157, 1993).

Zalpha11 Ligand antagonism of anti-IgM and IL4-induced B cell proliferation (commonly owned US Patent Application No. 09/522,217, and examples herein) could be due to competition for  $\gamma_c$ ; however, it is clear that IL4 can signal through a  $\gamma_c$ -independent receptor (IL4R $\alpha$  + IL13R $\alpha'$ ) (Murata, T. et al., Blood  
30 91:3884-3891, 1998). B cells from human SCID patients proliferate normally in response to anti-IgM and IL4 (Matthews, D.J. et al., Blood 85:38-42, 1995), and IL4

responsiveness in normal human B cells is associated with both IL13 responsiveness and levels of IL13R (Ford, D. et al., J. Immunol. 163:3185-3193, 1999). Similarly, Zalphal1 Ligand may signal through a heterodimeric, heterotrimeric or multimeric complex that includes zalphal1 receptor and a non-  $\gamma_C$ -subunit. As such, the present invention contemplates soluble zalphal1 receptor heterodimeric antagonists and binding agents to the zalphal1 Ligand that do not include the  $\gamma_C$  subunit, but include an additional Class I cytokine subunit, for example, IL13R $\alpha'$  and the like.

The soluble receptors of the present invention are useful as antagonists of the zalphal1 Ligand cytokine. Such antagonistic effects can be achieved by direct neutralization or binding of the zalphal1 Ligand. In addition to antagonistic uses, the soluble receptors of the present invention can bind zalphal1 Ligand and act as carrier proteins for the zalphal1 Ligand cytokine, in order to transport the Ligand to different tissues, organs, and cells within the body. As such, the soluble receptors of the present invention can be fused or coupled to molecules, polypeptides or chemical moieties that direct the soluble-receptor-Ligand complex to a specific site, such as a tissue, specific immune cell, or tumor. Thus, the soluble receptors of the present invention can be used to specifically direct the action of the zalphal1 Ligand. See, Cosman, D. Cytokine 5: 95-106, 1993; and Fernandez-Botran, R. Exp. Opin. Invest. Drugs 9:497-513, 2000.

Moreover, the soluble receptors of the present invention can be used to stabilize the zalphal1 Ligand, to increase the bio-availability, therapeutic longevity, and/or efficacy of the Ligand by stabilizing the Ligand from degradation or clearance, or by targeting the ligand to a site of action within the body. For example the naturally occurring IL-6/soluble IL-6R complex stabilizes IL-6 and can signal through the gp130 receptor. See, Cosman, D. supra., and Fernandez-Botran, R. supra.

For example, the Zalphal1 Ligand will be useful in treating tumorigenesis, and therefore would be useful in the treatment of cancer. Zalphal1 Ligand inhibits IL-4 stimulated proliferation of anti-IgM stimulated normal B-cells and a similar effect is observed in B-cell tumor lines suggesting that there may be therapeutic benefit in treating patients with the zalphal1 Ligand in order to induce the B cell tumor cells into a less proliferative state. The ligand could be administered in combination with other agents already in use including both conventional

chemotherapeutic agents as well as immune modulators such as interferon alpha. Alpha/beta interferons have been shown to be effective in treating some leukemias and animal disease models, and the growth inhibitory effects of interferon-alpha and zalpha11 Ligand are additive for at least one B-cell tumor-derived cell line. Moreover, 5 stabilization of the zalpha11 Ligand or ability to target the Ligand to specific sites of action with the soluble receptors of the present invention would be desirable in this therapeutic endeavor.

The present invention provides a method of reducing proliferation of neoplastic B or T cells comprising administering to a mammal with a B or T cell 10 neoplasm an amount of a composition of zalpha11 Ligand antagonist, such as the soluble receptors of the present invention, sufficient to reduce proliferation of the neoplastic B or T cells. In other embodiments, the composition can comprise at least one other cytokine selected from the group consisting of IL-2, IL-15, IL-4, GM-CSF, Flt3 ligand or stem cell factor. Furthermore, the zalpha11 Ligand antagonist can be a 15 toxic fusion. Similarly, soluble receptor-toxic fusions and soluble receptors of the present invention can be used to reduce proliferation of lymphoid and hematopoietic neoplasms that over-express or grow in response to zalpha11 Ligand. Moreover, indirect effects of the soluble receptors of the present invention can modulate NK cell function induced by zalpha11 Ligand, and hence indirectly enhance tumor cell killing.

20 The present invention provides polynucleotide molecules, including DNA and RNA molecules that encode the heterodimeric zalpha11 receptor polypeptides disclosed herein. Those skilled in the art will recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules. SEQ ID NO:7 is a degenerate DNA sequence that 25 encompasses all DNAs that encode the soluble zalpha11 receptor polypeptide of SEQ ID NO:6. SEQ ID NO:66 is a degenerate DNA sequence that encompasses all DNAs that encode the soluble zalpha11 receptor polypeptide of SEQ ID NO:69. SEQ ID NO:8 is a degenerate DNA sequence that encompasses all DNAs that encode the soluble human IL-2R $\gamma$  polypeptide of SEQ ID NO:4. Those skilled in the art will 30 recognize that the degenerate sequence of SEQ ID NO:7, SEQ ID NO:66 and SEQ ID NO:8 also provide all RNA sequences encoding SEQ ID NO:6, SEQ ID NO:69 and

SEQ ID NO:4 respectively by substituting U for T. Thus,  $\alpha$ 11 polypeptide-encoding polynucleotides comprising nucleotide 1 to nucleotide 654 of SEQ ID NO:7 or comprising nucleotide 1 to nucleotide 741 of SEQ ID NO:66, soluble human IL-2R $\gamma$  polypeptide-encoding polynucleotides comprising nucleotide 1 to nucleotide 696 of

5 SEQ ID NO:8, and their RNA equivalents are contemplated by the present invention. Table 1 sets forth the one-letter codes used within SEQ ID NO:7, SEQ ID NO:66 and SEQ ID NO:8 to denote degenerate nucleotide positions. "Resolutions" are the nucleotides denoted by a code letter. "Complement" indicates the code for the complementary nucleotide(s). For example, the code Y denotes either C or T, and its

10 complement R denotes A or G, A being complementary to T, and G being complementary to C.

TABLE 1

Nucleotide	Resolution	Complement	Resolution
A	A	T	T
C	C	G	G
G	G	C	C
T	T	A	A
R	A G	Y	C T
Y	C T	R	A G
M	A C	K	G T
K	G T	M	A C
S	C G	S	C G
W	A T	W	A T
H	A C T	D	A G T
B	C G T	V	A C G
V	A C G	B	C G T
D	A G T	H	A C T
N	A C G T	N	A C G T

The degenerate codons used in SEQ ID NO:7, SEQ ID NO:66 and SEQ  
5 ID NO:8 encompass all possible codons for a given amino acid, are set forth in Table 2.

TABLE 2

Amino Acid	One Letter Code	Codons	Degenerate Codon
Cys	C	TGC TGT	TGY
Ser	S	AGC AGT TCA TCC TCG TCT	WSN
Thr	T	ACA ACC ACG ACT	ACN
Pro	P	CCA CCC CCG CCT	CCN
Ala	A	GCA GCC GCG GCT	GCN
Gly	G	GGA GGC GGG GGT	GGN
Asn	N	AAC AAT	AAY
Asp	D	GAC GAT	GAY
Glu	E	GAA GAG	GAR
Gln	Q	CAA CAG	CAR
His	H	CAC CAT	CAY
Arg	R	AGA AGG CGA CGC CGG CGT	MGN
Lys	K	AAA AAG	AAR
Met	M	ATG	ATG
Ile	I	ATA ATC ATT	ATH
Leu	L	CTA CTC CTG CTT TTA TTG	YTN
Val	V	GTA GTC GTG GTT	GTN
Phe	F	TTC TTT	TTY
Tyr	Y	TAC TAT	TAY
Trp	W	TGG	TGG
Ter	.	TAA TAG TGA	TRR
Asn Asp	B		RAY
Glu Gln	Z		SAR
Any	X		NNN



One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding each amino acid. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequence of SEQ ID NO:6, SEQ ID NO:69 or SEQ ID NO:4. Variant sequences can be readily tested for functionality as described herein.

One of ordinary skill in the art will also appreciate that different species can exhibit "preferential codon usage." In general, see, Grantham, et al., Nuc. Acids Res. 8:1893-912, 1980; Haas, et al. Curr. Biol. 6:315-24, 1996; Wain-Hobson, et al., Gene 13:355-64, 1981; Grosjean and Fiers, Gene 18:199-209, 1982; Holm, Nuc. Acids Res. 14:3075-87, 1986; Ikemura, J. Mol. Biol. 158:573-97, 1982. As used herein, the term "preferential codon usage" or "preferential codons" is a term of art referring to protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few representatives of the possible codons encoding each amino acid (See Table 2). For example, the amino acid Threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential. Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Therefore, the degenerate codon sequence disclosed in SEQ ID NO:7, SEQ ID NO:66 and SEQ ID NO:8 serves as a template for optimizing expression of polynucleotides and polypeptides in various cell types and species commonly used in the art and disclosed herein. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein.

Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar sized regions of SEQ ID NO:5, SEQ ID NO:68 or SEQ ID NO:3, or a sequence complementary thereto, under stringent conditions. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Numerous equations for calculating  $T_m$  are known in the art, and are specific for DNA, RNA and DNA-RNA hybrids and polynucleotide probe sequences of varying length (see, for example, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition (Cold Spring Harbor Press 1989); Ausubel *et al.*, (eds.), Current Protocols in Molecular Biology (John Wiley and Sons, Inc. 1987); Berger and Kimmel (eds.), Guide to Molecular Cloning Techniques, (Academic Press, Inc. 1987); and Wetmur, Crit. Rev. Biochem. Mol. Biol. 26:227 (1990)). Sequence analysis software such as OLIGO 6.0 (LSR; Long Lake, MN) and *Primer Premier 4.0* (Premier Biosoft International; Palo Alto, CA), as well as sites on the Internet, are available tools for analyzing a given sequence and calculating  $T_m$  based on user-defined criteria. Such programs can also analyze a given sequence under defined conditions and identify suitable probe sequences. Typically, hybridization of longer polynucleotide sequences (e.g., >50 base pairs) is performed at temperatures of about 20-25°C below the calculated  $T_m$ . For smaller probes (e.g., <50 base pairs) hybridization is typically carried out at the  $T_m$  or 5-10°C below. This allows for the maximum rate of hybridization for DNA-DNA and DNA-RNA hybrids. Higher degrees of stringency at lower temperatures can be achieved with the addition of formamide which reduces the  $T_m$  of the hybrid about 1°C for each 1% formamide in the buffer solution. Suitable stringent hybridization conditions are equivalent to about a 5 h to overnight incubation at about 42°C in a solution comprising: about 40-50% formamide, up to about 6X SSC, about 5X Denhardt's solution, zero up to about 10% dextran sulfate, and about 10-20 µg/ml denatured commercially-available carrier DNA. Generally, such stringent conditions include temperatures of 20-70°C and a hybridization buffer containing up to 6x SSC and 0-50% formamide; hybridization is then followed by washing filters in up to about

2X SSC. For example, a suitable wash stringency is equivalent to 0.1X SSC to 2X SSC, 0.1% SDS, at 55°C to 65°C. Different degrees of stringency can be used during hybridization and washing to achieve maximum specific binding to the target sequence. Typically, the washes following hybridization are performed at increasing degrees of stringency to remove non-hybridized polynucleotide probes from hybridized complexes. Stringent hybridization and wash conditions depend on the length of the probe, reflected in the  $T_m$ , hybridization and wash solutions used, and are routinely determined empirically by one of skill in the art.

As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for preparing DNA and RNA are well known in the art. In general, RNA is isolated from a tissue or cell that produces large amounts of  $\alpha 11$  receptor RNA or the RNA for the heterodimeric component of the receptor, such as IL-2R $\gamma$ , or other class I cytokine receptor. Such tissues and cells are identified by Northern blotting (Thomas, Proc. Natl. Acad. Sci. USA 77:5201, 1980), and include PBLs, spleen, thymus, and lymph tissues, Raji cells, human erythroleukemia cell lines (e.g., TF-1), acute monocytic leukemia cell lines, other lymphoid and hematopoietic cell lines, and the like, for the  $\alpha 11$  receptor. RNA for a heterodimeric component of the receptor, such as IL-2R $\gamma$ , or other class I cytokine receptor can be isolated from lymphoid cells, such as those described above, and other cells and tissues as is known in the art for these receptors. Total RNA can be prepared using guanidinium isothiocyanate extraction followed by isolation by centrifugation in a CsCl gradient (Chirgwin et al., Biochemistry 18:52-94, 1979). Poly (A)<sup>+</sup> RNA is prepared from total RNA using the method of Aviv and Leder (Proc. Natl. Acad. Sci. USA 69:1408-12, 1972). Complementary DNA (cDNA) is prepared from poly(A)<sup>+</sup> RNA using known methods. In the alternative, genomic DNA can be isolated. Polynucleotides encoding  $\alpha 11$  polypeptides are then identified and isolated by, for example, hybridization or polymerase chain reaction (PCR) (Mullis, U.S. Patent No. 4,683,202).

The polynucleotides of the present invention can also be synthesized using DNA synthesis machines. Currently the method of choice is the phosphoramidite method. If chemically synthesized double stranded DNA is required for an application

such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately. The production of short polynucleotides (60 to 80 bp) is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealing them. However, for producing longer polynucleotides (>300 bp),  
5 special strategies are usually employed, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are assembled in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length.

An alternative way to prepare a full-length gene is to synthesize a  
10 specified set of overlapping oligonucleotides (40 to 100 nucleotides). After the 3' and 5' short overlapping complementary regions (6 to 10 nucleotides) are annealed, large gaps still remain, but the short base-paired regions are both long enough and stable enough to hold the structure together. The gaps are filled and the DNA duplex is completed via enzymatic DNA synthesis by *E. coli* DNA polymerase I. After the enzymatic synthesis  
15 is completed, the nicks are sealed with T4 DNA ligase. Double-stranded constructs are sequentially linked to one another to form the entire gene sequence which is verified by DNA sequence analysis. See Glick and Pasternak, Molecular Biotechnology, Principles & Applications of Recombinant DNA, (ASM Press, Washington, D.C. 1994); Itakura et al., Annu. Rev. Biochem. 53: 323-56, 1984 and Climie et al., Proc. Natl. Acad. Sci. USA 87:633-7, 1990. Moreover, other sequences are generally added that contain  
20 signals for proper initiation and termination of transcription and translation.

The present invention further provides counterpart polypeptides and polynucleotides from other species (orthologs). These species include, but are not limited to mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and  
25 invertebrate species. Of particular interest are heterodimeric soluble receptor complexes combining soluble  $\alpha$ 11 receptor and soluble human IL-2R $\gamma$  or other soluble Class I cytokine receptor polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primate polypeptides. Known and unknown orthologs of human soluble  $\alpha$ 11 receptor and  
30 soluble human IL-2R $\gamma$  or other soluble Class I cytokine receptors can be cloned using information and compositions provided by the present invention in combination with

conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type, such as lymphoid cells, that expresses zalpha11receptor, human IL-2R $\gamma$  or other Class I cytokine receptors. Moreover, suitable sources of mRNA can be identified by probing Northern blots with probes  
5 designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A zalpha11-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned using PCR (Mullis, supra), using primers designed from the  
10 representative human zalpha11 sequence, or soluble human IL-2R $\gamma$  sequence, disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to zalpha11 polypeptide. Similar techniques can also be applied to the isolation of genomic clones.

15 Cytokine receptor subunits are characterized by a multi-domain structure comprising an extracellular domain, a transmembrane domain that anchors the polypeptide in the cell membrane, and an intracellular domain. The extracellular domain the zalpha11 receptor is a ligand-binding domain, that binds zalpha11 Ligand, and the intracellular domain is an effector domain involved in signal transduction,  
20 although ligand-binding and effector functions can reside on separate subunits of a multimeric receptor. The ligand-binding domain may itself be a multi-domain structure. Multimeric receptors include homodimers (e.g., PDGF receptor  $\alpha\alpha$  and  $\beta\beta$  isoforms, erythropoietin receptor, MPL, and G-CSF receptor), heterodimers whose subunits each have ligand-binding and effector domains (e.g., PDGF receptor  $\alpha\beta$   
25 isoform), and multimers having component subunits with disparate functions (e.g., IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-13, IL-15 and GM-CSF receptors). Some receptor subunits are common to a plurality of receptors. For example, the AIC2B subunit, which cannot bind ligand on its own but includes an intracellular signal transduction domain, is a component of IL-3 and GM-CSF receptors. Many cytokine receptors can  
30 be placed into one of four related families on the basis of the structure and function. Hematopoietic receptors, for example, are characterized by the presence of a domain

containing conserved cysteine residues and the WSXWS motif (SEQ ID NO:13). Cytokine receptor structure has been reviewed by Urdal, Ann. Reports Med. Chem. 26:221-228, 1991; and Cosman, Cytokine 5:95-106, 1993. Under selective pressure for organisms to acquire new biological functions, new receptor family members likely  
5 arise from duplication of existing receptor genes leading to the existence of multi-gene families. Family members thus contain vestiges of the ancestral gene, and these characteristic features can be exploited in the isolation and identification of additional family members. Thus, the cytokine receptor superfamily is subdivided into several families, for example, the immunoglobulin family (including CSF-1, MGF, IL-1, and  
10 PDGF receptors); the hematopoietin family (including IL-2 receptor  $\beta$ -subunit, GM-CSF receptor  $\alpha$ -subunit, GM-CSF receptor  $\beta$ -subunit; and G-CSF, EPO, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-13 and IL-15 receptors); TNF receptor family (including TNF (p80) TNF (p60) receptors, CD27, CD30, CD40, Fas, and NGF receptor).

Analysis of the  $\alpha$ 11 receptor sequence suggests that it is a member  
15 of the same receptor subfamily as the IL-2 receptor  $\beta$ -subunit, IL-4, and IL-9, receptors. Certain receptors in this subfamily (e.g., EPO-R or MPL) associate to form homodimers that transduce a signal. Other members of the subfamily (e.g., IL-6, IL-11, and LIF receptors) combine with a second subunit (termed a  $\beta$ -subunit) to bind ligand and transduce a signal. Specific  $\beta$ -subunits associate with a plurality of specific cytokine  
20 receptor subunits. For example, the  $\beta$ -subunit gp130 (Hibi et al., Cell 63:1149-1157, 1990) associates with receptor subunits specific for IL-6, IL-11, and LIF (Gearing et al., EMBO J. 10:2839-2848, 1991; Gearing et al., U.S. Patent No. 5,284,755). Oncostatin M binds to a heterodimer of LIF receptor and gp130. CNTF binds to trimeric receptors comprising CNTF receptor, LIF receptor, and gp130 subunits. Moreover, IL-4 and IL-  
25 13 elicit responses through the IL-4 and IL-13 receptors by acting upon various functional heterodimeric receptor complexes, e.g. with and without the  $\gamma_c$  subunit, and such heterodimeric receptor complexes may affect whether the cytokines act upon hematopoietic or non-hematopoietic cells (Andersson, A. et al., Eur. J. Immunol. 27:1762-1768, 1997; Murata, T. et al., Blood 10:3884-3891, 1998). Moreover, binding  
30 affinity of IL-4 on its receptor is increased when the  $\gamma_c$  subunit of the IL4R complex is replaced by an IL-13R $\alpha'$  subunit (Murata, T. et al., supra.). Thus, the soluble receptors

of the present invention include zalpha11 receptor homodimers; and heterodimers that have a zalpha11 receptor component, such as soluble zalpha11/IL-2R $\gamma$  or soluble zalpha11 receptor heterodimerized with another soluble Class I cytokine receptor, such as IL-13R $\alpha$  (SEQ ID NO:84), IL-13R $\alpha'$  (SEQ ID NO:82) or an IL-15 (SEQ ID NO:86) receptor subunit.

For example, suitable Class I cytokine soluble receptors that can heterodimerize with a soluble zalpha11 receptor component (e.g., SEQ ID NO:6), include a soluble receptor for IL-13R $\alpha$  as shown in SEQ ID NO:84, IL-13R $\alpha'$  as shown in SEQ ID NO:82, or IL-15 as shown in SEQ ID NO:86. Moreover, functional sub-  
10 fragments, such as minimal cytokine binding fragments, of these Class I cytokine soluble receptors can be used. Such functional fragments include 1 to 322, 7 to 322, and 105 to 322 of SEQ ID NO:82; 1 to 317, 10 to 317, and 105 to 317 of SEQ ID NO:84; and 1 to 173 of SEQ ID NO:86. The corresponding polynucleotide sequences are as shown in SEQ ID NO:81, SEQ ID NO:83 and SEQ ID NO:85 respectively. It is  
15 well within the level of one of skill in the art to delineate what sequences of a known class I cytokine sequence comprise the extracellular cytokine binding domain free of a transmembrane domain and intracellular domain.

A polynucleotide sequence for the mouse ortholog of human zalpha11 receptor has been identified and is shown in SEQ ID NO:11 and the corresponding  
20 amino acid sequence shown in SEQ ID NO:12. Analysis of the mouse zalpha11 polypeptide encoded by the DNA sequence of SEQ ID NO:11 revealed an open reading frame encoding 529 amino acids (SEQ ID NO:12) comprising a predicted secretory signal peptide of 19 amino acid residues (residue 1 (Met) to residue 19 (Ser) of SEQ ID NO:12), and a mature polypeptide of 510 amino acids (residue 20 (Cys) to residue 529  
25 (Ser) of SEQ ID NO:12). In addition to the WSXWS motif (SEQ ID NO:13) corresponding to residues 214 to 218 of SEQ ID NO:12, the receptor comprises a cytokine-binding domain of approximately 200 amino acid residues (residues 20 (Cys) to 237 (His) of SEQ ID NO:12); a domain linker (residues 120 (Pro) to 123 (Pro) of SEQ ID NO:12); a penultimate strand region (residues 192 (Lys) to 202 (Ala) of SEQ  
30 ID NO:12); a transmembrane domain (residues 238 (Met) to 254 (Leu) of SEQ ID NO:12); complete intracellular signaling domain (residues 255 (Lys) to 529 (Ser) of

SEQ ID NO:12) which contains a "Box I" signaling site (residues 266 (Ile) to 273 (Pro) of SEQ ID NO:12), and a "Box II" signaling site (residues 301 (Ile) to 304 (Val) of SEQ ID NO:2). A comparison of the human and mouse amino acid sequences reveals that both the human and orthologous polypeptides contain corresponding structural features described above. The mature sequence for the mouse zalpha11 begins at Cys<sub>20</sub> (as shown in SEQ ID NO:12), which corresponds to Cys<sub>20</sub> (as shown in SEQ ID NO:2) in the human sequence. There is about 69% identity between the mouse and human zalpha11 sequences over the extracellular cytokine binding domain corresponding to residues 20 (Cys) to 237 (His) of SEQ ID NO:2 (SEQ ID NO:6) and residues 20 (Cys) to 237 (His) of SEQ ID NO:12. The above percent identities were determined using a FASTA program with ktup=1, gap opening penalty=12, gap extension penalty=2, and substitution matrix=BLOSUM62, with other FASTA program parameters set as default. The corresponding polynucleotides encoding the mouse zalpha11 polypeptide regions, domains, motifs, residues and sequences described above are as shown in SEQ ID NO:11.

The present invention also provides for a heterodimeric soluble receptor, wherein the isolated soluble zalpha11 receptor polypeptide therein is substantially similar to the polypeptides of SEQ ID NO:6 and their orthologs. Moreover, in a preferred embodiment, the present invention also provides for a heterodimeric soluble receptor, wherein an isolated soluble IL-2R $\gamma$  receptor polypeptide therein is substantially similar to the polypeptides of SEQ ID NO:4 and their orthologs. The term "substantially similar" is used herein to denote polypeptides having at least 70%, more preferably at least 80%, sequence identity to the sequences shown in SEQ ID NO:6 or their orthologs. Such polypeptides will more preferably be at least 90% identical, and most preferably 95% or more identical to SEQ ID NO:6 or SEQ ID NO:4 (their orthologs.) Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915-10919, 1992. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blosum 62" scoring matrix of Henikoff and



Henikoff (ibid.) as shown in Table 3 (amino acids are indicated by the standard one-letter codes). The percent identity is then calculated as:

$$5 \quad \frac{\text{Total number of identical matches}}{\text{[length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences]}} \times 100$$

Table 3

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
5	A 4																			
	R -1	5																		
	N -2	0	6																	
	D -2	-2	1	6																
	C 0	-3	-3	-3	9															
	Q -1	1	0	0	-3	5														
10	E -1	0	0	2	-4	2	5													
	G 0	-2	0	-1	-3	-2	-2	6												
	H -2	0	1	-1	-3	0	0	-2	8											
	I -1	-3	-3	-3	-1	-3	-3	-4	-3	4										
	L -1	-2	-3	-4	-1	-2	-3	-4	-3	2	4									
15	K -1	2	0	-1	-3	1	1	-2	-1	-3	-2	5								
	M -1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							
	F -2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
	P -1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7					
	S 1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
20	T 0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-1	-2	-1	1	5			
	W -3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
	Y -2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
	V 0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1	4

Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above.

Those skilled in the art appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for  
5 examining the level of identity shared by an amino acid sequence disclosed herein and the amino acid sequence of a putative variant zsig57. The FASTA algorithm is described by Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988), and by Pearson, Meth. Enzymol. 183:63 (1990).

10 Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (*e.g.*, SEQ ID NO:6) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by  
15 comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to  
20 determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, SIAM J. Appl. Math. 26:787 (1974)), which allows for amino acid insertions and deletions. Preferred program parameters for  
25 FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62, with other parameters set as default. These FASTA program parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, Meth. Enzymol. 183:63 (1990).

30 FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons,

the ktup value can range between one to six, preferably from three to six, most preferably three, with other program parameters set as default.

The BLOSUM62 table (Table 3) is an amino acid substitution matrix derived from about 2,000 local multiple alignments of protein sequence segments, representing highly conserved regions of more than 500 groups of related proteins (Henikoff and Henikoff, *Proc. Nat'l Acad. Sci. USA* 89:10915 (1992)). Accordingly, the BLOSUM62 substitution frequencies can be used to define conservative amino acid substitutions that may be introduced into the amino acid sequences of the present invention. Although it is possible to design amino acid substitutions based solely upon chemical properties (as discussed below), the language "conservative amino acid substitution" preferably refers to a substitution represented by a BLOSUM62 value of greater than -1. For example, an amino acid substitution is conservative if the substitution is characterized by a BLOSUM62 value of 0, 1, 2, or 3. According to this system, preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 1 (e.g., 1, 2 or 3), while more preferred conservative amino acid substitutions are characterized by a BLOSUM62 value of at least 2 (e.g., 2 or 3).

Variant zalphal1 polypeptides or substantially homologous zalphal1 polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 4) and other substitutions that do not significantly affect the folding or activity of the polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an affinity tag. The present invention thus includes zalphal1 soluble receptor polypeptides of from about 190 to about 245 amino acid residues that comprise a sequence that is at least 80%, preferably at least 90%, and more preferably 95% or more identical to the corresponding region of SEQ ID NO:6. Polypeptides comprising affinity tags can further comprise a proteolytic cleavage site between the zalphal1 polypeptide and the affinity tag. Suitable sites include thrombin cleavage sites and factor Xa cleavage sites.

Table 4Conservative amino acid substitutions

5	Basic:	arginine
		lysine
		histidine
	Acidic:	glutamic acid
		aspartic acid
10	Polar:	glutamine
		asparagine
	Hydrophobic:	leucine
		isoleucine
		valine
15	Aromatic:	phenylalanine
		tryptophan
		tyrosine
	Small:	glycine
		alanine
20		serine
		threonine
		methionine

The present invention further provides a variety of other polypeptide  
 fusions and related multimeric proteins comprising one or more polypeptide fusions.  
 For example, a soluble zalpall receptor or soluble zalpall heterodimeric  
 polypeptide, such as soluble zalpall/IL-2R $\gamma$  can be prepared as a fusion to a  
 dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584.  
 Preferred dimerizing proteins in this regard include immunoglobulin constant region  
 domains, e.g., IgG $\gamma$ 1, and the human  $\kappa$  light chain. Immunoglobulin-soluble zalpall  
 receptor or immunoglobulin-soluble zalpall heterodimeric polypeptide, such as  
 immunoglobulin-soluble zalpall/IL-2R $\gamma$  fusions can be expressed in genetically  
 engineered cells to produce a variety of multimeric zalpall receptor analogs.  
 Auxiliary domains can be fused to soluble zalpall receptor or soluble zalpall  
 heterodimeric polypeptide, such as soluble zalpall/IL-2R $\gamma$  to target them to specific

cells, tissues, or macromolecules (e.g., collagen, or cells expressing the  $\alpha 1$  Ligand). A  $\alpha 1$  polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al.,  
5 Connective Tissue Research 34:1-9, 1996.

The proteins of the present invention can also comprise non-naturally occurring amino acid residues. Non-naturally occurring amino acids include, without limitation, *trans*-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, *allo*-threonine, methylthreonine,  
10 hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipercolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4-methylproline, 3,3-dimethylproline, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example,  
15 an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is carried out in a cell-free system comprising an *E. coli* S30 extract and commercially available enzymes and other reagents. Proteins  
20 are purified by chromatography. See, for example, Robertson et al., J. Am. Chem. Soc. 113:2722, 1991; Ellman et al., Methods Enzymol. 202:301, 1991; Chung et al., Science 259:806-9, 1993; and Chung et al., Proc. Natl. Acad. Sci. USA 90:10145-9, 1993). In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., J.  
25 Biol. Chem. 271:19991-8, 1996). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart.  
30 See, Koide et al., Biochem. 33:7470-7476, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by *in vitro* chemical

modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993).

5 A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for zalpha11 amino acid residues.

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244: 1081-5, 1989; 10 Bass et al., Proc. Natl. Acad. Sci. USA 88:4498-502, 1991). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g. ligand binding and signal transduction) as disclosed below to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., J. Biol. Chem. 271:4699-4708, 15 1996. Sites of ligand-receptor, protein-protein or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., Science 255:306-312, 1992; Smith et al., J. Mol. Biol. 224:899-20 904, 1992; Wlodaver et al., FEBS Lett. 309:59-64, 1992. The identities of essential amino acids can also be inferred from analysis of homologies with related receptors.

Determination of amino acid residues that are within regions or domains that are critical to maintaining structural integrity can be determined. Within these regions one can determine specific residues that will be more or less tolerant of change 25 and maintain the overall tertiary structure of the molecule. Methods for analyzing sequence structure include, but are not limited to, alignment of multiple sequences with high amino acid or nucleotide identity and computer analysis using available software (e.g., the Insight II® viewer and homology modeling tools; MSI, San Diego, CA), secondary structure propensities, binary patterns, complementary packing and buried 30 polar interactions (Barton, Current Opin. Struct. Biol. 5:372-376, 1995; and, Cordes et al., Current Opin. Struct. Biol. 6:3-10, 1996). In general, when designing modifications

to molecules or identifying specific fragments determination of structure will be accompanied by evaluating activity of modified molecules.

Amino acid sequence changes are made in soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$ , so as to minimize disruption of higher order structure essential to biological activity. For example, where the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  comprises one or more helices, changes in amino acid residues will be made so as not to disrupt the helix geometry and other components of the molecule where changes in conformation abate some critical function, for example, binding of the molecule to the zalpha11 Ligand, or antagonizing zalpha11 Ligand activity. The effects of amino acid sequence changes can be predicted by, for example, computer modeling as disclosed above or determined by analysis of crystal structure (see, e.g., Laphorn et al., Nat. Struct. Biol. 2:266-268, 1995). Other techniques that are well known in the art compare folding of a variant protein to a standard molecule (e.g., the native protein). For example, comparison of the cysteine pattern in a variant and standard molecules can be made. Mass spectrometry and chemical modification using reduction and alkylation provide methods for determining cysteine residues which are associated with disulfide bonds or are free of such associations (Bean et al., Anal. Biochem. 201:216-226, 1992; Gray, Protein Sci. 2:1732-1748, 1993; and Patterson et al., Anal. Chem. 66:3727-3732, 1994). It is generally believed that if a modified molecule does not have the same disulfide bonding pattern as the standard molecule folding would be affected. Another well known and accepted method for measuring folding is circular dichroism (CD). Measuring and comparing the CD spectra generated by a modified molecule and standard molecule is routine (Johnson, Proteins 7:205-214, 1990). Crystallography is another well known method for analyzing folding and structure. Nuclear magnetic resonance (NMR), digestive peptide mapping and epitope mapping are also known methods for analyzing folding and structural similarities between proteins and polypeptides (Schaanan et al., Science 257:961-964, 1992).

A Hopp/Woods hydrophilicity profile of the zalpha11 protein sequence as shown in SEQ ID NO:6 can be generated (Hopp et al., Proc. Natl. Acad.



Sci.78:3824-3828, 1981; Hopp, J. Immun. Meth. 88:1-18, 1986 and Triquier et al., Protein Engineering 11:153-169, 1998). The profile is based on a sliding six-residue window. Buried G, S, and T residues and exposed H, Y, and W residues were ignored. For example, in the soluble zalpha11 receptor, hydrophilic regions include amino acid residues 55 through 60 of SEQ ID NO: 2, amino acid residues 56 through 61 of SEQ ID NO: 2, amino acid residues 139 through 144 of SEQ ID NO: 2, and amino acid residues 227 through 232 of SEQ ID NO: 2. The corresponding hydrophilic regions in reference to SEQ ID NO:6 can be made with cross-reference to the above amino acid residues of SEQ ID NO:2.

Those skilled in the art will recognize that hydrophilicity or hydrophobicity will be taken into account when designing modifications in the amino acid sequence of a soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$ , so as not to disrupt the overall structural and biological profile. Of particular interest for replacement are hydrophobic residues selected from the group consisting of Val, Leu and Ile or the group consisting of Met, Gly, Ser, Ala, Tyr and Trp. For example, residues tolerant of substitution could include such residues as shown in SEQ ID NO:6, SEQ ID NO:69 and SEQ ID NO:4. However, Cysteine residues could be relatively intolerant of substitution.

The identities of essential amino acids can also be inferred from analysis of sequence similarity between Class I cytokine receptor family members with soluble zalpha11 receptor or soluble IL-2R $\gamma$  receptor. Using methods such as "FASTA" analysis described previously, regions of high similarity are identified within a family of proteins and used to analyze amino acid sequence for conserved regions. An alternative approach to identifying a variant extracellular domain zalpha11 polynucleotide on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant zalpha11 polynucleotide can hybridize to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:5, or SEQ ID NO:68 as discussed above. Likewise, variants of soluble class I cytokine receptor contained within a zalpha11 heterodimeric polypeptide, such as the soluble IL-2R $\gamma$  receptor component in soluble zalpha11/IL-2R $\gamma$ , can be identified as described above.

Other methods of identifying essential amino acids in the polypeptides of the present invention are procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081 (1989), Bass et al., Proc. Natl Acad. Sci. USA 88:4498 (1991), Coombs and  
5 Corey, "Site-Directed Mutagenesis and Protein Engineering," in Proteins: Analysis and Design, Angeletti (ed.), pages 259-311 (Academic Press, Inc. 1998)). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity as disclosed below to identify amino acid residues that are critical to the activity of the molecule. See also,  
10 Hilton et al., J. Biol. Chem. 271:4699 (1996).

The present invention also includes functional fragments of soluble zalpha11 receptor polypeptides or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides and nucleic acid molecules encoding such functional fragments. A "functional" soluble zalpha11 receptor polypeptide or soluble  
15 zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptide, or fragment thereof defined herein is characterized by its ability to bind to an anti-zalpha11 antibody, or to zalpha11 Ligand (either soluble or immobilized), or to antagonize zalpha11 Ligand activity in, for example, a biological or binding assay. As previously described herein, zalpha11 receptor is characterized by a class I cytokine  
20 receptor structure. Thus, the present invention further provides fusion proteins encompassing: (a) homodimeric or multimeric polypeptide molecules comprising an extracellular domain described herein; and (b) functional fragments comprising one or more of these domains. The other polypeptide portion of the fusion protein may be contributed by another class I cytokine receptor, for example, IL-2R $\gamma$ , IL-2 receptor  $\beta$ -  
25 subunit and the  $\beta$ -common receptor (i.e., IL3, IL-5, and GM-CSF receptor  $\beta$ -subunits), IL-13 $\alpha$ , IL-13 $\alpha'$ , or IL-15 receptor subunits, or by a non-native and/or an unrelated secretory signal peptide that facilitates secretion of the soluble fusion protein.

Routine deletion analyses of nucleic acid molecules can be performed to obtain functional fragments of a nucleic acid molecule that encode a soluble zalpha11  
30 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$ . As an illustration, DNA molecules having the nucleotide sequence of SEQ ID

NO:1 or fragments thereof, can be digested with *Bal31* nuclease to obtain a series of nested deletions. These DNA fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for antagonizing zalpha11 Ligand biological or zalpha11 Ligand binding activity; or for the ability to bind anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide antibodies; or for the ability to bind zalpha11 Ligand. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce deletions or stop codons to specify production of a desired polypeptide fragment. Alternatively, particular fragments of a soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide polynucleotide can be synthesized using the polymerase chain reaction.

Standard methods for identifying functional domains, such as Ligand binding domains, are routine for those of skill in the art. For example, studies on the truncation at either or both termini of interferons have been summarized by Horisberger and Di Marco, Pharmac. Ther. 66:507 (1995). Moreover, standard techniques for functional analysis of proteins are described by, for example, Treuter et al., Molec. Gen. Genet. 240:113 (1993); Content et al., "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems, Cantell (ed.), pages 65-72 (Nijhoff 1987); Herschman, "The EGF Receptor," in Control of Animal Cell Proliferation 1, Boynton et al., (eds.) pages 169-199 (Academic Press 1985); Coumailleau et al., J. Biol. Chem. 270:29270 (1995); Fukunaga et al., J. Biol. Chem. 270:25291 (1995); Yamaguchi et al., Biochem. Pharmacol. 50:1295 (1995); and Meisel et al., Plant Molec. Biol. 30:1 (1996).

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-57, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-2156, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used

include phage display (e.g., Lowman et al., Biochem. 30:10832-10837, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/062045) and region-directed mutagenesis (Derbyshire et al., Gene 46:145, 1986; Ner et al., DNA 7:127, 1988).

5 Variants of the disclosed soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide DNA and polypeptide sequences can be generated through DNA shuffling as disclosed by Stemmer, Nature 370:389-91, 1994, Stemmer, Proc. Natl. Acad. Sci. USA 91:10747-51, 1994 and WIPO Publication WO 97/20078. Briefly, variant DNAs are generated by *in vitro* homologous recombination by random  
10 fragmentation of a parent DNA followed by reassembly using PCR, resulting in randomly introduced point mutations. This technique can be modified by using a family of parent DNAs, such as allelic variants or DNAs from different species, to introduce additional variability into the process. Selection or screening for the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid  
15 "evolution" of sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes.

Mutagenesis methods as disclosed herein can be combined with high-throughput, automated screening methods to detect zalpha11 Ligand antagonist or binding activity in host cells of cloned, mutagenized soluble zalpha11 receptor or  
20 soluble zalpha11 heterodimeric receptor polypeptides. Preferred assays in this regard include cell proliferation assays and biosensor-based ligand-binding assays, which are described below and in the Examples. Mutagenized DNA molecules that encode active receptors or portions thereof (e.g., ligand-binding fragments, and the like) can be recovered from the host cells and rapidly sequenced using modern equipment. These  
25 methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

The present invention thus provides a series of novel, hybrid molecules in which a segment comprising one or more of the domains of soluble zalpha11  
30 receptor is fused to another soluble receptor polypeptide. Fusion is preferably done by splicing at the DNA level to allow expression of chimeric molecules in recombinant

production systems. The resultant molecules are then assayed for such properties as improved solubility, improved stability, prolonged clearance half-life, improved expression and secretion levels, and pharmacodynamics. Such hybrid molecules may further comprise additional amino acid residues (e.g. a polypeptide linker) between the component proteins or polypeptides.

Using the methods discussed herein, one of ordinary skill in the art can identify and/or prepare a variety of polypeptide fragments or variants of SEQ ID NO:6 that retain  $\alpha 11$  Ligand binding or antagonist activity. For example, one can make a  $\alpha 11$  soluble receptor by preparing a variety of polypeptides that are substantially homologous to the cytokine-binding domain (residues 20 (Cys) to 237 (His) of SEQ ID NO:2 (SEQ ID NO:6), or a subsequence therein that binds  $\alpha 11$  Ligand, or allelic variants or species orthologs thereof) and retain ligand-binding activity of the wild-type  $\alpha 11$  protein. Such polypeptides may include additional amino acids from, for example, part or all of the signal peptide sequence, transmembrane and intracellular domains. Such polypeptides may also include additional polypeptide segments as generally disclosed herein such as labels, affinity tags, and the like. Similarly, one of ordinary skill in the art can identify and/or prepare a variety of polypeptide fragments or variants of SEQ ID NO:4, or other soluble class I cytokine receptors that form heterodimers with  $\alpha 11$  receptor.

For any soluble  $\alpha 11$  receptor polypeptide, including variants, and fusion polypeptides or proteins, one of ordinary skill in the art can readily generate a fully degenerate polynucleotide sequence encoding that variant using the information set forth in Tables 1 and 2 above.

The soluble  $\alpha 11$  receptor or soluble  $\alpha 11$  heterodimeric receptor polypeptides of the present invention, including full-length soluble receptor polypeptides, biologically active fragments, and fusion polypeptides, can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing

exogenous DNA into a variety of host cells are disclosed by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987.

5           In general, a DNA sequence encoding a zalpha11 polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more  
10           origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

15           To direct a soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of zalpha11 receptor disclosed herein, the IL-2R $\gamma$  (amino acid 1 (Met) to 22 (Gly)  
20           of SEQ ID NO:18), or may be derived from another secreted protein (e.g., t-PA) or synthesized *de novo*. The secretory signal sequence is operably linked to the zalpha11 DNA sequence, i.e., the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the DNA sequence  
25           encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

          Cultured mammalian cells are suitable hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include  
30           calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456,

1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982), DEAE-dextran mediated transfection (Ausubel et al., ibid.), and liposome-mediated transfection (Hawley-Nelson et al., Focus 15:73, 1993; Ciccarone et al., Focus 15:80, 1993, and viral vectors (Miller and Rosman, BioTechniques 7:980-90, 1989; Wang and Finer, Nature Med. 2:714-716, 1996). The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus (CMV). See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter.

Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin

acetyltransferase) can also be used. Alternative markers that introduce an altered phenotype, such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from untransfected cells by such means as FACS sorting, flow cytometry, or magnetic  
5 bead separation technology.

Other higher eukaryotic cells can also be used as hosts, including plant cells, insect cells and avian cells. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987. Transformation of insect cells and production of foreign polypeptides  
10 therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222 and WIPO publication WO 94/06463. Insect cells can be infected with recombinant baculovirus, commonly derived from *Autographa californica nuclear polyhedrosis virus* (AcNPV). See, King, L.A. and Possee, R.D., The Baculovirus Expression System: A Laboratory Guide, London, Chapman & Hall; O'Reilly, D.R. et al., Baculovirus Expression Vectors: A  
15 Laboratory Manual, New York, Oxford University Press., 1994; and, Richardson, C. D., Ed., Baculovirus Expression Protocols. Methods in Molecular Biology, Totowa, NJ, Humana Press, 1995. A second method of making recombinant zalpha11 baculovirus utilizes a transposon-based system described by Luckow (Luckow, V.A, et al., J Virol 67:4566-79, 1993). This system, which utilizes transfer vectors, is sold in the Bac-to-  
20 Bac™ kit (Life Technologies, Rockville, MD). This system utilizes a transfer vector, pFastBac1™ (Life Technologies) containing a Tn7 transposon to move the DNA encoding the zalpha11 polypeptide into a baculovirus genome maintained in *E. coli* as a large plasmid called a "bacmid." See, Hill-Perkins, M.S. and Possee, R.D., J Gen Virol 71:971-6, 1990; Bonning, B.C. et al., J Gen Virol 75:1551-6, 1994; and, Chazenbalk, G.D., and Rapoport, B., J Biol Chem 270:1543-9, 1995. In addition, transfer vectors  
25 can include an in-frame fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed zalpha11 polypeptide, for example, a Glu-Glu epitope tag (Grussenmeyer, T. et al., Proc. Natl. Acad. Sci. 82:7952-4, 1985). Using a technique known in the art, a transfer vector containing zalpha11 is transformed into *E. Coli*, and  
30 screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid DNA containing the recombinant baculovirus genome is



isolated, using common techniques, and used to transfect *Spodoptera frugiperda* cells, e.g. Sf9 cells. Recombinant virus that expresses zalpha11 is subsequently produced. Recombinant viral stocks are made by methods commonly used in the art.

The recombinant virus is used to infect host cells, typically a cell line  
5 derived from the fall armyworm, *Spodoptera frugiperda*. See, in general, Glick and Pasternak, Molecular Biotechnology: Principles and Applications of Recombinant DNA, ASM Press, Washington, D.C., 1994. Another suitable cell line is the High FiveO™ cell line (Invitrogen) derived from *Trichoplusia ni* (U.S. Patent No. 5,300,435). Commercially available serum-free media are used to grow and maintain  
10 the cells. Suitable media are Sf900 II™ (Life Technologies) or ESF 921™ (Expression Systems) for the Sf9 cells; and Ex-cello405™ (JRH Biosciences, Lenexa, KS) or Express FiveO™ (Life Technologies) for the *T. ni* cells. Procedures used are generally described in available laboratory manuals (King, L. A. and Possee, R.D., *ibid.*; O'Reilly, D.R. et al., *ibid.*; Richardson, C. D., *ibid.*). Subsequent purification of the zalpha11  
15 polypeptide from the supernatant can be achieved using methods described herein.

Fungal cells, including yeast cells, can also be used within the present invention. Yeast species of particular interest in this regard include *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Pichia methanolica*. Methods for transforming *S. cerevisiae* cells with exogenous DNA and producing recombinant polypeptides  
20 therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient  
25 (e.g., leucine). A preferred vector system for use in *Saccharomyces cerevisiae* is the *POT1* vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S.  
30 Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and

4,661,454. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., J. Gen. Microbiol. 132:3459-3465, 1986 and Cregg, U.S. Patent No. 4,882,279. *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

The use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed in WIPO Publications WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming *P. methanolica* will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in *P. methanolica*, it is preferred that the promoter and terminator in the plasmid be that of a *P. methanolica* gene, such as a *P. methanolica* alcohol utilization gene (*AUG1* or *AUG2*). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A preferred selectable marker for use in *Pichia methanolica* is a *P. methanolica* *ADE2* gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows *ade2* host cells to grow in the absence of adenine. For large-scale, industrial processes where it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol utilization genes (*AUG1* and *AUG2*) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes (*PEP4* and *PRB1*) are preferred. Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into *P. methanolica* cells. It is preferred to transform *P. methanolica* cells by electroporation using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm,

preferably about 3.75 kV/cm, and a time constant (t) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.

Prokaryotic host cells, including strains of the bacteria *Escherichia coli*, *Bacillus* and other genera are also useful host cells within the present invention.

5 Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al., *ibid.*). When expressing a  $\alpha$ 1 polypeptide in bacteria such as *E. coli*, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the

10 granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the latter case, the polypeptide can be recovered from the periplasmic space in a soluble

15 and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other

20 components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously

25 added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell. *P. methanolica* cells are cultured in a medium comprising adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means,

30 such as shaking of small flasks or sparging of fermentors. A preferred culture medium for *P. methanolica* is YEPD (2% D-glucose, 2% Bacto™ Peptone (Difco Laboratories,

Detroit, MI), 1% Bacto™ yeast extract (Difco Laboratories), 0.004% adenine and 0.006% L-leucine).

Mammalian cells suitable for use in assaying antagonist activity of the novel soluble receptors of the present invention express a  $\alpha$ 11 receptor or receptor fusion capable of signaling and transducing a receptor-mediated signal of the  $\alpha$ 11 Ligand. Such cells include cells that express a  $\beta$ -subunit, such as gp130, IL-2R $\gamma$  and cells that co-express receptors (Gearing et al., EMBO J. 10:2839-2848, 1991; Gearing et al., U.S. Patent No. 5,284,755). In this regard it is generally preferred to employ a cell that is responsive to other cytokines that bind to receptors in the same subfamily, such as IL-6 or LIF, because such cells will contain the requisite signal transduction pathway(s). Preferred cells of this type include the human TF-1 cell line (ATCC number CRL-2003) and the DA-1 cell line (Branch et al., Blood 69:1782, 1987; Broudy et al., Blood 75:1622-1626, 1990). In the alternative, suitable host cells can be engineered to produce a  $\beta$ -subunit or other cellular component needed for the desired cellular response. For example, the murine cell line BaF3 (Palacios and Steinmetz, Cell 41:727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986) has been used to produce a cell line responsive to the  $\alpha$ 11 Ligand (see Examples). Other such lines include a baby hamster kidney (BHK) cell line, or the CTLL-2 cell line (ATCC TIB-214) can be transfected to express an IL-2R $\gamma$  subunit in addition to  $\alpha$ 11 receptor. It is generally preferred to use a host cell and receptor(s) from the same species, however this approach allows cell lines to be engineered to express multiple receptor subunits from any species, thereby overcoming potential limitations arising from species specificity. In the alternative, species homologs of the human receptor cDNA can be cloned and used within cell lines from the same species, such as a mouse cDNA in the BaF3 cell line. Cell lines that are dependent upon one hematopoietic growth factor, such as IL-3, can thus be engineered to become dependent upon a  $\alpha$ 11 ligand. Such cells can be used as described herein in the presence of  $\alpha$ 11 Ligand to assess the antagonist activity of soluble  $\alpha$ 11 receptor or soluble  $\alpha$ 11 heterodimeric polypeptide, such as soluble  $\alpha$ 11/IL-2R $\gamma$  on  $\alpha$ 11 Ligand signaling and proliferative activity.

Cells expressing functional soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  are used within screening assays. A variety of suitable assays are known in the art. These assays are based on the detection of a biological response in the target cell to the zalpha11 Ligand in the presence or absence of the soluble receptors of the present invention. One such assay is a cell proliferation assay. Cells are cultured in the presence or absence of zalpha11 Ligand with or without the addition other cytokines or proliferative agents, and cell proliferation is detected by, for example, measuring incorporation of tritiated thymidine or by colorimetric assay based on the metabolic breakdown of Alamar Blue<sup>TM</sup> (AccuMed, Chicago, IL) or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Mosman, *J. Immunol. Meth.* 65: 55-63, 1983). An alternative assay format uses cells that are further engineered to express a reporter gene. The reporter gene is linked to a promoter element that is responsive to the receptor-linked pathway, and the assay detects activation of transcription of the reporter gene. DNA response elements can include, but are not limited to, cyclic AMP response elements (CRE), hormone response elements (HRE) insulin response element (IRE) (Nasrin et al., *Proc. Natl. Acad. Sci. USA* 87:5273-7, 1990) and serum response elements (SRE) (Shaw et al. *Cell* 56: 563-72, 1989). Cyclic AMP response elements are reviewed in Roestler et al., *J. Biol. Chem.* 263 (19):9063-6; 1988 and Habener, *Molec. Endocrinol.* 4 (8):1087-94; 1990. Hormone response elements are reviewed in Beato, *Cell* 56:335-44; 1989. A preferred promoter element in this regard is a serum response element, or SRE (see, for example, Shaw et al., *Cell* 56:563-572, 1989). A preferred such reporter gene is a luciferase gene (de Wet et al., *Mol. Cell. Biol.* 7:725, 1987). Expression of the luciferase gene is detected by luminescence using methods known in the art (e.g., Baumgartner et al., *J. Biol. Chem.* 269:19094-29101, 1994; Schenborn and Goiffin, *Promega Notes* 41:11, 1993). Luciferase assay kits are commercially available from, for example, Promega Corp., Madison, WI. Target cell lines of this type can be used to screen libraries of chemicals, cell-conditioned culture media, fungal broths, soil samples, water samples, and the like for antagonist activity. Such cells can be used as described herein in the presence of zalpha11 Ligand in a competitive inhibition type assay to assess the antagonist activity of soluble zalpha11

receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  on zalpha11 Ligand signaling and proliferative activity.

T-and B-cell proliferation assay methods can also be used to assess the antagonist activity of soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  on zalpha11 Ligand signaling and proliferative activity in the presence of other cytokines, for example, IL-15, Flt3 and the like. Such assays are described in the examples herein, and are known in the art. Briefly, using flow cytometry, mature or immature subsets of T-cells or B-cells are isolated based on the presence or absence of various cell surface molecules (e.g., CD4, CD8, CD19, CD3, CD40, CD28, etc.). Cells can be selected prior to or after exposure to zalpha11 Ligand, depending on the cell type being studied, and the effect of zalpha11 Ligand thereon. The soluble receptors or antibodies of the present invention can be added at a range of concentrations to assess the antagonistic or binding activity on the Ligand in the T-cell or B-cell proliferation assay. Such assays are well known in the art, and described herein.

Moreover, a secretion trap method employing soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides can be used to isolate transfected cells that express zalpha11 Ligand. For the method, see, Aldrich, et al, Cell 87: 1161-1169, 1996. A cDNA expression library prepared from a known or suspected ligand source is transfected into COS-7 cells. The cDNA library vector generally has an SV40 origin for amplification in COS-7 cells, and a CMV promoter for high expression. The transfected COS-7 cells are grown in a monolayer and then fixed and permeabilized. Tagged or biotin-labeled soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, described herein, is then placed in contact with the cell layer and allowed to bind cells in the monolayer that express an anti-complementary molecule, i.e., a zalpha11 Ligand. A cell expressing a ligand will thus be bound with receptor molecules. An anti-tag antibody (anti-Ig for Ig fusions, M2 or anti-FLAG for FLAG-tagged fusions, streptavidin, and the like) which is conjugated with horseradish peroxidase (HRP) is used to visualize these cells to which the tagged or biotin-labeled soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides has bound. The HRP catalyzes deposition of a tyramide reagent, for

example, tyramide-FITC. A commercially-available kit can be used for this detection (for example, Renaissance TSA-Direct™ Kit; NEN Life Science Products, Boston, MA). Cells which express zalpha11 receptor Ligand will be identified under fluorescence microscopy as green cells and picked for subsequent cloning of the ligand using procedures for plasmid rescue as outlined in Aldrich, et al, supra, followed by subsequent rounds of secretion trap assay until single clones are identified.

Moreover, histologic and immunohistochemical methods employing soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides can be used to identify cells and tissues cells that express zalpha11 Ligand. Such methods are known in the art and described herein.

Additional assays to detect the antagonist or binding activity of soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides provided by the present invention include the use of hybrid receptor polypeptides. These hybrid polypeptides fall into two general classes. Within the first class, the intracellular domain of zalpha11, comprising approximately residues 256 (Lys) to 528 (Ser) of SEQ ID NO:2, is joined to the ligand-binding domain of a second receptor. It is preferred that the second receptor be a hematopoietic cytokine receptor, such as mpl receptor (Souyri et al., Cell 63:1137-1147, 1990). The hybrid receptor will further comprise a transmembrane domain, which may be derived from either receptor. A DNA construct encoding the hybrid receptor is then inserted into a host cell. Cells expressing the hybrid receptor are cultured in the presence of a ligand for the binding domain and assayed for a response. This system provides a means for analyzing signal transduction mediated by zalpha11 while using readily available ligands. This system can also be used to determine if particular cell lines are capable of responding to signals transduced by zalpha11. A second class of hybrid receptor polypeptides comprise the extracellular (ligand-binding) domain of zalpha11 (approximately residues 20 (Cys) to 237 (His) of SEQ ID NO:2) (SEQ ID NO:6) with a cytoplasmic domain of a second receptor, preferably a cytokine receptor, and a transmembrane domain. The transmembrane domain may be derived from either receptor. Such hybrid receptors are expressed in cells known to be capable of responding to signals transduced by the receptor comprising the extracellular domain, such as in the presence of the zalpha11 Ligand.

Addition of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, in the presence of the zalpha11 Ligand, is used to assess the zalpha11 Ligand antagonist or binding activity of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides to the zalpha11 Ligand.

5           The tissue specificity and biological activities of zalpha11 Ligand expression suggest a role in early NK cell and thymocyte development, mature B-cell expansion, general immune response stimulation, and immune response regulation. These processes involve stimulation of cell proliferation and differentiation in response to the binding of the zalpha11 Ligand to its cognate receptor, comprising at least one  
10       zalpha11 receptor subunit. In view of the biological activity observed for this Ligand, antagonists have enormous potential in both *in vitro* and *in vivo* applications. As antagonists of the zalpha11 Ligand, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides can find utility in the suppression of the immune system, such as in the treatment of autoimmune diseases, including rheumatoid arthritis,  
15       multiple sclerosis, diabetes mellitus, inflammatory bowel disease, Crohn's disease, and the like. Immune suppression can also be used to reduce rejection of tissue or organ transplants and grafts and to treat B-cell malignancies, T-cell specific leukemias or lymphomas by inhibiting proliferation of the affected cell type.

          Soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor  
20       polypeptides may also be used within diagnostic systems for the detection of circulating levels of zalpha11 Ligand. Within a related embodiment, antibodies or other agents that specifically bind to soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides can be used to detect circulating receptor polypeptides. Elevated or depressed levels of Ligand or receptor polypeptides may be indicative of pathological  
25       conditions, including cancer. Soluble receptor polypeptides may contribute to pathologic processes and can be an indirect marker of an underlying disease. For example, elevated levels of soluble IL-2 receptor in human serum have been associated with a wide variety of inflammatory and neoplastic conditions, such as myocardial infarction, asthma, myasthenia gravis, rheumatoid arthritis, acute T-cell leukemia, B-  
30       cell lymphomas, chronic lymphocytic leukemia, colon cancer, breast cancer, and ovarian cancer (Heaney et al., Blood 87:847-857, 1996).



A ligand-binding polypeptide of a  $\alpha$ 11 receptor, such as soluble  $\alpha$ 11 receptor or soluble  $\alpha$ 11 heterodimeric polypeptide, such as soluble  $\alpha$ 11/IL-2R $\gamma$  can be prepared by expressing a truncated DNA encoding the  $\alpha$ 11 cytokine binding domain (approximately residue 20 (Cys) through residue 237 (His) of the human receptor (SEQ ID NO:2) (SEQ ID NO:6)) or the corresponding region of a non-human receptor (e.g., SEQ ID NO:12). A soluble  $\alpha$ 11 heterodimeric polypeptide, such as soluble  $\alpha$ 11/IL-2R $\gamma$  can be prepared by co-expressing a truncated DNA encoding the  $\alpha$ 11 cytokine binding domain (SEQ ID NO:6) and the truncated DNA encoding the extracellular domain of another class I cytokine receptor, such as IL-2R $\gamma$  (SEQ ID NO:4). It is preferred that the extracellular domains of the soluble  $\alpha$ 11 homodimer or heterodimer be prepared in a form substantially free of transmembrane and intracellular polypeptide segments. Moreover, ligand-binding polypeptide fragments within the soluble  $\alpha$ 11 receptor or soluble  $\alpha$ 11 heterodimeric polypeptide (e.g., soluble  $\alpha$ 11/IL-2R $\gamma$ ), or cytokine-binding domain, described above, can also serve as  $\alpha$ 11 soluble receptors for uses described herein. To direct the export of a receptor polypeptide from the host cell, the receptor DNA is linked to a second DNA segment encoding a secretory peptide, such as a t-PA secretory peptide, secretory peptide from another cytokine receptor, other secreted molecule, or a  $\alpha$ 11 receptor secretory peptide. To facilitate purification of the secreted receptor polypeptide, a C-terminal extension, such as a poly-histidine tag, substance P, Flag<sup>TM</sup> peptide (Hopp et al., Bio/Technology 6:1204-1210, 1988; available from Eastman Kodak Co., New Haven, CT), Glu-glu tag (SEQ ID NO:14) or another polypeptide or protein for which an antibody or other specific binding agent is available, can be fused to the soluble receptor polypeptide.

In an alternative approach, a receptor extracellular domain can be expressed as a fusion with immunoglobulin heavy chain constant regions, typically an F<sub>C</sub> fragment, which contains two constant region domains and lacks the variable region. Such fusions are typically secreted as multimeric molecules wherein the Fc portions are disulfide bonded to each other and two receptor polypeptides are arrayed in close proximity to each other. Fusions of this type can be used to affinity purify the cognate ligand from solution, as an *in vitro* assay tool, to block signals *in vitro* by specifically

titrating out Ligand, and as antagonists *in vivo* by administering them parenterally to bind circulating ligand and clear it from the circulation. To purify ligand, a zalpha11-Ig chimera (e.g., Zalpha11-Fc4 described herein), is added to a sample containing the ligand (e.g., cell-conditioned culture media or tissue extracts) under conditions that  
5 facilitate receptor-ligand binding (typically near-physiological temperature, pH, and ionic strength). The chimera-ligand complex is then separated by the mixture using protein A, immobilized on a solid support (e.g., insoluble resin beads). The ligand is then eluted using conventional chemical techniques, such as with a salt or pH gradient. In the alternative, the chimera itself can be bound to a solid support, with binding and  
10 elution carried out as above. Collected fractions can be re-fractionated until the desired level of purity is reached.

Moreover, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$ , can be used as a "ligand sink," i.e., antagonist, to bind ligand *in vivo* or *in vitro* in therapeutic or other applications  
15 where the presence of the ligand is not desired. For example, in cancers that are expressing large amounts of bioactive zalpha11 Ligand, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  can be used as a direct antagonist of the ligand *in vivo*, and may aid in reducing progression and symptoms associated with the disease, and can be used in conjunction  
20 with other therapies (e.g., chemotherapy) to enhance the effect of the therapy in reducing progression and symptoms, and preventing relapse. Moreover, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  can be used to slow the progression of cancers that over-express zalpha11 receptors, by binding ligand *in vivo* that would otherwise enhance  
25 proliferation of those cancers.

Moreover, soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  can be used *in vivo* or in diagnostic applications to detect zalpha11 Ligand-expressing cancers *in vivo* or in tissue samples. For example, the soluble zalpha11 receptor or soluble zalpha11 heterodimeric  
30 receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  can be conjugated to a radio-label or fluorescent label as described herein, and used to detect the presence of the

zalpha11 Ligand in a tissue sample using an *in vitro* ligand-receptor type binding assay, or fluorescent imaging assay. Moreover, a radiolabeled soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  could be administered *in vivo* to detect Ligand-expressing solid tumors through a radio-imaging method known in the art.

It is preferred to purify the polypeptides of the present invention to  $\geq 80\%$  purity, more preferably to  $\geq 90\%$  purity, even more preferably  $\geq 95\%$  purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.

Expressed recombinant soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  (or zalpha11 chimeric or fusion polypeptides) can be purified using fractionation and/or conventional purification methods and media. Ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties. Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino

derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Methods for binding receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine design and is determined in part  
5 by the properties of the chosen support. See, for example, Affinity Chromatography: Principles & Methods, Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988.

The polypeptides of the present invention can be isolated by exploitation of their biochemical, structural, and biological properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich  
10 proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate (Sulkowski, Trends in Biochem. 3:1-7, 1985). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include  
15 purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography (Methods in Enzymol., Vol. 182, "Guide to Protein Purification", M. Deutscher, (ed.), Acad. Press, San Diego, 1990, pp.529-39). Within additional embodiments of the invention, a fusion of the polypeptide of interest and an affinity tag (e.g., maltose-binding protein, an immunoglobulin domain) may be  
20 constructed to facilitate purification. Moreover zalpha11 Ligand affinity columns can be used to purify soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$ . Such affinity chromatography methods are well known in the art.

Moreover, using methods described in the art, polypeptide fusions, or  
25 hybrid zalpha11 proteins, are constructed using regions or domains of the inventive zalpha11 in combination with those of other human cytokine receptor family proteins, or heterologous proteins (Sambrook et al., ibid., Altschul et al., ibid., Picard, Cur. Opin. Biology, 5:511-5, 1994, and references therein). These methods allow the determination of the biological importance of larger domains or regions in a  
30 polypeptide of interest. Such hybrids may alter reaction kinetics, binding, constrict or

expand the substrate specificity, or alter tissue and cellular localization of a polypeptide, and can be applied to polypeptides of unknown structure.

Soluble receptor fusion polypeptides or proteins can be prepared by methods known to those skilled in the art by preparing each component of the fusion protein and chemically conjugating them. Alternatively, a polynucleotide encoding one or more components of the fusion protein in the proper reading frame can be generated using known techniques and expressed by the methods described herein. For example, part or all of a domain(s) conferring a biological function may be swapped between zalpha11 of the present invention with the functionally equivalent domain(s) from another cytokine family member. Such domains include, but are not limited to, the extracellular cytokine binding domain, ligand binding domain and residues, transmembrane domain, , as disclosed herein. Such fusion proteins would be expected to have a biological functional profile that is the same or similar to polypeptides of the present invention or other known family proteins, depending on the fusion constructed. Moreover, such fusion proteins may exhibit other properties as disclosed herein.

Standard molecular biological and cloning techniques can be used to swap the equivalent domains between the zalpha11 polypeptide and those polypeptides to which they are fused. Generally, a DNA segment that encodes a domain of interest, e.g., a zalpha11 domain described herein, is operably linked in frame to at least one other DNA segment encoding an additional polypeptide (for instance a domain or region from another cytokine receptor, such as the IL-2R $\gamma$  receptor), and inserted into an appropriate expression vector, as described herein. Generally DNA constructs are made such that the several DNA segments that encode the corresponding regions of a polypeptide are operably linked in frame to make a single construct that encodes the entire fusion protein, or a functional portion thereof. For example, a DNA construct would encode from N-terminus to C-terminus a fusion protein comprising a signal polypeptide followed by a cytokine-binding domain. Such fusion proteins can be expressed, isolated, and assayed for activity as described herein.

Soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  polypeptides, or fragments thereof may also be prepared through chemical synthesis. Such polypeptides may be monomers or

multimers; glycosylated or non-glycosylated; pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue.

Polypeptides of the present invention can also be synthesized by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. Methods for synthesizing polypeptides are well known in the art. See, for example, Merrifield, J. Am. Chem. Soc. 85:2149, 1963; and Kaiser et al., Anal. Biochem. 34:595, 1970. After the entire synthesis of the desired peptide on a solid support, the peptide-resin is with a reagent that cleaves the polypeptide from the resin and removes most of the side-chain protecting groups. Such methods are well established in the art.

The activity of molecules of the present invention can be measured using a variety of assays that measure cell differentiation and proliferation. Such assays are well known in the art and described herein.

Proteins of the present invention are useful for example, in treating lymphoid, immune, hematopoietic, inflammatory disorders and the like, and can be measured *in vitro* using cultured cells or *in vivo* by administering molecules of the claimed invention to the appropriate animal model. For instance, host cells expressing a soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  can be embedded in an alginate environment and injected (implanted) into recipient animals. Alginate-poly-L-lysine microencapsulation, permselective membrane encapsulation and diffusion chambers are a means to entrap transfected mammalian cells or primary mammalian cells. These types of non-immunogenic "encapsulations" permit the diffusion of proteins and other macromolecules secreted or released by the captured cells to the recipient animal. Most importantly, the capsules mask and shield the foreign, embedded cells from the recipient animal's immune response. Such encapsulations can extend the life of the injected cells from a few hours or days (naked cells) to several weeks (embedded cells). Alginate threads provide a simple and quick means for generating embedded cells.

The materials needed to generate the alginate threads are known in the art. In an exemplary procedure, 3% alginate is prepared in sterile H<sub>2</sub>O, and sterile filtered. Just prior to preparation of alginate threads, the alginate solution is again

filtered. An approximately 50% cell suspension (containing about  $5 \times 10^5$  to about  $5 \times 10^7$  cells/ml) is mixed with the 3% alginate solution. One ml of the alginate/cell suspension is extruded into a 100 mM sterile filtered  $\text{CaCl}_2$  solution over a time period of ~15 min, forming a "thread". The extruded thread is then transferred into a solution of 50 mM  $\text{CaCl}_2$ , and then into a solution of 25 mM  $\text{CaCl}_2$ . The thread is then rinsed with deionized water before coating the thread by incubating in a 0.01% solution of poly-L-lysine. Finally, the thread is rinsed with Lactated Ringer's Solution and drawn from solution into a syringe barrel (without needle). A large bore needle is then attached to the syringe, and the thread is intraperitoneally injected into a recipient in a minimal volume of the Lactated Ringer's Solution.

Adenoviral and other viral systems, such as vaccinia virus can be used to express and produce the proteins of the present invention. For example, using adenovirus vectors where portions of the adenovirus genome are deleted, inserts are incorporated into the viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid. In an exemplary system, the essential E1 gene has been deleted from the viral vector, and the virus will not replicate unless the E1 gene is provided by the host cell (the human 293 cell line is exemplary). If the adenoviral delivery system has an E1 gene deletion, the virus cannot replicate in human cells, but will express and process (and, if a secretory signal sequence is present, secrete) the heterologous protein. Moreover, by deleting the entire adenovirus genome, very large inserts of heterologous DNA can be accommodated. Generation of so called "gutless" adenoviruses where all viral genes are deleted are particularly advantageous for insertion of large inserts of heterologous DNA. For review, see Yeh, P. and Perricaudet, M., FASEB J. 11:615-623, 1997.

The adenovirus system can be used for protein production *in vitro*. By culturing adenovirus-infected non-293 cells under conditions where the cells are not rapidly dividing, the cells can produce proteins for extended periods of time. For instance, BHK cells are grown to confluence in cell factories, are exposed to the adenoviral vector encoding the secreted protein of interest. The cells are then grown under serum-free conditions, which allows infected cells to survive for several weeks without significant cell division. Alternatively, adenovirus vector infected 293 cells can

be grown as adherent cells or in suspension culture at relatively high cell density to produce significant amounts of protein (See Garnier et al., Cytotechnol. 15:145-55, 1994). With either protocol, an expressed, secreted heterologous protein can be repeatedly isolated from the cell culture supernatant, lysate, or membrane fractions depending on the disposition of the expressed protein in the cell. Within the infected 293 cell production protocol, non-secreted proteins may also be effectively obtained.

Soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  receptor antagonists can be used in vitro in an assay to measure a decrease in stimulation of colony formation by zalpha11 Ligand from isolated primary bone marrow cultures. Such assays are disclosed herein and are well known in the art.

Zalpha11 Ligand antagonists and binding agents are also useful as research reagents for characterizing sites of ligand-receptor interaction. Inhibitors of zalpha11 Ligand activity (zalpha11 Ligand antagonists) include anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric receptor polypeptide antibodies, such as anti-soluble zalpha11/IL-2R $\gamma$  antibodies and soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  receptors, as well as other peptidic and non-peptidic agents (including ribozymes).

A soluble zalpha11 receptor or soluble zalpha11 heterodimeric receptor polypeptides, such as soluble zalpha11/IL-2R $\gamma$  ligand-binding polypeptide of the present invention, can also be used for purification of zalpha11 Ligand. The polypeptide is immobilized on a solid support, such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use. Methods for linking polypeptides to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and hydrazide activation. The resulting medium will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor polypeptide. The ligand is then eluted using changes in salt concentration, chaotropic agents (guanidine HCl), or pH to disrupt ligand-receptor binding.



An assay system that uses a ligand-binding receptor (or an antibody, one member of a complement/ anti-complement pair) or a binding fragment thereof, and a commercially available biosensor instrument may be advantageously employed (e.g., BIAcore™, Pharmacia Biosensor, Piscataway, NJ; or SELDI™ technology, CIPHERGEN, Inc., Palo Alto, CA). Such receptor, antibody, member of a complement/anti-complement pair or fragment is immobilized onto the surface of a receptor chip. Use of this instrument is disclosed by Karlsson, *J. Immunol. Methods* 145:229-240, 1991 and Cunningham and Wells, *J. Mol. Biol.* 234:554-63, 1993. A receptor, antibody, member or fragment is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within the flow cell. A test sample is passed through the cell. If a ligand, epitope, or opposite member of the complement/anti-complement pair is present in the sample, it will bind to the immobilized receptor, antibody or member, respectively, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film. This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding.

Ligand-binding receptor polypeptides, such as those of the present invention, can also be used within other assay systems known in the art. Such systems include Scatchard analysis for determination of binding affinity (see Scatchard, *Ann. NY Acad. Sci.* 51: 660-672, 1949) and calorimetric assays (Cunningham et al., *Science* 253:545-48, 1991; Cunningham et al., *Science* 245:821-25, 1991).

Soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides can also be used to prepare antibodies that bind to epitopes, peptides, or polypeptides contained within the antigen. The zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides or a fragment thereof serves as an antigen (immunogen) to inoculate an animal and elicit an immune response. One of skill in the art would recognize that antigenic, epitope-bearing polypeptides contain a sequence of at least 6, preferably at least 9, and more preferably at least 15 to about 30 contiguous amino acid residues of a zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides (e.g., SEQ ID NO:2, SEQ ID NO:6, SEQ ID

NO:4). Polypeptides comprising a larger portion of a zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides i.e., from 30 to 100 residues up to the entire length of the amino acid sequence are included. Antigens or immunogenic epitopes can also include attached tags, adjuvants and carriers, as described herein. Suitable antigens include the zalpha11 polypeptide encoded by SEQ ID NO:2 from amino acid number 20 (Cys) to amino acid number 237 (His) (SEQ ID NO:6), or a contiguous 9 to 218 AA amino acid fragment thereof. Preferred peptides to use as antigens are the cytokine binding domain, disclosed herein, and zalpha11 hydrophilic peptides such as those predicted by one of skill in the art from a hydrophobicity plot, determined for example, from a Hopp/Woods hydrophilicity profile based on a sliding six-residue window, with buried G, S, and T residues and exposed H, Y, and W residues ignored. For example, zalpha11 hydrophilic peptides include peptides comprising amino acid sequences selected from the group consisting of: (1) amino acid number 51 (Trp) to amino acid number 61 (Glu) of SEQ ID NO:2; (2) amino acid number 136 (Ile) to amino acid number 143 (Glu) of SEQ ID NO:2; (3) amino acid number 187 (Pro) to amino acid number 195 (Ser) of SEQ ID NO:2; and (4) amino acid number 223 (Phe) to amino acid number 232 (Glu) of SEQ ID NO:2. The corresponding hydrophilic regions in reference to SEQ ID NO:6 can be made with cross-reference to the above amino acid residues of SEQ ID NO:2. Moreover, antigenic epitope-bearing polypeptides as predicted by a Jameson-Wolf plot, e.g., using DNASTAR Protean program (DNASTAR, Inc., Madison, WI) are suitable antigens. In addition, conserved motifs, and variable regions between conserved motifs of zalpha11 soluble receptor are suitable antigens. Suitable antigens also include the zalpha11 polypeptides disclosed above in combination with another class I cytokine extracellular domain, such as those that form soluble zalpha11 heterodimeric polypeptides, such as soluble zalpha11/IL-2R $\gamma$ . Moreover, corresponding regions of the mouse soluble zalpha11 receptor polypeptide (residues 20 (Cys) to 237 (His) SEQ ID NO:12) can be used to generate antibodies against the soluble mouse zalpha11 receptor. In addition Antibodies generated from this immune response can be isolated and purified as described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in

Immunology, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995; Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R., Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press, Inc., Boca Raton, FL, 1982.

As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptide or a fragment thereof. The immunogenicity of a zalpha11 polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of zalpha11 or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab')<sub>2</sub> and Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced.

Antibodies are considered to be specifically binding if: 1) they exhibit a threshold level of binding activity, and 2) they do not significantly cross-react with related polypeptide molecules. A threshold level of binding is determined if anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R $\gamma$  antibodies herein bind to a soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptide, peptide or epitope with an affinity at least 10-fold greater than the binding affinity to control (non-soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  ) polypeptide. It is preferred that the antibodies exhibit a binding affinity ( $K_a$ ) of  $10^6 M^{-1}$  or greater, preferably  $10^7 M^{-1}$  or greater, more preferably  $10^8 M^{-1}$  or greater, and most preferably  $10^9 M^{-1}$  or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 51: 660-672, 1949).

Whether anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R $\gamma$  antibodies do not significantly cross-react with related polypeptide molecules is shown, for example, by the antibody detecting soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptide but not known related polypeptides using a standard Western blot analysis (Ausubel et al., ibid.). Examples of known related polypeptides are those disclosed in the prior art, such as known orthologs, and paralogs, and similar known members of a protein family. Screening can also be done using non-human soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$ , and soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  mutant polypeptides. Moreover, antibodies can be "screened against" known related polypeptides, to isolate a population that specifically binds to the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides. For example, antibodies raised to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  are adsorbed to related polypeptides adhered to insoluble matrix; antibodies

specific to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  will flow through the matrix under the proper buffer conditions. Screening allows isolation of polyclonal and monoclonal antibodies non-crossreactive to known closely related polypeptides (Antibodies: A Laboratory Manual, 5 Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; Current Protocols in Immunology, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995). Screening and isolation of specific antibodies is well known in the art. See, Fundamental Immunology, Paul (eds.), Raven Press, 1993; Getzoff et al., Adv. in Immunol. 43: 1-98, 1988; Monoclonal Antibodies: Principles and Practice, 10 Goding, J.W. (eds.), Academic Press Ltd., 1996; Benjamin et al., Ann. Rev. Immunol. 2: 67-101, 1984. Specifically binding anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R $\gamma$  antibodies can be detected by a number of methods in the art, and disclosed below.

A variety of assays known to those skilled in the art can be utilized to 15 detect antibodies that bind to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  proteins or polypeptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, 20 radioimmuno-precipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  protein or polypeptide.

25 Alternative techniques for generating or selecting antibodies useful herein include *in vitro* exposure of lymphocytes to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled soluble zalpha11 receptor or soluble 30 zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  protein or peptide). Genes encoding polypeptides having potential binding domains for soluble

zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptide, can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as

5 through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art

10 (Ladner et al., US Patent NO. 5,223,409; Ladner et al., US Patent NO. 4,946,778; Ladner et al., US Patent NO. 5,403,484 and Ladner et al., US Patent NO. 5,571,698) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA) and Pharmacia LKB Biotechnology

15 Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  sequences disclosed herein to identify proteins which bind to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$ . These "binding polypeptides" which interact with soluble

20 zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and the like. These binding polypeptides can also be used in analytical methods such as for screening expression libraries and neutralizing

25 activity, e.g., for blocking interaction between ligand and receptor, or viral binding to a receptor. The binding polypeptides can also be used for diagnostic assays for determining circulating levels of soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides; for detecting or quantitating soluble zalpha11 receptor or soluble zalpha11 heterodimeric

30 polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides as marker of underlying pathology or disease. These binding polypeptides can also act as zalpha11 receptor or

zalphal1 heterodimeric polypeptide, such as zalphal1/IL-2R $\gamma$  "antagonists" to block zalphal1 receptor or zalphal1 heterodimeric polypeptide, such as zalphal1/IL-2R $\gamma$  binding and signal transduction *in vitro* and *in vivo*. Again, these anti-soluble zalphal1 receptor or anti-soluble zalphal1 heterodimeric polypeptide, such as anti-soluble zalphal1/IL-2R $\gamma$  binding polypeptides would be useful for inhibiting zalphal1 Ligand activity, as well as receptor activity or protein-binding. Antibodies raised to the heterodimer or multimeric combinations of the present invention are preferred embodiments, as they may act more specifically against the zalphal1 Ligand, or more potently than antibodies raised to only one subunit. Moreover, the antagonistic and binding activity of the antibodies of the present invention can be assayed in the zalphal1 Ligand proliferation and other biological assays described herein.

Antibodies to soluble zalphal1 receptor or soluble zalphal1 heterodimeric polypeptide, such as soluble zalphal1/IL-2R $\gamma$  may be used for tagging cells that express zalphal1 receptor or zalphal1 heterodimeric polypeptides, such as zalphal1/IL-2R $\gamma$ ; for isolating soluble zalphal1 receptor or soluble zalphal1 heterodimeric polypeptide, such as soluble zalphal1/IL-2R $\gamma$  polypeptide by affinity purification; for diagnostic assays for determining circulating levels of soluble zalphal1 receptor or soluble zalphal1 heterodimeric polypeptide, such as soluble zalphal1/IL-2R $\gamma$  polypeptides; for detecting or quantitating soluble zalphal1 receptor or soluble zalphal1 heterodimeric polypeptide, such as soluble zalphal1/IL-2R $\gamma$  as marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block zalphal1 receptor or zalphal1 heterodimeric polypeptide, such as zalphal1/IL-2R $\gamma$ , or zalphal1 Ligand activity *in vitro* and *in vivo*. Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. Moreover, antibodies to soluble zalphal1 receptor or soluble zalphal1 heterodimeric polypeptide, such as soluble zalphal1/IL-

2R $\gamma$  or fragments thereof may be used *in vitro* to detect denatured or non-denatured soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  or fragments thereof in assays, for example, Western Blots or other assays known in the art.

5           Antibodies to soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  are useful for tagging cells that express the corresponding receptors and assaying their expression levels, for affinity purification, within diagnostic assays for determining circulating levels of soluble receptor polypeptides, analytical methods employing fluorescence-activated cell  
10 sorting. Moreover, divalent antibodies, and anti-idiotypic antibodies may be used as agonists to mimic the effect of the zalpha11 Ligand.

          Antibodies herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. For instance, antibodies or binding polypeptides which  
15 recognize soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  polypeptides of the present invention can be used to identify or treat tissues or organs that express a corresponding anti-complementary molecule (i.e., a zalpha11 receptor, or zalpha11 heterodimeric receptor, such as zalpha11/IL-2R $\gamma$ ). More specifically, anti- soluble zalpha11 receptor or anti-soluble  
20 zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R $\gamma$  antibodies; or bioactive fragments or portions thereof, can be coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the zalpha11 receptor or a zalpha11 heterodimeric receptor, such as zalpha11/IL-2R $\gamma$  receptor molecules.

25           Suitable detectable molecules may be directly or indirectly attached to polypeptides that bind soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  ("binding polypeptides," including binding peptides disclosed above), antibodies, or bioactive fragments or portions thereof. Suitable detectable molecules include radionuclides, enzymes, substrates,  
30 cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly



attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, *Pseudomonas* exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Binding polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the binding polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/ anticomplementary pair.

In another embodiment, binding polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Alternatively, if the binding polypeptide has multiple functional domains (i.e., an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the fusion protein including only a single domain includes a complementary molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/ cytotoxic molecule conjugates.

In another embodiment, soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  binding polypeptide-cytokine or antibody-cytokine fusion proteins can be used for enhancing *in vivo* killing of target tissues (for example, blood, lymphoid, colon, and bone marrow cancers), if the binding polypeptide-cytokine or anti-soluble zalpha11 receptor or anti-soluble zalpha11 heterodimeric polypeptide, such as anti-soluble zalpha11/IL-2R $\gamma$  antibody targets the hyperproliferative cell (See, generally, Hornick et al., Blood 89:4437-47, 1997). The described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable anti-zalpha11

homodimer and heterodimer antibodies target an undesirable cell or tissue (i.e., a tumor or a leukemia), and the fused cytokine mediates improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), for instance.

5                   Alternatively, soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  binding polypeptide or antibody fusion proteins described herein can be used for enhancing *in vivo* killing of target tissues by directly stimulating a zalpha11 receptor-modulated apoptotic pathway, resulting in cell death of hyperproliferative cells expressing zalpha11 receptor or a  
10                   zalpha11 heterodimeric receptor, such as soluble zalpha11/IL-2R $\gamma$  receptor.

                  Four-helix bundle cytokines that bind to cytokine receptors as well as other proteins produced by activated lymphocytes play an important biological role in cell differentiation, activation, recruitment and homeostasis of cells throughout the body. Therapeutic utility includes treatment of diseases that require immune regulation  
15                   including autoimmune diseases, such as, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosis and diabetes. Zalpha11 Ligand antagonists, including soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$ , may be important in the regulation of inflammation, and therefore would be useful in treating rheumatoid arthritis, asthma,  
20                   ulcerative colitis, inflammatory bowel disease, Crohn's disease, and sepsis. There may be a role of zalpha11 Ligand antagonists, including soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$ , in mediating tumorigenesis, and therefore would be useful in the treatment of cancer. Zalpha11 Ligand antagonists, including soluble zalpha11 receptor or soluble zalpha11  
25                   heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$ , may be a potential therapeutic in suppressing the immune system that would be important for reducing graft rejection. Soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  may have usefulness in prevention of graft vs. host disease.

30                   Alternatively, zalpha11 Ligand antagonists, including soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-

2R $\gamma$  receptors in conjunction with other cytokines may enable selective activation, enhancement, or selective suppression, of the immune system in conjunction with zalphal1 Ligand on other cytokines which would be important in boosting immunity to infectious diseases, treating immunocompromised patients, such as HIV+ patient, or in improving vaccines. In particular, zalphal1 antagonists, including soluble zalphal1 receptor or soluble zalphal1 heterodimeric polypeptide, such as soluble zalphal1/IL-2R $\gamma$ , could prevent the expansion of a subset of the immune system involving zalphal1 Ligand (e.g., NK cells and mature B-cells), while enabling expansion of progenitors induced by other cytokines (e.g., T-cells), and would provide therapeutic value in treatment of viral infection and other infection. For example, with Dengue virus infection, which causes dengue hemorrhagic fever/Dengue Shock syndrome (DHF/DSS) it is believed that severe DHF/DSS occurs as a result of "immune enhancement" i.e., enhanced replication of the virus in the presence of pre-existing antibodies against another serotype. In the second infection by a different Dengue virus serotype, the immune system raises antibodies against the first virus that cross-react but do not neutralize the virus, and that potentially aid its entry into macrophages. Thus, suppression of the antibody immune response, or B cell response, during a second or third Dengue infection may help the immune system react appropriately in the second infection to neutralize the virus by suppressing the "enhancing" antibodies from the first serotype infection, and consequently avoiding severe DHF/DSS. For review, see White, D.O. and Fenner F.J. (Eds.) Medical Virology, 3<sup>rd</sup> ed., Academic Press, Orlando Fl, 1986, pages 479-508). Similarly, suppression of maternal antibody responses against fetal antigens by soluble receptors of the present invention can aid in preventing birth defects and spontaneous abortion. Moreover, in such applications the soluble receptors of the present invention can be used in conjunction with other cytokines to suppress some immune system activities (e.g., B-cell proliferation, using the soluble receptors) but allowing others to increase, e.g., in the presence of other cytokines described herein and known in the art.

The bioactive binding polypeptide or antibody conjugates described herein can be delivered orally, intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action. For pharmaceutical use, the soluble

zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  receptor polypeptides of the present invention are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods. Intravenous administration will be by bolus injection or infusion over a  
5 typical period of one to several hours. In general, pharmaceutical formulations will include a zalpha11 soluble receptor polypeptide in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like. Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of  
10 formulation are well known in the art and are disclosed, for example, in Remington: The Science and Practice of Pharmacy, Gennaro, ed., Mack Publishing Co., Easton, PA, 19th ed., 1995. Therapeutic doses will generally be in the range of 0.1 to 100  $\mu$ g/kg of patient weight per day, preferably 0.5-20 mg/kg per day, with the exact dose determined by the clinician according to accepted standards, taking into account the nature and  
15 severity of the condition to be treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years. In general, a therapeutically effective amount of zalpha11 soluble receptor polypeptide is an amount sufficient to  
20 produce a clinically significant effect.

The invention is further illustrated by the following non-limiting examples.

## 25 EXAMPLES

### Example 1

#### Construction of Expression Vector Expressing Full-length zalpha11

The entire zalpha11 receptor was isolated from a plasmid containing zalpha11 receptor cDNA (SEQ ID NO:1) using PCR with primers ZC19,905 (SEQ ID  
30 NO:19) and ZC19,906 (SEQ ID NO:20). The reaction conditions were as follows: 95°C for 1 min; 35 cycles at 95°C for 1 min, 55°C for 1 min, 72°C for 2 min; followed

by 72°C at 10 min; then a 10°C soak. The PCR product was run on a 1% low melting point agarose (Boehringer Mannheim) gel and the approximately 1.5 kb zalpha11 cDNA isolated using Qiaquick™ gel extraction kit (Qiagen) as per manufacturer's instructions.

5           The purified zalpha11 cDNA was digested with BamHI (Boehringer Mannheim) and EcoRI (BRL) as per manufacturer's instructions. The entire digest was run on a 1% low melting point agarose (Boehringer Mannheim) gel and the cleaved zalpha11 fragment was purified the using Qiaquick™ gel extraction kit as per manufacturer's instructions. The resultant cleaved zalpha11 fragment was inserted into  
10 an expression vector as described below.

          Recipient expression vector pZP-5N was digested with BamHI (Boehringer Mannheim) and EcoRI (BRL) as per manufacturer's instructions, and gel purified as described above. This vector fragment was combined with the BamHI and EcoRI cleaved zalpha11 fragment isolated above in a ligation reaction using T4 Ligase  
15 (BRL). The ligation was incubated at 15°C overnight. A sample of the ligation was electroporated in to DH10B electroMAX™ electrocompetent *E. coli* cells (25µF, 200Ω, 2.3V). Transformants were plated on LB+Ampicillin plates and single colonies screened by PCR to check for the zalpha11 sequence using ZC19,905 (SEQ ID NO:19) and ZC19,906 (SEQ ID NO:20) using the PCR conditions as described above.  
20 Confirmation of the zalpha11 sequence was made by sequence analysis. The insert was approximately 1.6 kb, and was full-length.

### Example 2

#### Zalpha11 Based Proliferation in BAF3 Assay Using Alamar Blue

25           BaF3 cells expressing the full-length zalpha11 receptor were constructed, using the zalpha11 expression vector, described in Example 1. The BaF3 cells expressing the zalpha11 receptor mRNA were designated BaF3/zalpha11. These cells provide an assay system for detecting zalpha11 Ligand activity as described in numerous Examples below. Conversely, these cells provide also an assay system for  
30 detecting zalpha11 Ligand antagonist or inhibitory activity by the soluble receptors and antibodies of the present invention.

#### A. Construction of BaF3 Cells Expressing human $\alpha$ 11 receptor

BaF3, an interleukin-3 (IL-3) dependent pre-lymphoid cell line derived from murine bone marrow (Palacios and Steinmetz, Cell 41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986), was maintained in complete media (RPMI medium (JRH Bioscience Inc., Lenexa, KS) supplemented with 10% heat-inactivated fetal calf serum, 2ng/ml murine IL-3 (mIL-3) (R & D, Minneapolis, MN), 2mM L-glutaMax-1™ (Gibco BRL), 1 mM Sodium Pyruvate (Gibco BRL), and PSN antibiotics (GIBCO BRL)). Prior to electroporation, pZP-5N/ $\alpha$ 11 plasmid DNA (Example 1) was prepared and purified using a Qiagen Maxi Prep kit (Qiagen) as per manufacturer's instructions. BaF3 cells for electroporation were washed once in RPMI media and then resuspended in RPMI media at a cell density of  $10^7$  cells/ml. One ml of resuspended BaF3 cells was mixed with 30  $\mu$ g of the pZP-5N/ $\alpha$ 11 plasmid DNA and transferred to separate disposable electroporation chambers (GIBCO BRL). Following a 15 minute incubation at room temperature the cells were given two serial shocks (800 IFad/300 V.; 1180 IFad/300 V.) delivered by an electroporation apparatus (CELL-PORATOR™; GIBCO BRL). After a 5 minute recovery time, the electroporated cells were transferred to 50 ml of complete media and placed in an incubator for 15-24 hours (37°C, 5% CO<sub>2</sub>). The cells were then spun down and resuspended in 50 ml of complete media containing Geneticin™ (Gibco) selection (500  $\mu$ g/ml G418) in a T-162 flask to isolate the G418-resistant pool. Pools of the transfected BaF3 cells, hereinafter called BaF3/ $\alpha$ 11 cells, were assayed for signaling capability as described below.

#### B. Testing the signaling capability of the BaF3/ $\alpha$ 11 cells using an Alamar Blue Proliferation Assay

BaF3/ $\alpha$ 11 cells were spun down and washed in the complete media, described above, but without mIL-3 (hereinafter referred to as "mIL-3 free media"). The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100  $\mu$ l per well using the mIL-3 free media.

Proliferation of the BaF3/zalpa11 cells was assessed using conditioned media from zalpa11 Ligand-expressing cells diluted with mIL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations; or purified zalpa11 Ligand (commonly owned US Patent application No. 09/522,217) diluted with mIL-3 free media to 500 ng/ml, 250ng/ml, 125 ng/ml, 62 ng/ml, 30 ng/ml, 15 ng/ml, 7.5 ng/ml, 3.75 ng/ml, 1.8 ng/ml, 0.9 ng/ml, 0.5 ng/ml and 0.25 ng/ml concentrations. 100  $\mu$ l of the diluted mTPO was added to the BaF3/zalpa11 cells. The total assay volume is 200  $\mu$ l. Negative controls were run in parallel using mIL-3 free media only. The assay plates were incubated at 37°C, 5% CO<sub>2</sub> for 3 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20 $\mu$ l/well. Alamar Blue gives a fluourometric readout based on the metabolic activity of cells, and is thus a direct measurement of cell proliferation in comparison to a negative control. Plates were again incubated at 37°C, 5% CO<sub>2</sub> for 24 hours. Plates were read on the Fmax™ plate reader (Molecular Devices Sunnyvale, CA) using the SoftMax™ Pro program, at wavelengths 544 (Excitation) and 590 (Emmission). Results confirmed the signaling capability of the zalpa11 receptor, as the zalpa11 Ligand significantly induced proliferation over over background levels.

### Example 3

#### 20      Screening for zalpa11 Ligand Using BaF3/Zalpa11 Cells Using an Alamar Blue Proliferation Assay

##### A. Activation of primary Monkey splenocytes to test for presence of zalpa11 Ligand

Monkey splenocytes were stimulated *in vitro* to produce conditioned media to test for the presence of zalpa11 Ligand activity as described below. Monkey spleens were obtained from 8 year old female *M. nesestrian* monkeys. The spleens were teased part to produce a single cell suspension. The mononuclear cells were isolated by Ficoll-Paque® PLUS (Pharmacia Biotech, Uppsala, Sweden) density gradient. The mononuclear cells were seeded at  $2 \times 10^6$  cells/ml in RPMI-1640 media supplemented with 10% FBS and activated with with 5 ng/ml Phorbol-12-myristate-13-acetate (PMA) (Calbiochem, San Diego, CA), and 0.5mg/ml Ionomycin™

(Calbiochem) for 48 h. The supernatant from the stimulated monkey spleen cells was used to assay proliferation of the BaF3/zalpa11 cells as described below.

B. Screening for zalpa11 Ligand using BaF3/Zalpa11 cells using an Alamar Blue Proliferation Assay

BaF3/Zalpa11 cells were spun down and washed in mIL-3 free media. The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100  $\mu$ l per well using the mIL-3 free media.

Proliferation of the BaF3/Zalpa11 cells was assessed using conditioned media from activated monkey spleen (see Example 3A). Conditioned media was diluted with mIL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. 100  $\mu$ l of the diluted conditioned media was added to the BaF3/Zalpa11 cells. The total assay volume is 200  $\mu$ l. The assay plates were incubated at 37°C, 5% CO<sub>2</sub> for 3 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20  $\mu$ l/well. Plates were again incubated at 37°C, 5% CO<sub>2</sub> for 24 hours. Plates were read on the Fmax™ plate reader (Molecular devices) as described above (Example 2).

Results confirmed the proliferative response of the BaF3/Zalpa11 cells to a factor present in the activated monkey spleen conditioned media. The response, as measured, was approximately 4-fold over background at the 50% concentration. The untransfected BaF3 cells did not proliferate in response to this factor, showing that this factor is specific for the Zalpa11 receptor.

C. Human Primary Source used to isolate zalpa11 Ligand

100 ml blood draws were taken from each of six donors. The blood was drawn using 10X 10 ml vacutainer tubes containing heparin. Blood was pooled from six donors (600ml), diluted 1:1 in PBS, and separated using a Ficoll-Paque® PLUS (Pharmacia Biotech). The isolated primary human cell yield after separation on the ficoll gradient was  $1.2 \times 10^9$  cells.



Cells were suspended in 9.6 ml MACS buffer (PBS, 0.5% EDTA, 2mM EDTA). 1.6 ml of cell suspension was removed and 0.4 ml CD3 microbeads (Miltenyi Biotec, Auburn, CA) added. The mixture was incubated for 15 min. at 4°C. These cells labeled with CD3 beads were washed with 30 ml MACS buffer, and then  
5 resuspended in 2 ml MACS buffer.

A VS+ column (Miltenyi) was prepared according to the manufacturer's instructions. The VS+ column was then placed in a VarioMACS™ magnetic field (Miltenyi). The column was equilibrated with 5 ml MACS buffer. The isolated primary human cells were then applied to the column. The CD3 negative cells were allowed to  
10 pass through. The column was rinsed with 9 ml (3 X 3 ml) MACS buffer. The column was then removed from the magnet and placed over a 15 ml falcon tube. CD3+ cells were eluted by adding 5 ml MACS buffer to the column and bound cells flushed out using the plunger provided by the manufacturer. The incubation of the cells with the CD3 magnetic beads, washes, and VS+ column steps (incubation through elution)  
15 above were repeated five more times. The resulting CD3+ fractions from the six column separations were pooled. The yield of CD3+ selected human cells were  $3 \times 10^8$  total cells.

A sample of the pooled CD3+ selected human cells was removed for staining and sorting on a fluorescent antibody cell sorter (FACS) to assess their purity.  
20 The human CD3+ selected cells were 91% CD3+ cells.

The human CD3+ selected cells were activated by incubating in RPMI + 5% FBS + PMA 10 ng/ml and Ionomycin 0.5 µg/ml (Calbiochem) for 13 hours 37°C. The supernatant from these activated CD3+ selected human cells was tested for zalpha11 Ligand activity as described below. Moreover, the activated CD3+ selected  
25 human cells were used to prepare a cDNA library, as described in commonly owned US Pat. Application No. 09/522,217.

D. Testing supernatant from activated CD3+ selected human cells for zalpha11 Ligand using BaF3/Zalpha11 cells and an Alamar Blue Proliferation Assay

BaF3/Zalpha11 cells were spun down and washed in mL-3 free media.  
30 The cells were spun and washed 3 times to ensure the removal of the mL-3. Cells were

then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100  $\mu$ l per well using the mIL-3 free media.

Proliferation of the BaF3/Zalpa11 cells was assessed using conditioned media from activated CD3+ selected human cells (see Example 5C) diluted with mIL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. 100  $\mu$ l of the diluted conditioned media was added to the BaF3/Zalpa11 cells. The total assay volume is 200  $\mu$ l. The assay plates were incubated and assayed as described in Example 5B.

Results confirmed the proliferative response of the BaF3/Zalpa11 cells to a factor present in the activated CD3+ selected human cell conditioned media. The response, as measured, was approximately 10-fold over background at the 50% concentration. The untransfected BaF3 cells did not proliferate in response to this factor, showing that this factor is specific for the Zalpa11 receptor. Moreover soluble zalpa11 receptor blocked this proliferative activity in the BaF3/Zalpa11 cells (see, Example 16).

#### Example 4

##### Construction of Mammalian Expression Vectors That Express zalpa11 Soluble

##### Receptors: zalpa11CEE, zalpa11CFLG, zalpa11CHIS and zalph11-Fc4

##### A. Construction of zalpa11 Mammalian Expression Vector containing zalph11CEE, zalph11CFLG and zalph11CHIS

An expression vector was prepared for the expression of the soluble, extracellular domain of the zalpa11 polypeptide, pC4zalph11CEE, wherein the construct is designed to express a zalpa11 polypeptide comprised of the predicted initiating methionine and truncated adjacent to the predicted transmembrane domain, and with a C-terminal Glu-Glu tag (SEQ ID NO:14).

A 700 bp PCR generated zalpa11 DNA fragment was created using ZC19,931 (SEQ ID NO:21) and ZC19,932 (SEQ ID NO:22) as PCR primers to add Asp718 and BamHI restriction sites. A plasmid containing the zalpa11 receptor cDNA (SEQ ID NO:1) was used as a template. PCR amplification of the zalpa11 fragment was performed as follows: Twenty five cycles at 94C for 0.5 minutes; five

cycles at 94°C for 10 seconds, 50°C for 30 seconds, 68°C for 45 seconds, followed by a 4°C hold. The reaction was purified by chloroform/phenol extraction and isopropanol precipitation, and digested with Asp718 and BamHI (Gibco BRL) following manufacturer's protocol. A band of the predicted size, 700 bp, was visualized by 1% agarose gel electrophoresis, excised and the DNA was purified using a QiaexII™ purification system (Qiagen) according the manufacturer's instructions.

The excised DNA was subcloned into plasmid pC4EE which had been cut with BamHI and Asp718. The pC4zalpha11CEE expression vector uses the native zalpha11 signal peptide and attaches the Glu-Glu tag (SEQ ID NO:14) to the C-terminus of the zalpha11 polypeptide-encoding polynucleotide sequence. Plasmid pC4EE, is a mammalian expression vector containing an expression cassette having the mouse metallothionein-1 promoter, multiple restriction sites for insertion of coding sequences, a stop codon and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene and the SV40 terminator.

About 30 ng of the restriction digested zalpha11 insert and about 12 ng of the digested vector were ligated overnight at 16°C. One microliter of each ligation reaction was independently electroporated into DH10B competent cells (GIBCO BRL, Gaithersburg, MD) according to manufacturer's direction and plated onto LB plates containing 50 mg/ml ampicillin, and incubated overnight. Colonies were screened by restriction analysis of DNA prepared from 2 ml liquid cultures of individual colonies. The insert sequence of positive clones was verified by sequence analysis. A large scale plasmid preparation was done using a QIAGEN® Maxi prep kit (Qiagen) according to manufacturer's instructions.

The same process was used to prepare the zalpha11 soluble receptors with a C-terminal his tag, composed of 6 His residues in a row; and a C-terminal flag (SEQ ID NO:23) tag, zalpha11CFLAG. To construct these constructs, the aforementioned vector has either the HIS or the FLAG® tag in place of the glu-glu tag (SEQ ID NO:14).

### B. Mammalian Expression Construction of Soluble zalpha11 receptor zalpha11-Fc4

An expression plasmid containing all or part of a polynucleotide encoding zalpha11 was constructed via homologous recombination. A fragment of zalpha11 cDNA was isolated using PCR that includes the polynucleotide sequence from extracellular domain of the zalpha11 receptor. The two primers used in the production of the zalpha11 fragment were: (1) The primers for PCR each include from 5' to 3' end: 40 bp of the vector flanking sequence (5' of the insert) and 17 bp corresponding to the 5' end of the zalpha11 extracellular domain (SEQ ID NO:24); and (2) 40 bp of the 5' end of the Fc4 polynucleotide sequence (SEQ ID NO:25) and 17 bp corresponding to the 3' end of the zalpha11 extracellular domain (SEQ ID NO:26). The fragment of Fc4 for fusion with the zalpha11 was generated by PCR in a similar fashion. The two primers used in the production of the Fc4 fragment were: (1) a 5' primer consisting of 40 bp of sequence from the 3' end of zalpha11 extracellular domain and 17 bp of the 5' end of Fc4 (SEQ ID NO:27); and (2) a 3' primer consisting of 40 bp of vector sequence (3' of the insert) and 17 bp of the 3' end of Fc4 (SEQ ID NO:28).

PCR amplification of the each of the reactions described above was performed as follows: one cycle at 94°C for 2 minutes; twenty-five cycles at 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute; one cycle at 72°C for 5 minutes; followed by a 4°C hold. Ten µl of the 100 µl PCR reaction was run on a 0.8% LMP agarose gel (Seaplaque GTG) with 1 x TBE buffer for analysis. The remaining 90 µl of PCR reaction is precipitated with the addition of 5 µl 1 M NaCl and 250 µl of absolute ethanol. The expression vector used was derived from the plasmid pCZR199 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, designated No. 98668), and was cut with SmaI (BRL). The expression vector was derived from the plasmid pCZR199, and is a mammalian expression vector containing an expression cassette having the CMV immediate early promoter, a consensus intron from the variable region of mouse immunoglobulin heavy chain locus, multiple restriction sites for insertion of coding sequences, a stop codon and a human growth hormone terminator. The expression vector also has an *E. coli* origin of

replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene and the SV40 terminator. The expression vector used was constructed from pCZR199 by the replacement of the metallothionein promoter with the CMV immediate early promoter.

5                   One hundred microliters of competent yeast cells (*S. cerevisiae*) were combined with 10  $\mu$ l containing approximately 1  $\mu$ g each of the zalpha11 and Fc4 inserts, and 100 ng of SmaI (BRL) digested expression vector and transferred to a 0.2 cm electroporation cuvette. The yeast/DNA mixtures were electropulsed at 0.75 kV (5 kV/cm), "infinite" ohms, 25  $\mu$ F. To each cuvette is added 600  $\mu$ l of 1.2 M sorbitol and  
10                  the yeast was plated in two 300  $\mu$ l aliquots onto two URA-D plates and incubated at 30°C.

                  After about 48 hours, the Ura+ yeast transformants from a single plate were resuspended in 1 ml H<sub>2</sub>O and spun briefly to pellet the yeast cells. The cell pellet was resuspended in 1 ml of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10  
15                  mM Tris, pH 8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture was added to an Eppendorf tube containing 300  $\mu$ l acid washed glass beads and 200  $\mu$ l phenol-chloroform, vortexed for 1 minute intervals two or three times, followed by a 5 minute spin in a Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase was transferred to a fresh tube, and the DNA precipitated with 600  $\mu$ l  
20                  ethanol (EtOH), followed by centrifugation for 10 minutes at 4°C. The DNA pellet was resuspended in 100  $\mu$ l H<sub>2</sub>O.

                  Transformation of electrocompetent *E. coli* cells (DH10B, GibcoBRL) is done with 0.5-2 ml yeast DNA prep and 40  $\mu$ l of DH10B cells. The cells were electropulsed at 2.0 kV, 25 mF and 400 ohms. Following electroporation, 1 ml SOC  
25                  (2% Bacto® Tryptone (Difco, Detroit, MI), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl<sub>2</sub>, 10 mM MgSO<sub>4</sub>, 20 mM glucose) was plated in 250  $\mu$ l aliquots on four LB AMP plates (LB broth (Lennox), 1.8% Bacto Agar (Difco), 100 mg/L Ampicillin).

                  Individual clones harboring the correct expression construct for  
30                  zalpha11-Fc4 were identified by restriction digest to verify the presence of the zalpha11-Fc4 insert and to confirm that the various DNA sequences have been joined

correctly to one another. The insert of positive clones were subjected to sequence analysis. Larger scale plasmid DNA is isolated using the Qiagen Maxi kit (Qiagen) according to manufacturer's instructions.

5

### Example 5

#### Transfection And Expression Of Zalpha11 Soluble Receptor Polypeptides

BHK 570 cells (ATCC No. CRL-10314), passage 27, were plated at  $1.2 \times 10^6$  cells/well (6-well plate) in 800  $\mu$ l of serum free (SF) DMEM media (DMEM, Gibco/BRL High Glucose) (Gibco BRL, Gaithersburg, MD). The cells were  
10 transfected with expression plasmids containing zalpha11CEE, zalpha11CFLG or zalpha11CHIS described above (see, Example 4), using Lipofectin™ (Gibco BRL), in serum free (SF) DMEM. Three micrograms of zalpha11CEE, zalpha11CFLG or zalpha11CHIS each were separately diluted into 1.5 ml tubes to a total final volume of 100  $\mu$ l SF DMEM. In separate tubes, 15  $\mu$ l of Lipofectin™ (Gibco BRL) was mixed  
15 with 100  $\mu$ l of SF DMEM. The Lipofectin™ mix was incubated at room temperature for 30-45 minutes then the DNA mix was added and allowed to incubate approximately 10-15 minutes at room temperature.

The entire DNA: Lipofectin™ mixture was added to the plated cells and distributed evenly over them. The cells were incubated at 37°C for approximately five  
20 hours, then transferred to separate 150 mm MAXI plates in a final volume of 30 ml DMEM/5% fetal bovine serum (FBS) (Hyclone, Logan, UT). The plates were incubated at 37°C, 5% CO<sub>2</sub>, overnight and the DNA: Lipofectin™ mixture was replaced with selection media (5% FBS/DMEM with 1  $\mu$ M methotrexate (MTX) the next day.

25 Approximately 10-12 days post-transfection, the plates were washed with 10 ml SF DMEM. The wash media was aspirated and replaced with 7.25 ml serum-free DMEM. Sterile Teflon meshes (Spectrum Medical Industries, Los Angeles, CA) pre-soaked in SF DMEM were then placed over the clonal cell colonies. A sterile nitrocellulose filter pre-soaked in SF DMEM was then placed over the mesh.  
30 Orientation marks on the nitrocellulose were transferred to the culture dish. The plates were then incubated for 5-6 hours in a 37°C, 5% CO<sub>2</sub> incubator.

Following incubation, the filters/meshes were removed, and the media aspirated and replaced with 5% FBS/DMEM with 1  $\mu$ M MTX. The filters were then blocked in 10% nonfat dry milk/Western A buffer (Western A: 50mM Tris pH 7.4, 5 mM EDTA, 0.05% NP-40, 150 mM NaCl and 0.25% gelatin) for 15 minutes at room temperature on a rotating shaker. The filters were then incubated with an anti-Glu-Glu, anti-FLAG®, or anti-HIS antibody-HRP conjugates, respectively, in 2.5% nonfat dry milk/Western A buffer for one hour at room temperature on a rotating shaker. The filters were then washed three times at room temperature with Western A for 5-10 minutes per wash. The filters were developed with ultra ECL reagent (Amersham Corp., Arlington Heights, IL) according the manufacturer's directions and visualized on the Lumi-Imager (Roche Corp.)

Positive expressing clonal colonies were mechanically picked to 12-well plates in one ml of 5%FCS/DMEM with 5  $\mu$ M MTX, then grown to confluence. Conditioned media samples were then tested for expression levels via SDS-PAGE and Western anlysis. The three highest expressing clones for each construct were picked; two out of three were frozen down as back up and one was expanded for mycoplasma testing and large-scale factory seeding.

#### B. Mammalian Expression of soluble zalpha11 receptor zalpha11-Fc4

BHK 570 cells (ATCC NO: CRL-10314) were plated in 10 cm tissue culture dishes and allowed to grow to approximately 50 to 70% confluency overnight at 37°C, 5% CO<sub>2</sub>, in DMEM/FBS media (DMEM, Gibco/BRL High Glucose, (Gibco BRL, Gaithersburg, MD), 5% fetal bovine serum (Hyclone, Logan, UT), 1 mM L-glutamine (JRH Biosciences, Lenexa, KS), 1 mM sodium pyruvate (Gibco BRL)). The cells were then transfected with the plasmid containing zalpha11-Fc4 (see, Example 9), using Lipofectamine™ (Gibco BRL), in serum free (SF) media formulation (DMEM, 10 mg/ml transferrin, 5 mg/ml insulin, 2 mg/ml fetuin, 1% L-glutamine and 1% sodium pyruvate). The plasmid containing zalpha11-Fc4 was diluted into 15 ml tubes to a total final volume of 640 ml with SF media. 35 ml of Lipofectamine™ (Gibco BRL) was mixed with 605 ml of SF medium. The Lipofectamine™ mix was added to the DNA mix and allowed to incubate approximately 30 minutes at room temperature. Five

milliliters of SF media was added to the DNA:Lipofectamine™ mixture. The cells were rinsed once with 5 ml of SF media, aspirated, and the DNA:Lipofectamine™ mixture is added. The cells were incubated at 37°C for five hours, then 6.4 ml of DMEM/10% FBS, 1% PSN media was added to each plate. The plates were incubated at 37°C overnight and the DNA:Lipofectamine™ mixture was replaced with fresh 5% FBS/DMEM media the next day. On day 2 post-transfection, the cells were split into the selection media (DMEM/FBS media from above with the addition of 1 mM methotrexate (Sigma Chemical Co., St. Louis, Mo.)) in 150 mm plates at 1:10, 1:20 and 1:50. The media on the cells was replaced with fresh selection media at day 5 post-transfection. Approximately 10 days post-transfection, two 150 mm culture dishes of methotrexate resistant colonies from each transfection were trypsinized and the cells are pooled and plated into a T-162 flask and transferred to large scale culture.

#### Example 6

##### 15. Purification of zalpha11 Soluble Rreceptors From BHK 570 Cells

##### A. Purification of zalpha11CEE polypeptide from BHK 570

Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying zalpha11 polypeptide containing C-terminal GluGlu (EE) tags. Thirty liters of cell factory conditioned media was concentrated to 1.6 liters with an Amicon S10Y3 spiral cartridge on a ProFlux A30. A Protease inhibitor solution was added to the concentrated 1.6 liters of cell factory conditioned media from transfected BHK 570 cells (Example 5) to final concentrations of 2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Chemical Co. St. Louis, MO), 0.003 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim). Samples were removed for analysis and the bulk volume was frozen at -80°C until the purification was started. Total target protein concentrations of the concentrated cell factory conditioned media was determined via SDS-PAGE and Western blot analysis with the anti-EE HRP conjugated antibody.

30 A 100 ml column of anti-EE G-Sepharose (prepared as described below) was poured in a Waters AP-5, 5 cm x 10 cm glass column. The column was flow



packed and equilibrated on a BioCad Sprint (PerSeptive BioSystems, Framingham, MA) with phosphate buffered saline (PBS) pH 7.4. The concentrated cell factory conditioned media was thawed, 0.2 micron sterile filtered, pH adjusted to 7.4, then loaded on the column overnight with 1 ml/minute flow rate. The column was washed with 10 column volumes (CVs) of phosphate buffered saline (PBS, pH 7.4), then plug eluted with 200 ml of PBS (pH 6.0) containing 0.5 mg/ml EE peptide (Anaspec, San Jose, CA) at 5 ml/minute. The EE peptide used has the sequence EYMPME (SEQ ID NO:14). The column was washed for 10 CVs with PBS, then eluted with 5 CVs of 0.2M glycine, pH 3.0. The pH of the glycine-eluted column was adjusted to 7.0 with 2 CVs of 5X PBS, then equilibrated in PBS (pH 7.4). Five ml fractions were collected over the entire elution chromatography and absorbance at 280 and 215 nM were monitored; the pass through and wash pools were also saved and analyzed. The EE-polypeptide elution peak fractions were analyzed for the target protein via SDS-PAGE Silver staining and Western Blotting with the anti-EE HRP conjugated antibody. The polypeptide elution fractions of interest were pooled and concentrated from 60 ml to 5.0 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

To separate  $\alpha$ 11CEE from other co-purifying proteins, the concentrated polypeptide elution pooled fractions were subjected to a POROS HQ-50 (strong anion exchange resin from PerSeptive BioSystems, Framingham, MA) at pH 8.0. A 1.0 x 6.0 cm column was poured and flow packed on a BioCad Sprint. The column was counter ion charged then equilibrated in 20mM TRIS pH 8.0 (Tris (Hydroxymethyl Aminomethane)). The sample was diluted 1:13 (to reduce the ionic strength of PBS) then loaded on the Poros HQ column at 5 ml/minute. The column was washed for 10 CVs with 20mM Tris pH 8.0 then eluted with a 40 CV gradient of 20 mM Tris/ 1 M sodium chloride (NaCl) at 10 ml/minute. 1.5 ml fractions were collected over the entire chromatography and absorbance at 280 and 215 nM were monitored. The elution peak fractions were analyzed via SDS-PAGE Silver staining. Fractions of interest were pooled and concentrated to 1.5-2 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

To separate zalpha11CEE polypeptide from free EE peptide and any contaminating co-purifying proteins, the pooled concentrated fractions were subjected to chromatography on a 1.5 x 90 cm Sephadex S200 (Pharmacia, Piscataway, NJ) column equilibrated and loaded in PBS at a flow rate of 1.0 ml/min using a BioCad Sprint. 1.5 ml fractions were collected across the entire chromatography and the absorbance at 280 and 215 nM were monitored. The peak fractions were characterized via SDS-PAGE Silver staining, and only the most pure fractions were pooled. This material represented purified zalpha11CEE polypeptide.

This purified material was finally subjected to a 4 ml ActiClean Etox (Sterogene) column to remove any remaining endotoxins. The sample was passed over the PBS equilibrated gravity column four times then the column was washed with a single 3 ml volume of PBS, which was pooled with the "cleaned" sample. The material was then 0.2 micron sterile filtered and stored at -80°C until it was aliquoted.

On Western blotted, Coomassie Blue and Silver stained SDS-PAGE gels, the zalpha11CEE polypeptide was one major band of an apparent molecular weight of 50,000 Daltons. The mobility of this band was the same on reducing and non-reducing gels.

The protein concentration of the purified material was performed by BCA analysis (Pierce, Rockford, IL) and the protein was aliquoted, and stored at -80°C according to our standard procedures. On IEF (isoelectric focusing) gels the protein runs with a PI of less than 4.5. The concentration of zalpha11CEE polypeptide was 1.0 mg/ml.

Purified zalpha11CEE polypeptide was prepared for injection into rabbits and sent to R & R Research and Development (Stanwood, WA) for antibody production. Rabbits were injected to produce anti-huzalpa11-CEE-BHK serum (Example 10, below).

To prepare anti-EE Sepharose, a 100 ml bed volume of protein G-Sepharose (Pharmacia, Piscataway, NJ) was washed 3 times with 100 ml of PBS containing 0.02% sodium azide using a 500 ml Nalgene 0.45 micron filter unit. The gel was washed with 6.0 volumes of 200 mM triethanolamine, pH 8.2 (TEA, Sigma, St. Louis, MO), and an equal volume of EE antibody solution containing 900 mg of

antibody was added. After an overnight incubation at 4°C, unbound antibody was removed by washing the resin with 5 volumes of 200 mM TEA as described above. The resin was resuspended in 2 volumes of TEA, transferred to a suitable container, and dimethylpimilimide-2HCl (Pierce, Rockford, IL) dissolved in TEA, was added to a  
5 final concentration of 36 mg/ml of protein G-Sepharose gel. The gel was rocked at room temperature for 45 min and the liquid was removed using the filter unit as described above. Nonspecific sites on the gel were then blocked by incubating for 10 min. at room temperature with 5 volumes of 20 mM ethanolamine in 200 mM TEA. The gel was then washed with 5 volumes of PBS containing 0.02% sodium azide and  
10 stored in this solution at 4°C.

#### B. Purification of zalpha11CFLAG polypeptide from BHK 570

Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying zalpha11 polypeptide containing C-terminal  
15 FLAG® (FLAG) (Sigma-Aldrich Co.) tags. Thirty liters of cell factory conditioned media was concentrated to 1.7 liters with an Amicon S10Y3 spiral cartridge on a ProFlux A30. A Protease inhibitor solution was added to the 1.7 liters of concentrated cell factory conditioned media from transfected BHK 570 cells (see, Example 5) to final concentrations of 2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma  
20 Chemical Co. St. Louis, MO), 0.003 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim). Samples were removed for analysis and the bulk volume was frozen at -80°C until the purification was started. Total target protein concentrations of the cell factory conditioned media was determined via SDS-PAGE and Western blot  
25 analysis with the anti-FLAG® (Kodak) HRP conjugated antibody. A 125 ml column of anti- FLAG® M2-Agarose affinity gel (Sigma-Aldrich Co.) was poured in a Waters AP-5, 5 cm x 10 cm glass column. The column was flow packed and equilibrated on a BioCad Sprint (PerSeptive BioSystems, Framingham, MA) with phosphate buffered saline (PBS) pH 7.4. The concentrated cell factory conditioned media was thawed, 0.2  
30 micron sterile filtered, pH adjusted to 7.4, then loaded on the column overnight with 1 ml/minute flow rate. The column was washed with 10 column volumes (CVs) of

phosphate buffered saline (PBS, pH 7.4), then plug eluted with 250 ml of PBS (pH 6.0) containing 0.5 mg/ml FLAG® (Sigma-Aldrich Co.) peptide at 5 ml/minute. The FLAG® peptide used has the sequence DYKDDDDK (SEQ ID NO:23). The column was washed for 10 CVs with PBS, then eluted with 5 CVs of 0.2M glycine, pH 3.0. The pH of the glycine-eluted column was adjusted to 7.0 with 2 CVs of 5X PBS, then equilibrated in PBS (pH 7.4). Five ml fractions were collected over the entire elution chromatography and absorbance at 280 and 215 nM were monitored; the pass through and wash pools were also saved and analyzed. The FLAG®-polypeptide elution peak fractions were analyzed for the target protein via SDS-PAGE Silver staining and Western Blotting with the anti-FLAG HRP conjugated antibody. The polypeptide elution fractions of interest were pooled and concentrated from 80 ml to 12 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

To separate zalpha11CFLG from other co-purifying proteins, the polypeptide elution pooled fractions were subjected to a POROS HQ-50 (strong anion exchange resin from PerSeptive BioSystems, Framingham, MA) at pH 8.0. A 1.0 x 6.0 cm column was poured and flow packed on a BioCad Sprint. The column was counter ion charged then equilibrated in 20mM TRIS pH 8.0 (Tris (Hydroxymethyl Aminomethane)). The sample was diluted 1:13 (to reduce the ionic strength of PBS) then loaded on the Poros HQ-50 column at 5 ml/minute. The column was washed for 10 column volumes (CVs) with 20mM Tris pH 8.0 then eluted with a 40 CV gradient of 20 mM Tris/ 1 M sodium chloride (NaCl) at 10 ml/minute. 1.5 ml fractions were collected over the entire chromatography and absorbance at 280 and 215 nM were monitored. The elution peak fractions were analyzed via SDS-PAGE Silver staining. Fractions of interest were pooled and concentrated to 1.5-2 ml using a 10,000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

To separate zalpha11CFLG polypeptide from free FLAG® peptide and any contaminating co-purifying proteins, the pooled concentrated fractions were subjected to chromatography on a 1.5 x 90 cm Sephacryl S200 (Pharmacia, Piscataway, NJ) column equilibrated and loaded in PBS at a flow rate of 1.0 ml/min using a BioCad

Sprint. 1.5 ml fractions were collected across the entire chromatography and the absorbance at 280 and 215 nm were monitored. The peak fractions were characterized via SDS-PAGE Silver staining, and only the most pure fractions were pooled. This material represented purified zalpha11CFLG polypeptide.

5           This purified material was finally subjected to a 4 ml ActiClean Etox (Sterogene) column to remove any remaining endotoxins. The sample was passed over the PBS equilibrated gravity column four times then the column was washed with a single 3 ml volume of PBS, which was pooled with the "cleaned" sample. The material was then 0.2 micron sterile filtered and stored at -80°C until it was aliquoted.

10           On Western blotted, Coomassie Blue and Silver stained SDS-PAGE gels, the zalpha11CFLG polypeptide was one major band of an apparent molecular weight of 50,000 Daltons. The mobility of this band was the same on reducing and non-reducing gels.

          The protein concentration of the purified material was performed by  
15   BCA analysis (Pierce, Rockford, IL) and the protein was aliquoted, and stored at -80°C according to our standard procedures. On IEF (isoelectric focusing) gels the protein runs with a PI of less than 4.5. The concentration of zalpha11CFLG polypeptide was 1.2 mg/ml.

20   C. Purification of zalpha11-Fc4 polypeptide from transfected BHK 570 cells

          Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying zalpha11 polypeptide containing C-terminal fusion to human IgG/Fc (zalpha11-Fc4; Examples 4 and 5). 12,000 ml of conditioned media from BHK 570 cells transfected with zalpha11-Fc4 (Example 5) was filtered  
25   through a 0.2 mm sterilizing filter and then supplemented with a solution of protease inhibitors, to final concentrations of 0.001 mM leupeptin (Boehringer-Mannheim, Indianapolis, IN), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc (Boehringer-Mannheim). A protein G sepharose (6 ml bed volume, Pharmacia Biotech) was packed and washed with 500 ml PBS (Gibco/BRL) The supplemented conditioned  
30   media was passed over the column with a flow rate of 10 ml/minute, followed by washing with 1000 ml PBS (BRL/Gibco). zalpha11-Fc4 was eluted from the column

with 0.1 M Glycine pH 3.5 and 2 ml fractions were collected directly into 0.2 ml 2M Tris pH 8.0, to adjust the final pH to 7.0 in the fractions.

The eluted fractions were characterized by SDS-PAGE and western blotting with anti-human Fc (Amersham) antibodies. Western blot analysis of reducing SDS-PAGE gels reveal an immunoreactive protein of 80,000 KDa in fractions 2-10. Silver stained SDS-PAGE gels also revealed an 80,000 KDa zalpha11:Fc polypeptide in fractions 2-10. Fractions 2-10 were pooled.

The protein concentration of the pooled fractions was performed by BCA analysis (Pierce, Rockford, IL) and the material was aliquoted, and stored at -80°C according to our standard procedures. The concentration of the pooled fractions was 0.26 mg/ml.

#### Example 7

##### Assay Using zalpha11 Soluble Receptor zalpha11CEE, zalpha11CFLG and zalpha11-

##### Fc4 Soluble Receptors in Competitive Inhibition Assay

BaF3/Zalpha11 cells were spun down and washed in mIL-3 free media. The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 µl per well using the mIL-3 free media.

Both media from the monkey spleen cell activation and the CD3+ selected cells, described in Example 3, were added in separate experiments at 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations, with or without zalpha11 soluble receptors (CEE, C-flag, and Fc4 constructs; See, Example 6) at 10µg/ml. The total assay volume was 200 µl.

The assay plates were incubated 37°C, 5% CO<sub>2</sub> for 3 days at which time Alamar Blue (Accumed) was added at 20µl/well. Plates were again incubated at 37°C, 5% CO<sub>2</sub> for 24 hours. Plates were read on the Fmax™ plate reader (Molecular Devices) as described above (Example 2). Results demonstrated complete inhibition of cell growth from each of the different zalpha11 soluble receptor constructs at 10µg/ml, confirming that the factor in each sample was specific for the zalpha11 receptor.

Titration curves, diluting out the soluble receptors, were also run using the above stated assay. Both the zalpha11CEE and zalpha11CFLG soluble zalpha11 receptors were able to completely inhibit growth as low as 20 ng/ml. The zalpha11-Fc4 soluble zalpha11 receptor was only as effective at 1.5 µg/ml.

5

### Example 8

#### Expression of Human zalpha11 Soluble Receptor in *E. coli*

A. Construction of expression vector pCZR225 that expresses huzalpa11/MBP-6H fusion polypeptide

10 An expression plasmid containing a polynucleotide encoding a human zalpha11 soluble receptor fused C-terminally to maltose binding protein (MBP) was constructed via homologous recombination. The polynucleotide sequence for the MBP-zalpa11 soluble receptor fusion polypeptide is shown in SEQ ID NO:29, with the corresponding protein sequence shown in SEQ ID NO:30. The fusion polypeptide, designated huzalpa11/MBP-6H, in Example 9, contains an MBP portion (amino acid 1 (Met) to amino acid 388 (Ser) of SEQ ID NO:30) fused to the human zalpha11 soluble receptor (amino acid 389 (Cys) to amino acid 606 (His) of SEQ ID NO:30). A fragment of human zalpha11 cDNA (SEQ ID NO:31) was isolated using PCR. Two primers were used in the production of the human zalpha11 fragment in a PCR reaction:

20 (1) Primer ZC20,187 (SEQ ID NO:32), containing 40 bp of the vector flanking sequence and 25 bp corresponding to the amino terminus of the human zalpha11, and (2) primer ZC20,185 (SEQ ID NO:33), containing 40 bp of the 3' end corresponding to the flanking vector sequence and 25 bp corresponding to the carboxyl terminus of the human zalpha11. The PCR Reaction conditions were as follows: 25 cycles of 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for 1 minute; followed by 4°C soak, run in duplicate. Two µl of the 100 µl PCR reaction was run on a 1.0% agarose gel with 1 x TBE buffer for analysis, and the expected approximately 660 bp fragment was seen.

25 The remaining 90 µl of PCR reaction was combined with the second PCR tube precipitated with 400 µl of absolute ethanol. The precipitated DNA used for recombining into the SmaI cut recipient vector pTAP98 to produce the construct encoding the MBP-zalpa11 fusion, as described below.

30

Plasmid pTAP98 was derived from the plasmids pRS316 and pMAL-c2. The plasmid pRS316 is a *Saccharomyces cerevisiae* shuttle vector (Hieter P. and Sikorski, R., *Genetics* 122:19-27, 1989). pMAL-C2 (NEB) is an *E. coli* expression plasmid. It carries the tac promoter driving *MalE* (gene encoding MBP) followed by a His tag, a thrombin cleavage site, a cloning site, and the *rrnB* terminator. The vector pTAP98 was constructed using yeast homologous recombination. 100ng of EcoR1 cut pMAL-c2 was recombined with 1µg Pvu1 cut pRS316, 1µg linker, and 1µg Sca1/EcoR1 cut pRS316. The linker consisted of oligos ZC19,372 (SEQ ID NO:34) (100 pmol): ZC19,351 (SEQ ID NO:35) (1 pmol): ZC19,352 (SEQ ID NO:36) (1 pmol), and ZC19,371 (SEQ ID NO:37) (100 pmol) combined in a PCR reaction. PCR reaction conditions were as follows: 10 cycles of 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for 30 seconds; followed by 4°C soak. PCR products were concentrated via 100% ethanol precipitation.

One hundred microliters of competent yeast cells (*S. cerevisiae*) were combined with 10 µl of a mixture containing approximately 1 µg of the human zalpha11 receptor PCR product above, and 100 ng of SmaI digested pTAP98 vector, and transferred to a 0.2 cm electroporation cuvette. The yeast/DNA mixture was electropulsed at 0.75 kV (5 kV/cm), infinite ohms, 25 µF. To each cuvette was added 600 µl of 1.2 M sorbitol and the yeast was then plated in two 300 µl aliquots onto two - URA D plates and incubated at 30°C.

After about 48 hours, the Ura+ yeast transformants from a single plate were resuspended in 1 ml H<sub>2</sub>O and spun briefly to pellet the yeast cells. The cell pellet was resuspended in 1 ml of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA). Five hundred microliters of the lysis mixture was added to an Eppendorf tube containing 300 µl acid washed glass beads and 200 µl phenol-chloroform, vortexed for 1 minute intervals two or three times, followed by a 5 minute spin in a Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase was transferred to a fresh tube, and the DNA precipitated with 600 µl ethanol (EtOH), followed by centrifugation for 10 minutes at 4°C. The DNA pellet was resuspended in 100 µl H<sub>2</sub>O.



100

Transformation of electrocompetent *E. coli* cells (MC1061, Casadaban et. al. J. Mol. Biol. 138, 179-207) was done with 1 µl yeast DNA prep and 40 µl of MC1061 cells. The cells were electropulsed at 2.0 kV, 25 µF and 400 ohms. Following electroporation, 0.6 ml SOC (2% Bacto™ Tryptone (Difco, Detroit, MI), 5 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl<sub>2</sub>, 10 mM MgSO<sub>4</sub>, 20 mM glucose) was plated in one aliquot on MM/CA +AMP 100 mg/L plates (Pryor and Leiting, Protein Expression and Purification 10:309-319, 1997).

Cells harboring the correct expression construct for human zalpha11 receptor were identified by expression. Cells were grown in MM/CA with 100 µg/ml 10 Ampicillin for two hours, shaking, at 37°C. 1ml of the culture was induced with 1mM IPTG. 2-4 hours later the 250 µl of each culture was mixed with 250 µl acid washed glass beads and 250 µl Thorner buffer with 5% βME and dye (8M urea, 100 mM Tris pH7.0, 10% glycerol, 2mM EDTA, 5% SDS). Samples were vortexed for one minute and heated to 65°C for 10 minutes. 20 µl were loaded per lane on a 4%-12% PAGE gel 15 (NOVEX). Gels were run in 1XMES buffer. The positive clones were designated pCZR225 and subjected to sequence analysis. The polynucleotide sequence of MBP-zalpha11 fusion is shown in SEQ ID NO:50.

#### B. Bacterial Expression of human huzalpa11/MBP-6H fusion polypeptide

One microliter of sequencing DNA was used to transform strain BL21. 20 The cells were electropulsed at 2.0 kV, 25 µF and 400 ohms. Following electroporation, 0.6 ml MM/CA with 100 mg/L Ampicillin.

Cells were grown in MM/CA with 100µg/ml Ampicillin for two hours, shaking, at 37°C. 1ml of the culture was induced with 1mM IPTG. 2-4 hours later the 250 µl of each culture was mixed with 250µl acid washed glass beads and 250 µl 25 Thorner buffer with 5% βME and dye (8M urea, 100 mM Tris pH7.0, 10% glycerol, 2mM EDTA, 5% SDS). Samples were vortexed for one minute and heated to 65°C for 10 minutes. 20µl were loaded per lane on a 4%-12% PAGE gel (NOVEX). Gels were run in 1XMES buffer. The positive clones were used to grow up for protein purification of the huzalpa11/MBP-6H fusion protein (Example 9, below).

30

### Example 9

#### Purification of huzalpha11/MBP-6H Soluble Receptor From E.coli Fermentation

Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying huzalpha11/MBP-6H soluble receptor polypeptide. *E. coli* cells containing the pCZR225 construct and expressing huzalpha11/MBP-6H soluble receptor (Example 8) were grown up in SuperBroth II (12 g/L Casien, 24 g/L Yeast Extract, 11.4 g/L di-potassium phosphate, 1.7 g/L Mono-potassium phosphate; Becton Dickenson, Cockeysville, MD), and frozen in 0.5% glycerol. Twenty grams of the frozen cells in SuperBroth II + Glycerol were used to purify the protein. The frozen cells were thawed and diluted 1:10 in a protease inhibitor solution (Extraction buffer) prior to lysing the cells and releasing the huzalpha11/MBP-6H soluble receptor protein. The diluted cells contained final concentrations of 20 mM Tris (JT Baker, Philipsburg, NJ) 100 mM Sodium Chloride (NaCl, Mallinkrodt, Paris, KY), 0.5 mM phenylmethylsulfonyl fluoride (PMSF, Sigma Chemical Co., St. Louis, MO), 2 µg/ml Leupeptin (Fluka, Switzerland), and 2 µg/ml Aprotinin (Sigma). A French Press cell breaking system (Constant Systems Ltd., Warwick, UK) with temperature of -7 to -10°C and 30K PSI was used to lyse the cells. The diluted cells were checked for breakage by A<sub>600</sub> readings before and after the French Press. The lysed cells were centrifuged @ 18,000G for 45 minutes to remove the broken cell debris, and the supernatant used to purify the protein. Total target protein concentrations of the supernatant was determined via BCA Protein Assay (Pierce, Rockford, IL), according to manufacturer's instructions.

A 25 ml column of Talon Metal Affinity resin (Clontech, Palo Alto, CA) (prepared as described below) was poured in a Bio-Rad, 2.5 cm D x 10 cm H glass column. The column was packed and equilibrated by gravity with 10 column volumes (CVs) of Talon Equilibration buffer (20mM Tris, 100mM NaCl, pH 8.0). The supernatant was batch loaded to Talon metal affinity resin and was rocked overnight. The resin was poured back into the column and was washed with 10 CV's of Talon Equilibration buffer by gravity, then gravity eluted with 140 ml of Elution buffer (Talon Equilibration buffer + 200mM Imidazole-Fluka Chemical). The talon column was cleaned with 5 CVs of 20mM 2-(N-Morpholino) ethanesulfonic acid pH 5.0 (MES,

Sigma), 5 CVs of distilled H<sub>2</sub>O, then stored in 20% Ethanol/0.1% Sodium Azide. Fourteen ml fractions were collected over the entire elution chromatography and the fractions were read with absorbance at 280 and 320 nm and BCA protein assay; the pass through and wash pools were also saved and analyzed. The protein elution  
5 fractions of interest were pooled and loaded straight to Amylose resin (New England Biolabs, Beverly, MA).

To obtain more pure huzalpha11/MBP-6H polypeptide, the talon affinity elution pooled fractions were subjected to Amylose resin (22mls) at pH 7.4. A 2.5 cm D x 10 cm H Bio-Rad column was poured, packed and equilibrated in 10 CVs of  
10 Amylose equilibration buffer-20mM Tris (JT Baker), 100mM NaCl (Mallinkrodt), 1mM PMSF (Sigma), 10mM *beta*-Mercaptoethanol (BME, ICN Biomedicals Inc., Aurora, OH) pH 7.4. The sample was loaded by gravity flow rate of 0.5 ml/min. The column was washed for 10 CVs with Amylose equilibration buffer, then eluted with ~2 CV of Amylose equilibration buffer + 10 mM Maltose (Fluka Biochemical,  
15 Switzerland) by gravity. 5 ml fractions were collected over the entire chromatography and absorbance at 280 and 320 nm were read. The Amylose column was regenerated with 1 CV of distilled H<sub>2</sub>O, 5 CVs of 0.1% (w/v) SDS (Sigma), 5 CVs of distilled H<sub>2</sub>O, and then 5 CVs of Amylose equilibration buffer.

Fractions of interest were pooled and dialyzed in a Slide-A-Lyzer  
20 (Pierce) with 4 x 4L PBS pH 7.4 (Sigma) to remove low molecular weight contaminants, buffer exchange and desalt. After the changes of PBS, the material harvested represented the purified huzalpha11/MBP-6H polypeptide. The purified huzalpha11/MBP-6H polypeptide was analyzed via SDS-PAGE Coomassie staining and Western blot analysis with the anti-rabbit HRP conjugated antibody (Rockland,  
25 Gilbertsville, PA). The concentration of the huzalpha11/MBP-6H polypeptide was 1.92 mg/ml as determined by BCA analysis.

Purified huzalpha11/MBP-6H polypeptide was prepared for injection into rabbits and sent to R & R Research and Development (Stanwood, WA) for antibody production. Rabbits were injected to produce anti anti-huzalpha11/MBP-6H  
30 serum (Example 10, below).

### Example 10

#### Zalpha11 Soluble Receptor Polyclonal Antibodies

Polyclonal antibodies were prepared by immunizing two female New Zealand white rabbits with the purified huzalpha11/MBP-6H polypeptide (Example 9),  
5 or the purified recombinant zalpha11CEE soluble receptor (Example 6A). Corresponding polyclonal antibodies were designated rabbit anti-huzalpha11/MBP-6H and rabbit anti-huzalpha11-CEE-BHK respectively. The rabbits were each given an initial intraperitoneal (IP) injection of 200 mg of purified protein in Complete Freund's Adjuvant (Pierce, Rockford, IL) followed by booster IP injections of 100 mg purified  
10 protein in Incomplete Freund's Adjuvant every three weeks. Seven to ten days after the administration of the third booster injection, the animals were bled and the serum was collected. The rabbits were then boosted and bled every three weeks.

The zalpha11-specific polyclonal antibodies were affinity purified from the rabbit serum using an CNBr-SEPHAROSE 4B protein column (Pharmacia LKB)  
15 that was prepared using 10 mg of the purified huzalpha11/MBP-6H polypeptide (Example 9) per gram CNBr-SEPHAROSE, followed by 20X dialysis in PBS overnight. Zalpha11-specific antibodies were characterized by an ELISA titer check using 1 mg/ml of the appropriate protein antigen as an antibody target. The lower limit of detection (LLD) of the rabbit anti-huzalpha11/MBP-6H affinity purified antibody is a  
20 dilution of 500 pg/ml. The LLD of the rabbit anti-huzalpha11-CEE-BHK affinity purified antibody is a dilution of 50 pg/ml.

### Example 11

#### Identification of Cells Expressing zalpha11 Receptor Using RT-PCR

25 Specific human cell types were isolated and screened for zalpha11 expression by RT-PCR. B-cells were isolated from fresh human tonsils by mechanical disruption through 100 µm nylon cell strainers (Falcon™; Bectin Dickenson, Franklin Lakes, NJ). The B-cell suspensions were enriched for CD19+ B-cells by positive selection with VarioMACS VS+ magnetic column and CD19 microbeads (Miltenyi  
30 Biotec, Auburn, CA) as per manufacturer's instructions. T-cells and monocytes were isolated from human apheresed blood samples. CD3+ T-cells were purified by CD3

microbead VarioMACS positive selection and monocytes were purified by VarioMACS negative selection columns (Miltyeni) as per manufacturer's instructions. Samples from each population were stained and analyzed by fluorescent antibody cell sorting (FACS) (Bectin Dickinson, San Jose, CA) analysis to determine the percent enrichment and  
5 resulting yields. CD19+ B-cells were approximately 96%, purified CD3+ T-cells were approximately 95% purified, and monocytes were approximately 96% purified.

RNA was prepared, using a standard method in the art, from all three cell types that were either resting or activated. RNA was isolated from resting cells directly from the column preparations above. The CD19+ and CD3+ cells were  
10 activated by culturing at 500,000 cells/ml in RPMI + 10%FBS containing PMA 5ng/ml (Calbiochem, La Jolla, CA) and Ionomycin 0.5ug/ml (Calbiochem) for 4 and 24 hours. The monocytes were activated by culturing in RPMI + 10% FBS containing LPS 10ng/ml (Sigma St. Louis MO) and rhIFN- $\gamma$  10 ng/ml (R&D, Minneapolis, MN) for 24 hours. Cells were harvested and washed in PBS. RNA was prepared from the cell  
15 pellets using RNeasy Midiprep™ Kit (Qiagen, Valencia, CA) as per manufacturer's instructions and first strand cDNA synthesis was generated with Superscript II™ Kit (GIBCO BRL, Grand Island, NY) as per manufacturer's protocol.

Oligos ZC19907 (SEQ ID NO:38) and ZC19908 (SEQ ID NO:39) were used in a PCR reaction to screen the above described samples for a 1.2 kb fragment  
20 corresponding to  $\alpha$ 11 message. PCR amplification was performed with Taq Polymerase (BRL Grand Island NY), and conditions as follows: 35 cycles of 95°C for 1 min., 60°C for 1 min., 72°C for 30 sec.; 1 cycle at 72°C for 10 min.; and 4°C soak. 10ul of each 50  $\mu$ l reaction volume was run on a 2% agarose 1XTAE gel to identify resultant products. PCR products were scored as (-) for no product, (+) for band  
25 visible, (++) increased presence of band and (+++) being the most predominant band, with results shown in Table 5 below.

Table 5

cDNA Source	Activation	PCR Product
CD19+ cells	0hr resting	+
	4hr activated	++
	24hr activated	+++
CD3+ cells	0hr resting	-
	4hr activated	++
	24hr activated	-
monocytes	0hr resting	-
	24hr activated	-

These results indicated that zalpha11 message is present in resting human CD19+ B-cells and increases with mitogenic activation. It also appears to be expressed by human CD3+ T-cells only after 4 hour activation. There was no apparent message in either resting or activated human monocytes.

Example 12Zalpha11 Immunohistochemistry10 A. Cell and tissue preparations

Positive controls consisted of BaF3 cells transfected with zalpha11 receptor (Example 2) and lymphoid tissues known to express zalpha11 receptor including mouse lymph node, spleen and thymus received from HSD (Harlan Sprague Dawley, Indianapolis, IN), monkey lymph node and spleen received from Regional Primate Research Center (University of Washington, Seattle, WA), human lymph node and spleen received from CHTN (Cleveland, OH). Negative controls performed on each sample included: (1) untransfected BaF3 cells, (2) liver and brain tissue from mouse and human known not to express zalpha11 receptor, (3) staining with antibody dilution buffer (Ventann Biotech Systems, Tucson AZ) in the absence of primary antibody, and (4) using zalpha11 soluble receptor protein in competition experiments.

Other cell samples were examined. Both non-stimulated and stimulated HL60 cells were assayed. HL60 cells are a promyelocytic cell line, which can be

differentiated into myeloid or granulocyte lineages with different reagents. Stimulated HL60 samples were prepared as follows: (1) HL60 cells were treated with 10ng/ml of phorbol-myristate-acetate (PMA) (Sigma, St. Louis, MO) for 48 hours to differentiate into monocyte lineage cells; and (2) HL60 cells treated with 1.25% DMSO (Sigma) for 4 days to differentiate into neutrophil-like cells. In addition, human polymorphonuclear (PMN) cells, human granulocytes, human peripheral blood lymphocytes (PBL) and human monocytes from fresh human blood were examined (prepared in house using routine methods in the art). The cells and tissues described above were fixed overnight in 10% NBF (Surgipath, Richmond, IL), and embedded in paraplast X-tra (Oxford Scientific, St. Louis, MO), and sectioned at 5  $\mu$ m with a Reichart-Jung 2050 microme (Leica Instruments GmbH, Nussloch, Germany).

#### B. Immunohistochemistry

Tissue slides were deparaffinized, hydrated to buffer (water), and subjected to steam HIER treatment in Antigen Retrieval Citra buffer (BioGenex, San Roman, CA) for 20 minutes. 5% normal goat serum (Vector, Burlingame, CA) was used to block non-specific binding for 10 minutes. Immunocytochemical screening analyses were performed using polyclonal antibodies to zalpha11 soluble receptor protein (rabbit anti-huzalpa11-MBP-6H and rabbit anti-huzalpa11-CEE-BHK; Example 10) as the primary antibodies, at dilutions of 1:200 and 1:400 respectively. Biotin conjugated goat anti-rabbit IgG (Vector; Cat. No. BA-1000, 1.5 mg/ml) was used as the secondary antibody at dilution of 1:200. In separate samples, protein competition was performed by using additional zalpha11CEE soluble receptor protein (in 10X fold excess) (Example 6A) to the primary antibody to pre-block primary antibody immunoreaction. This competition was used as a control for the rabbit polyclonal antibody specificity to zalpha11. Detection was performed on the Ventana ChemMate 500 instrument using a ChemMate DAB Kit (labeled Streptavidin-Biotin Kit with application of a streptavidin-horseradish peroxidase conjugate, and DAB substrate) according to manufacturer's instruction and using the manufacturer's hematoxylin counterstain for 30 seconds (Ventana Biotek Systems, Tucson, AZ).

High expression of zalpha11 was observed in the PMA-activated HL60 cells. Low level expression was observed in PBL and HL60 cells without stimulation. A subset of cells in the spleen, thymus and lymph node of mouse showed positive staining. Lymph node and spleen of both human and monkey, and HL60 cells with  
5 DMSO stimulation showed minimal or no staining. The signal seen in the cells and tissues was mostly competed out by using the excess zalpha11 soluble receptor protein. The negative control tissues of brain and liver showed no staining.

### Example 13

#### 10 Identifying Peripheral Blood Mononuclear Cells (PBMNC's) That Express zalpha11 Receptor Using Polyclonal Rabbit Anti-sera to zalpha11 Soluble Receptor

200 ml fresh heparinized blood was obtained from a normal donor. Blood was diluted 1:1 in PBS, and separated using a Ficoll-Paque PLUS gradient (Pharmacia Biotech, Uppsala, Sweden), and the lymphocyte interface collected. Cells  
15 were washed 2X in PBS and resuspended in RPMI + 5% FBS media at a concentration of  $2 \times 10^6$  cells/ml.

In order to determine whether expression of zalpha11 receptor is affected by the activation state of the lymphocyte cells, i.e., between resting and activated cells several stimulation conditions were used: 1) unstimulated, i.e., media  
20 alone (RPMI + 5% FBS media); 2) stimulated with PMA 10 ng/ml + Ionomycin 0.5  $\mu$ g/ml (both from Calbiochem); and 3) PHA activation (phytohemagglutinin-P, Difco/VWR). The cells were incubated at 37°C for 17 hours then collected for staining to detect expression of zalpha11 receptor.

An indirect staining protocol was used. Briefly, the human lymphocyte  
25 cells were suspended in staining buffer (PBS + 0.02% NaN<sub>3</sub> + BSA 1% normal human serum 2%) and plated at  $2 \times 10^5$  cells in 50  $\mu$ l/well in a 96 well plate. Antibodies to the zalpha11CEE soluble receptor (Example 15) were used to determine whether they co-stained with a B-cell (CD19), T-cell (CD3) or monocyte marker (CD14) on the isolated human lymphocytes. A rabbit polyclonal sera to zalpha11 soluble receptor (Rb anti-  
30 huzalpa11-CEE-BHK) (Example 10) at 10  $\mu$ g/ml was used as the antibody to identify zalpha11 on the lymphocytes. A secondary antibody, goat anti-rabbit Ig-FITC



(Biosource, Camarillo, CA), was used to visualize the Rb anti-huzalpha11-CEE-BHK antibody binding to the zalpha11 receptors. Other antibodies were simultaneously used to stain T cells (CD3-PE; PharMingen, San Diego, CA), B cells (CD19-PE) (PharMingen), and monocytes (CD14-PE) (PharMingen) in order to identify co-staining of the anti-zalpha11 receptor antibody on these cell types. Various controls were used to determine non-specific binding and background levels of staining: (1) an irrelevant rabbit polyclonal sera was used as a non-specific control; and (2) secondary antibody alone was used to determine background binding of that reagent. Purified, zalpha11CEE soluble receptor (Example 6) was used in about a 10-fold excess as a competitive inhibitor to verify the specificity of the rabbit anti-huzalpha11-CEE-BHK antibody to zalpha11 soluble receptor.

After plating the cells and adding the primary and co-staining antibodies, the cells were incubated on ice for 30 minutes, washed 2X with staining buffer, and stained with the secondary antibody, goat anti-rabbit Ig-FITC (Biosource), for 30 minutes on ice. Cells were washed 2X staining buffer, and resuspended at 200 µl per well in staining buffer containing the viability stain 7AAD at about 1 µg/ml final concentration (Sigma, St. Louis, MO). Samples were read on the FACS-Caliber (Becton-Dickinson, San Jose, CA) and viable cells analyzed.

The rabbit polyclonal to zalpha11 receptor stained resting B cells. The signal on resting B cells was brighter than the signal achieved using the irrelevant rabbit sera, and the signal was diminished to a greater extent on B cells than on T cells with the addition of excess zalpha11-CEE soluble receptor. This experiment was repeated using separated B and T cells, and the results were very similar. Again the staining with the polyclonal rabbit anti-huzalpha11-CEE-BHK antibody to zalpha11 receptor was highest on resting B cells.

Example 14Zalpa11 Receptor Expression in Various Tissues Using Real-Time QuantitativeRT/PCRA. Primers and Probes for Quantitative RT-PCR-

5 Real-time quantitative RT-PCR using the ABI PRISM 7700 Sequence  
Detection System (PE Applied Biosystems, Inc., Foster City, CA) has been previously  
described (See, Heid, C.A. et al., Genome Research 6:986-994, 1996; Gibson, U.E.M.  
et al., Genome Research 6:995-1001, 1996; Sundaresan, S. et al., Endocrinology  
139:4756-4764, 1998. This method incorporates use of a gene specific probe  
10 containing both reporter and quencher fluorescent dyes. When the probe is intact the  
reporter dye emission is negated due to the close proximity of the quencher dye.  
During PCR extension using additional gene-specific forward and reverse primers, the  
probe is cleaved by 5' nuclease activity of Taq polymerase which releases the reporter  
dye from the probe resulting in an increase in fluorescent emission.

15 The primers and probes used for real-time quantitative RT-PCR analyses  
of zalpa11 receptor expression were designed using the primer design software Primer  
Express™ (PE Applied Biosystems, Foster City, CA). Primers for human zalpa11  
receptor were designed spanning an intron-exon junction to eliminate amplification of  
genomic DNA. The forward primer, ZC22,277 (SEQ ID NO:40) and the reverse  
20 primer, ZC22,276 (SEQ ID NO:41) were used in a PCR reaction (below) at about 300  
nM concentration to synthesize a 143 bp product. The corresponding zalpa11  
TaqMan® probe, designated ZG31 (SEQ ID NO:42) was synthesized and labeled by PE  
Applied Biosystems. The ZG31 probe was labeled at the 5' end with a reporter  
fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied Biosystems) and at the 3'  
25 end with a quencher fluorescent dye (6-carboxy-tetramethyl-rhodamine) (TAMRA) (PE  
Applied Biosystems).

As a control to test the integrity and quality of RNA samples tested, all  
RNA samples (below) were screened for rRNA using a primer and probe set ordered  
from PE Applied Biosystems (cat No. 4304483). The kit contains an rRNA forward  
30 primer (SEQ ID NO:43) and the rRNA reverse primer (SEQ ID NO:44), rRNA  
TaqMan® probe (SEQ ID NO:45) The rRNA probe was labeled at the 5'end with a

reporter fluorescent dye VIC (PE Applied Biosystems) and at the 3' end with the quencher fluorescent dye TAMRA (PE Applied Biosystems). The rRNA results also serve as an internal control and allow for the normalization of the zalpha11 mRNA expression results seen in the test samples.

5 RNA samples from human CD3, CD19 and monocyte cell types were prepared and described as per Example 11 above. Control RNA was prepared, using RNeasy Miniprep™ Kit (Qiagen, Valencia, CA) as per manufacturer's instructions, from approximately 10 million BaF3 cells expressing human zalpha11 receptor (Example 2A).

#### 10 B. Real-time quantitative RT-PCR

Relative levels of zalpha11 mRNA were determined by analyzing total RNA samples using the one-step RT-PCR method (PE Applied Biosystems). Total RNA from BaF3 cells expressing human zalpha11 receptor was isolated by standard  
15 methods and used to generate a standard curve used for quantitation. The curve consisted of 10-fold serial dilutions ranging from  $2.5\text{--}2.5 \times 10^{-4}$  ng/ $\mu$ l for the rRNA screen and 250-0.025 ng/ $\mu$ l for the zalpha11 screen with each standard curve point analyzed in triplicate. The total RNA samples from the cells were also analyzed in triplicate for human zalpha11 receptor transcript levels and for levels of rRNA as an  
20 endogenous control. In a total volume of 25  $\mu$ l, each RNA sample was subjected to a One-Step RT-PCR reaction containing: approximately 25 ng of total RNA in buffer A (50 mM KCL, 10 mM Tris-HCL); the internal standard dye, carboxy-x-rhodamine (ROX); appropriate primers (approximately 50 nM rRNA primers (SEQ ID NO:43 and SEQ ID NO:44) for the rRNA samples; and approximately 300 nM ZC22,277 (SEQ ID  
25 NO:40) and ZC22,276 (SEQ ID NO:41) primers for zalpha11 samples); the appropriate probe (approximately 50 nM rRNA TaqMan® probe (SEQ ID NO:45) for rRNA samples, approximately 100 nM ZG31 (SEQ ID NO:42) probe for zalpha11 samples); 5.5 mM MgCl<sub>2</sub>; 300  $\mu$ M each d-CTP, d-ATP, and d-GTP and 600  $\mu$ M of d-UTP; MuLV reverse transcriptase (0.25 U/ $\mu$ l); AmpliTaq™ Gold DNA polymerase (0.025  
30 U/ $\mu$ l) (PE Applied Biosystems); and RNase Inhibitor (0.4 U/ $\mu$ l) (PE Applied Biosystems). PCR thermal cycling conditions were as follows: an initial reverse

transcription (RT) step of one cycle at 48°C for 30 minutes; followed by an AmpliTaq Gold™ (PE Applied Biosystems) activation step of one cycle at 95°C for 10 minutes; followed by 40 cycles of amplification at 95°C for 15 seconds and 60°C for 1 minute.

Relative zalpha11 RNA levels were determined by using the Standard Curve Method as described by the manufacturer, PE Biosystems (User Bulletin No.2: ABI Prism 7700 Sequence Detection System, Relative Quantitation of Gene Expression, December 11, 1997). The rRNA measurements were used to normalize the zalpha11 levels and the resting CD3+ RNA sample was used as a calibrator. Resting CD3 was arbitrarily chosen as the calibrator and given a value of 1.00. The rest of the samples were compared relative to the calibrator. Data are shown in Table 6 below:

Table 6

Sample	Resting	4hr Stimulation	24hr Stimulation
CD3	1.00	15.27	16.70
CD19	20.14	65.08	25.42
Monocytes	0.05	no data	0.26

There was a 15-fold increase in zalpha11 receptor expression in CD3+ at 4 and 24 hrs. Resting CD19 had 20 fold increase in receptor expression relative to resting CD3+. There was a 3 fold increase with 4 hr stimulation that fell back to resting levels by 24 hrs. Monocytes showed no detectable zalpha11 receptor expression in this assay.

C. Purified Human T, NK, and B cells as a Primary Source used to assess human zalpha11 receptor Expression

Whole blood (150 ml) was collected from a healthy human donor and mixed 1:1 with PBS in 50ml conical tubes. Thirty ml of diluted blood was then underlayed with 15 ml of Ficoll Paque Plus (Amersham Pharmacia Biotech, Uppsala, Sweden). These gradients were centrifuged 30 min at 500 g and allowed to stop without braking. The RBC-depleted cells at the interface (PBMC) were collected and

washed 3 times with PBS. The isolated human PBMC yield was  $200 \times 10^6$  prior to selection described below.

The PBMCs were suspended in 1.5 ml MACS buffer (PBS, 0.5% EDTA, 2mM EDTA) and  $3 \times 10^6$  cells were set aside for control RNA and for flow cytometric analysis. The 0.25 ml anti-human CD8 microbeads (Miltenyi Biotec) were added and the mixture was incubated for 15 min at 4 degrees C. These cells labeled with CD8 beads were washed with 30 ml MACS buffer, and then resuspended in 2 ml MACS buffer.

A VS+ column (Miltenyi) was prepared according to the manufacturer's instructions. The VS+ column was then placed in a VarioMACS magnetic field (Miltenyi). The column was equilibrated with 5 ml MACS buffer. The isolated primary mouse cells were then applied to the column. The CD8 negative cells were allowed to pass through. The column was rinsed with 9 ml (3 X 3 ml) MACS buffer. The column was then removed from the magnet and placed over a 15 ml falcon tube. CD8+ cells were eluted by adding 5 ml MACS buffer to the column and bound cells flushed out using the plunger provided by the manufacturer. The yield of CD8+ selected human peripheral T cells was  $51 \times 10^6$  total cells. The CD8-negative flow through cells were collected, counted, stained with anti-human CD4 coated beads, then incubated and passed over a new VS+ column at the same concentrations as described above. The yield of CD4+ selected human peripheral T cells was  $42 \times 10^6$  total cells.

A sample of each of the CD8+ and CD4+ selected human T cells was removed for staining and sorting on a fluorescence activated cell sorter (FACS) to assess their purity. A PE-conjugated anti-human CD4 antibody, an anti-human CD8-FITC Ab, and an anti-human CD19-CyChrome Ab (all from PharMingen) were used for staining the CD8+ and CD4+ selected cells. The CD8-selected cells in this first experiment were 80% CD8+, and the CD4-selected cells were 85% CD4+. In 2 subsequent experiments (Example 14B), the CD8+ purified cells were 84% and 81% pure, and the CD4+ cells were 85% and 97% pure, respectively. In one experiment, we stained the non-binding (flow-through) cells with anti-human CD19-coated beads (Miltenyi) and ran them over a third magnetic bead column to isolate CD19+ B cells (these were 92% pure).

The human CD8+, CD4+ and CD19+ selected cells were activated by incubating  $0.5 \times 10^6$  cells/ml in RPMI + 5% human ultraserum (Gemini Bioproducts, Calabasas, CA) + PMA 10 ng/ml and Ionomycin 0.5  $\mu$ g/ml (Calbiochem) for 4, 16, or 24 hours at 37°C. The T-cells ( $2.5 \times 10^6$ /well) were alternately stimulated in 24-well plates pre-coated overnight with 0.5  $\mu$ g/ml plate-bound anti-CD3 mAb UCHT1 (PharMingen) with or without soluble anti-CD28 mAb (PharMingen) at 5  $\mu$ g/ml. At each timepoint, the cells were harvested, pelleted, washed once with PBS, and pelleted again. The supernatant was removed and the pellets were snap-frozen in a dry ice/ethanol bath, then stored at -80°C for RNA preparation at a later date.

In a separate experiment, human NK cells were enriched from Ficoll PBMC by negative selection using the human NK enrichment system (consisting of antibodies to CD3, CD4, CD14, CD19, CD66b, and glycophorin A) from Stem Cell Technologies (Vancouver, B.C., Canada). Cell pellets were prepared from freshly isolated NK cells from 2 different donors, or from NK cells cultured 24 hours in media only or in media supplemented with 20 ng/ml IL-15. RNA from a human NK cell line derived from a malignant non-Hodgkin's lymphoma and designated NK-92 (ATCC No. CRL-2407) was also tested. As positive controls, RNA was isolated from the human B cell lines CESS (ATCC No. TIB-190), IM-9 (ATCC No. CCL-159), and HS-Sultan (CRL-1484).

Real Time-PCR was performed on these human NK, CD8+, CD4+ and CD19+ selected cells as described above for assessing human zalpha11 receptor expression. Relative levels of zalpha11 receptor RNA were determined by analysis of total RNA samples using the One-Step RT-PCR method (PE Applied Biosystems). RNA from BaF3 cells expressing human zalpha11 receptor was used to generate appropriate control for standard curves for the real-time PCR described in Example 14C above. Results of the experiments analyzing the expression of the zalpha11 Ligand and zalpha receptor in stimulated and unstimulated cells are as described in Example 14D-E below.

D. Expression of human zalph11 Receptor and Ligand in CD4+, CD8+ and CD19+ cells

The first experiment used RT-PCR, described above, to assess zalph11 receptor expression in unstimulated and anti-CD3 stimulated CD4+ and CD8+ samples at timepoints of 0h (unstimulated ("resting") cells), and at 4h, 15.5h and 24h, after stimulatoin. The resting CD4+ sample was arbitrarily chosen as the calibrator and given a value of 1.00. There was approximately a 4-fold increase in receptor expression in unstimulated CD4+ cells from 4h to 24h of culture and about an 8-fold increase over the same time period in anti-CD3 stimulated CD4+ cells. The CD8+ cells showed a 7-fold increase in zalph11 receptor expression that peaked at 4hrs and decreased over time. With anti-CD3 stimulation, the CD8+ cells had a constant 8-fold increase in receptor expression.

The second experiment used RT-PCR to assess zalph11 receptor expression in anti-CD3-stimulated, PMA + Ionomycin-stimulated and unstimulated CD4+ and CD8+ samples at timepoints of 0 h, and at 3.5 h, 16 h and 24 h after activation. The resting CD8+ sample was arbitrarily chosen as the calibrator and given a value of 1.00. The resting CD4+ and CD8+ cells did not have significant amounts of receptor expression. The expression was about 3 fold higher in the PMA + Ionomycin-stimulated CD4+ samples at 3.5 h, 16 h and 24 h after stimulation. The expression in anti-CD3 activated CD4+ cells peaked at 10-fold above background levels at 3.5 h after stimulation, then fell back to levels 4-fold above background at 16 h after stimulation. The CD8+ cells showed a 4-fold expression increase at 3.5 h after PMA + Ionomycin stimulation, with expression decreasing at subsequent timepoints. As in the first experiment, the anti-CD3 stimulated CD8+ cells again exhibited an 8-fold above background induction of receptor expression.

The final experiment used RT-PCR to assess zalph11-receptor expression in anti-CD3- and anti-CD3/anti-CD28-stimulated and unstimulated CD4+ and CD8+ samples at timepoints of 0 h, and at 2 h, 4 h, and 16 h after stimulation. CD19+ cells activated with PMA + Ionomycin were also screened for receptor expression at the same time intervals. The resting CD4+ sample was arbitrarily chosen as the calibrator and given a value of 1.00. The 2h anti-CD3 stimulated CD4+ cells

only had a 4-fold induction of receptor, compared to the 10-fold induction seen at 3.5h in the previous experiment. The combination of anti-CD3 and anti-CD28 increased expression to 8-fold above background. The 16 h anti-CD3/anti-CD28 stimulated CD8+ cells had very low receptor expression levels, as seen in the CD8+ cells in previous experiments (above). The CD19+ cells stimulated with PMA + Ionomycin had the most significant receptor expression with a 19-fold increase at 2h, but the expression levels decreased back to those of resting cells by 16h.

A certain amount of variation was expected between blood draws (i.e. multiple samples at different times from the same patient and between multiple patients). Therefore, data trends were analyzed within each study or from a single blood sample and the three experiments above were compared for an overall conclusion. The trend from the Real Time PCR experiments described above is that of all the cell types tested, CD19+ B cells activated with PMA + ionomycin expressed the highest levels of  $\alpha 11$  receptor RNA. CD4+ and CD8+ cells can also be stimulated to express receptor, but at lower levels than in B cells.

#### E. Expression of human $\alpha 11$ Receptor in human NK cells

Real Time PCR was also performed on human NK cells, purified as described in Example 14C, above. The NK-92 sample was arbitrarily chosen as the calibrator and given a value of 1.00. There was approximately a 4.5-fold increase in receptor expression in the positive control CESS cells, a 1.5-fold increase in IM-9 cells, and no increase in the HS-Sultan cells (0.9-fold relative to NK-92). The NK cells, either fresh or cultured overnight with or without IL-15, expressed very similar levels of  $\alpha 11$  Receptor as NK-92 (with values ranging from 0.9–1.2-fold different relative to NK-92).

#### Example 15

##### Identification of Cells Expressing $\alpha 11$ Receptor Using *in situ* Hybridization

Specific human tissues were isolated and screened for  $\alpha 11$  expression by *in situ* hybridization. Various human tissues prepared, sectioned and subjected to *in situ* hybridization included thymus, spleen, tonsil, lymph node and lung.



The tissues were fixed in 10% buffered formalin and blocked in paraffin using standard techniques. Tissues were sectioned at 4 to 8 microns. Tissues were prepared using a standard protocol ("Development of non-isotopic *in situ* hybridization" at <http://dir.niehs.nih.gov/dirlep/ish.html>). Briefly, tissue sections were deparaffinized with HistoClear (National Diagnostics, Atlanta, GA) and then dehydrated with ethanol. Next they were digested with Proteinase K (50 µg/ml) (Boehringer Diagnostics, Indianapolis, IN) at 37°C for 2 to 20 minutes. This step was followed by acetylation and re-hydration of the tissues.

Two *in situ* probes generated by PCR were designed against the human *zalpha11* sequence. Two sets of oligos were designed to generate probes for separate regions of the *zalpha11* cDNA: (1) Oligos ZC23,684 (SEQ ID NO:60) and ZC23,656 (SEQ ID NO:61) were used to generate a 413 bp probe for *zalpha11*; and (2) Oligos ZC23,685 (SEQ ID NO:62) and ZC23,657 (SEQ ID NO:63) were used to generate a 430 bp probe for *zalpha11*. The second probe is 1500 bp 3' of the first *zalpha11* probe. The antisense oligo from each set also contained the working sequence for the T7 RNA polymerase promoter to allow for easy transcription of antisense RNA probes from these PCR products. The PCR reaction conditions were as follows: 30 cycles at 94°C for 30 sec, 60°C for 1 min., 72°C for 1.5 min. The PCR products were purified by Qiagen spin columns followed by phenol/chloroform extraction and ethanol precipitation. Probes were subsequently labeled with digoxigenin (Boehringer) or biotin (Boehringer) using an *In Vitro* transcription System (Promega, Madison, WI) as per manufacturer's instruction.

*In situ* hybridization was performed with a digoxigenin- or biotin-labeled *zalpha11* probe (above). The probe was added to the slides at a concentration of 1 to 5 pmol/ml for 12 to 16 hours at 55-60°C. Slides were subsequently washed in 2XSSC and 0.1XSSC at 50°C. The signals were amplified using tyramide signal amplification (TSA) (TSA, *in situ* indirect kit; NEN) and visualized with Vector Red substrate kit (Vector Lab) as per manufacturer's instructions. The slides were then counter-stained with hematoxylin (Vector Laboratories, Burlingame, CA).

A signal was seen in the thymus, tonsil, lung, and lymph node. The positive-staining cells appeared to be lymphocytes.

### Example 16

#### Secretion Trap Assay

A secretion trap assay was used to identify the cDNA for the zalpha11  
5 Ligand. The positive DNA pools obtained from the expression cloning effort were described in commonly owned US Patent application No. 09/522,217.

Conditioned medium from DNA clones transfected into BHK cells in  
96-well format, were put into the proliferation assay using BaF3/zalpha11 cells  
described in Example 2. Several DNA pools gave positive activities that were repeated  
10 and neutralized with zalpha11 soluble receptors (Example 6). One positive DNA pool was transfected into COS cells in 12-well format, using the Lipofectamine™ method described below.

A secretion trap assay was then performed using zalpha11 soluble  
receptors (C-terminal Glu-Glu tagged either with or without biotinylation; C-terminal  
15 Flag tagged; or Fc4 zalpha11 soluble receptor fusions) (Example 6) to test the direct binding between the zalpha11 Ligand in the positive pool and zalpha11 soluble receptors (see below). The result was positive, enabling the detection and isolation of clones expressing the zalpha11 Ligand. Plates were shaken at 37°C for 24 hours, and then DNA minipreps (QiaPrep™ 96 Turbo Miniprep Kit; Qiagen) were prepared in 96-  
20 well format using a TomTech Quadra 9600. The plasmid DNA was then pooled in the format of rows and columns, transfected into COS cells, and then the positive pools were determined by secretion trap as described below.

#### COS Cell Transfections

25 The COS cell transfection was performed as follows: Mix 3ul pooled DNA and 5ul Lipofectamine™ in 92ul serum free DMEM media (55mg sodium pyruvate, 146mg L-glutamine, 5mg transferrin, 2.5mg insulin, 1µg selenium and 5mg fetuin in 500ml DMEM), incubate at room temperature for 30 minutes and then add 400ul serum free DMEM media. Add this 500ul mixture onto  $1.5 \times 10^5$  COS cells/well  
30 plated on 12-well tissue culture plate and incubate for 5 hours at 37°C. Add 500ul 20%

FBS DMEM media (100 ml FBS, 55 mg sodium pyruvate and 146mg L-glutamine in 500ml DMEM) and incubate overnight.

#### Secretion Trap Assay

5                   The secretion trap was performed as follows: Media was rinsed off cells with PBS and then fixed for 15 minutes with 1.8% Formaldehyde in PBS. Cells were then washed with TNT (0.1M Tris-HCL, 0.15M NaCl, and 0.05% Tween-20 in H<sub>2</sub>O), and permeated with 0.1% Triton-X in PBS for 15 minutes, and again washed with TNT. Cells were blocked for 1 hour with TNB (0.1M Tris-HCL, 0.15M NaCl and 0.5%  
10   Blocking Reagent (NEN Renaissance TSA-Direct Kit) in H<sub>2</sub>O), and washed again with TNT. If using the biotinylated protein, the cells were blocked for 15 minute incubations with Avidin and then Biotin (Vector Labs), washing in-between with TNT. Depending on which soluble receptor was used, the cells were incubated for 1 hour with: (A) 1-3 µg/ml zalpha11 soluble receptor zalpha11-Fc4 fusion protein (Example  
15   6); (B) 3 µg/ml zalpha11 soluble receptor C-terminal FLAG tagged, zalpha11CFLG (Example 6); (C) 3 µg/ml zalpha11 soluble receptor C-terminal GluGlu tagged, zalpha11CEE (Example 6); or (D) 3 µg/ml biotinylated zalpha11 soluble receptor zalpha11CEE (Example 6) in TNB. Cells were then washed with TNT. Depending on which soluble receptor was used, cells were incubated for another hour with: (A) 1:200  
20   diluted goat-anti-human Ig-HRP (Fc specific); (B) 1:1000 diluted M2-HRP; (C) 1:1000 diluted anti-GluGlu antibody-HRP; or (D) 1:300 diluted streptavidin-HRP (NEN kit) in TNB. Again cells were washed with TNT.

                  Positive binding was detected with fluorescein tyramide reagent diluted 1:50 in dilution buffer (NEN kit) and incubated for 4-6 minutes, and washed with TNT.  
25   Cells were preserved with Vectashield Mounting Media (Vector Labs Burlingame, CA) diluted 1:5 in TNT. Cells were visualized using a FITC filter on fluorescent microscope.

Example 17Mouse zalpha11 Ligand Binds to Human zalpha11 Soluble Receptor in  
Secretion Trap Assay

5 A plasmid containing DNA encoding the mouse zalpha11 Ligand (SEQ ID NO:47) was transfected into COS cells, and the binding of human zalpha11 soluble receptor zalpha11-Fc4 (Example 6C) to the transfected COS cells was tested by a secretion trap assay (Example 16). The assay confirmed that the mouse zalpha11 Ligand binds to human zalpha11 soluble receptor.

The COS cell transfection was performed as per Example 16 using 0.7  
10 µg of the plasmid in 3 µl. The secretion trap was performed as as per Example 16 using 1 µg/ml zalpha11 soluble receptor Fc4 fusion protein (Example 6C) in TNB, and 1:200 diluted goat-anti-human Ig-HRP (Fc specific) in TNB for the detectable antibody. Positive binding of the soluble human zalpha11 receptor to the prepared fixed cells was detected with fluorescein tyramide reagent, preserved and visualized according to  
15 Example 16. The positive result indicated the mouse zalpha11 Ligand binds to human zalpha11 soluble receptor.

Example 18Mouse zalpha11 Ligand Activates Human zalpha11 Receptor in BaF3 AassayUsing Alamar Blue

20 BaF3/Zalpha11 cells were spun down, washed and plated in mIL-3 free media as described in Example 2. Proliferation of the BaF3/Zalpha11 cells was assessed using serum-free conditioned media from BHK cells expressing mouse zalpha11 Ligand (SEQ ID NO:47). Conditioned media was diluted with mIL-3 free  
25 media to: 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. The proliferation assay was performed as per Example 2. Results confirmed the proliferative response of the BaF3/Zalpha11 cells to mouse zalpha11 Ligand. The response, as measured, was approximately 5-fold over background at the 50% concentration.

### Example 19

#### Zalpa11 Ligand Activates Human zalpa11 Receptor in Luciferase Assay

##### A. Construction of BaF3/KZ134/zalpa11 cell line

The KZ134 plasmid was constructed with complementary  
5 oligonucleotides ZC12,749 (SEQ ID NO:48) and ZC12,748 (SEQ ID NO:49) that  
contain STAT transcription factor binding elements from 4 genes. A modified c-fos Sis  
inducible element (m67SIE, or hSIE) (Sadowski, H. et al., Science 261:1739-1744,  
1993), the p21 SIE1 from the p21 WAF1 gene (Chin, Y. et al., Science 272:719-722,  
1996), the mammary gland response element of the  $\beta$ -casein gene (Schmitt-Ney, M. et  
10 al., Mol. Cell. Biol. 11:3745-3755, 1991), and a STAT inducible element of the Fcg RI  
gene, (Seidel, H. et al., Proc. Natl. Acad. Sci. 92:3041-3045, 1995). These  
oligonucleotides contain Asp718-XhoI compatible ends and were ligated, using  
standard methods, into a recipient firefly luciferase reporter vector with a c-fos  
promoter (Poulsen, L.K. et al., J. Biol. Chem. 273:6229-6232, 1998) digested with the  
15 same enzymes and containing a neomycin selectable marker. The KZ134 plasmid was  
used to stably transfect BaF3 cells, using standard transfection and selection methods,  
to make the BaF3/KZ134 cell line.

A stable BaF3/KZ134 indicator cell line, expressing the full-length  
zalpa11 receptor was constructed as per Example 1, using about 30 $\mu$ g of the zalpa11  
20 expression vector. Clones were diluted, plated and selected using standard techniques.  
Clones were screened by luciferase assay (see Example 19B, below) using the human  
zalpa11 Ligand conditioned media as an inducer. Clones with the highest luciferase  
response (via STAT luciferase) and the lowest background were selected. A stable  
transfectant cell line was selected. The cell line was called BaF3/KZ134/zalpa11.

25

##### B. Human and mouse Zalpa11 Ligand activates human zalpa11 receptor in BaF3/KZ134/Zalpa11 luciferase assay

BaF3/KZ134/Zalpa11 cells were spun down and washed in mIL-3 free  
media. The cells were spun and washed 3 times to ensure removal of mIL-3. Cells  
30 were then counted in a hemacytometer. Cells were plated in a 96-well format at about  
30,000 cells per well in a volume of 100  $\mu$ l per well using the mIL-3 free media. The

same procedure was used for untransfected BaF3/KZ134 cells for use as a control in the subsequent assay.

STAT activation of the BaF3/KZ134/Zalpa11 cells was assessed using conditioned media from (1) BHK570 cells transfected with an expression vector encoding the human zalpa11 Ligand (SEQ ID NO:10) or (2) BHK570 cells transfected with an expression vector encoding the mouse zalpa11 Ligand (SEQ ID NO:47), or (3) mIL-3 free media to measure media-only control response. Conditioned media was diluted with RPMI mIL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. 100 µl of the diluted conditioned media was added to the BaF3/KZ134/Zalpa11 cells. The assay using the conditioned media was done in parallel on untransfected BaF3/KZ134 cells as a control. The total assay volume was 200 µl. The assay plates were incubated at 37°C, 5% CO<sub>2</sub> for 24 hours at which time the cells were pelleted by centrifugation at 2000 rpm for 10 min., and the media was aspirated and 25 µl of lysis buffer (Promega) was added. After 10 minutes at room temperature, the plates were measured for activation of the STAT reporter construct by reading them on a luminometer (Labsystems Luminoskan, model RS) which added 40 µl of luciferase assay substrate (Promega) at a five second integration.

Results confirmed the STAT reporter response of the BaF3/KZ134/Zalpa11 cells to the human zalpa11 Ligand. The response, as measured, was approximately 50 fold over media-only control at the 50% concentration. STAT activation in response to human zalpa11 Ligand was absent in the untransfected BaF3/KZ134 control cells, showing that the response is mediated through the Zalpa11 receptor.

Results also confirmed the STAT reporter response of the BaF3/KZ134/Zalpa11 cells to the mouse zalpa11 Ligand. The response, as measured, was approximately 40 fold over media-only control at the 50% concentration. Moreover, STAT activation in response to mouse zalpa11 Ligand was evident (about 5-fold) on the untransfected BaF3/KZ134 control cells, suggesting that the murine BaF3 cells may have endogenous mouse receptor.

Example 20Mouse  $\alpha$ 11 Ligand is Active in Mouse Bone Marrow AssayA. Isolation of Non-adherent Low Density Marrow Cells:

Fresh mouse femur aspirate (marrow) was obtained from 6-10 week old male Balb/C or C57BL/6 mice. The marrow was then washed with RPMI+10% FBS (JRH, Lenexa KS; Hyclone, Logan UT) and suspended in RPMI+10% FBS as a whole marrow cell suspension. The whole marrow cell suspension was then subjected to a density gradient (Nycoprep, 1.077, Animal; Gibco BRL) to enrich for low density, mostly mononuclear, cells as follows: The whole marrow cell suspension (About 8 ml) was carefully pipetted on top of about 5 ml Nycoprep gradient solution in a 15 ml conical tube, and then centrifuged at 600X g for 20 minutes. The interface layer, containing the low density mononuclear cells, was then removed, washed with excess RPMI+10% FBS, and pelleted by centrifugation at 400X g for 5-10 minutes. This pellet was resuspended in RPMI +10% FBS and plated in a T-75 flask at approximately  $10^6$  cells/ml, and incubated at 37°C 5% CO<sub>2</sub> for approximately 2 hours. The resulting cells in suspension were Non-Adherent Low Density (NA LD) Marrow Cells.

B. 96-Well Assay

NA LD Mouse Marrow Cells were plated at 25,000 to 45,000 cells/well in 96 well tissue culture plates in RPMI +10% FBS + 1ng/mL mouse Stem Cell Factor (mSCF) (R&D Systems, Minneapolis, MN), plus 5% conditioned medium from one of the following: (1) BHK 570 cells expressing mouse  $\alpha$ 11 Ligand (SEQ ID NO:47), (2) BHK 570 cells expressing human  $\alpha$ 11 Ligand (SEQ ID NO:10), or (3) control BHK 570 cells containing vector and not expressing either Ligand. These cells were then subjected to a variety of cytokine treatments to test for expansion or differentiation of hematopoietic cells from the marrow. To test, the plated NA LD mouse marrow cells were subjected to human Interleukin-15 (hIL-15) (R&D Systems), or one of a panel of other cytokines (R&D Systems). Serial dilution of hIL-15, or the other cytokines, were tested, with 2-fold serial dilution from about 50 ng/ml down to about 6025 ng/ml concentration. After 8 to 12 days the 96-well assays were scored for cell proliferation by Alamar blue assay as described in Example 2.

C. Results from the 96-well NA LD Mouse Marrow assay

Conditioned media from the BHK cells expressing both mouse and human zalpha11 Ligand acted in synergy with hIL-15 to promote the expansion of a population of hematopoietic cells in the NA LD mouse marrow. This expansion of hematopoietic cells was not shown with control BHK conditioned medium plus IL-15. The population hematopoietic cells expanded by the mouse zalpha11 Ligand with hIL-15, and those hematopoietic cells expanded by the human zalpha11 Ligand with hIL-15, were further propagated in cell culture. These hematopoietic cells were stained with a Phycoerythrin labeled anti-Pan NK cell antibody (PharMingen) and subjected to flow cytometry analysis, which demonstrated that the expanded cells stained positively for this natural killer (NK) cell marker.

The same 96-well assay was run, using fresh human marrow cells bought from Poietic Technologies, Gaithersburg, MD. Again, in conjunction with IL-15, the mouse and human zalpha11 Ligand expanded a hematopoietic cell population that stained positively for the NK cell marker using the antibody disclosed above.

The soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  can be used in this assay to measure binding, antagonist or inhibitory effects of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  on the zalpha11 Ligand.

Example 21Purification of zalpha11-MBP Receptor

Unless otherwise stated, all operations were carried out at 4°C. The following procedure was used for purifying human (or mouse) zalpha11-MBP soluble receptor fusions from *E. coli* (Example 8). Pre-spun frozen *E. coli* paste was thawed and diluted into 2 liters of Buffer B (0.02 M TRIS (EM Science); 0.2 M NaCl (Mallincrodt); 0.01 M 2-mercapto-ethanol (EM Science); pH 8.0; with 5 mg/l Pepstatin A (Boehringer Mannheim); 5 mg/l Aprotinin (Boehringer Mannheim); and 1 mg/l PMSF (Fluka)) plus 1-2 ml of an anti-foaming reagent AF289 antifoam (Sigma). The



mixture was processed in a pre-chilled French Press cell disrupter (Constant Systems LTD) with 20-30 kPSI

The lysate was then centrifuged at 18,000 x g for 45 minutes at 4°C and the supernatant retained. A 200 ml slurry of Amylose resin (New England BioLabs),  
5 pre-equilibrated in Buffer A (0.02 M TRIS (EM Science); 0.2 M NaCl (Mallincrodt); 0.01 M 2-mercapto-ethanol (EM Science); pH 8.0), was added to the lysate supernatant and incubated overnight in 2l roller bottles to allow for maximum batch absorption of the MBP fusion protein. The resin was washed in batch column format for  $\geq 5$  column volumes with Buffer A, then batch eluted with Buffer C (Buffer A with 0.02 M Maltose  
10 (Sigma). Crude fractions were collected and monitored by absorbance 280 nm.

The eluted protein was analyzed by SDS NuPAGE (NOVEX) Coomassie (Sigma) staining. Sample and bulk protein were stored at -80°C.

### Example 22

#### 15 Activity of Human and Mouse $\alpha$ 11 Ligand Expanded Cells and Mature Murine NK Cells in NK Cell Cytotoxicity Assays

##### A. NK cell assay

NK cell-mediated target cytolysis was examined by a standard  $^{51}\text{Cr}$ -release assay. Target cells (K562 cells (ATCC No. CCL-243) in human assays, and  
20 YAC-1 cells (ATCC No. TIB-160) in mouse assays) lack expression of major histocompatibility complex (MHC) molecules, rendering them susceptible to NK cell-mediated lysis. A negative control target cell line in mouse assays is the MHC<sup>+</sup> thymoma EL4 (ATCC No. TIB-39). We grew K562, EL4, and YAC-1 cells in RP10 medium (standard RPMI 1640 (Gibco/BRL, Grand Island, NY) supplemented with  
25 10% FBS (Hyclone, Logan, UT), as well as 4 mM glutamine (Gibco/BRL), 100 IU/ml penicillin+100 MCG/ml streptomycin (Gibco/BRL), 50  $\mu\text{M}$   $\beta$ -mercaptoethanol (Gibco/BRL) and 10mM HEPES buffer (Gibco/BRL). On the day of assay,  $1\text{-}2 \times 10^6$  target cells were harvested and resuspended at  $2.5\text{-}5 \times 10^6$  cells/ml in RP10 medium. We added 50-100  $\mu\text{l}$  of 5 mCi/ml  $^{51}\text{Cr}$ -sodium chromate (NEN, Boston, MA) directly to the  
30 cells and incubated them for 1 hour at 37°C, then washed them twice with 12 ml of PBS and resuspended them in 2 ml of RP10 medium. After counting the cells on a

hemacytometer, the target cells were diluted to  $0.5-1 \times 10^5$  cells/ml and 100  $\mu$ l ( $0.5-1 \times 10^4$  cells) were mixed with effector cells as described below.

In human assays, effector cells were prepared from selected and expanded human CD34<sup>+</sup> BM cells which were harvested, washed, counted, mixed at various concentrations with <sup>51</sup>Cr-labeled target cells in 96-well round bottomed plates, and incubated for 4 hours at 37°C. After co-incubation of effector cells and the labeled target cells, half of the supernatant from each well was collected and counted in a gamma counter for 1 min/sample. The percentage of specific <sup>51</sup>Cr release was calculated from the formula  $100 \times (X-Y)/(Z-Y)$ , where X is <sup>51</sup>Cr release in the presence of effector cells, Y is the spontaneous release in the absence of effectors, and Z is the total <sup>51</sup>Cr release from target cells incubated with 0.5% Triton X-100. Data were plotted as the % specific lysis versus the effector-to-target ratio in each well.

#### B. Activity of human $\alpha$ 11 Ligand expanded cells

Isolated CD34<sup>+</sup> human HPCs cultured with flt3 +/-  $\alpha$ 11 Ligand and flt3 +IL-15 +/-  $\alpha$ 11 Ligand, were harvested the cells on day 15 to assess their capacity to lyse MHC<sup>-</sup> K562 cells in a standard <sup>51</sup>Cr-release assay as described above, and to analyze their surface phenotype by flow cytometry. As expected from previous reports (Mrozek, E et al., Blood 87:2632-2640, 1996; and Yu, H et al., Blood 92:3647-3657, 1998), simultaneous addition of IL-15 and flt3L did induce the outgrowth of a small population of CD56<sup>+</sup> cells. Interestingly, although BM cells cultured simultaneously with  $\alpha$ 11 Ligand and flt3L did not expand significantly, there was a significant increase in total cell numbers in cultures containing a combination of flt3L,  $\alpha$ 11 Ligand and IL-15.

For an assessment of the surface phenotype of these human BM cultures, we stained small aliquots of the cells for 3-color flow cytometric analysis with anti-CD3-FITC, anti-CD56-PE and anti-CD16-CyChrome mAbs (all from PharMingen, San Diego, CA) and analyzed them on a FACSCalibur using CellQuest software (Becton Dickinson, Mountain View, CA). This flow cytometric analysis confirmed that the cells growing out of these cultures were differentiated NK cells, as they were large and granular and expressed both CD56 and CD16, and were CD3<sup>-</sup> (Lanier, LL Annu. Rev.

Immunol. 16:359-393, 1998). Furthermore, these cells exhibited significantly higher effector function than those cells grown with IL-15 and flt3. More specifically, cells grown in all three cytokines lysed more than 40% of the K562 targets at an effector-to-target ratio (E:T) of 1.5, whereas cells grown in IL-15+flt3L lysed fewer than 5% of the targets at an E:T of 2. These data demonstrate that, in combination with IL-15, 5      zalpha11 Ligand (commonly owned US Pat. Application No. 09/522,217) stimulates the differentiation of NK cells from CD34<sup>+</sup> BM cells.

#### C. Activity of mouse zalpha11 Ligand expanded cells

10                      To test the effects of mouse zalpha11 Ligand (commonly owned US Pat. Application No. 09/522,217) on murine hematopoietic progenitor cells, purified Lineage-negative (Lin<sup>-</sup>) bone marrow cells from C57Bl/6 mice were expanded in flt3+IL-15+/- zalpha11 Ligand. On day 6 of culture, the cells ("effectors") were harvested and counted, then resuspended in 0.4 ml of RP10 medium (Example 22A).  
15      Two aliquots (0.15 ml each) of each sample expanded with or without zalpha11 Ligand (Example 22A) were diluted serially 3-fold in duplicate in 96-well round bottomed plates, for a total of 6 wells of 100 µl each. The remaining 100 µl of cells were stained for NK cell surface markers with FITC-anti-2B4 and PE-anti-DX5 mAbs (PharMingen) and analyzed by flow cytometry. Each group of cells exposed to flt3+IL-15 with or  
20      without the presence of mouse zalpha11 Ligand had similar fractions of 2B4+DX5+ cells, ranging from 65-75% positive for both NK markers.

For the NK lysis assay, target cells (YAC-1 and EL4) were labeled with <sup>51</sup>Cr as described above. After counting the target cells on a hemacytometer, the target cells were diluted to 0.5-1x10<sup>5</sup> cells/ml and 100 µl of YAC-1 or EL4 (0.5-1x10<sup>4</sup> cells)  
25      were mixed with 100 µl effector cells and incubated for 4 hours at 37°C. Specific lysis was determined for each well as described above.

We found that cells grown in the presence of flt3+IL-15+zalpha11 Ligand exhibited enhanced lytic activity (roughly 2-fold) against the YAC-1 targets (but did not kill the MHC<sup>+</sup> control cell line EL4). At an effector-to-target ratio (E:T) of 5,  
30      NK cells generated in the presence of all 3 cytokines (zalpha11 Ligand+flt3+IL-15) lysed 12% of the YAC-1 cells, whereas those NK cells expanded with flt3+IL-15 lysed

6% of the YAC-1 targets. Subsequent experiments confirmed this trend.

In a second approach to determine the biological activity of zalpha11 Ligand on murine NK cells, we isolated immature CD4<sup>-</sup>CD8<sup>-</sup> ("double negative", DN) mouse thymocytes using routine methods and cultured them with IL-15+flt3+IL-7 or IL-15+flt3+IL-2, with or without zalpha11 Ligand. On day 6 of culture, the cells were harvested and assayed for NK lytic activity on YAC-1 and EL4 cells as described above. We found that cells cultured in the presence of zalpha11 Ligand had the greatest lytic activity in this assay, with enhanced lytic activity over those cells cultured in the presence of the other cytokines. Specifically, DN thymocytes grown with IL-15+flt3+IL-7 killed 18% of the YAC-1 cells at E:T of 24 while cells grown in the presence of IL-15+flt3+IL-7 plus zalpha11 Ligand killed 48% of the targets at the same E:T. DN thymocytes grown in IL-15+flt3+IL-2 killed 15% of the YAC-1 targets at an E:T of 6, whereas cells grown with these 3 cytokines and zalpha11 Ligand killed 35% of the YAC-1 cells at an E:T of 9. Flow cytometry was performed on the cultured cells one day before the NK lysis assay. As was true for the bone marrow cultures, despite the proliferative effect of zalpha11 Ligand (cell numbers increase approximately 2-fold when zalpha11 Ligand is added), it did not significantly enhance the fraction of DX5<sup>+</sup> cells (17-20% of total cells in the cultures with IL-7, and 35-46% of total in cultures with IL-2). These data imply that zalpha11 Ligand, in combination with IL-15 and flt3, enhances the lytic activity of NK cells generated from murine bone marrow or thymus.

#### D. Activity of mouse zalpha11 Ligand on Mature murine NK cells

In order to test the effects of mouse zalpha11 Ligand on mature NK cells, we isolated spleens from four 5-week old C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) and mashed them with frosted-end glass slides to create a cell suspension. Red blood cells were removed by hypotonic lysis as follows: cells were pelleted and the supernatant removed by aspiration. We disrupted the pellet with gentle vortexing, then added 900 µl of sterile water while shaking, followed quickly (less than 5 sec later) by 100 µl of 10X HBSS (Gibco/BRL). The cells were then resuspended in 10 ml of 1X HBSS and debris was removed by passing the cells over a nylon mesh-lined cell strainer (Falcon). These RBC-depleted spleen cells were then pelleted and

resuspended in MACS buffer (PBS+1%BSA+2mM EDTA) and counted. We stained  $300 \times 10^6$  of the cells with anti-DX5-coated magnetic beads (Miltenyi Biotec) and positively selected DX5<sup>+</sup> NK cells over a MACS VS+ separation column, according to the manufacturer's instructions, leading to the recovery of  $8.4 \times 10^6$  DX5<sup>+</sup> cells and 5  $251 \times 10^6$  DX5<sup>-</sup> cells. Each of these groups of cells were cultured in 24-well plates ( $0.67 \times 10^6$  cells/well, 2 wells per treatment condition) in RP10 medium (Example 22A) alone or with 1) 30 ng/ml mouse zalpha11 Ligand (commonly owned US Pat. Application No. 09/522,217), 2) 30 ng/ml recombinant mouse IL-2 (R&D Systems, Inc., Minneapolis, MN), 3) 30 ng/ml recombinant human IL-15 (R&D), 4) 30 ng/ml 10 each of mouse zalpha11 Ligand and hIL-15, or 5) 30 ng/ml each of mIL-2 and hIL-15. The cells were harvested after 21 hours, washed, and resuspended in RP10 medium and counted. The cells were then assayed for their ability to lyse <sup>51</sup>Cr-labeled YAC-1 or EL4 targets cells, as described in Example 22A.

In general, there was little NK activity from the DX5<sup>-</sup> (non-NK cells) 15 groups, but the DX5<sup>-</sup> cells cultured with zalpha11 Ligand and hIL-15 did lyse 25% of the YAC-1 target cells at an E:T of 82. By comparison, DX5<sup>-</sup> cells cultured with hIL-15 alone lysed 14% of the YAC-1 targets at an E:T of 110. This suggests that zalpha11 Ligand and IL-15 are acting together on the residual NK1.1<sup>+</sup> NK cells in this cell preparation. As for the DX5<sup>+</sup> cell preparation, treatment with mouse zalpha11 Ligand 20 alone did not significantly increase their effector function (their lysis of YAC-1 cells was similar to the untreated group). As expected, both IL-2 and IL-15 significantly improved NK activity. The highest level of lysis, however, was detected in the group treated with zalpha11 Ligand and hIL-15 (65% lysis of YAC-1 cells at an E:T of 3.3, vs. 45% lysis at an E:T of 4 for the hIL-15 treatment group). Taken together, these 25 results suggest that although zalpha11 Ligand alone may not increase NK cell lysis activity, it does enhance NK lysis activity of mature NK cells, when administered with IL-15.

The soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  can be used in this assay to measure 30 binding, antagonist or inhibitory effects of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  on the zalpha11

Ligand.

Example 23

Zalpa11 Ligand Proliferation of Human and Mouse T-cells in a

5

T-cell Proliferation Assay

A. Murine Zalpa11 Ligand Proliferation of Mouse T-cells

T cells from C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were isolated from pooled splenocytes and lymphocytes from axillary, brachial, inguinal, cervical, and mesenteric lymph nodes (LNs). Spleens were mashed with  
10 frosted-end glass slides to create a cell suspension. LNs were teased apart with forceps and passed through a cell strainer to remove debris. Pooled splenocytes and LN cells were separated into CD8<sup>+</sup> and CD4<sup>+</sup> subsets using two successive MACS magnetic separation columns, according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA). Whole thymocytes were collected from the same mice.

15

Cells were cultured at  $3 \times 10^5$  cells/well (thymocytes) or  $10^5$  cells/well (mature T cells) with increasing concentrations of purified murine zalpa11 Ligand (0-30 ng/ml) (commonly owned US Patent Application No. 09/522,217) in 96-well flat bottomed plates pre-coated overnight at 4°C with various concentrations of anti-CD3 mAb 2C11 (PharMingen) for 3 days at 37°C. The anti-CD3 antibody served to activate  
20 the murine T-cells through the T-cell receptor. Each well was pulsed with  $1 \mu\text{Ci } ^3\text{H}$ -thymidine on day 2 and plates were harvested and counted 16 hours later to assess proliferation.

When we tested zalpa11 Ligand in T cell proliferation assays, we found that it co-stimulated anti-CD3-activated murine thymocytes, leading to an accelerated  
25 outgrowth of CD8<sup>+</sup>CD4<sup>-</sup> cells (the majority of the thymocytes cultured with anti-CD3+zalpa11 Ligand were CD8<sup>+</sup>CD4<sup>-</sup> by day 3 of culture, while cells cultured with anti-CD3 alone did not significantly skew to this phenotype until day 5). We did not observe significant levels of proliferation of thymocytes to zalpa11 Ligand in the absence of anti-CD3.

30

Interestingly, when we assayed mature peripheral murine T cells for their ability to respond to zalpa11 Ligand+anti-CD3, we found that only the CD8<sup>+</sup>, but not

the CD4<sup>+</sup> subset, responded in a dose-dependent manner to zalpha11 Ligand. We also observed weak but reproducible proliferation of CD8<sup>+</sup> cells (but not CD4<sup>+</sup> cells) in response to zalpha11 Ligand alone. Interestingly, this was not observed for human T cells (see Example 22B, below).

5

#### B. Human Zalpha11 Ligand Proliferation of Human T-cells

Human CD4<sup>+</sup> and CD8<sup>+</sup> T cells were isolated from PBMC as described in Example 14. Cells were cultured at about 10<sup>5</sup> cells/well with increasing concentrations of purified human zalpha11 Ligand (0-50 ng/ml) (commonly owned US Patent Application No. 09/522,217) in 96-well flat bottomed plates pre-coated overnight at 4°C with various concentrations of anti-human CD3 mAb UCHT1 (PharMingen) for 3 days at 37°C. Each well was pulsed with 1uCi <sup>3</sup>H-thymidine on day 2 and plates were harvested and counted 16 hours later. Unlike our results with mouse T cells, our preliminary data suggests that human zalpha11 Ligand co-stimulates CD4<sup>+</sup>, but not CD8<sup>+</sup>, human T cells in a dose-dependent fashion.

15

The soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  can be used in this assay to measure binding, antagonist or inhibitory effects of the soluble zalpha11 receptor or soluble zalpha11 heterodimeric polypeptide, such as soluble zalpha11/IL-2R $\gamma$  on the zalpha11 Ligand

20

#### Example 24

##### Human zalpha11 Receptor Monoclonal Antibodies

Zalpha11 receptor Monoclonal antibodies were prepared by immunizing 5 male BalbC mice (Harlan Sprague Dawley, Indianapolis, IN) with the purified recombinant protein, huzalpha11-CEE-BHK (Example 6). The mice were each given an initial intraperitoneal (IP) injection of 20 mg of purified protein in Complete Freund's Adjuvant (Pierce, Rockford, IL) followed by booster IP injections of 10 mg purified protein in Incomplete Freund's Adjuvant every two weeks. Seven to ten days after the administration of the third booster injection, the animals were bled and the serum was collected.

25

30

The mouse sera samples raised to the huzalpha11-CEE-BHK were characterized by an ELISA titer check using purified recombinant CHO huzalpha11-Fc protein (Example 10C) as an antibody target. One mouse serum sample had titer to the specific antibody target at a dilution of 1:1,000,000 (1:1E6). Four mouse serum samples had titer to the specific antibody target at a dilution of 1:100,000 (1:1E5).

Splenocytes were harvested from the 4 high-titer mice and fused to murine SP2/0 myeloma cells using PEG 1500 (Boehringer Mannheim, UK) in two separate fusion procedures using a 4:1 fusion ratio of splenocytes to myeloma cells (Antibodies: A Laboratory Manual, E. Harlow and D. Lane, Cold Spring Harbor Press). Following 10 days growth post-fusion, specific antibody-producing hybridomas were identified by ELISA using purified recombinant BHK human zalpha11-Fc4 protein (Example 6C) as an antibody target and by FACS using Baf3 cells expressing the huzalpha11 sequence (Example 2) as an antibody target. The resulting 4 hybridomas positive by both methods were cloned three times by limiting dilution. The antibodies were designated: 249.28.2.1.2.2; 247.10.2.15.4.6; 249.19.2.2.3.5; and 249.15.2.4.2.7.

#### Example 25

##### Zalpa11 Receptor Purified Recombinant Human Protein

##### Dose-Response Study in Normal Mice

###### A. Summary

Normal nine week old female C57Bl/6 (Harlan Sprague Dawley, Indianapolis, IN) mice were treated by intraperitoneal injection once daily for seven days with one of three dose levels of purified recombinant human zalpha11-Fc4 soluble receptor (Example 6C) (5, 50 or 250µg/mouse/day) or PBS vehicle plus 250µg per dose of BSA. Body weights were monitored every other day. On day seven the five mice from the highest dose group and five of the vehicle control group were sacrificed. Blood, bone marrow and tissues were harvested and analyzed. The remaining mice were sacrificed and harvests done the following day. Potential perturbations in lymphoid tissues were examined, as well as general physiologic and toxicologic parameters.



There was no clinical evidence of toxicity. Liver, kidney, spleen, thymus and brain were weighed, and there were no differences between the treatment groups in organ weights. No histologic changes were found in the examined tissues.

B. Dosing solution preparation

5                   Purified recombinant human  $\alpha$ 11 receptor-FC4 fusion protein (zalpha11-FC4) (Example 6C) was diluted into sterile phosphate buffered saline (PBS) (GibcoBRL, Grand Island, NY) at concentrations to deliver 5, 50 or 250 micrograms of protein in 0.1 ml of PBS vehicle. Bovine serum albumin (BSA) (Sigma, St. Louis, MO) was dissolved in PBS to make a 250 $\mu$ g dose per 0.1ml then filtered through an  
10                   0.2 $\mu$ m syringe-tip filter for the vehicle control treatment. The solutions for daily dosing were made on Day 0, aliquotted and frozen in a frosty -20°C freezer for use. On the day of administration the appropriate aliquots were thawed and 0.1 ml of solution was injected intraperitoneally at approximately mid-morning each day for seven days.

C. Study design

15                   The mice were nine weeks old at the start of the study. Each  $\alpha$ 11-FC4 treatment group consisted of five mice; the control group had 10 mice. The mice in the highest dose and half of the control mice were sacrificed the day after the last of seven treatments (Day 7). The two lower dose and remaining control groups were sacrificed the following day (Day 8).

20                   The body weights of the mice were recorded every other day during treatment. There was no difference in weight gain between the treatment groups over the week of treatment.

                  At sacrifice, tissues harvested to assess lymphocyte populations by FACS analysis included bone marrow, thymus and spleen. Flow Cytometry analysis of  
25                   the lymphoid organs and bone marrow was performed with the FACSCalibur, (Becton Dickinson, Mansfield, MA). The tissues harvested for histologic examination for signs of toxicity of the protein included: spleen, thymus, liver, kidney, adrenal gland, mesenteric lymph node, duodenum, pancreas, jejunum, sternum, uterus, ovaries, urinary and gall bladders, salivary gland, heart and lungs. All tissues fixed for histology were  
30                   kept at 4°C overnight in 10% Normal Buffered Saline (Surgipath, Richmond, IL). The

following day the NBF was replaced with 70% ethanol and the tissues returned to 4°C until processing for histology.

The tissues were processed and stained for H&E analysis in house, then sent to the contract pathologist, David Fairchild. Blood was collected for complete blood cell counts and serum chemistry profiles. The CBC's were done in-house with the Cell Dyn 3500 Hematology Analyzer (Abbott Diagnostics Division, Abbott Park, IL). The serum was kept frozen in a frosty -20°C freezer until submission to Phoenix Central Laboratory (Everett, WA) for complete serum chemistry panels. To compare myeloid:erythroid ratios between the 250µg dose groups of zalpha11R and BSA, an aliquot of the bone marrow from one femur was applied to CytoSpin slides (CYTOSPIN 3 CYTOCENTRIFUGE and CYTO SLIDES, Shandon, Pittsburgh,PA). The bone marrow slides were analyzed at Phoenix Central Laboratories.

#### D. Study results

There were no apparent clinical indications of physiologic effects or of toxicity of rh-zalpha11R-FC4 fusion protein at doses tested (250µg/day or lower). Body weights remained normal for the duration of the treatments. Red blood cell and platelet counts were normal. There were two mice in the 250µg dose zalpha11-FC4 group whose differential WBC count revealed a possible elevation in the percentage of monocytes, however the other three mice in the group had monocyte percentages equivalent to the average of the control mice. The differential white blood cell monocyte count difference is not considered a significant finding. There were no other differences in complete blood counts. The bone marrow cytology did not reveal a shift in the myeloid and erythroid progenitor populations, and all cell types present appeared normal. All the standard serum chemistry parameters were in normal ranges. There were no differences between the treatment groups in the weights of the thymus, spleen, kidney, liver or brain. Histologic evaluation of the following tissues showed no evidence of abnormalities: thymus, spleen, liver, kidney, adrenal gland, duodenum, pancreas, jejunum, caecum, colon, mesenteric lymph nodes, uterus, ovaries, salivary gland, heart, trachea, lung and brain. The absence of physiologic effects in normal mice indicates that the zalpha11 soluble receptor has low toxicity *in vivo*, which is desirable for a therapeutic agent.

Example 26Zalpha11 Ligand-dependent Proliferation of B-cell Cells StimulatedAnti-CD40 or Anti-IgM5 A. Purification of Human B cells

A vial containing  $1 \times 10^8$  frozen, apheresed human peripheral blood mononuclear cells (PBMCs) was quickly thawed in a  $37^\circ\text{C}$  water bath and resuspended in 25 ml B cell medium (RPMI Medium 1640 (JRH Biosciences, Lenexa, KS), 10% Heat inactivated fetal bovine serum, 5% L-glutamine, 5% Pen/Strep) (Gibco BRL)) in a  
10 50 ml tube (Falcon VWR, Seattle, WA). Cells were tested for viability using Trypan Blue (Gibco BRL). Ten milliliters of Ficoll/Hypaque Plus (Pharmacia LKB Biotechnology Inc., Piscataway, NJ) was layered under the cell suspension and spun for 30 minutes at 1800 rpm and allowed to stop with the brake off. The interface was then removed and transferred to a fresh 50 ml Falcon tube, brought up to a final volume of  
15 40 ml with PBS and spun for 10 minutes at 1200 rpm with the brake on. The viability of the isolated cells was tested using Trypan Blue. Alternately fresh drawn human blood was diluted 1:1 with PBS (Gibco BRL) and layered over Ficoll/Hypaque Plus (Pharmacia), spun and washed as above. Cells isolated from either fresh or frozen sources gave equivalent results.

20 B cells were purified from the Ficoll floated peripheral blood cells of normal human donors (above) with anti-CD19 magnetic beads (Miltenyi Biotec, Auburn, CA) following the manufacturer's instructions. The purity of the resulting preparations was monitored by flow cytometric analysis with anti-CD22 FITC Ab (Pharmingen, San Diego, CA). B cell preparations were typically >90% pure.

25

B. Purification of Murine B cells

A suspension of murine splenocytes was prepared by teasing adult C57Bl/6 mouse (Charles River Laboratories, Wilmington, MA) spleens apart with bent needles in B cell medium. RBCs were removed by hypotonic lysis. CD43 positive cells  
30 were removed with CD43 magnetic beads (Miltenyi Biotec) following the manufacturer's instructions. The purity of the resulting preparations was monitored by

flow cytometric analysis with anti-CD45R FITC Ab (Pharmingen). B cell preparations were typically >90% pure.

C. Proliferation of anti-CD40-stimulated B-Cells in the presence of human or murine zalpha11 Ligand

5                   The B cells from either the human or mouse source were resuspended at a final concentration of  $1 \times 10^6$  cells/ml in B cell medium and plated at 100  $\mu$ l/well in a 96 well U bottom plate (Falcon, VWR) containing various stimulation conditions to bring the final volume to 200  $\mu$ l/well. For anti-CD40 stimulation human cultures were  
10                   supplemented with 1ug/ml anti-human CD40 (Genzyme, Cambridge, MA) and mouse cultures were supplemented with 1 $\mu$ g/ml anti-murine CD40 (Serotec, UK). Human or murine zalpha11 Ligand (commonly owned US Pat. Application No. 09/522,217) was added at dilutions ranging from 1 pg/ml-100 ng/ml as appropriate. The specificity of the effect of zalpha11 Ligand was confirmed by inhibition of zalpha11 Ligand with  
15                   25mg/ml soluble human zalpha11CEE (Example 6A). All treatments were performed in triplicate. The cells were then incubated at 37°C in a humidified incubator for 120 hours (human) or 72 hours (mouse). Sixteen hours prior to harvesting, 1  $\mu$ Ci  $^3$ H-thymidine (Amersham, Piscataway, NJ) was added to all wells to assess whether the B-cells had proliferated. The cells were harvested into a 96 well filter plate (UniFilter  
20                   GF/C, Packard, Meriden, CT) using a cell harvester (Packard) and collected according to manufacturer's instructions. The plates were dried at 55°C for 20-30 minutes and the bottom of the wells were sealed with an opaque plate sealer. To each well was added 0.25 ml of scintillation fluid (Microscint-O, Packard) and the plate was read using a TopCount Microplate Scintillation Counter (Packard).

25                   Incubation with Zalpha11 Ligand at concentrations of 3 ng/ml or more enhanced the proliferation induced by soluble anti-CD40 in a dose dependent manner in both murine and human B cells by as much as 30 fold. The murine and human B cells responded equally as well to their respective zalpha11 Ligand. In both species, the stimulation was specific to zalpha11 Ligand, as it was reversed by the presence of  
30                   soluble zalpha11 receptor in the culture.

D. Proliferation of anti-IgM-stimulated B-Cells in the presence of human or murine zalpha11 Ligand

The B cells from either human or mouse source as described above (parts A and B) were plated as described above (part C). For anti-IgM stimulation of human cells the plates were pre-coated overnight with 10mg/ml F(ab')<sub>2</sub> anti-human IgM Abs (Southern Biotech Associates, Birmingham, Alabama) and washed with sterile media just prior to use. The cultures were supplemented with 0-10 ng/ml hu rIL-4 (R&D Systems, Minneapolis, MN). For anti-IgM stimulation of murine cells soluble anti-IgM (Biosource, Camarillo, CA) was added to the cultures at 10 mg/ml. To each of the preceding anti-IgM/IL-4 conditions, human or murine Zalpha11 ligand was added at dilutions ranging from 1 pg/ml-100 ng/ml as described above. The specificity of the effect of zalpha11 Ligand was confirmed by inhibition with soluble human zalpha11 receptor as described above (Part C). All treatments were performed in triplicate. The cells were incubated, labeled with <sup>3</sup>H-thymidine, harvested, and analyzed as described in part C above.

Incubation with Zalpha11 ligand at concentrations of 0.3 ng/ml or more inhibited the proliferation induced by insoluble anti-IgM (mouse) or anti-IgM and IL-4 (human) in a dose-dependent manner. This inhibition was specific to zalpha11 Ligand, as it was reversed by the presence of soluble zalpha11 receptor in the culture.

20

E. Anti-CD40 B Cell proliferation requires IL-2 receptor gamma

Murine B-cells were purified and stimulated with anti-CD40 monoclonal antibody as described in Example 26B and C above. The co-stimulation induced by murine zalpha11 Ligand was completely blocked by the addition of anti-IL-2 receptor gamma (IL-2R $\gamma$ ) monoclonal antibodies that block IL-2 $\gamma$  utilization. The antibodies 3E12 and TUG/m2 (PharMingen, San Diego, CA) were included in the proliferation assay at 50  $\mu$ g/ml. These results demonstrate that the IL-2R $\gamma$  in B cells is physiologically involved with the zalpha11 Ligand stimulation of B cells. Moreover, these results provide indirect functional support *in vivo* for the finding that the IL-2R $\gamma$  heterodimerizes with the zalpha11 receptor *in vitro* (Example 27, below).

30

F. The effects of zalpha11 Ligand on B cells are inhibited by soluble zalpha11 receptor constructs

Murine B-cells were purified and stimulated with anti-CD40 monoclonal antibody or anti-IgM antibodies as described in Example 26C and D above. The effect induced by murine zalpha11 Ligand was completely blocked by the addition of either purified hu-zalpha11R: IL-2R $\gamma$  a heterodimeric soluble receptor (Example 28), or a mu-zalpha11-Fc, a homodimeric soluble receptor (Example 6C). Again, these results provide further functional support for the finding that the IL-2R $\gamma$  heterodimerizes with the zalpha11 receptor (Example 27, below), and acts as an antagonist to the zalpha11 Ligand's effect on B-cells.

Example 27

Human Zalpha11 Receptor Heterodimerizes With IL-2 Receptor Gamma

A. Assay using conditioned media from transfected BHK-570 cells expressing human zalpha11 Ligand

Soluble human zalpha11 receptor zalpha11CFLAG (Example 6B), or gp130 (Hibi, M. et al., *Cell* 63:1149-1157, 1990) were biotinylated by reaction with a five-fold molar excess of sulfo-NHS-LC-Biotin (Pierce, Inc., Rockford, IL) according to the manufacturer's protocol. Soluble zalpha11 receptor and soluble IL-2 receptor- $\gamma$  (sIL-2R $\gamma$ ) (R&D Systems, Minneapolis, MN) were labeled with a five fold molar excess of Ru-BPY-NHS (Igen, Inc., Gaithersburg, MD) according to manufacturer's protocol. The biotinylated and Ru-BPY-NHS-labeled forms of the soluble zalpha11 receptor were respectively designated Bio-zalpha11 receptor and Ru-zalpha11; the biotinylated and Ru-BPY-NHS-labeled forms of the soluble IL-2R $\gamma$  were respectively designated Bio- IL2R $\gamma$  and Ru- IL2R $\gamma$ .

For initial receptor binding characterization of human zalpha11 Ligand, conditioned media from transfected BHK-570 cells expressing human zalpha11 Ligand or control media from untransfected BHK-570 cells was used to determine if zalpha11 Ligand could mediate homodimerization of zalpha11 receptor and if it could mediate the heterodimerization of zalpha11 receptor with IL-2R $\gamma$  or gp130. To do this, 50  $\mu$ l of conditioned media, from control cells or conditioned media from cells expressing

zalpha11 Ligand, was combined with 50 µl of TBS-B (20 mM Tris, 150 mM NaCl, 1 mg/ml BSA, pH 7.2) containing 400 ng/ml of Ru-zalpha11 receptor and Bio-zalpha11, or 400 ng/ml of Ru-zalpha11 receptor and Bio-gp130, or 400 ng/ml of Ru-IL2Rγ and Bio-zAlph11. Following incubation for one hour at room temperature, 30 µg of streptavidin coated, 2.8 mm magnetic beads (Dyna1, Inc., Oslo, Norway) were added and the reaction incubated an additional hour at room temperature. 200 µl ORIGEN assay buffer (Igen, Inc., Gaithersburg, MD) was then added and the extent of receptor association measured using an M8 ORIGEN analyzer (Igen, Inc.).

Conditioned media containing zalpha11 Ligand caused the heterodimerization of Bio-zalpha11 receptor with Ru-IL2Rγ. No receptor dimerization was observed in the presence of control media. Conditioned media containing zalpha11 Ligand did not cause the homodimerization of RU-zalpha11 receptor with Bio-zalpha11 receptor, nor the heterodimerization of Ru-zalpha11 receptor with Bio-gp130.

#### B. Assay using purified human zalpha11 Ligand

To assess the ligand specificity of the heterodimerization of zalpha11 receptor and IL2Rγ, 50 µl of TBS-B containing 400 ng/ml of Ru-zalpha11 receptor and Bio-zAlph11, or 400 ng/ml Ru-IL2Rγ and Bio-zAlph11 was combined 50 µl of TBS-B containing IL-2, IL-4, IL-15 or purified human zalpha11 Ligand (commonly owned US Patent Application No. 09/522,217) at concentrations from 133 pg/ml to 300 ng/ml. Following incubation for one hour a room temperature, 3 µg of streptavidin coated, 2.8 mm magnetic beads (Dyna1, Inc.) were added and the reaction incubated an additional hour at room temperature. 200 µl Origlo assay buffer (Igen, Inc.) was then added and the extent of receptor association measured using an M8 Origen analyzer (Igen, Inc.). The human zalpha11 Ligand caused the heterodimerization of Bio-zalpha11 receptor with Ru-IL-2Rγ in a dose dependent manner with a half maximal concentration of 10 ng/ml. No homodimerization of Ru-zalpha11 receptor with Bio-zalpha11 receptor was observed at any concentration of zalpha11 Ligand tested. No homodimerization of Ru-zalpha11 receptor with Bio-zalpha11 receptor or heterodimerization of Bio-zalpha11 receptor with Ru-IL2Rγ was observed with IL-2, IL-4 or IL-15, at any of the concentrations tested. Thus, the results show that the human zalpha11 receptor

heterodimerizes specifically with the IL-2 receptor- $\gamma$  in the presence of human  $\alpha$ 11 Ligand, and that the  $\alpha$ 11 receptor does not homodimerize or heterodimerize in the presence of other cytokines tested.

5

### Example 28

#### Construct for Generating Human $\alpha$ 11 Receptor/ IL-2R $\gamma$ Heterodimer

A vector expressing a secreted human h $\alpha$ 11/hIL2R $\gamma$  heterodimer was constructed. In this construct, the extracellular domain of h $\alpha$ 11 was fused to the heavy chain of IgG gamma 1 (IgG $\gamma$ 1) (SEQ ID NO:16), while the  
10 extracellular portion of hIL-2R $\gamma$  was fused to a human kappa light chain (human  $\kappa$  light chain) (SEQ ID NO:18).

#### A. Construction of IgG gamma 1 and human $\kappa$ light chain fusion vectors

The heavy chain of IgG $\gamma$ 1 was cloned into the Zem229R mammalian expression vector (ATCC deposit No. 69447) such that any extracellular portion of a  
15 receptor having a 5' EcoRI and 3' NheI site can be cloned in resulting in an N-terminal extracellular domain-C-terminal IgG $\gamma$ 1 fusion. The IgG $\gamma$ 1 fragment used in this construct was made by using PCR to isolate the IgG $\gamma$ 1 sequence from a Clontech hFetal Liver cDNA library as a template. A PCR reaction using oligos ZC11,450 (SEQ ID NO:50) and ZC11,443 (SEQ ID NO:51) was run as follows: 40 cycles of 94°C for 60  
20 sec., 53°C for 60 sec., and 72°C for 120 sec.; and 72°C for 7 min.. PCR products were separated by agarose gel electrophoresis and purified using a QiaQuick™ (Qiagen) gel extraction kit. The isolated, 990 bp, DNA fragment was digested with Mlu I and EcoRI (Boehringer-Mannheim), ethanol precipitated and ligated with oligos ZC11,440 (SEQ ID NO:52) and ZC11,441 (SEQ ID NO:53), which comprise an MluI/EcoRI linker, into  
25 Zem229R previously digested with and EcoRI using standard molecular biology techniques disclosed herein. This generic cloning vector was called Vector#76 hIgGgamma1 w/ Ch1 #786 Zem229R (Vector #76). The polynucleotide sequence of the extracellular domain of h $\alpha$ 11 fused to the heavy chain of IgG gamma 1 is shown in SEQ ID NO:15 and the corresponding polypeptide sequence shown in SEQ  
30 ID NO:16.



The human  $\kappa$  light chain was cloned in the Zem228R mammalian expression vector (ATCC deposit No. 69446) such that any extracellular portion of a receptor having a 5' EcoRI site and a 3' KpnI site can be cloned in resulting in a N-terminal extracellular domain-C-terminal human  $\kappa$  light chain fusion. The human  $\kappa$  light chain fragment used in this construct was made by using PCR to isolate the human  $\kappa$  light chain sequence from the same Clontech hFetal Liver cDNA library used above. A PCR reaction using oligos ZC11,501 (SEQ ID NO:54) and ZC11,451 (SEQ ID NO:55) was run under conditions described above. PCR products were separated by agarose gel electrophoresis and purified using a QiaQuick™ (Qiagen) gel extraction kit. The isolated, 315 bp, DNA fragment was digested with MluI and EcoRI (Boehringer-Mannheim), ethanol precipitated and ligated with the MluI/EcoRI linker described above, into Zem228R previously digested with and EcoRI using standard molecular biology techniques disclosed herein. This generic cloning vector was called Vector #77 hKlight #774 Zem228R (Vector #77). The polynucleotide sequence of the extracellular portion of hIL-2R $\gamma$  was fused to a human kappa light chain is shown in SEQ ID NO:17 and the corresponding polypeptide sequence shown in SEQ ID NO:18.

B. Insertion of zalpha11 receptor or IL-2R $\gamma$  extracellular domains into fusion vector constructs

Using the construction vectors above, a construct having human zalpha11 fused to IgG $\gamma$ 1 was made. This construction was done by PCRing human zalpha11 receptor from a CD4+ bone marrow library (selected, and made in house) with oligos ZC24,052 (SEQ ID NO:56) and ZC24,053 (SEQ ID NO:57), under conditions described as follows: 30 cycles of 94°C for 60 sec., 57°C for 60 sec., and 72°C for 120 sec.; and 72°C for 7 min.. The resulting PCR product was digested with EcoRI and NheI, gel purified, as described herein, and ligated into a previously EcoRI and NheI digested and band-purified Vector#76 (above). The resulting vector was sequenced to confirm that the human zalpha11/IgG gamma 1 fusion (hzalpha11/Ch1 IgG) was correct. The hzalpha11/Ch1 IgG gamma1 vector was called Vector #190.

A separate construct having IL-2R $\gamma$  fused to  $\kappa$  light was also constructed. The IL-2R $\gamma$ /human  $\kappa$  light chain construction was performed as above by

PCRing from the same CD4+ library mentioned above with oligos ZC12,834 (SEQ ID NO:58) and ZC12,831 (SEQ ID NO:59), digesting the resulting band with EcoRI and KpnI and then ligating this product into a previously EcoRI and KpnI digested and band-purified Vec#77 (above). The resulting vector was sequenced to confirm that the  
5 human IL-2R $\gamma$ / human  $\kappa$  light chain fusion (hIL-2R $\gamma$ /Klight) was correct. This hIL-2gamma/Klight #1052 Zem228R vector was called Vector #101.

#### D. Co-expression of the human $\alpha$ 11 and human IL-2R $\gamma$ receptors

Approximately 16  $\mu$ g of each of Vectors #190 and #101, above, were co-  
10 transfected into BHK-570 cells (ATCC No. CRL-10314) using LipofectaminePlus™ reagent (Gibco/BRL), as per manufacturer's instructions. The transfected cells were selected for 10 days in DMEM + 5%FBS (Gibco/BRL) containing 1  $\mu$ M of methotrexate (MTX) (Sigma, St. Louis, MO) and 0.5 mg/ml G418 (Gibco/BRL) for 10 days. The resulting pool of transfectants was selected again in 10  $\mu$ M of MTX and 0.5  
15 mg/ml G418 for 10 days.

The resulting pool of doubly-selected cells was used to generate protein. Three Factories (Nunc, Denmark) of this pool were used to generate 10 L of serum free conditioned medium. This conditioned media was passed over a 1 ml protein-A column and eluted in (10) 750 microliter fractions. 4 of these fractions found to have  
20 the highest concentration were pooled and dialyzed (10 kD MW cutoff) against PBS. Finally the dialyzed material was submitted for amino acid analysis (AAA) and found to have a concentration of 227.17  $\mu$ g/ml AAA. A total of 681.5  $\mu$ g was obtained from this 10 L purification. The purified soluble human  $\alpha$ 11 receptor/IL-2R $\gamma$  receptor was used to assess its ability to compete with the human  $\alpha$ 11 Ligand a BaF3 proliferation assay (Example 29, below).  
25

#### Example 29

##### Soluble Human $\alpha$ 11 Receptor/Human IL2 Gamma Receptor-Fc as a $\alpha$ 11

##### Ligand Antagonist

30 BaF3 cells stably expressing the human  $\alpha$ 11 receptor (Example 2) were plated at 5500 cells per well in standard 96-well tissue culture plates in base

medium plus 3 ng/ml human zalpha11 Ligand. Base medium is 500 ml RPMI 1640 (JRH Biosciences), 5 ml 100x Sodium Pyruvate (Gibco BRL), 5 ml 100x L-glutamine (Gibco BRL), and 50 ml heat-inactivated Fetal Bovine Serum (FBS) (Hyclone Laboratories). To the cells, a decreasing dose of either purified soluble human zalpha11 receptor-Fc homodimer (Example 6C) or purified soluble human zalpha11 receptor/human IL2 gamma receptor-Fc heterodimer (Example 27) were added. An Alamar Blue proliferation assay was run and fluorimetry performed as per Example 2B.

The zalpha11 receptor/ IL2 gamma receptor-Fc heterodimer inhibited human zalpha11 Ligand activity in a dose dependent manner, with 0.312 µg/ml able to completely inhibit the activity of 3 ng/ml human zalpha11 Ligand. The soluble zalpha11 receptor-Fc homodimer also was able to inhibit zalpha11 Ligand activity in a dose dependent manner, however it required about 10 µg/ml of soluble homodimer to completely inhibit the activity of 3 ng/ml zalpha11 Ligand. These data suggested the zalpha11 receptor/ IL2 gamma receptor-Fc heterodimer soluble receptor is approximately 30 to 100 fold more potent than the homodimeric soluble zalpha11 receptor in inhibiting human zalpha11 Ligand.

### Example 30

#### Zalpha11 Receptor Distribution

To assess zalpha11 receptor distribution on various cells types, we generated both rabbit polyclonal and mouse monoclonal antibodies (mAbs) directed against the human receptor (Example 24 and Example 10) and conjugated these antibodies to biotin for use in flow cytometry. We initially used the polyclonal antibodies, which were of relatively low affinity, to stain a panel of cell lines: IL-3 dependent murine pre-B cell line wild-type BaF3 cells (Palacios and Steinmetz, *ibid.*; Mathey-Prevot et al., *ibid.*); BaF3 cells transfected with human zalpha11 (Example 2); human Burkitt's lymphoma cell lines Raji (ATCC No. CCL-86), Ramos (ATCC No. CRL-1596), RPMI 8226 (ATCC No. CCL-155), and Daudi (ATCC No. CCL-213); human T cell leukemia cell line Jurkat (ATCC No. TIB-152); human myelomonocytic leukemia cell lines Thp-1 (ATCC No. TIB-202) and U937 (ATCC No. CRL-1593.2); human pro-myelomonocytic cells HL-60 (ATCC No. CCL-240); murine B cell

lymphoma cell line A20 (ATCC No TIB-208); and murine thymoma cell line EL4 (ATCC No. TIB-39).

The cells were harvested, washed once with FACS wash buffer with serum (WBS). WBS consisted of Hank's balanced salt solution (Gibco/BRL) + 10mM HEPES (Gibco/BRL) + 1% BSA (Sigma) + 10% normal goat serum (Gemini Bioproducts, Woodland, CA) + 10% normal rabbit serum (Sigma); wash buffer (WB) was identical to WBS except that it is serum free. After washing, the cells were resuspended in 100  $\mu$ l WB containing 10  $\mu$ g/ml rabbit anti-zalpa11 polyclonal antibodies (Example 10). The cells were kept on ice with Ab for 20 min, then washed with WB and resuspended in WB containing goat anti-rabbit-FITC (BioSource, International), incubated another 20 min on ice, then washed and resuspended in 400  $\mu$ l WB for analysis on a FACSCalibur flow cytometer (Becton Dickinson). Control samples were stained with the secondary goat anti-rabbit-FITC Ab only. Positive staining was defined as a shift above the staining with secondary alone. Although the polyclonal antibodies were of low affinity, we were reasonably confident that we detected zalpa11 expression on the BaF3/zalpa11 transfectant, on all four human Burkitt's lymphomas (Raji, Ramos, Daudi, and RPMI 8226), and on Jurkat T cells. Our data with the monocytic cell lines were more ambiguous. Resting (undifferentiated) HL-60 cells did not bind the anti-zalpa11 antibodies, but we did detect a positive signal on HL-60 cells activated for 24 hours with PMA (Calbiochem, La Jolla, CA) which induces HL-60 cell differentiation into a monocyte-like cell. We also saw a positive signal on U937 and Thp-1 cells, although this signal may have been due to non-specific binding. The polyclonal antibodies weakly cross-reacted on the mouse B cell line A20, but we saw no staining of the EL4 murine thymoma.

The four anti-zalpa11 monoclonal antibodies (Example 24) were conjugated to biotin, and a subset of the cells described above were screened for zalpa11 receptor expression (BaF3, BaF3/zalpa11, Raji, Jurkat, and resting HL-60). Cells were harvested, washed, then resuspended in 100  $\mu$ l WB containing 15  $\mu$ g/ml of one of each of the 4 biotinylated mAbs. The cells were incubated with mAb for 20 min on ice, then washed with 1.5 ml WB and pelleted in a centrifuge. The supernatant was removed by aspiration and the pellets were resuspended in 100  $\mu$ l of CyChrome-

conjugated streptavidin (CyC-SA; PharMingen), then incubated on ice for another 20 min and washed and pelleted as before. Control tubes contained cells stained only with CyC-SA. Pellets were resuspended in 400  $\mu$ l WB and flow cytometry performed as above. Positive staining was defined as a signal exceeding the background level of staining with CyC-SA alone. Using the BaF3/zalpa11 transfectant as a control, we were able to rank the 4 mAbs in terms of their respective mean fluorescence intensities (MFI), which can reflect antibody affinity and/or the extent of biotinylation of the mAbs. The mAbs were ranked as follows, from highest to lowest MFI: 249.28.2.1.2.2, 247.10.2.15.4.6, 249.19.2.2.3.5, and 249.15.2.4.2.7. This pattern was essentially the same on both Raji and Jurkat cells, indicating that zalpa11 is expressed on these B and T cell lines. The staining patterns on non-activated HL60 cells were identical for all the mAbs, and the signal was very weak. We speculate that this does not reflect actual expression of zalpa11 by this cell line, but rather is a function of non-specific binding of the mouse mAbs to the human cells, probably via Fc-receptors.

### Example 31

#### Reconstitution of Human zalpa11 Receptor *in vitro*

To identify components involved in the zalpa11-signaling complex, receptor reconstitution studies were performed as follows. BHK 570 cells (ATCC No. CRL-10314) transfected, using standard methods described herein, with the KZ134 luciferase reporter plasmid (Example 19) served as a bioassay cell line to measure signal transduction response from a transfected zalpa11 receptor complex to the luciferase reporter in the presence of zalpa11 Ligand. BHK cells do not endogenously express the zalpa11 receptor. The bioassay cell line was transfected with zalpa11 receptor alone, or co-transfected with zalpa11 receptor along with one of a variety of other known receptor subunits. Each receptor subunit was cloned using PCR followed by ligation into appropriate expression vectors; correct sequence of each construct was confirmed before transfection. Cell lines were tested for receptor expression by RT/PCR prior to assays. Receptor complexes tested included: zalpa11 receptor alone; zalpa11 receptor with IL-2R $\gamma$ ; zalpa11 receptor with IL-2R $\gamma$  and IL-2R $\beta$ ; zalpa11 receptor with IL-2R $\gamma$  and IL-13R $\alpha$ ; zalpa11 receptor with IL-2R $\gamma$  and IL-2R $\alpha$ ; and

zalpha11 receptor with IL-2R $\gamma$  and IL-4R $\alpha$ . Each independent receptor complex cell line was assayed in the presence of human zalpha11 Ligand and luciferase activity measured as described in Example 19. The untransfected bioassay cell line served as a control for the background luciferase activity, and was used as a baseline to compare signaling by the various receptor complex combinations. In each cell line containing both zalpha11 receptor and IL-2R $\gamma$ , maximal luciferase activity was about two-fold over background in the presence of zalpha11 Ligand. No increase in signal was observed in the presence of any other receptor subunit tested (IL-2R $\beta$ , IL-2R $\alpha$ , IL-4R $\alpha$ , or IL-13R $\alpha$ ).

Other zalpha11 receptor complexes that can be assessed by this method include combinations of zalpha11 receptor with one or more of the IL-4/IL-13 receptor family receptor components (IL-13R $\alpha'$ ), as well as other Interleukin receptors (e.g., IL-15 R $\alpha$ , IL-7R $\alpha$ , IL-9R $\alpha$ ).

15

### Example 32

#### <sup>125</sup>I-labeled Human zalpha11 Ligand Binding Study in Cell Lines

25 micrograms of purified human zalpha11 Ligand (commonly owned US Patent Application No. 09/522,217) was labeled with 2 mCi <sup>125</sup>I using iodobeads (Pierce, Rockford Illinois), according to manufacturer's instructions. This labeled protein was used to assess human zalpha11 Ligand binding to human Raji cells (ATCC No. CCL-86), using binding to wild-type murine BaF3 cells, and BaF3 cells transfected with zalpha11 receptor (BaF3/hzalpha11 cells) as controls. Zalpha11 Ligand binding to BaF3/hzalpha11 cells was expected (positive control), while no binding to wild-type BaF3 cells was expected (negative control), based on proliferation assay results (Example 2). About 5X10<sup>5</sup> Raji cells/well, 1X10<sup>6</sup> BaF3/hzalpha11 and 1X10<sup>6</sup> BaF3 cells/well, were each plated in 96-well plates. Ten ng/ml of labeled human zalpha11 Ligand was added in duplicate to wells, with a dilution series of unlabeled human zalpha11 Ligand competitor added from 250 fold molar excess in 1:4 dilutions down to .061 fold molar excess. Each point was run in duplicate. After the labeled human zalpha11 Ligand was added to wells, it was allowed to incubate at 4°C for 2 h to allow for binding of Ligand to the cells. The cells were then washed 3X in binding

buffer (RPMI-1710 (JRH Biosciences) with 1% BSA (Sigma)), and counted on the COBRA II AUTO-GAMMA gamma counter (Packard Instrument Company, Meriden, CT).

Binding of the labeled zalpha11 Ligand to cells was evident in the Raji  
5 and the BaF3/hzalpha11 cells. In addition, for Raji cells, an average 250 fold molar excess of unlabeled zalpha11 Ligand decreased binding 3 fold in the presence of a non-specific unlabeled competitor (Interferon Gamma from R&D Systems, Minneapolis, MN), and 3.7 fold relative to no competitor. Competition was observed in a dose dependent fashion for the specific unlabeled competitor, human zalpha11 Ligand.  
10 Thus, the zalpha11 Ligand binding to Raji cells was specific. Similarly, for positive control BaF3/zalpha11 cells, the 250 fold molar excess of unlabeled zalpha11 Ligand decreased binding 2 fold relative to the non-specific competitor and 3.06 fold relative to no competitor. Thus, the zalpha11 Ligand binding to BaF3/zalpha11 cells also was specific. No competable binding was observed with the wild-type BaF3 cells. Thus,  
15 the zalpha11 Ligand was shown to bind specifically to Raji cells, and to BaF3/hzalpha11 cells, but not to the negative control Baf3 cells.

The bound radiolabeled zalpha11 Ligand is then cross-linked to the molecule to which it binds on the cell surface of Raji cells using standard cross-linking methods, to identify the receptor complex to which it binds on these cells. Moreover,  
20 anti-zalpha11 receptor antibodies (Example 24 and Example 10), and other anti-cytokine receptor subunit antibodies are employed to assess which subunit components comprise a functional hzalpha11 receptor complex, for example, on the Raji cells and other cell lines to which zalpha11 Ligand binds. Such antibodies can be used to compete for zalpha11 Ligand in a binding assay as described above, and hence show  
25 which receptor subunits are present of the Raji cell surface, and on other cell lines to which zalpha11 Ligand binds. Moreover, such antibodies can be used to immunoprecipitate radiolabeled zalpha11 Ligand cross-linked material using methods known in the art and described herein. In addition anti-zalpha11 Ligand antibodies (commonly owned US Patent Application No. 09/522,217) can be used to  
30 immunoprecipitate radiolabeled zalpha11 Ligand cross-linked material.

Example 33Zalpa11 Receptor Expression On Human Blood CellsA. Preparation and Culture of Human Peripheral Blood Cells

Fresh drawn human blood was diluted 1:1 with PBS (GIBCO BRL) and  
5 layered over Ficoll/Hypaque Plus (Pharmacia LKB Biotechnology Inc., Piscataway, NJ)  
and spun for 30 minutes at 1800 rpm and allowed to stop with the brake off. The  
interface layer was removed and transferred to a fresh 50 ml Falcon tube (Falcon,  
VWR, Seattle, WA), brought up to a final volume of 40 ml with PBS and spun for 10  
minutes at 1200 rpm with the brake on. The viability of the isolated cells was tested  
10 using Trypan Blue (GIBCO BRL) and the cells were resuspended at a final  
concentration of  $1 \times 10^6$  cells/ml cell medium (RPMI Medium 1640, 10% Heat  
inactivated fetal bovine serum, 5% L-glutamine, 5% Pen/Strep) (GIBCO BRL).

Cells were cultured in 6 well plates (Falcon, VWR) for 0, 4 or 24 hours  
with a variety of different stimuli described below. Anti-IgM, anti-CD40 and anti-CD3  
15 stimulation were done as in Example 26. Phorbol myristate acetate (PMA) and  
ionomycin (Sigma, St. Louis, MO) were added to appropriate wells at 10 ng/ml and 0.5  
mg/ml respectively. The cells were incubated at 37°C in a humidified incubator for  
various times.

20 B. Antibody Staining and Analysis

Cells were collected out of the plates, washed and resuspended in ice  
cold staining media (HBSS, 1% fetal bovine serum, 0.1% sodium azide) at a  
concentration of about ten million cells per milliliter. Blocking of Fc receptor and non-  
specific binding of antibodies to the cells was achieved by adding 10% normal goat  
25 serum (Gemini Bioproducts, Woodland, CA) and 10% normal human serum  
(Ultraserum, Gemini) to the cell suspension. Aliquots of the cell suspensions were  
mixed with a FITC labeled monoclonal antibody against one of the lineage markers  
CD3, CD19 or CD14 (PharMingen, La Jolla, CA) and a biotinylated monoclonal  
antibody against the human zalpa11 receptor (hu-zalpa11) (Example 24). After  
30 incubation on ice for 60 minutes the cells were washed twice with ice cold staining  
media and resuspended in 50 ml staining media containing streptavidin-PE (Caltag,



Burlingame, CA). After a 30 minute incubation on ice, the cells were washed twice with ice cold wash buffer (PBS, 1% fetal bovine serum, 0.1% sodium azide) and resuspended in wash buffer containing 1mg/ml 7-AAD (Molecular Probes, Eugene, OR) as a viability marker. Flow data was acquired on living cells using a FACSCalibur  
5 flow cytometer (BD Immunocytometry Systems, San Jose, CA). Both acquisition and analysis were performed using CellQuest software (BD Immunocytometry Systems).

Results showed that the human zalpha11 receptor is expressed on human peripheral blood cells expressing either CD3, CD19 or CD14. Activation of either T cells with anti-CD3 or B cells with anti-CD40 resulted in an increased level of cell  
10 surface zalpha11 at 24 hours. No increase in the level of expression of zalpha11 was seen at 4 hours with any stimulus on either cell population. Treatment of the cells with zalpha11ligand resulted in a decrease of zalpha11 staining on CD3 positive and CD19 positive cells but not CD14 positive cells at both 4 and 24 hours.

15

#### Example 34

##### Human zalpha11 Ligand Activity is Blocked With Anti- IL-2R $\gamma$ Antibodies in a BaF3/zalpha11 Proliferation Assay

The role of the IL-2 $\gamma$  receptor was investigated using anti- IL-2 $\gamma$  receptor monoclonal antibodies to assess whether they would block zalpha11 Ligand activity in  
20 a BaF3/zalpha11 proliferation assay (Example 2). Conditioned-media from BHK570 cells transfected with the human zalpha11 Ligand was added to the assay at 5%, 2.5%, 1.25% and 0.625% concentrations, with or without IL-2 receptor antibodies.

The following mouse anti-IL-2 receptor monoclonal antibodies from PharMingen International, San Diego, California were added at 50  $\mu$ g/ml each: (a) 4G3 + TUGm2 or (b) TM- $\beta$ 1. 4G3 and TUGm2 are purified rat anti-mouse  $\gamma_c$  chain  
25 antibodies, TM- $\beta$ 1 is a purified rat anti-mouse CD122 (IL-2 receptor  $\beta$  chain) antibody. Assay results demonstrated almost complete inhibition of the zalpha11 Ligand response with the 4G3 + TUGm2 antibody combination in comparison to the no-antibody control. The TM- $\beta$ 1 antibody had no effect. These results suggest a role for the IL-2  $\gamma$   
30 receptor in the zalpha11 Ligand proliferative response, and further supports that the IL-2R $\gamma$  heterodimerizes with the zalpha11 receptor to elicit that response.

Example 35Post-translational Mannosylation of zalpha11 Receptor Polypeptide on a  
Highly Conserved Trp Residue

5 Mannosylation of the human zalpha11 receptor was assessed using the method for C-2 mannosylation of Tryptophan as described in Hofsteenge, J et al., Biochemistry 33:13524-13530, 1994, and Loeffler, A et al., Biochemistry 35:12005-14, 1996. Moreover, these investigators showed that in a motif of amino acids, WXXW (SEQ ID NO:67), that Trp can be mannosylated.

10 A soluble zalpha11 receptor bearing a C-terminal Glu-Glu (CEE) (SEQ ID NO:14) or FLAG (SEQ ID NO:23) tag was expressed in BHK cells and purified by anti-Flag or anti-EE affinity chromatography (Example 4A). A soluble zalpha11 receptor C-terminally tagged with an Fc4 tag (SEQ ID NO:25) and expressed in CHO cells was affinity purified by anti-Fc4 affinity chromatography (Example 4B). These  
15 polypeptides were enzymatically cleaved to generate peptide fragments for the study.

All enzymatic digestions were performed overnight at a protein concentration of 1.0 mg/ml. PNGaseF (Oxford GlycoSciences, Abingdon, Oxford UK) digestion was performed by diluting each soluble zalpha11 receptor polypeptide into a 50 mM EDTA, 20 mM Na-Phosphate pH 7.5 buffer and incubating it with 0.4 U of  
20 enzyme per µg of protein. Glu-C (Roche Molecular Biochemicals, Indianapolis, Indiana) digestion was performed at a 1:50 ratio of enzyme to protein by buffer exchanging the sample into 25 mM NH<sub>4</sub>HCO<sub>3</sub> pH 7.8 and incubating it at 25°C, except for the Fc4 tagged material, which was digested in 50 mM Na-Phosphate pH 7.8 + 5% Acetonitrile (EM Science, Darmstadt, Germany) at 37°C. The Glu-C digestion  
25 generated a zalpha11 WSXWS-containing peptide as shown from amino acid 178 (Leu) to amino acid 199 (Ser) of SEQ ID NO:6 (197 (Leu) to amino acid 218 (Ser) of SEQ ID NO:2). Asp-N (Roche Molecular Biochemicals, Indianapolis, Indiana) digestion was performed by buffer exchanging the protein into 50 mM Na-Phosphate pH 7.7 and incubating it at 37°C with enzyme at a 1:50 ratio to zalpha11 receptor polypeptide. The  
30 Asp-N digestion generated a zalpha11 WSXWS-containing peptide as shown from

amino acid 179 (Glu) to amino acid 210 (Ser) of SEQ ID NO:6 (198 (Leu) to amino acid 229 (Glu) of SEQ ID NO:2).

LCMS and LCMS-MS analyses were performed on a Magic HPLC (Michrom Bioresources, Auburn, CA) connected in-line to a Finnigan LCQ mass spectrometer (Finnigan MAT, San Jose, CA). LC separation was done on a Vydac C4 5  $\mu$  300Å column (Michrom Bioresources) with an elution gradient of 20% - 80% solvent B over 80 minutes where solvent A was 2% Acetonitrile + 0.1 % TFA and solvent B was 90% Acetonitrile + 0.095% TFA (EM Science; Sigma, St. Louis, MO). The LCQ mass spectrometer was set to collect MS spectra for the duration of the run.

LCMS-MS analysis of polypeptide digests was performed on the same instrument system using a Vydac C18 5  $\mu$  300Å column (Michrom Bioresources) with an elution gradient of 5-65% solvent B over 80 minutes with the same solvent system described for LCMS analysis above. The LCQ mass spectrometer was configured to collect MS, zoom-scan and MS-MS spectra for each ion over a minimum threshold.

The extent of tryptophan mannosylation was estimated by comparing ion intensities for the 2+ and 3+ ions of the peptides containing the WSXWS motif (SEQ ID NO:13) from both Glu-C and Asp-N digestion described above. Peak composition was first determined utilizing the MS data and a peptide map was generated. Next, an average spectrum was created starting approximately 1 minute before the early eluting mannosylated WSXWS (SEQ ID NO:13) containing peptide and ending approximately 1 minute after its later eluting non-mannosylated companion peptide. The normalized intensities of the ions corresponding to mannosylated and non-mannosylated peptide were compared and used to generate a percentage occupancy number. Values generated for both 2+ and 3+ charge states were averaged to generate a percent occupancy value for each digest. This value was then averaged with the value from the companion digest for each lot of protein to generate a final value.

Table 7 below summarizes the data that were calculated for each Peptide-tag and host cell used for zalp11 soluble receptor expression.

Table 7

C-terminal-Tag	Expression Host	% WSXWS Mannosylated
Glu-Glu	BHK	~46%
FLAG	BHK	~35%
Fc4	CHO	~11%

One of skill in the art would appreciate that mannosylation or non-mannosylation of the zalpha11 receptor WSXWS motif (SEQ ID NO:13) can affect the ability of the zalpha11 receptor or zalpha11 soluble receptor to homodimerize, heterodimerize, and/or it's ability to bind the zalpha11 Ligand. As the mannosylation on zalpha11 receptor appears to differ depending on the cell type in which the receptor so expressed, optimization of the expression and production of zalpha11 receptor and soluble receptor polypeptides may take into consideration whether the zalpha11 receptor produced by the cell is mannosylated or non-mannosylated. As such, one of skill in the art would appreciate that the polypeptides of the present invention can be either mannosylated or non-mannosylated.

As the mannosylation event is within the WSXWS motif (SEQ ID NO:13) of the zalpha11 class I cytokine receptor, the mannosylation of the Trp or the lack thereof can affect the polypeptide functionally. For example, insertions or deletions in the WSXWS motif (SEQ ID NO:13) of the EPOR can abrogate cell surface expression, destroy or reduce proliferative response, decrease receptor internalization, and affect EPO binding (Yoshimura, A et al., *J. Biol. Chem.* 267:11619-11625, 1992; Quelle, DE et al., *Mol. Cell. Biol.* 12:4553-4561, 1992; Hilton, DJ et al., *Proc. Natl. Acad. Sci. USA* 92:190-194, 1995). However, mutation in the WSXWS motif (SEQ ID NO:13) can also result in more efficient export from the ER and greater expression of the receptor on the cell surface (Hilton, DJ et al., *supra.*). Effects on cell surface expression, ligand binding and stimulatory response have also been seen with studies on WSXWS motif (SEQ ID NO:13) and related motifs in mutational analysis on IL-2R $\beta$ , GM-CSFR, and GHR (Miyazaki, et al., *EMBO J.* 10:3191-3197, 1991; Ronco, L.V. et al., *J. Biol. Chem.* 269:277-283, 1994; Baumgartner, JW et al., *J. Biol. Chem.* 269:29094-29101, 1994).

Similarly, mannosylation of the first Trp residue in the WSXWS motif (SEQ ID NO:13) of zalpha11 receptor polypeptides, including full-length and soluble receptors described herein, can have important structural and functional implications such as having affects on the overall stability of the receptor, rate of proteolysis, intracellular processing, antigenicity, cell surface expression, dimerization or multimerization, co-receptor binding, signaling or internalization, affects on zalpha11 Ligand binding and stability of receptor-ligand interaction. Comparison of mannosylated and non-mannosylated zalpha11 receptors can be made using X-ray crystallography or NMR on purified zalpha11 polypeptides (e.g., soluble receptors), or functional studies comparing zalpha11 expressed in cell lines that either mannosylated (e.g., BHK or other cell line) or are defective or reduced in mannosylation (e.g., CHO or other cell line) and comparing the receptors in the various assays described herein.

Example 36  
BHK Transfectant Binding Studies

Purified human zalpha11 Ligand (25µg) protein (commonly owned US Patent Application No. 09/522,217) was iodinated with  $^{125}\text{I}$  (Amersham) using iodo-beads (Pierce) and purified on a Sephadex G25 PD-10 column (Pharmacia). BHK transfectants (Example 31) expressing either human zalpha11 alone or human zalpha11 + human IL-2R $\gamma$  receptor were plated at 30K/well in a 24-well dish 24 hours prior to the binding study. BHK transfectants were incubated for 2 hours at 4 °C with 2.5 ng (0.147 pMoles)  $^{125}\text{I}$  zalpha11 Ligand (specific activity  $6.4 \times 10^7$  cpm/ug) in the presence of various concentrations of cold zalpha11 Ligand (in a range from about a 10,884 fold excess to no competition in 15, 4-fold dilutions). Cells were washed three times with binding buffer before lysis in 0.8M NaOH, followed by gamma emission counting. Analysis of these data yielded an affinity of approximately 1 nM for the zalpha11 transfectants and approximately 0.1nM for the human zalpha11 + human IL-2R $\gamma$  receptor transfectants. This result suggested that zalpha11 Ligand has high affinity on both the homodimeric human zalpha11 or heterodimeric human zalpha11 + human IL-2R $\gamma$  receptor, and that the affinity is higher for the heterodimer.

Example 37Murine Homodimeric zalpha11Receptor-mG2a Fusion Protein

5 The expression vector pEZE2 was used to express the murine zalpha11receptor-murine IgGamma2a Fc fusion protein (zalpha11m-mG2a). The mouse zalpha11 extracellular domain murine immunoglobulin gamma 2a heavy chain Fc region fusion protein (zalpha11m-mG2a) DNA sequence is shown in SEQ ID NO:72, and the corresponding polypeptide sequence is shown in SEQ ID NO:73.

10 The pEZE2 vector is a plasmid derived from pDC312 (Immunex Corp., Seattle, WA), and contains an EASE segment as described in WIPO Publication WO 97/25420. The presence of the EASE segment in an expression vector can improve expression of recombinant proteins about two to eight fold in stable cell pools. The pEZE2 plasmid is a dicistronic expression vector that can be used to express two different proteins in mammalian cells, such as Chinese Hamster Ovary (CHO) cells.

15 The pEZE2 expression unit contains a CMV enhancer/promoter; an adenovirus tripartite leader sequence; a multiple cloning site (MCS) for insertion of the coding region for the recombinant protein of interest; an encephalomyocarditis virus internal ribosome entry site; a coding segment for mouse dihydrofolate reductase; and the SV40 transcription terminator. In addition, pEZE2 contains an *E. coli* origin of replication

20 and the bacterial beta lactamase gene.

The zalpha11m-mG2a fusion protein is a disulfide-linked homodimer consisting of two chains of the mouse zalpha11 extracellular domain fused to a wild type murine immunoglobulin gamma 2a Fc region. The murine immunoglobulin gamma 2a Fc confers effector functions, FcγRI binding and C1q complement fixation.

25 The mouse zalpha11 extracellular domain murine immunoglobulin gamma 2a Fc constant region fusion construct was generated by overlap PCR of three separate DNA fragments, each generated by separate PCR amplification reactions. The first fragment contained an optimized tPA (tissue plasminogen activator) signal sequence (SEQ ID NO:80). The optimized tPA (otPA) signal sequence was amplified using

30 oligonucleotide primers ZC26,644 (SEQ ID NO:74) and ZC26,641 (SEQ ID NO:75) using an in-house previously generated expression vector as the template. PCR reaction

mix contained 20 pmoles of each primer, 10 ng template cDNA, 20  $\mu$ M each dNTP, 1 X Taq buffer (Life Technologies, Gaithersburg, MD), 0.5  $\mu$ l Taq polymerase in a 100  $\mu$ l reaction. PCR conditions: 1 cycle, 94°C, 2 minutes, 25 cycles, 94°C, 30 seconds, 60°C, 30 seconds, 72°C, 30 seconds, 1 cycle, 72°C, 5 minutes. The second fragment  
5 contained the mouse  $\alpha$ 11 extracellular domain coding region of amino acids 20 to 257 of SEQ ID NO:12. Oligonucleotide primers ZC26,642 (SEQ ID NO:76) and ZC26,662 (SEQ ID NO:77) were used to amplify this mouse  $\alpha$ 11 segment using a previously generated clone of mouse  $\alpha$ 11 (SEQ ID NO:11) as the template. This PCR fragment was made using the same PCR reaction mix specified above. PCR  
10 reaction conditions were as follows: 1 cycle, 94°C, 2 minutes, 25 cycles, 94°C, 30 seconds, 50°C, 30 seconds, 72°C, 45 seconds, 1 cycle, 72°C, 5 minutes.

The murine gamma 2a heavy chain Fc region was generated from a previously generated clone of murine Ig gamma 2a heavy chain cDNA. The segment containing the hinge, C<sub>H</sub>2, and C<sub>H</sub>3 domains of the murine immunoglobulin gamma 2a  
15 heavy chain constant region was generated by PCR amplification using oligonucleotide primers ZC26,643 (SEQ ID NO:78) and ZC26,645 (SEQ ID NO:79). This PCR fragment was made using the same reaction mix specified above. PCR conditions were as follows: 1 cycle, 94°C, 2 minutes, 25 cycles, 94°C, 30 seconds, 60°C, 30 seconds, 72°C, 30 seconds, 1 cycle, 72°C, 5 minutes.

20 To prepare the fusion protein-coding segment, three protein coding domains were linked by overlap PCR using oligonucleotides ZC26,644 (SEQ ID NO:74) and ZC26,662 (SEQ ID NO:77) to link the first two PCR products and ZC26,644 (SEQ ID NO:74) and ZC26,645 (SEQ ID NO:79) to link in the Fc region. Two reactions were set up: The first ran 25 cycles of 94°C for 2 min., 55°C for 30 sec.  
25 and 72°C for 1 min. 30 sec.. The other reaction ran 25 cycles of 94 degrees C for 2 min., 60°C for 30 sec and 72°C for 1 min. and 30 sec.. The PCR products in the two reactions were pooled and purified by using the QIAquick PCR purification kit (Qiagen) as per manufacturer's protocol. The product was eluted in 60  $\mu$ l of buffer. 30  $\mu$ l of this eluate was digested with FseI and AscI restriction enzymes in diluted NEB  
30 10x buffer No. 4 (New England Biolabs, Beverly, MA) as per manufacturer's directions. The material was then run on a 1% TAE agarose gel and the approximately

1500 bp band was excised and the DNA purified using a Qiagen Agarose gel extraction kit (Qiagen) as per manufacturers instructions. The fragment was eluted in 30  $\mu$ l H<sub>2</sub>O.

To prepare the recipient vector for the insert, about 3  $\mu$ g of pEZE2 vector was digested w/ AscI and FseI in the same manner as above, with the exception of 1  $\mu$ l of Calf Intestinal Phosphatase (CIP) (New England Biolabs) added after restriction enzyme digest (the reaction was allowed to proceed an additional 2hrs). The vector was then run on an agarose gel and purified as per above. The material was eluted in 30  $\mu$ l of H<sub>2</sub>O.

The fusion protein-coding segment was cloned into the MCS of pEZE2 from the FseI site to the AscI site in the polylinker, and ligated in 20  $\mu$ l using standard molecular biological reagents and procedures. The ligation reaction was incubated O/N at 16 °C. About 4 $\mu$ l of this ligation mix was electroporated into 50  $\mu$ l of DH12s *E. coli* electrocompetent cells (Life Technologies, Rockville, MD) and the cells rescued in 1 ml of LB media and allowed to shake/incubate for 1hr. and 100  $\mu$ l spread on Amp 100 agar plates. The plates were allowed to incubate o/n at 37°C. A single colony was sequence analyzed. A mutation was found that would result in a change from Glu to Lys at position 25 in SEQ ID NO:73. This amino acid substitution is within the otPA leader, and may have resulted in improper processing of the signal peptide, as N-terminal showed that the leader sequence was incompletely cleaved and started at a pyroglutamine residue upstream of the predicted start. However, this homodimeric construct was still active in inhibiting the  $\alpha$ 11 Ligand (Example 40).

A large prep was created using the Qiagen Maxi prep kit (Qiagen) as per manufacturers instructions. The plasmid was used to transfect CHO cells. The cells were selected in medium without hypoxanthine or thymidine and the transgene was amplified using methotrexate (Example 38). The presence of protein was assayed by Western blotting using anti human gamma 1heavy chain constant region and anti human kappa light chain antibodies (Rockland Immunochemicals, Gilbertsville PA).



Example 38Production of zAlphallm-mG2A in DG-44 CHO Cells

20µg of a zAlphallm-mG2A/pEZE2 construct (Example 37) was digested with 40 units of Pvu I at 37°C for three hours and was then precipitated with isopropanol and pelleted in a 1.5 mL microfuge tube. The supernatant was aspirated away from the pellet and the pellet was resuspended in 100 µl of water. About 200µg (20µl) of sheared salmon sperm DNA was added to the digested zAlphallm-mG2A/pEZE2 construct. The DNA mixture was co-precipitated using 0.1 volumes of sodium acetate (pH 5.2) and 2.2 volumes of ethanol. The tube was placed on dry ice for 15 minutes then was spun down in a microfuge at 14,000 RPM for 15 minutes forming a DNA pellet. The supernatant was aspirated off the pellet, and the pellet was washed with 1 mL of 70% ethanol and allowed to incubate for 5 minutes at room temperature. The tube was spun in a microfuge for 10 minutes at 14,000 RPM and the supernatant was aspirated off the pellet. The pellet was allowed to air dry for 30 minutes. The pellet was then resuspended in 100 µl of water and allowed to incubate at room temperature for 10 minutes. 500 µl containing about  $5 \times 10^6$  DG-44 CHO cells was added to the DNA in the microfuge tube, then the DNA/cell mixture was placed in a 0.4 cm gap cuvette and electroporated using the following parameters: 1,070 µF, high capacitance and 376 V. The contents of the cuvette were then removed and diluted to 25 mLs with EX-CELL™ 325 PF-CHO Protein Free Media (JRH Biosciences, Lenexa, KS) with 3 mM L-Glutamine and placed in a 125 mL shake flask. The flask was placed in an incubator on a shaker at 37°C, 6% CO<sub>2</sub> and shaking at 120 RPM.

The DG-44 CHO zAlphallm-mG2A culture was amplified with methotrexate (MTX) using standard methods to a final MTX level of 50 nM MTX. The culture was dilution-cloned and screened using a series of western blots. A final clone was chosen and further selected in MTX to a level of 200 nM MTX and was then scaled up for production. Production of each lot of the clone was accomplished by seeding 8X 4L spinner flasks with 2 L of culture at approximately  $5 \times 10^5$  cells/mL. Cultures were spun at 70 RPM, maintained at 37°C, 6% CO<sub>2</sub> and allowed to incubate for either 72 or 96 hours. The cells were spun down and the supernatants were 0.2 µm

filtered. A sufficient number of cells were recovered to seed the next series of flasks. Four total lots were produced in this manner for protein purification (Example 39).

#### Example 39

##### 5      Purification of the homodimeric zalpha11m-mG2a soluble receptor protein

All procedures performed at 4°C, unless otherwise noted. Conditioned media (Example 38) was directly captured on an appropriately sized POROS 50 A (coupled protein A; PerSeptive BioSystems, Framingham, MA) column at an optimal capture flow rate. The column was washed with 20 column volumes (CV) of loading  
10      buffer, then rapidly eluted with 3 CV of 0.1 M Glycine pH 2.5. The collected fractions had a predetermined volume of 2M TRIS pH 8.0 added prior to the elution to neutralize the pH to about 7.2.

Brilliant Blue (Sigma) stained NuPAGE gels were ran to analyze the elution. Fractions of interested were pooled and concentrated against a 30 kD MWCO  
15      centrifugal concentrator to a nominal volume. The concentrated Protein A pool was injected onto an appropriately sized Pharmacia Sephacryl 200 column (Pharmacia) to remove aggregates and to buffer exchange the protein into PBS pH 7.2.

Brilliant Blue (Sigma) stained NuPAGE gels (NOVEX) were again used to analyze the elution. Fractions were pooled and concentrated as before to ~1-2  
20      mgs/ml. Western and Brilliant Blue (Sigma) stained NuPAGE gels (NOVEX) were ran to confirm purity and content. In addition, the protein was submitted for amino acid analysis (AAA), and N-terminal sequencing for further analysis.

#### Example 40

##### 25      Soluble homodimeric zalpha11m-mg2a fusion protein as a zalpha11 Ligand Antagonist

BaF3 cells stably expressing the mouse zalpha11 receptor (constructed as per Example 2 using primers to SEQ ID NO:11) were plated at 5500 cells per well in standard 96-well tissue culture plates in base medium plus 3 ng/ml human zalpha11  
Ligand. Base medium is 500 ml RPMI 1640 (JRH Biosciences), 5 ml 100x Sodium  
30      Pyruvate (Gibco BRL), 5 ml 100x L-glutamine (Gibco BRL), and 50 ml heat-inactivated Fetal Bovine Serum (FBS) (Hyclone Laboratories). To the cells, a

decreasing dose of either purified homodimeric zalpha11m-mg2a (Example 39) was added. An Alamar Blue proliferation assay was run and fluorimetry performed as per Example 2B.

5 The homodimeric zalpha11m-mG2a fusion protein inhibited human zalpha11 Ligand activity in a dose dependent manner, with 1-5  $\mu\text{g/ml}$  able to inhibit the activity of 1.25 ng/ml human zalpha11 Ligand.

10 From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

## CLAIMS

What is claimed is:

1. An isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:6, and

wherein the soluble receptor polypeptide encoded by the polynucleotide sequence binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

2. An isolated polynucleotide according to claim 1, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a homodimeric receptor complex.

3. An isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to the amino acid sequence as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex.

4. An Isolated polynucleotide according to claim 3, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I cytokine receptor.

5. An isolated polynucleotide according to claim 3, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha$ ' receptor polypeptide (SEQ ID NO:82).

6. An isolated polynucleotide according to claim 3, wherein the polypeptide further comprises a WSXWS motif as shown in SEQ ID NO:13.

7. An isolated polynucleotide that encodes a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex.

8. An Isolated polynucleotide according to claim 7, wherein the soluble receptor polypeptide encoded by the polynucleotide further comprises a soluble Class I cytokine receptor.

9. An isolated polynucleotide according to claim 7, wherein the soluble receptor polypeptide encoded by the polynucleotide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82).

10. An isolated polynucleotide according to claim 7, wherein the soluble receptor polypeptide is encoded by the polynucleotide as shown in SEQ ID NO:7.

11. An isolated polynucleotide according to claim 3, wherein the soluble receptor polypeptide further comprises an affinity tag.

12. An expression vector comprising the following operably linked elements:

(a) a transcription promoter; a first DNA segment encoding a soluble receptor polypeptide having an amino acid sequence as shown in SEQ ID NO:6; and a transcription terminator; and

(b) a second transcription promoter; a second DNA segment encoding a soluble Class I cytokine receptor polypeptide; and a transcription terminator; and

wherein the first and second DNA segments are contained within a single expression vector or are contained within independent expression vectors.

13. An expression vector according to claim 12, further comprising a secretory signal sequence operably linked to the first and second DNA segments.

14. An expression vector according to claim 12, wherein the second DNA segment encodes a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82).

15. A cultured cell comprising an expression vector according to claim 12, wherein the cell expresses the polypeptides encoded by the DNA segments.

16. A cultured cell comprising an expression vector according to claim 12, wherein the first and second DNA segments are located on independent expression vectors and are co-transfected into the cell, and cell expresses the polypeptides encoded by the DNA segments.

17. A cultured cell into which has been introduced an expression vector according to claim 12, wherein the cell expresses a heterodimeric or multimeric soluble receptor polypeptide encoded by the DNA segments.

18. A cell according to claim 15, wherein the cell secretes a soluble receptor polypeptide heterodimer or multimeric complex.

19. A cell according to claim 15, wherein the cell secretes a soluble receptor polypeptide heterodimer or multimeric complex that binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

20. A DNA construct encoding a fusion protein comprising:  
a first DNA segment encoding a polypeptide having a sequence of amino acid residues as shown in SEQ ID NO:6; and  
at least one other DNA segment encoding a soluble Class I cytokine receptor polypeptide,

wherein the first and other DNA segments are connected in-frame; and  
wherein the first and other DNA segments encode the fusion protein.

21. A DNA construct encoding a fusion protein according to claim 20, wherein at least one other DNA segment encodes a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha$ ' receptor polypeptide (SEQ ID NO:82).

22. An expression vector comprising the following operably linked elements:

a transcription promoter;

a DNA construct encoding a fusion protein according to claim 20; and

a transcription terminator,

wherein the promoter is operably linked to the DNA construct, and the DNA construct is operably linked to the transcription terminator.

23. A cultured cell comprising an expression vector according to claim 22, wherein the cell expresses a polypeptide encoded by the DNA construct.

24. A method of producing a fusion protein comprising:

culturing a cell according to claim 23; and

isolating the polypeptide produced by the cell.

25. An isolated soluble receptor polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:6, and

wherein the soluble receptor polypeptide binds a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizes the ligand activity.

26. An isolated polypeptide according to claim 25, wherein the soluble receptor polypeptide forms a homodimeric receptor complex.

27. An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to an amino acid sequence as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex.

28. An isolated polypeptide according to claim 27, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I cytokine receptor.

29. An isolated polypeptide according to claim 27, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82).

30. An isolated polypeptide according to claim 27, wherein the polypeptide further comprises a WSXWS motif as shown in SEQ ID NO:13.

31. An isolated soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex.

32. An isolated polypeptide according to claim 31, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex further comprising a soluble Class I cytokine receptor.

33. An isolated polypeptide according to claim 31, wherein the soluble receptor polypeptide forms a heterodimeric or multimeric receptor complex comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82).



34. An isolated polypeptide according to claim 31, wherein the soluble receptor polypeptide further comprises an affinity tag, chemical moiety, toxin, or label.

35. An isolated heterodimeric or multimeric soluble receptor complex comprising soluble receptor subunits, wherein at least one of soluble receptor subunits comprises a soluble receptor polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:6.

36. An isolated heterodimeric or multimeric soluble receptor complex according to claim 35, further comprising a soluble Class I cytokine receptor polypeptide.

37. An isolated heterodimeric or multimeric soluble receptor complex according to claim 35, further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4) or a soluble IL-13 $\alpha'$  receptor polypeptide (SEQ ID NO:82).

38. A method of producing a soluble receptor polypeptide that form a heterodimeric or multimeric complex comprising:

culturing a cell according to claim 15; and

isolating the soluble receptor polypeptides produced by the cell.

39. A method of producing an antibody to a soluble receptor polypeptide comprising:

inoculating an animal with a soluble receptor polypeptide complex from the group of:

(a) a polypeptide comprising a homodimeric soluble receptor complex comprising SEQ ID NO:6;

(b) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6;

(b) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble Class I cytokine receptor polypeptide;

(c) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble IL-2R $\gamma$  receptor polypeptide (SEQ ID NO:4);

(d) a polypeptide comprising a soluble receptor heterodimeric or multimeric receptor complex comprising SEQ ID NO:6, and further comprising a soluble IL-13 $\alpha$ ' receptor polypeptide (SEQ ID NO:82); and

wherein the polypeptide complex elicits an immune response in the animal to produce the antibody; and

isolating the antibody from the animal.

40. An antibody produced by the method of claim 39, which specifically binds to a homodimeric, heterodimeric or multimeric receptor complex comprising a soluble receptor polypeptide comprising SEQ ID NO:6.

41. The antibody of claim 40, wherein the antibody is a monoclonal antibody.

42. An antibody which specifically binds to a homodimeric, heterodimeric or multimeric receptor complex according to claim 35.

43. A method for inhibiting a ligand comprising a polypeptide of SEQ ID NO:10 or SEQ ID NO:47, or antagonizing the ligand activity-induced proliferation of hematopoietic cells and hematopoietic cell progenitors comprising culturing bone marrow or peripheral blood cells with a composition comprising an amount of soluble receptor comprising SEQ ID NO:6 sufficient to reduce proliferation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble receptor.

44. The method of claim 43, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.

45. The method of claim 44, wherein the lymphoid cells are NK cells or cytotoxic T cells.

46. A method of reducing proliferation of neoplastic B or T cells comprising administering to a mammal with a B or T cell neoplasm an amount of a composition of soluble receptor comprising SEQ ID NO:6 sufficient to reduce proliferation of the neoplastic B or T cells.

47. A method of suppressing an immune response in a mammal exposed to an antigen or pathogen comprising:

- (1) determining a level of an antigen- or pathogen-specific antibody;
- (2) administering a composition of soluble receptor polypeptide comprising SEQ ID NO:6 in an acceptable pharmaceutical vehicle;
- (3) determining a post administration level of antigen- or pathogen-specific antibody;
- (4) comparing the level of antibody in step (1) to the level of antibody in step (3), wherein a lack of increase or a decrease in antibody level is indicative of suppressing an immune response.

## SEQUENCE LISTING

&lt;110&gt; ZymoGenetics, Inc.

&lt;120&gt; SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

&lt;130&gt; 00-22PC

&lt;150&gt; US 60/194,731

&lt;151&gt; 2000-04-05

&lt;150&gt; US 60/222,121

&lt;151&gt; 2000-07-28

&lt;160&gt; 86

&lt;170&gt; FastSEQ for Windows Version 3.0

&lt;210&gt; 1

&lt;211&gt; 1614\*

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(1614)

&lt;400&gt; 1

atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga	48
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly	
1 5 10 15	
ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg	96
Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr	
20 25 30	
gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc	144
Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr	
35 40 45	
ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc	192

Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser	
50 55 60	
tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc	240
Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr	
65 70 75 80	
tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc	288
Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val	
85 90 95	
aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt	336
Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe	
100 105 110	
ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg	384
Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val	
115 120 125	
acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac	432
Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp	
130 135 140	
cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac	480
Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr	
145 150 155 160	
agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc	528
Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile	
165 170 175	
tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa	576
Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys	
180 185 190	
gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc	624
Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser	
195 200 205	
tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag	672
Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln	
210 215 220	

acc cag tca gag gag tta aag gaa ggc tgg aac cct cac ctg ctg ctt	720
Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu	
225 230 235 240	
ctc ctc ctg ctt gtc ata gtc ttc att cct gcc ttc tgg agc ctg aag	768
Leu Leu Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys	
245 250 255	
acc cat cca ttg tgg agg cta tgg aag aag ata tgg gcc gtc ccc agc	816
Thr His Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser	
260 265 270	
cct gag cgg ttc ttc atg ccc ctg tac aag ggc tgc agc gga gac ttc	864
Pro Glu Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe	
275 280 285	
aag aaa tgg gtg ggt gca ccc ttc act ggc tcc agc ctg gag ctg gga	912
Lys Lys Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly	
290 295 300	
ccc tgg agc cca gag gtg ccc tcc acc ctg gag gtg tac agc tgc cac	960
Pro Trp Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His	
305 310 315 320	
cca cca cgg agc ccg gcc aag agg ctg cag ctc acg gag cta caa gaa	1008
Pro Pro Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu	
325 330 335	
cca gca gag ctg gtg gag tct gac ggt gtg ccc aag ccc agc ttc tgg	1056
Pro Ala Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp	
340 345 350	
ccg aca gcc cag aac tcg ggg ggc tca gct tac agt gag gag agg gat	1104
Pro Thr Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp	
355 360 365	
cgg cca tac ggc ctg gtg tcc att gac aca gtg act gtg cta gat gca	1152
Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala	
370 375 380	
gag ggg cca tgc acc tgg ccc tgc agc tgt gag gat gac ggc tac cca	1200

Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro	
385 390 395 400	
gcc ctg gac ctg gat gct ggc ctg gag ccc agc cca ggc cta gag gac	1248
Ala Leu Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp	
405 410 415	
cca ctc ttg gat gca ggg acc aca gtc ctg tcc tgt ggc tgt gtc tca	1296
Pro Leu Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser	
420 425 430	
gct ggc agc cct ggg cta gga ggg ccc ctg gga agc ctc ctg gac aga	1344
Ala Gly Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg	
435 440 445	
cta aag cca ccc ctt gca gat ggg gag gac tgg gct ggg gga ctg ccc	1392
Leu Lys Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro	
450 455 460	
tgg ggt ggc cgg tca cct gga ggg gtc tca gag agt gag gcg ggc tca	1440
Trp Gly Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser	
465 470 475 480	
ccc ctg gcc ggc ctg gat atg gac acg ttt gac agt ggc ttt gtg ggc	1488
Pro Leu Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly	
485 490 495	
tct gac tgc agc agc cct gtg gag tgt gac ttc acc agc ccc ggg gac	1536
Ser Asp Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp	
500 505 510	
gaa gga ccc ccc cgg agc tac ctc cgc cag tgg gtg gtc att cct ccg	1584
Glu Gly Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro	
515 520 525	
cca ctt tcg agc cct gga ccc cag gcc agc	1614
Pro Leu Ser Ser Pro Gly Pro Gln Ala Ser	
530 535	

<210> 2

<211> 538

<212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly  
 1 5 10 15  
 Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr  
 20 25 30  
 Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr  
 35 40 45  
 Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser  
 50 55 60  
 Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr  
 65 70 75 80  
 Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val  
 85 90 95  
 Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe  
 100 105 110  
 Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val  
 115 120 125  
 Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp  
 130 135 140  
 Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr  
 145 150 155 160  
 Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile  
 165 170 175  
 Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys  
 180 185 190  
 Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser  
 195 200 205  
 Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln  
 210 215 220  
 Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu  
 225 230 235 240  
 Leu Leu Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys  
 245 250 255  
 Thr His Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser  
 260 265 270  
 Pro Glu Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe  
 275 280 285  
 Lys Lys Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly  
 290 295 300



Pro Trp Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His  
 305 310 315 320  
 Pro Pro Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu  
 325 330 335  
 Pro Ala Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp  
 340 345 350  
 Pro Thr Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp  
 355 360 365  
 Arg Pro Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala  
 370 375 380  
 Glu Gly Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro  
 385 390 395 400  
 Ala Leu Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp  
 405 410 415  
 Pro Leu Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser  
 420 425 430  
 Ala Gly Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg  
 435 440 445  
 Leu Lys Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro  
 450 455 460  
 Trp Gly Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser  
 465 470 475 480  
 Pro Leu Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly  
 485 490 495  
 Ser Asp Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp  
 500 505 510  
 Glu Gly Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro  
 515 520 525  
 Pro Leu Ser Ser Pro Gly Pro Gln Ala Ser  
 530 535

<210> 3  
 <211> 696  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (1)...(696)

<400> 3

ctg aac acg aca att ctg acg ccc aat ggg aat gaa gac acc aca gct

Leu	Asn	Thr	Thr	Ile	Leu	Thr	Pro	Asn	Gly	Asn	Glu	Asp	Thr	Thr	Ala	
1				5					10						15	
gat ttc ttc ctg acc act atg ccc act gac tcc ctc agt gtt tcc act																96
Asp Phe Phe Leu Thr Thr Met Pro Thr Asp Ser Leu Ser Val Ser Thr																
			20					25					30			
ctg ccc ctc cca gag gtt cag tgt ttt gtg ttc aat gtc gag tac atg																144
Leu Pro Leu Pro Glu Val Gln Cys Phe Val Phe Asn Val Glu Tyr Met																
			35				40					45				
aat tgc act tgg aac agc agc tct gag ccc cag cct acc aac ctc act																192
Asn Cys Thr Trp Asn Ser Ser Ser Glu Pro Gln Pro Thr Asn Leu Thr																
			50				55					60				
ctg cat tat tgg tac aag aac tcg gat aat gat aaa gtc cag aag tgc																240
Leu His Tyr Trp Tyr Lys Asn Ser Asp Asn Asp Lys Val Gln Lys Cys																
			65			70				75					80	
agc cac tat cta ttc tct gaa gaa atc act tct ggc tgt cag ttg caa																288
Ser His Tyr Leu Phe Ser Glu Glu Ile Thr Ser Gly Cys Gln Leu Gln																
				85				90						95		
aaa aag gag atc cac ctc tac caa aca ttt gtt gtt cag ctc cag gac																336
Lys Lys Glu Ile His Leu Tyr Gln Thr Phe Val Val Gln Leu Gln Asp																
			100					105					110			
cca cgg gaa ccc agg aga cag gcc aca cag atg cta aaa ctg cag aat																384
Pro Arg Glu Pro Arg Arg Gln Ala Thr Gln Met Leu Lys Leu Gln Asn																
			115				120						125			
ctg gtg atc ccc tgg gct cca gag aac cta aca ctt cac aaa ctg agt																432
Leu Val Ile Pro Trp Ala Pro Glu Asn Leu Thr Leu His Lys Leu Ser																
			130				135						140			
gaa tcc cag cta gaa ctg aac tgg aac aac aga ttc ttg aac cac tgt																480
Glu Ser Gln Leu Glu Leu Asn Trp Asn Asn Arg Phe Leu Asn His Cys																
			145			150				155					160	
ttg gag cac ttg gtg cag tac cgg act gac tgg gac cac agc tgg act																528
Leu Glu His Leu Val Gln Tyr Arg Thr Asp Trp Asp His Ser Trp Thr																
				165					170						175	

gaa caa tca gtg gat tat aga cat aag ttc tcc ttg cct agt gtg gat 576  
 Glu Gln Ser Val Asp Tyr Arg His Lys Phe Ser Leu Pro Ser Val Asp  
                   180                  185                  190

ggg cag aaa cgc tac acg ttt cgt gtt cgg agc cgc ttt aac cca ctc 624  
 Gly Gln Lys Arg Tyr Thr Phe Arg Val Arg Ser Arg Phe Asn Pro Leu  
                   195                  200                  205

tgt gga agt gct cag cat tgg agt gaa tgg agc cac cca atc cac tgg 672  
 Cys Gly Ser Ala Gln His Trp Ser Glu Trp Ser His Pro Ile His Trp  
                   210                  215                  220

ggg agc aat act tca aaa gag aat 696  
 Gly Ser Asn Thr Ser Lys Glu Asn  
                   225                  230

<210> 4  
 <211> 232  
 <212> PRT  
 <213> Homo sapiens

<400> 4

Leu Asn Thr Thr Ile Leu Thr Pro Asn Gly Asn Glu Asp Thr Thr Ala  
   1                  5                  10                  15  
 Asp Phe Phe Leu Thr Thr Met Pro Thr Asp Ser Leu Ser Val Ser Thr  
                   20                  25                  30  
 Leu Pro Leu Pro Glu Val Gln Cys Phe Val Phe Asn Val Glu Tyr Met  
                   35                  40                  45  
 Asn Cys Thr Trp Asn Ser Ser Ser Glu Pro Gln Pro Thr Asn Leu Thr  
                   50                  55                  60  
 Leu His Tyr Trp Tyr Lys Asn Ser Asp Asn Asp Lys Val Gln Lys Cys  
   65                  70                  75                  80  
 Ser His Tyr Leu Phe Ser Glu Glu Ile Thr Ser Gly Cys Gln Leu Gln  
                   85                  90                  95  
 Lys Lys Glu Ile His Leu Tyr Gln Thr Phe Val Val Gln Leu Gln Asp  
                   100                  105                  110  
 Pro Arg Glu Pro Arg Arg Gln Ala Thr Gln Met Leu Lys Leu Gln Asn  
                   115                  120                  125  
 Leu Val Ile Pro Trp Ala Pro Glu Asn Leu Thr Leu His Lys Leu Ser  
                   130                  135                  140  
 Glu Ser Gln Leu Glu Leu Asn Trp Asn Asn Arg Phe Leu Asn His Cys  
   145                  150                  155                  160

Leu Glu His Leu Val Gln Tyr Arg Thr Asp Trp Asp His Ser Trp Thr  
                     165                    170                    175  
 Glu Gln Ser Val Asp Tyr Arg His Lys Phe Ser Leu Pro Ser Val Asp  
                     180                    185                    190  
 Gly Gln Lys Arg Tyr Thr Phe Arg Val Arg Ser Arg Phe Asn Pro Leu  
                     195                    200                    205  
 Cys Gly Ser Ala Gln His Trp Ser Glu Trp Ser His Pro Ile His Trp  
                     210                    215                    220  
 Gly Ser Asn Thr Ser Lys Glu Asn  
 225                    230

<210> 5  
 <211> 654  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (1)...(654)

<400> 5

tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg gtc atc tgc	48
Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys	
1                    5                    10                    15	
atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc ctt acc tgg	96
Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp	
20                    25                    30	
caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc tgc agc ctc	144
Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu	
35                    40                    45	
cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc tgc cac atg	192
His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met	
50                    55                    60	
gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc aac atc aca	240
Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr	
65                    70                    75                    80	
gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt ctc ctg gct	288

Asp	Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu	Cys	Gly	Ser	Phe	Leu	Leu	Ala		
				85					90					95			
gag	agc	atc	aag	ccg	gct	ccc	cct	ttc	aac	gtg	act	gtg	acc	ttc	tca		336
Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Phe	Asn	Val	Thr	Val	Thr	Phe	Ser		
			100					105					110				
gga	cag	tat	aat	atc	tcc	tgg	cgc	tca	gat	tac	gaa	gac	cct	gcc	ttc		384
Gly	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser	Asp	Tyr	Glu	Asp	Pro	Ala	Phe		
			115				120					125					
tac	atg	ctg	aag	ggc	aag	ctt	cag	tat	gag	ctg	cag	tac	agg	aac	cgg		432
Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr	Arg	Asn	Arg		
	130					135					140						
gga	gac	ccc	tgg	gct	gtg	agt	ccg	agg	aga	aag	ctg	atc	tca	gtg	gac		480
Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg	Arg	Lys	Leu	Ile	Ser	Val	Asp		
145					150					155					160		
tca	aga	agt	gtc	tcc	ctc	ctc	ccc	ctg	gag	ttc	cgc	aaa	gac	tcg	agc		528
Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu	Glu	Phe	Arg	Lys	Asp	Ser	Ser		
				165				170						175			
tat	gag	ctg	cag	gtg	cgg	gca	ggg	ccc	atg	cct	ggc	tcc	tcc	tac	cag		576
Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro	Met	Pro	Gly	Ser	Ser	Tyr	Gln		
			180					185					190				
ggg	acc	tgg	agt	gaa	tgg	agt	gac	ccg	gtc	atc	ttt	cag	acc	cag	tca		624
Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln	Thr	Gln	Ser		
		195					200					205					
gag	gag	tta	aag	gaa	ggc	tgg	aac	cct	cac								654
Glu	Glu	Leu	Lys	Glu	Gly	Trp	Asn	Pro	His								
	210					215											
<210> 6																	
<211> 218																	
<212> PRT																	
<213> Homo sapiens																	
<400> 6																	
Cys	Pro	Asp	Leu	Val	Cys	Tyr	Thr	Asp	Tyr	Leu	Gln	Thr	Val	Ile	Cys		
1				5					10					15			

Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp  
                   20                                  25                                  30  
 Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu  
                   35                                  40                                  45  
 His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met  
                   50                                  55                                  60  
 Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr  
                   65                                  70                                  75                                  80  
 Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala  
                                   85                                  90                                  95  
 Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val Thr Phe Ser  
                                   100                                  105                                  110  
 Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe  
                                   115                                  120                                  125  
 Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg  
                                   130                                  135                                  140  
 Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp  
                                   145                                  150                                  155                                  160  
 Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser  
                                   165                                  170                                  175  
 Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln  
                                   180                                  185                                  190  
 Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser  
                                   195                                  200                                  205  
 Glu Glu Leu Lys Glu Gly Trp Asn Pro His  
                                   210                                  215

&lt;210&gt; 7

&lt;211&gt; 654

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Degenerate polynucleotide sequence of soluble  
 zalpha11 Receptor polypeptide as shown in SEQ ID  
 NO:6

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(654)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 7

tgycngayy tngtntgyta yacngaytay ytnacaracng tnathtgyat hytngaratg	60
tggaayytnc ayccnwsnac nytnacnytn acntggcarg aycartayga rgarytnaar	120
gaygargcna cnwsntgyws nytncaymgn wsnccncaya aygcnacnca ygcnacntay	180
acntgycaya tggaygtntt ycayttyatg gcngaygaya thttywsngt naayathacn	240
gaycarwsng gnaaytayws ncargartgy ggnwsnttyy tnytngcnga rwsnathaar	300
ccngcncnc cnttyaaygt nacngtnacn ttywsnggnc artayaayat hwsntggmgn	360
wsngaytayg argayccngc nttytayatg ytnaarggna arytncarta ygarytncar	420
taymgnaaym gngngaycc ntgggcngtn wsnccnmgnm gnaarytnat hwsngtngay	480
wsnmgnwsng tnwsnytnyt nccnytngar ttymgnaarg aywsnwsnta ygarytncar	540
gtmngngcng gncnatgcc nggnwsnwsn taycarggna cntggwsnga rtggwsngay	600
ccngtnatht tyacaracnca rwsngargar ytnaargarg gntggaaycc ncay	654

&lt;210&gt; 8

&lt;211&gt; 696

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Degenerate polynucleotide sequence of IL-2Rgamma polypeptide as shown in SEQ ID NO:4

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(696)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 8

ytnaayacna cnathytnac nccnaayggn aaygargaya cnacngcnga yttyttyytn	60
acnacnatgc cnacngayws nytnwsngtn wsnacnytn cnytnccnga rgtncartgy	120
ttygtnttya aygtngarta yatgaaytg acntggaayw snwsnwsnga rccncarccn	180
acnaayytna cnytncayta ytggtayaar aaywsngaya aygayaargt ncaraartgy	240
wsncaytayy tnttywsnga rgarathacn wsngngtgyc arytncaraa raargarath	300
cayytnayc aracnttygt ngtnacarytn cargayccnm gngarccnmg nmngcargcn	360
acncaratgy tnaarytnca raayytngtn athccntggg cncngaraa yytnacnytn	420
cayaarytnw sngarwsnca rytngarytn aaytggaaya aymgnttyt naaycaytg	480
ytngarcayy tngtncarta ymgnaacngay tgggaycayw sntggacnga rcarwsngtn	540
gaytaymgnc ayaarttyws nytnccnwsn gtngayggnc araarmgnta yacnttymg	600
gtmgnwsnm gnttyaaycc nytnthyggg wsnccncarc aytggwsnga rtggwsncay	660
ccnathcayt ggggnwsnaa yacnwsnaar garaay	696

&lt;210&gt; 9

&lt;211&gt; 486

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(486)

&lt;400&gt; 9

atg	aga	tcc	agt	cct	ggc	aac	atg	gag	agg	att	gtc	atc	tgt	ctg	atg	48
Met	Arg	Ser	Ser	Pro	Gly	Asn	Met	Glu	Arg	Ile	Val	Ile	Cys	Leu	Met	
1				5				10					15			

gtc	atc	ttc	ttg	ggg	aca	ctg	gtc	cac	aaa	tca	agc	tcc	caa	ggc	caa	96
Val	Ile	Phe	Leu	Gly	Thr	Leu	Val	His	Lys	Ser	Ser	Ser	Gln	Gly	Gln	
			20					25					30			

gat	cgc	cac	atg	att	aga	atg	cgt	caa	ctt	ata	gat	att	gtt	gat	cag	144
Asp	Arg	His	Met	Ile	Arg	Met	Arg	Gln	Leu	Ile	Asp	Ile	Val	Asp	Gln	
		35					40						45			

ctg	aaa	aat	tat	gtg	aat	gac	ttg	gtc	cct	gaa	ttt	ctg	cca	gct	cca	192
Leu	Lys	Asn	Tyr	Val	Asn	Asp	Leu	Val	Pro	Glu	Phe	Leu	Pro	Ala	Pro	
	50					55					60					

gaa	gat	gta	gag	aca	aac	tgt	gag	tgg	tca	gct	ttt	tcc	tgt	ttt	cag	240
Glu	Asp	Val	Glu	Thr	Asn	Cys	Glu	Trp	Ser	Ala	Phe	Ser	Cys	Phe	Gln	
65					70					75				80		

aag	gcc	caa	cta	aag	tca	gca	aat	aca	gga	aac	aat	gaa	agg	ata	atc	288
Lys	Ala	Gln	Leu	Lys	Ser	Ala	Asn	Thr	Gly	Asn	Asn	Glu	Arg	Ile	Ile	
			85						90					95		

aat	gta	tca	att	aaa	aag	ctg	aag	agg	aaa	cca	cct	tcc	aca	aat	gca	336
Asn	Val	Ser	Ile	Lys	Lys	Leu	Lys	Arg	Lys	Pro	Pro	Ser	Thr	Asn	Ala	
			100					105						110		

ggg	aga	aga	cag	aaa	cac	aga	cta	aca	tgc	cct	tca	tgt	gat	tct	tat	384
Gly	Arg	Arg	Gln	Lys	His	Arg	Leu	Thr	Cys	Pro	Ser	Cys	Asp	Ser	Tyr	
			115				120					125				

gag	aaa	aaa	cca	ccc	aaa	gaa	ttc	cta	gaa	aga	ttc	aaa	tca	ctt	ctc	432
Glu	Lys	Lys	Pro	Pro	Lys	Glu	Phe	Leu	Glu	Arg	Phe	Lys	Ser	Leu	Leu	
	130					135					140					



caa aag atg att cat cag cat ctg tcc tct aga aca cac gga agt gaa 480  
 Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly Ser Glu  
 145 150 155 160

gat tcc 486  
 Asp Ser

<210> 10

<211> 162

<212> PRT

<213> Homo sapiens

<400> 10

Met Arg Ser Ser Pro Gly Asn Met Glu Arg Ile Val Ile Cys Leu Met  
 1 5 10 15  
 Val Ile Phe Leu Gly Thr Leu Val His Lys Ser Ser Ser Gln Gly Gln  
 20 25 30  
 Asp Arg His Met Ile Arg Met Arg Gln Leu Ile Asp Ile Val Asp Gln  
 35 40 45  
 Leu Lys Asn Tyr Val Asn Asp Leu Val Pro Glu Phe Leu Pro Ala Pro  
 50 55 60  
 Glu Asp Val Glu Thr Asn Cys Glu Trp Ser Ala Phe Ser Cys Phe Gln  
 65 70 75 80  
 Lys Ala Gln Leu Lys Ser Ala Asn Thr Gly Asn Asn Glu Arg Ile Ile  
 85 90 95  
 Asn Val Ser Ile Lys Lys Leu Lys Arg Lys Pro Pro Ser Thr Asn Ala  
 100 105 110  
 Gly Arg Arg Gln Lys His Arg Leu Thr Cys Pro Ser Cys Asp Ser Tyr  
 115 120 125  
 Glu Lys Lys Pro Pro Lys Glu Phe Leu Glu Arg Phe Lys Ser Leu Leu  
 130 135 140  
 Gln Lys Met Ile His Gln His Leu Ser Ser Arg Thr His Gly Ser Glu  
 145 150 155 160  
 Asp Ser

<210> 11

<211> 1735

<212> DNA

<213> mus musculus

<220>

<221> CDS

&lt;222&gt; (143)...(1729)

&lt;400&gt; 11

ctgccacct caaaccttca cctcccacca ccaccactcc gagtcccgt gtgactccca	60
cgcccaggag accaccaag tgcccagcc taaagaatgg ctttctgaga aagaccctga	120
aggagtaggt ctgggacaca gc atg ccc cgg ggc cca gtg gct gcc tta ctc	172
Met Pro Arg Gly Pro Val Ala Ala Leu Leu	
1 5 10	
ctg ctg att ctc cat gga gct tgg agc tgc ctg gac ctc act tgc tac	220
Leu Leu Ile Leu His Gly Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr	
15 20 25	
act gac tac ctc tgg acc atc acc tgt gtc ctg gag aca cgg agc ccc	268
Thr Asp Tyr Leu Trp Thr Ile Thr Cys Val Leu Glu Thr Arg Ser Pro	
30 35 40	
aac ccc agc ata ctc agt ctc acc tgg caa gat gaa tat gag gaa ctt	316
Asn Pro Ser Ile Leu Ser Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu	
45 50 55	
cag gac caa gag acc ttc tgc agc cta cac agg tct ggc cac aac acc	364
Gln Asp Gln Glu Thr Phe Cys Ser Leu His Arg Ser Gly His Asn Thr	
60 65 70	
aca cat ata tgg tac acg tgc cat atg cgc ttg tct caa ttc ctg tcc	412
Thr His Ile Trp Tyr Thr Cys His Met Arg Leu Ser Gln Phe Leu Ser	
75 80 85 90	
gat gaa gtt ttc att gtc aat gtg acg gac cag tct ggc aac aac tcc	460
Asp Glu Val Phe Ile Val Asn Val Thr Asp Gln Ser Gly Asn Asn Ser	
95 100 105	
caa gag tgt ggc agc ttt gtc ctg gct gag agc atc aaa cca gct .ccc	508
Gln Glu Cys Gly Ser Phe Val Leu Ala Glu Ser Ile Lys Pro Ala Pro	
110 115 120	
ccc ttg aac gtg act gtg gcc ttc tca gga cgc tat gat atc tcc tgg	556
Pro Leu Asn Val Thr Val Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp	
125 130 135	
gac tca gct tat gac gaa ccc tcc aac tac gtg ctg agg ggc aag cta	604

Asp Ser Ala Tyr Asp Glu Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu	
140 145 150	
caa tat gag ctg cag tat cgg aac ctc aga gac ccc tat gct gtg agg	652
Gln Tyr Glu Leu Gln Tyr Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg	
155 160 165 170	
ccg gtg acc aag ctg atc tca gtg gac tca aga aac gtc tct ctt ctc	700
Pro Val Thr Lys Leu Ile Ser Val Asp Ser Arg Asn Val Ser Leu Leu	
175 180 185	
cct gaa gag ttc cac aaa gat tct agc tac cag ctg cag gtg cgg gca	748
Pro Glu Glu Phe His Lys Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala	
190 195 200	
gcg cct cag cca ggc act tca ttc agg ggg acc tgg agt gag tgg agt	796
Ala Pro Gln Pro Gly Thr Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser	
205 210 215	
gac ccc gtc atc ttt cag acc cag gct ggg gag ccc gag gca ggc tgg	844
Asp Pro Val Ile Phe Gln Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp	
220 225 230	
gac cct cac atg ctg ctg ctc ctg gct gtc ttg atc att gtc ctg gtt	892
Asp Pro His Met Leu Leu Leu Leu Ala Val Leu Ile Ile Val Leu Val	
235 240 245 250	
ttc atg ggt ctg aag atc cac ctg cct tgg agg cta tgg aaa aag ata	940
Phe Met Gly Leu Lys Ile His Leu Pro Trp Arg Leu Trp Lys Lys Ile	
255 260 265	
tgg gca cca gtg ccc acc cct gag agt ttc ttc cag ccc ctg tac agg	988
Trp Ala Pro Val Pro Thr Pro Glu Ser Phe Phe Gln Pro Leu Tyr Arg	
270 275 280	
gag cac agc ggg aac ttc aag aaa tgg gtt aat acc cct ttc acg gcc	1036
Glu His Ser Gly Asn Phe Lys Lys Trp Val Asn Thr Pro Phe Thr Ala	
285 290 295	
tcc agc ata gag ttg gtg cca cag agt tcc aca aca aca tca gcc tta	1084
Ser Ser Ile Glu Leu Val Pro Gln Ser Ser Thr Thr Thr Ser Ala Leu	
300 305 310	



Glu Ala Gly Ser Pro Pro Gly Leu Asp Met Asp Thr Phe Asp Ser Gly  
 475 480 485 490  
 ttt gca ggt tca gac tgt ggc agc ccc gtg gag act gat gaa gga ccc 1660  
 Phe Ala Gly Ser Asp Cys Gly Ser Pro Val Glu Thr Asp Glu Gly Pro  
 495 500 505  
 cct cga agc tat ctc cgc cag tgg gtg gtc agg acc cct cca cct gtg 1708  
 Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Arg Thr Pro Pro Pro Val  
 510 515 520  
 gac agt gga gcc cag agc agc tagcat 1735  
 Asp Ser Gly Ala Gln Ser Ser  
 525

<210> 12  
 <211> 529  
 <212> PRT  
 <213> mus musculus

<400> 12  
 Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Ile Leu His Gly  
 1 5 10 15  
 Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr  
 20 25 30  
 Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser  
 35 40 45  
 Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe  
 50 55 60  
 Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr  
 65 70 75 80  
 Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val  
 85 90 95  
 Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe  
 100 105 110  
 Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val  
 115 120 125  
 Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu  
 130 135 140  
 Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr  
 145 150 155 160

Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile  
 165 170 175  
 Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys  
 180 185 190  
 Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr  
 195 200 205  
 Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln  
 210 215 220  
 Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Pro His Met Leu Leu  
 225 230 235 240  
 Leu Leu Ala Val Leu Ile Ile Val Leu Val Phe Met Gly Leu Lys Ile  
 245 250 255  
 His Leu Pro Trp Arg Leu Trp Lys Lys Ile Trp Ala Pro Val Pro Thr  
 260 265 270  
 Pro Glu Ser Phe Phe Gln Pro Leu Tyr Arg Glu His Ser Gly Asn Phe  
 275 280 285  
 Lys Lys Trp Val Asn Thr Pro Phe Thr Ala Ser Ser Ile Glu Leu Val  
 290 295 300  
 Pro Gln Ser Ser Thr Thr Thr Ser Ala Leu His Leu Ser Leu Tyr Pro  
 305 310 315 320  
 Ala Lys Glu Lys Lys Phe Pro Gly Leu Pro Gly Leu Glu Glu Gln Leu  
 325 330 335  
 Glu Cys Asp Gly Met Ser Glu Pro Gly His Trp Cys Ile Ile Pro Leu  
 340 345 350  
 Ala Ala Gly Gln Ala Val Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro  
 355 360 365  
 Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Gly Asp Ala Glu Gly  
 370 375 380  
 Leu Cys Val Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Met  
 385 390 395 400  
 Asn Leu Asp Ala Gly Arg Glu Ser Gly Pro Asn Ser Glu Asp Leu Leu  
 405 410 415  
 Leu Val Thr Asp Pro Ala Phe Leu Ser Cys Gly Cys Val Ser Gly Ser  
 420 425 430  
 Gly Leu Arg Leu Gly Gly Ser Pro Gly Ser Leu Leu Asp Arg Leu Arg  
 435 440 445  
 Leu Ser Phe Ala Lys Glu Gly Asp Trp Thr Ala Asp Pro Thr Trp Arg  
 450 455 460  
 Thr Gly Ser Pro Gly Gly Gly Ser Glu Ser Glu Ala Gly Ser Pro Pro  
 465 470 475 480  
 Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Ala Gly Ser Asp Cys  
 485 490 495

Gly Ser Pro Val Glu Thr Asp Glu Gly Pro Pro Arg Ser Tyr Leu Arg  
                   500                  505                  510  
 Gln Trp Val Val Arg Thr Pro Pro Pro Val Asp Ser Gly Ala Gln Ser  
                   515                  520                  525  
 Ser

<210> 13  
 <211> 5  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> WSXWS polypeptide consensus motif  
 <221> VARIANT  
 <222> (1)...(5)  
 <223> Xaa = Any Amino Acid

<400> 13  
 Trp Ser Xaa Trp Ser  
 1                  5

<210> 14  
 <211> 6  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Glu-Glu (CEE) Tag amino acid sequence

<400> 14  
 Glu Tyr Met Pro Met Glu  
 1                  5

<210> 15  
 <211> 1701  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> soluble zalpha11R/IgGgamma1 construct

<221> CDS

&lt;222&gt; (1)...(1701)

&lt;400&gt; 15

atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga	48
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly	
1 5 10 15	
ggc tgg ggc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag acg	96
Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr	
20 25 30	
gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc acc	144
Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr	
35 40 45	
ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc tcc	192
Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser	
50 55 60	
tgc agc ctc cac agg tcg gcc cac aat gcc acg cat gcc acc tac acc	240
Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr	
65 70 75 80	
tgc cac atg gat gta ttc cac ttc atg gcc gac gac att ttc agt gtc	288
Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val	
85 90 95	
aac atc aca gac cag tct ggc aac tac tcc cag gag tgt ggc agc ttt	336
Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe	
100 105 110	
ctc ctg gct gag agc atc aag ccg gct ccc cct ttc aac gtg act gtg	384
Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val	
115 120 125	
acc ttc tca gga cag tat aat atc tcc tgg cgc tca gat tac gaa gac	432
Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp	
130 135 140	
cct gcc ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac	480
Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr	
145 150 155 160	



agg aac cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc	528
Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile	
165 170 175	
tca gtg gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa	576
Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys	
180 185 190	
gac tcg agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc	624
Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser	
195 200 205	
tcc tac cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag	672
Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln	
210 215 220	
acc cag tca gag gag tta aag gaa ggc tgg aac cct cac gct agc acc	720
Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Ala Ser Thr	
225 230 235 240	
aag ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct	768
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser	
245 250 255	
ggg ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa	816
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu	
260 265 270	
ccg gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac	864
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His	
275 280 285	
acc ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc	912
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser	
290 295 300	
gtg gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc	960
Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys	
305 310 315 320	
aac gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag	1008

Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu	
325 330 335	
ccc aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct	1056
Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro	
340 345 350	
gaa ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag	1104
Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys	
355 360 365	
gac acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg	1152
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val	
370 375 380	
gac gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac	1200
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp	
385 390 395 400	
ggc gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac	1248
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr	
405 410 415	
aac agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac	1296
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp	
420 425 430	
tgg ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc	1344
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu	
435 440 445	
cca gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga	1392
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg	
450 455 460	
gaa cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag	1440
Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys	
465 470 475 480	
aac cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac	1488
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp	
485 490 495	

atc gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag 1536  
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys  
                   500                  505                  510

acc acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc 1584  
 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser  
                   515                  520                  525

aag ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca 1632  
 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser  
                   530                  535                  540

tgc tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc 1680  
 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser  
                   545                  550                  555                  560

ctc tcc ctg tct ccg ggt aaa 1701  
 Leu Ser Leu Ser Pro Gly Lys  
                   565

<210> 16

<211> 567

<212> PRT

<213> Artificial Sequence

<400> 16

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly  
 1                  5                  10                  15  
 Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr  
                   20                  25                  30  
 Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu Thr  
                   35                  40                  45  
 Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser  
                   50                  55                  60  
 Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr  
 65                  70                  75                  80  
 Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val  
                   85                  90                  95  
 Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe  
                   100                  105                  110  
 Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr Val  
                   115                  120                  125

25

Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp  
 130 135 140  
 Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr  
 145 150 155 160  
 Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile  
 165 170 175  
 Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys  
 180 185 190  
 Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser  
 195 200 205  
 Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln  
 210 215 220  
 Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Ala Ser Thr  
 225 230 235 240  
 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser  
 245 250 255  
 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu  
 260 265 270  
 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His  
 275 280 285  
 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser  
 290 295 300  
 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys  
 305 310 315 320  
 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu  
 325 330 335  
 Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro  
 340 345 350  
 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys  
 355 360 365  
 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val  
 370 375 380  
 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp  
 385 390 395 400  
 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr  
 405 410 415  
 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp  
 420 425 430  
 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu  
 435 440 445  
 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg  
 450 455 460

Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys  
 465 470 475 480  
 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp  
 485 490 495  
 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys  
 500 505 510  
 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser  
 515 520 525  
 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser  
 530 535 540  
 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser  
 545 550 555 560  
 Leu Ser Leu Ser Pro Gly Lys  
 565

<210> 17  
 <211> 1083  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> soluble human IL-2Rgamma/human kappa light chain  
 construct

<221> CDS  
 <222> (1)...(1083)

<400> 17  
 atg ttg aag cca tca tta cca ttc aca tcc ctc tta ttc ctg cag ctg 48  
 Met Leu Lys Pro Ser Leu Pro Phe Thr Ser Leu Leu Phe Leu Gln Leu  
 1 5 10 15  
 ccc ctg ctg gga gtg ggg ctg aac acg aca att ctg acg ccc aat ggg 96  
 Pro Leu Leu Gly Val Gly Leu Asn Thr Thr Ile Leu Thr Pro Asn Gly  
 20 25 30  
 aat gaa gac acc aca gct gat ttc ttc ctg acc act atg ccc act gac 144  
 Asn Glu Asp Thr Thr Ala Asp Phe Phe Leu Thr Thr Met Pro Thr Asp  
 35 40 45  
 tcc ctc agt gtt tcc act ctg ccc ctc cca gag gtt cag tgt ttt gtg 192

Ser	Leu	Ser	Val	Ser	Thr	Leu	Pro	Leu	Pro	Glu	Val	Gln	Cys	Phe	Val		
50						55					60						
ttc	aat	gtc	gag	tac	atg	aat	tgc	act	tgg	aac	agc	agc	tct	gag	ccc	240	
Phe	Asn	Val	Glu	Tyr	Met	Asn	Cys	Thr	Trp	Asn	Ser	Ser	Ser	Glu	Pro		
65					70				75					80			
cag	cct	acc	aac	ctc	act	ctg	cat	tat	tgg	tac	aag	aac	tcg	gat	aat	288	
Gln	Pro	Thr	Asn	Leu	Thr	Leu	His	Tyr	Trp	Tyr	Lys	Asn	Ser	Asp	Asn		
				85					90					95			
gat	aaa	gtc	cag	aag	tgc	agc	cac	tat	cta	ttc	tct	gaa	gaa	atc	act	336	
Asp	Lys	Val	Gln	Lys	Cys	Ser	His	Tyr	Leu	Phe	Ser	Glu	Glu	Ile	Thr		
			100					105					110				
tct	ggc	tgt	cag	ttg	caa	aaa	aag	gag	atc	cac	ctc	tac	caa	aca	ttt	384	
Ser	Gly	Cys	Gln	Leu	Gln	Lys	Lys	Glu	Ile	His	Leu	Tyr	Gln	Thr	Phe		
		115					120						125				
gtt	gtt	cag	ctc	cag	gac	cca	cgg	gaa	ccc	agg	aga	cag	gcc	aca	cag	432	
Val	Val	Gln	Leu	Gln	Asp	Pro	Arg	Glu	Pro	Arg	Arg	Gln	Ala	Thr	Gln		
		130				135						140					
atg	cta	aaa	ctg	cag	aat	ctg	gtg	atc	ccc	tgg	gct	cca	gag	aac	cta	480	
Met	Leu	Lys	Leu	Gln	Asn	Leu	Val	Ile	Pro	Trp	Ala	Pro	Glu	Asn	Leu		
145					150				155					160			
aca	ctt	cac	aaa	ctg	agt	gaa	tcc	cag	cta	gaa	ctg	aac	tgg	aac	aac	528	
Thr	Leu	His	Lys	Leu	Ser	Glu	Ser	Gln	Leu	Glu	Leu	Asn	Trp	Asn	Asn		
				165					170					175			
aga	ttc	ttg	aac	cac	tgt	ttg	gag	cac	ttg	gtg	cag	tac	cgg	act	gac	576	
Arg	Phe	Leu	Asn	His	Cys	Leu	Glu	His	Leu	Val	Gln	Tyr	Arg	Thr	Asp		
			180					185					190				
tgg	gac	cac	agc	tgg	act	gaa	caa	tca	gtg	gat	tat	aga	cat	aag	ttc	624	
Trp	Asp	His	Ser	Trp	Thr	Glu	Gln	Ser	Val	Asp	Tyr	Arg	His	Lys	Phe		
		195					200					205					
tcc	ttg	cct	agt	gtg	gat	ggg	cag	aaa	cgc	tac	acg	ttt	cgt	gtt	cgg	672	
Ser	Leu	Pro	Ser	Val	Asp	Gly	Gln	Lys	Arg	Tyr	Thr	Phe	Arg	Val	Arg		
		210					215					220					

agc cgc ttt aac cca ctc tgt gga agt gct cag cat tgg agt gaa tgg 720  
 Ser Arg Phe Asn Pro Leu Cys Gly Ser Ala Gln His Trp Ser Glu Trp  
 225 230 235 240

agc cac cca atc cac tgg ggg agc aat act tca aaa gag aat act gtg 768  
 Ser His Pro Ile His Trp Gly Ser Asn Thr Ser Lys Glu Asn Thr Val  
 245 250 255

gct gca cca tct gtc ttc atc ttc ccg cca tct gat gag cag ttg aaa 816  
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys  
 260 265 270

tct ggt acc gcc tct gtt gtg tgc ctg ctg aat aac ttc tat ccc aga 864  
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg  
 275 280 285

gag gcc aaa gta cag tgg aag gtg gat aac gcc ctc caa tcg ggt aac 912  
 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn  
 290 295 300

tcc cag gag agt gtc aca gag cag gac agc aag gac agc acc tac agc 960  
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser  
 305 310 315 320

ctc agc agc acc ctg acg ctg agc aaa gca gac tac gag aaa cac aaa 1008  
 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys  
 325 330 335

gtc tac gcc tgc gaa gtc acc cat cag ggc ctg agc tcg ccc gtc aca 1056  
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr  
 340 345 350

aag agc ttc aac agg gga gag tgt tag 1083  
 Lys Ser Phe Asn Arg Gly Glu Cys \*  
 355 360

<210> 18

<211> 360

<212> PRT

<213> Artificial Sequence

&lt;400&gt; 18

Met Leu Lys Pro Ser Leu Pro Phe Thr Ser Leu Leu Phe Leu Gln Leu  
 1 5 10 15  
 Pro Leu Leu Gly Val Gly Leu Asn Thr Thr Ile Leu Thr Pro Asn Gly  
 20 25 30  
 Asn Glu Asp Thr Thr Ala Asp Phe Phe Leu Thr Thr Met Pro Thr Asp  
 35 40 45  
 Ser Leu Ser Val Ser Thr Leu Pro Leu Pro Glu Val Gln Cys Phe Val  
 50 55 60  
 Phe Asn Val Glu Tyr Met Asn Cys Thr Trp Asn Ser Ser Ser Glu Pro  
 65 70 75 80  
 Gln Pro Thr Asn Leu Thr Leu His Tyr Trp Tyr Lys Asn Ser Asp Asn  
 85 90 95  
 Asp Lys Val Gln Lys Cys Ser His Tyr Leu Phe Ser Glu Glu Ile Thr  
 100 105 110  
 Ser Gly Cys Gln Leu Gln Lys Lys Glu Ile His Leu Tyr Gln Thr Phe  
 115 120 125  
 Val Val Gln Leu Gln Asp Pro Arg Glu Pro Arg Arg Gln Ala Thr Gln  
 130 135 140  
 Met Leu Lys Leu Gln Asn Leu Val Ile Pro Trp Ala Pro Glu Asn Leu  
 145 150 155 160  
 Thr Leu His Lys Leu Ser Glu Ser Gln Leu Glu Leu Asn Trp Asn Asn  
 165 170 175  
 Arg Phe Leu Asn His Cys Leu Glu His Leu Val Gln Tyr Arg Thr Asp  
 180 185 190  
 Trp Asp His Ser Trp Thr Glu Gln Ser Val Asp Tyr Arg His Lys Phe  
 195 200 205  
 Ser Leu Pro Ser Val Asp Gly Gln Lys Arg Tyr Thr Phe Arg Val Arg  
 210 215 220  
 Ser Arg Phe Asn Pro Leu Cys Gly Ser Ala Gln His Trp Ser Glu Trp  
 225 230 235 240  
 Ser His Pro Ile His Trp Gly Ser Asn Thr Ser Lys Glu Asn Thr Val  
 245 250 255  
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys  
 260 265 270  
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg  
 275 280 285  
 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn  
 290 295 300  
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser  
 305 310 315 320



Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys  
325 330 335  
Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr  
340 345 350  
Lys Ser Phe Asn Arg Gly Glu Cys  
355 360

<210> 19  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primer ZC19905

<400> 19  
acaggatccg tcagcatgcc gcgtggtgg gccgcc 36

<210> 20  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<223> Oligonucleotide primer ZC19906

<400> 20  
acagaattct tagctggcct ggggtccagg cgt 33

```
<210> 21
<211> 36
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Oligonucleotide primer ZC19931

<400> 21  
ggttggtacc gcaagatgcc gcgtggctgg gccgcc 36

$\langle 210 \rangle$  22  
 $\langle 211 \rangle$  29

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC19932

&lt;400&gt; 22

cggaggatcc gtgagggtc cagccttcc

29

&lt;210&gt; 23

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; FLAG tag amino acid sequence

&lt;400&gt; 23

Asp Tyr Lys Asp Asp Asp Asp Lys

1

5

&lt;210&gt; 24

&lt;211&gt; 66

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Oligonucleotide primer spanning vector flanking  
region and the 5' end of the *zalpha11*

&lt;400&gt; 24

tccactttgc ctttctctcc acaggtgtcc agggaattca tcgataatgc cgcgtggctg  
ggccgc

60

66

&lt;210&gt; 25

&lt;211&gt; 699

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

gagcccagat cttcagacaa aactcacaca tgcccaccgt gccagcacc tgaagccgag  
ggggcaccgt cagtcttctt cttccccca aaaccaagg acaccctcat gatctcccgg  
accctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc

60

120

180

aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag	240
tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat	300
ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc catcctccat cgagaaaacc	360
atctccaaag ccaaagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccgg	420
gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc	480
gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct	540
cccgtgctgg actccgacgg ctctttcttc ctctacagca agctcaccgt ggacaagagc	600
aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac	660
tacacgcaga agagcctctc cctgtctccg ggtaaataa	699

&lt;210&gt; 26

&lt;211&gt; 62

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> First Oligonucleotide primer spanning 3' end of  
the zalphall extracellular domain and the 5' end  
of Fc4

&lt;400&gt; 26

gcacgggtggg catgtgtgag ttttgtctga agatctgggc tcgtgagggt tccagccttc	60
ct	62

&lt;210&gt; 27

&lt;211&gt; 61

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Second Oligonucleotide primer spanning 3' end of  
the zalphall extracellular domain and the 5' end  
of Fc4

&lt;400&gt; 27

agaccagtc agaggagtta aaggaaggct ggaaccctca cgagcccaga tcttcagaca	60
a	61

&lt;210&gt; 28

&lt;211&gt; 67

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Oligonucleotide primer spanning the 3' end of Fc4  
and the vector flanking region

&lt;400&gt; 28

gtgggcctct ggggtgggta caacccaga gctgttttaa tctagattat ttaccggag 60  
acagga 67

&lt;210&gt; 29

&lt;211&gt; 1821

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Polynucleotide encoding MBP-human zalpha11 soluble  
receptor fusion

&lt;221&gt; CDS

&lt;222&gt; (1)...(1821)

&lt;400&gt; 29

atg aaa atc gaa gaa ggt aaa ctg gta atc tgg att aac ggc gat aaa 48  
Met Lys Ile Glu Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys  
1 5 10 15

ggc tat aac ggt ctc gct gaa gtc ggt aag aaa ttc gag aaa gat acc 96  
Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr  
20 25 30

gga att aaa gtc acc gtt gag cat ccg gat aaa ctg gaa gag aaa ttc 144  
Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe  
35 40 45

cca cag gtt gcg gca act ggc gat ggc cct gac att atc ttc tgg gca 192  
Pro Gln Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala  
50 55 60

cac gac cgc ttt ggt ggc tac gct caa tct ggc ctg ttg gct gaa atc 240  
His Asp Arg Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu Ile  
65 70 75 80

acc ccg gac aaa gcg ttc cag gac aag ctg tat ccg ttt acc tgg gat 288

Thr	Pro	Asp	Lys	Ala	Phe	Gln	Asp	Lys	Leu	Tyr	Pro	Phe	Thr	Trp	Asp		
				85					90					95			
gcc	gta	cgt	tac	aac	ggc	aag	ctg	att	gct	tac	ccg	atc	gct	gtt	gaa	336	
Ala	Val	Arg	Tyr	Asn	Gly	Lys	Leu	Ile	Ala	Tyr	Pro	Ile	Ala	Val	Glu		
			100					105					110				
gcg	tta	tcg	ctg	att	tat	aac	aaa	gat	ctg	ctg	ccg	aac	ccg	cca	aaa	384	
Ala	Leu	Ser	Leu	Ile	Tyr	Asn	Lys	Asp	Leu	Leu	Pro	Asn	Pro	Pro	Lys		
			115				120					125					
acc	tgg	gaa	gag	atc	ccg	gcg	ctg	gat	aaa	gaa	ctg	aaa	gcg	aaa	ggt	432	
Thr	Trp	Glu	Glu	Ile	Pro	Ala	Leu	Asp	Lys	Glu	Leu	Lys	Ala	Lys	Gly		
			130				135				140						
aag	agc	gcg	ctg	atg	ttc	aac	ctg	caa	gaa	ccg	tac	ttc	acc	tgg	ccg	480	
Lys	Ser	Ala	Leu	Met	Phe	Asn	Leu	Gln	Glu	Pro	Tyr	Phe	Thr	Trp	Pro		
			145			150				155					160		
ctg	att	gct	gct	gac	ggg	ggt	tat	gcg	ttc	aag	tat	gaa	aac	ggc	aag	528	
Leu	Ile	Ala	Ala	Asp	Gly	Gly	Tyr	Ala	Phe	Lys	Tyr	Glu	Asn	Gly	Lys		
				165				170					175				
tac	gac	att	aaa	gac	gtg	ggc	gtg	gat	aac	gct	ggc	gcg	aaa	gcg	ggt	576	
Tyr	Asp	Ile	Lys	Asp	Val	Gly	Val	Asp	Asn	Ala	Gly	Ala	Lys	Ala	Gly		
			180					185					190				
ctg	acc	ttc	ctg	gtt	gac	ctg	att	aaa	aac	aaa	cac	atg	aat	gca	gac	624	
Leu	Thr	Phe	Leu	Val	Asp	Leu	Ile	Lys	Asn	Lys	His	Met	Asn	Ala	Asp		
			195				200					205					
acc	gat	tac	tcc	atc	gca	gaa	gct	gcc	ttt	aat	aaa	ggc	gaa	aca	gcg	672	
Thr	Asp	Tyr	Ser	Ile	Ala	Glu	Ala	Ala	Phe	Asn	Lys	Gly	Glu	Thr	Ala		
			210			215					220						
atg	acc	atc	aac	ggc	ccg	tgg	gca	tgg	tcc	aac	atc	gac	acc	agc	aaa	720	
Met	Thr	Ile	Asn	Gly	Pro	Trp	Ala	Trp	Ser	Asn	Ile	Asp	Thr	Ser	Lys		
			225			230				235					240		
gtg	aat	tat	ggt	gta	acg	gta	ctg	ccg	acc	ttc	aag	ggt	caa	cca	tcc	768	
Val	Asn	Tyr	Gly	Val	Thr	Val	Leu	Pro	Thr	Phe	Lys	Gly	Gln	Pro	Ser		
				245				250					255				

aaa ccg ttc gtt ggc gtg ctg agc gca ggt att aac gcc gcc agt ccg	816
Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro	
260 265 270	
aac aaa gag ctg gca aaa gag ttc ctc gaa aac tat ctg ctg act gat	864
Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp	
275 280 285	
gaa ggt ctg gaa gcg gtt aat aaa gac aaa ccg ctg ggt gcc gta gcg	912
Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala	
290 295 300	
ctg aag tct tac gag gaa gag ttg gcg aaa gat cca cgt att gcc gcc	960
Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala	
305 310 315 320	
acc atg gaa aac gcc cag aaa ggt gaa atc atg ccg aac atc ccg cag	1008
Thr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro Gln	
325 330 335	
atg tcc gct ttc tgg tat gcc gtg cgt act gcg gtg atc aac gcc gcc	1056
Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala	
340 345 350	
agc ggt cgt cag act gtc gat gaa gcc ctg aaa gac gcg cag act aat	1104
Ser Gly Arg Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr Asn	
355 360 365	
tcg agc tcc cac cat cac cat cac cac gcg aat tcg gta ccg ctg gtt	1152
Ser Ser Ser His His His His His His Ala Asn Ser Val Pro Leu Val	
370 375 380	
ccg cgt gga tcc tgc ccc gac ctc gtc tgc tac acc gat tac ctc cag	1200
Pro Arg Gly Ser Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln	
385 390 395 400	
acg gtc atc tgc atc ctg gaa atg tgg aac ctc cac ccc agc acg ctc	1248
Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu	
405 410 415	
acc ctt acc tgg caa gac cag tat gaa gag ctg aag gac gag gcc acc	1296

Thr	Leu	Thr	Trp	Gln	Asp	Gln	Tyr	Glu	Glu	Leu	Lys	Asp	Glu	Ala	Thr		
			420					425					430				
tcc	tgc	agc	ctc	cac	agg	tgc	gcc	cac	aat	gcc	acg	cat	gcc	acc	tac		1344
Ser	Cys	Ser	Leu	His	Arg	Ser	Ala	His	Asn	Ala	Thr	His	Ala	Thr	Tyr		
		435					440					445					
acc	tgc	cac	atg	gat	gta	ttc	cac	ttc	atg	gcc	gac	gac	att	ttc	agt		1392
Thr	Cys	His	Met	Asp	Val	Phe	His	Phe	Met	Ala	Asp	Asp	Ile	Phe	Ser		
		450				455					460						
gtc	aac	atc	aca	gac	cag	tct	ggc	aac	tac	tcc	cag	gag	tgt	ggc	agc		1440
Val	Asn	Ile	Thr	Asp	Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu	Cys	Gly	Ser		
465					470					475				480			
ttt	ctc	ctg	gct	gag	agc	atc	aag	ccg	gct	ccc	cct	ttc	aac	gtg	act		1488
Phe	Leu	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Phe	Asn	Val	Thr		
			485					490					495				
gtg	acc	ttc	tca	gga	cag	tat	aat	atc	tcc	tgg	cgc	tca	gat	tac	gaa		1536
Val	Thr	Phe	Ser	Gly	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser	Asp	Tyr	Glu		
		500					505					510					
gac	cct	gcc	ttc	tac	atg	ctg	aag	ggc	aag	ctt	cag	tat	gag	ctg	cag		1584
Asp	Pro	Ala	Phe	Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln		
		515					520					525					
tac	agg	aac	cgg	gga	gac	ccc	tgg	gct	gtg	agt	ccg	agg	aga	aag	ctg		1632
Tyr	Arg	Asn	Arg	Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg	Arg	Lys	Leu		
	530					535					540						
atc	tca	gtg	gac	tca	aga	agt	gtc	tcc	ctc	ctc	ccc	ctg	gag	ttc	cgc		1680
Ile	Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu	Glu	Phe	Arg		
545				550				555				560					
aaa	gac	tgc	agc	tat	gag	ctg	cag	gtg	cgg	gca	ggg	ccc	atg	cct	ggc		1728
Lys	Asp	Ser	Ser	Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro	Met	Pro	Gly		
			565					570				575					
tcc	tcc	tac	cag	ggg	acc	tgg	agt	gaa	tgg	agt	gac	ccg	gtc	atc	ttt		1776
Ser	Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe		
			580					585				590					

cag acc cag tca gag gag tta aag gaa ggc tgg aac cct cac tag 1821  
 Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His \*  
 595 600 605

<210> 30

<211> 606

<212> PRT

<213> Artificial Sequence

<400> 30

Met Lys Ile Glu Gly Lys Leu Val Ile Trp Ile Asn Gly Asp Lys  
 1 5 10 15  
 Gly Tyr Asn Gly Leu Ala Glu Val Gly Lys Lys Phe Glu Lys Asp Thr  
 20 25 30  
 Gly Ile Lys Val Thr Val Glu His Pro Asp Lys Leu Glu Glu Lys Phe  
 35 40 45  
 Pro Gln Val Ala Ala Thr Gly Asp Gly Pro Asp Ile Ile Phe Trp Ala  
 50 55 60  
 His Asp Arg Phe Gly Gly Tyr Ala Gln Ser Gly Leu Leu Ala Glu Ile  
 65 70 75 80  
 Thr Pro Asp Lys Ala Phe Gln Asp Lys Leu Tyr Pro Phe Thr Trp Asp  
 85 90 95  
 Ala Val Arg Tyr Asn Gly Lys Leu Ile Ala Tyr Pro Ile Ala Val Glu  
 100 105 110  
 Ala Leu Ser Leu Ile Tyr Asn Lys Asp Leu Leu Pro Asn Pro Pro Lys  
 115 120 125  
 Thr Trp Glu Glu Ile Pro Ala Leu Asp Lys Glu Leu Lys Ala Lys Gly  
 130 135 140  
 Lys Ser Ala Leu Met Phe Asn Leu Gln Glu Pro Tyr Phe Thr Trp Pro  
 145 150 155 160  
 Leu Ile Ala Ala Asp Gly Gly Tyr Ala Phe Lys Tyr Glu Asn Gly Lys  
 165 170 175  
 Tyr Asp Ile Lys Asp Val Gly Val Asp Asn Ala Gly Ala Lys Ala Gly  
 180 185 190  
 Leu Thr Phe Leu Val Asp Leu Ile Lys Asn Lys His Met Asn Ala Asp  
 195 200 205  
 Thr Asp Tyr Ser Ile Ala Glu Ala Ala Phe Asn Lys Gly Glu Thr Ala  
 210 215 220  
 Met Thr Ile Asn Gly Pro Trp Ala Trp Ser Asn Ile Asp Thr Ser Lys  
 225 230 235 240  
 Val Asn Tyr Gly Val Thr Val Leu Pro Thr Phe Lys Gly Gln Pro Ser  
 245 250 255



Lys Pro Phe Val Gly Val Leu Ser Ala Gly Ile Asn Ala Ala Ser Pro  
 260 265 270  
 Asn Lys Glu Leu Ala Lys Glu Phe Leu Glu Asn Tyr Leu Leu Thr Asp  
 275 280 285  
 Glu Gly Leu Glu Ala Val Asn Lys Asp Lys Pro Leu Gly Ala Val Ala  
 290 295 300  
 Leu Lys Ser Tyr Glu Glu Glu Leu Ala Lys Asp Pro Arg Ile Ala Ala  
 305 310 315 320  
 Thr Met Glu Asn Ala Gln Lys Gly Glu Ile Met Pro Asn Ile Pro Gln  
 325 330 335  
 Met Ser Ala Phe Trp Tyr Ala Val Arg Thr Ala Val Ile Asn Ala Ala  
 340 345 350  
 Ser Gly Arg Gln Thr Val Asp Glu Ala Leu Lys Asp Ala Gln Thr Asn  
 355 360 365  
 Ser Ser Ser His His His His His His Ala Asn Ser Val Pro Leu Val  
 370 375 380  
 Pro Arg Gly Ser Cys Pro Asp Leu Val Cys Tyr Thr Asp Tyr Leu Gln  
 385 390 395 400  
 Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu His Pro Ser Thr Leu  
 405 410 415  
 Thr Leu Thr Trp Gln Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr  
 420 425 430  
 Ser Cys Ser Leu His Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr  
 435 440 445  
 Thr Cys His Met Asp Val Phe His Phe Met Ala Asp Asp Ile Phe Ser  
 450 455 460  
 Val Asn Ile Thr Asp Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser  
 465 470 475 480  
 Phe Leu Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Phe Asn Val Thr  
 485 490 495  
 Val Thr Phe Ser Gly Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu  
 500 505 510  
 Asp Pro Ala Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln  
 515 520 525  
 Tyr Arg Asn Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu  
 530 535 540  
 Ile Ser Val Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg  
 545 550 555 560  
 Lys Asp Ser Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly  
 565 570 575  
 Ser Ser Tyr Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe  
 580 585 590

Gln Thr Gln Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His  
 595 600 605

<210> 31  
 <211> 657  
 <212> DNA  
 <213> Artificial Sequence

<400> 31  
 tgccccgacc tcgtctgcta caccgattac ctccagacgg tcatctgcat cctggaaatg 60  
 tggaacctcc accccagcac gtcaccctt acctggcaag accagtatga agagctgaag 120  
 gacgaggcca cctcctgcag cctccacagg tcggcccaca atgccacgca tgccacctac 180  
 acctgqcaca tggatgtatt ccacttcatt gccagcagaca ttttcagtgt caacatcaca 240  
 gaccagtctg gcaactactc ccaggagtgt ggcagctttc tcctggctga gagcatcaag 300  
 ccggctcccc ctttcaacgt gactgtgacc ttctcaggac agtataatat ctctggcgc 360  
 tcagattacg aagaccctgc cttctacatg ctgaaggcca agcttcagta tgagctgcag 420  
 tacaggaacc ggggagaccc ctgggctgtg agtccgagga gaaagctgat ctcaaggac 480  
 tcaagaagtg tctccctcct cccctggag ttccgcaaag actcgagcta tgagctgcag 540  
 gtgcgggcag ggcccatgcc tggctcctcc taccagggga cctggagtga atggagtgc 600  
 ccggtcatct ttcagaccca gtcagaggag ttaaaggaag gctggaacct tcactag 657

<210> 32  
 <211> 65  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide primerZC20187

<400> 32  
 tcaccacgcg aattcggtag cgctggttcc gcgtggatcc tgccccgacc tcgtctgcta 60  
 caccg 65

<210> 33  
 <211> 68  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide primerZC20185

<400> 33

40

tctgtatcag gctgaaaatc ttatctcatc cgccaaaaca ctagtgaggg ttccagcctt 60  
cctttaac 68

<210> 34  
<211> 40  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primerZC19372

<400> 34  
tgtcgatgaa gccctgaaag acgcgagac taattcgagc 40

<210> 35  
<211> 60  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primerZC19351

<400> 35  
acgcgagac taattcgagc tcccaccatc accatcacca cggaattcg gtaccgctgg 60

<210> 36  
<211> 60  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primerZC19352

<400> 36  
actcactata gggcgaattg cccgggggat ccacgcggaa ccagcggtac cgaattcgcg 60

<210> 37  
<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primerZC19371

<400> 37  
acggccagtg aattgtaata cgactcacta tagggcgaat tg 42

<210> 38  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primerZC19907

<400> 38  
atggatgtat tccacttcat ggcc 24

<210> 39  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primerZC19908

<400> 39  
actgtcaaac gtgtccatat ccag 24

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primerZC22277

<400> 40  
ccaggagtgt ggcagctttc 20

<210> 41  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Oligonucleotide primerZC22276

<400> 41

gcttgccctt cagcatgtag a

21

<210> 42

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Zalpha11 TaqMan Probe, ZG31

<400> 42

cggctcccc tttcaacgtg act

23

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer, rRNA forward primer

<400> 43

cggctaccac atccaaggaa

20

<210> 44

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer, rRNA reverse primer

<400> 44

gctggaatta ccgcggct

18

<210> 45

<211> 22

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; rRNA TaqMan probe

&lt;400&gt; 45

tgctggcacc agacttgccc tc

22

&lt;210&gt; 46

&lt;211&gt; 3072

&lt;212&gt; DNA

&lt;213&gt; Mus musculus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (54)...(491)

&lt;400&gt; 46

gagaaccaga ccaagggcct gtcacacagct cctggagact cagttctggt ggc atg 56  
 Met  
 1

\* gag agg acc ctt gtc tgt ctg gta gtc atc ttc ttg ggg aca gtg gcc 104  
 Glu Arg Thr Leu Val Cys Leu Val Val Ile Phe Leu Gly Thr Val Ala  
 5 10 15

cat aaa tca agc ccc caa ggg cca gat cgc ctc ctg att aga ctt cgt 152  
 His Lys Ser Ser Pro Gln Gly Pro Asp Arg Leu Leu Ile Arg Leu Arg  
 20 25 30

cac ctt att gac att gtt gaa cag ctg aaa atc tat gaa aat gac ttg 200  
 His Leu Ile Asp Ile Val Glu Gln Leu Lys Ile Tyr Glu Asn Asp Leu  
 35 40 45

gat cct gaa ctt cta tca gct cca caa gat gta aag ggg cac tgt gag 248  
 Asp Pro Glu Leu Leu Ser Ala Pro Gln Asp Val Lys Gly His Cys Glu  
 50 55 60 65

cat gca gct ttt gcc tgt ttt cag aag gcc aaa ctc aag cca tca aac 296  
 His Ala Ala Phe Ala Cys Phe Gln Lys Ala Lys Leu Lys Pro Ser Asn  
 70 75 80

cct gga aac aat aag aca ttc atc att gac ctc gtg gcc cag ctc agg 344  
 Pro Gly Asn Asn Lys Thr Phe Ile Ile Asp Leu Val Ala Gln Leu Arg  
 85 90 95

agg agg ctg cct gcc agg agg gga gga aag aaa cag aag cac ata gct 392  
 Arg Arg Leu Pro Ala Arg Arg Gly Gly Lys Lys Gln Lys His Ile Ala  
 100 105 110

aaa tgc cct tcc tgt gat tgc tat gag aaa agg aca ccc aaa gaa ttc 440  
 Lys Cys Pro Ser Cys Asp Ser Tyr Glu Lys Arg Thr Pro Lys Glu Phe  
 115 120 125

cta gaa aga cta aaa tgg ctc ctt caa aag atg att cat cag cat ctc 488  
 Leu Glu Arg Leu Lys Trp Leu Leu Gln Lys Met Ile His Gln His Leu  
 130 135 140 145

tcc tagaacacat aggacccgaa gattcctgag gatccgagaa gattcccagag 541  
 Ser

gactgaggag acgccggaca ctatagacgc tcacgaatgc aggagtacat cttgcctctt 601  
 gggattgcaa gtggagaagt acgatacgtt atgataagaa caactcagaa aagctatagg 661  
 ttaagatcct ttgcgccatt aactaagcag acattgtggt tccctgcaca gactccatgc 721  
 tgtcaacatg gaaaatctca actcaacaag agcccagctt cccgtgtcag ggatttctgg 781  
 tgcttctcaa gctgtggctt catcttattg cccaactgtg acattctttg attggaaggg 841  
 gaaaactaaa gcttttagca aaaatacagc tagggaattt gtcgatctgc gagagtaaga 901  
 cctcttatga tcctaacgga atgatgtaag ctggaataa taagcataag atgaaattga 961  
 aaattgaagt ctttattctt taagaaaac tttgtacttg aaagcatgtc tgaagagttt 1021  
 actcattacc acaaacatct agcatattga taactaacat ctttatactc tacaagagag 1081  
 gctttccaga taggtacagt ttttctctc tattagggtc atcaaaattt aacctattat 1141  
 gagggtcacc cctggctttc actgtttttc taaagaggca aggggtgtagt aagaagcagg 1201  
 ctttaagttgc cttcctccca atgtcaagtt cttttataag ctaatagttt aatcttgtag 1261  
 agatggcaat gaaagcctgt ggaagtgcac acctcactat cttctggagc caagtagaat 1321  
 tttcaagttt gtagctctca cctcaagtgg ttatgggtgt cctgtgatga atctgctagc 1381  
 tccagcctca gtctctctc ccacatcctt tcctttcttt cctctttgaa acttctaaga 1441  
 aaaagcaatc caaacaagtt cagcacttaa gacacattgc atgcacactt ttgataagtt 1501  
 aaatccaacc atctatttaa aatcaaaatc aggagatgag ccaagagacc agaggttctg 1561  
 ttccagtttt aaacagactt ttactgaaca tcccaatctt ttaaccacag aggctaaatt 1621  
 gagcaaatag ttttgccatt tgatataatt tccaacagta tgtttcaatg tcaagttaaa 1681  
 aagtctacaa agctattttc cctggagtgg tatcatcgct ttgagaattt cttatggtta 1741  
 aaatggatct gagatccaag catggcctgg gggatgggtt tgatctaagg aaaaagggtg 1801  
 ctgtacctca cagtgccttt aaaacaagca gagatcccgt gtaccgccct aagatagcac 1861  
 agactagtgt taactgattc ccagaaaagt gtcacaatca gaaccaacgc attctcttaa 1921  
 actttaaaaa tatgtattgc aaagaacttg tgtaactgta aatgtgtgac tgttgatgac 1981  
 attatacaca catagccac gtaagtgtcc aatggtgcta gcattggttg ctgagtttgc 2041  
 tgctcgaaag ctgaagcaga gatgcagtcc ttacaaaagc aatgatggac agagagggga 2101  
 gtctccatgt tttattcttt tgttgtttct ggctgtgtaa ctgttgactt cttgacattg 2161

```

tgatttttat atttaagaca atgtatttat tttggtgtgt ttattgttct agccttttaa 2221
atcactgaca atttctaatac aagaagtaca aataattcaa tgcagcacag gctaagagct 2281
tgtatcgttt ggaaaagcca gtgaaggctt ctccactagc catgggaaag ctacgcttta 2341
gagtaaacta gacaaaattg cacagcagtc ttgaacctct ctgtgctcaa gactcagcca 2401
gtcctttgac attattgttc actgtgggtg ggaacacatt ggacctgaca cactgttgtg 2461
tgtccatgaa ggttgccact ggtgtaagct ttttttggtt ttcattctct tatctgtaga 2521
acaagaatgt ggggctttcc taagtctatt ctgtatttta ttctgaactt cgtatgtctg 2581
agttttaatg ttttgagtac tcttacagga acacctgacc acacttttga gttaaathtt 2641
atcccaagtg tgatatttag ttgttcaaaa agggaaggga tatacatata tacatacata 2701
catacatata tatatatata tatatatata tatatatata tatatatatg tatatatata 2761
tatatataga gagagagaga gagagagaga gagaaagaga gagaggttgt ttaggtcat 2821
aggagttcag aggaaatcag ttatggcgt taatactgta gctgaaagtg ttttcttgt 2881
gaataaattc atagcattat tgatctatgt tattgctctg ttttatttac agtcacacct 2941
gagaatttag ttttaatatg aatgatgtac ttataactt aatgattatt tattatgtat 3001
ttggttttga atgtttgtgt tcatggcttc ttatttaaga cctgatcata ttaaatgcta 3061
cccagtcgga a 3072

```

&lt;210&gt; 47

&lt;211&gt; 146

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 47

```

Met Glu Arg Thr Leu Val Cys Leu Val Val Ile Phe Leu Gly Thr Val
1           5           10          15
Ala His Lys Ser Ser Pro Gln Gly Pro Asp Arg Leu Leu Ile Arg Leu
20          25          30
Arg His Leu Ile Asp Ile Val Glu Gln Leu Lys Ile Tyr Glu Asn Asp
35          40          45
Leu Asp Pro Glu Leu Leu Ser Ala Pro Gln Asp Val Lys Gly His Cys
50          55          60
Glu His Ala Ala Phe Ala Cys Phe Gln Lys Ala Lys Leu Lys Pro Ser
65          70          75          80
Asn Pro Gly Asn Asn Lys Thr Phe Ile Ile Asp Leu Val Ala Gln Leu
85          90          95
Arg Arg Arg Leu Pro Ala Arg Arg Gly Gly Lys Lys Gln Lys His Ile
100         105         110
Ala Lys Cys Pro Ser Cys Asp Ser Tyr Glu Lys Arg Thr Pro Lys Glu
115        120        125
Phe Leu Glu Arg Leu Lys Trp Leu Leu Gln Lys Met Ile His Gln His
130        135        140
Leu Ser
145

```



<210> 48  
<211> 100  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primer ZC12749

<400> 48  
gtaccttccc gtaaaccct ccccttcccg gaattacacc cgcgtatttc ccagaaaagg 60  
aactgtagat ttctaggaat tcaatccttg gccacgcgctc 100

<210> 49  
<211> 100  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primer ZC12748

<400> 49  
tcgagacgcg tggccaagga ttgaattcct agaaatctac agttcctttt ctgggaaata 60  
cgcggttgta attccgggaa ggggagggat ttacgggaag 100

<210> 50  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primer ZC11450

<400> 50  
acttgtggaa ttcgctagca ccaagggcc atcggt 36

<210> 51  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primer ZC11443

<400> 51  
gcctagaacg cgttcattta cccggagaca gg 32

<210> 52  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primer ZC11440

<400> 52  
aattgaga 8

<210> 53  
<211> 8  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primer ZC11441

<400> 53  
cgcgtctc 8

<210> 54  
<211> 37  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide primer ZC11501

<400> 54  
gtcacttgaa ttcggtaccg cctctgttgt gtgcctg 37

<210> 55  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC11451

<400> 55

gacctgaacg cgtctaacac tctcccctgt tg

32

<210> 56

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC24052

<400> 56

tcagtcggaa ttgcgagaag ccatgccgcg tggctgggcc g

41

<210> 57

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC24053

<400> 57

ctgtgacgct agcgtgaggg ttccagcctt cctt

34

<210> 58

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC12834

<400> 58

tcagtcggaa ttgcgagaag ccatgttgaa gccatcatta c

41

<210> 59

<211> 90

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC12831

&lt;400&gt; 59

aagacggtac cagatttcaa ctgctcatca gatggcggga agatgaagac agatggtgca 60  
gccacagtag gattctcttt tgaagtattg 90

&lt;210&gt; 60

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC23684

&lt;400&gt; 60

tcacccttac ctggcaagac 20

&lt;210&gt; 61

&lt;211&gt; 43

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC23656

&lt;400&gt; 61

taatacgact cactataggg agggggagac acttcttgag tcc 43

&lt;210&gt; 62

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC23685

&lt;400&gt; 62

aggctctgaat cccgactctg 20

&lt;210&gt; 63

&lt;211&gt; 43

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC23657

<400> 63

taatacgact cactataggg aggacgtaat tgggtgttaa taa 43

<210> 64

<211> 1707

<212> DNA

<213> homo sapiens

<220>

<221> CDS

<222> (1)...(1707)

<400> 64

atg ccg cgt ggc tgg gcc gcc ccc ttg ctc ctg ctg ctg ctc cag gga 48  
Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Leu Gln Gly  
1 5 10 15

gcc ctc gag ggg atg gag agg aag ctc tgc agt ccc aag cca ccc ccc 96  
Ala Leu Glu Gly Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro  
20 25 30

acc aag gcc tct ctc ccc act gac cct cca ggc tgg ggc tgc ccc gac 144  
Thr Lys Ala Ser Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp  
35 40 45

ctc gtc tgc tac acc gat tac ctc cag acg gtc atc tgc atc ctg gaa 192  
Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu  
50 55 60

atg tgg aac ctc cac ccc agc acg ctc acc ctt acc tgg ata ctt tct 240  
Met Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser  
65 70 75 80

aat aat act ggg tgc tat atc aag gac aga aca ctg gac ctc agg caa 288  
Asn Asn Thr Gly Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln  
85 90 95

gac cag tat gaa gag ctg aag gac gag gcc acc tcc tgc agc ctc cac 336

Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His	
100 105 110	
agg tcg gcc cac aat gcc acg cat gcc acc tac acc tgc cac atg gat	384
Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp	
115 120 125	
gta ttc cac ttc atg gcc gac gac att ttc agt gtc aac atc aca gac	432
Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp	
130 135 140	
cag tct ggc aac tac tcc cag gag tgt ggc agc ttt ctc ctg gct gag	480
Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu	
145 150 155 160	
agc aga cag tat aat atc tcc tgg cgc tca gat tac gaa gac cct gcc	528
Ser Arg Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala	
165 170 175	
ttc tac atg ctg aag ggc aag ctt cag tat gag ctg cag tac agg aac	576
Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn	
180 185 190	
cgg gga gac ccc tgg gct gtg agt ccg agg aga aag ctg atc tca gtg	624
Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val	
195 200 205	
gac tca aga agt gtc tcc ctc ctc ccc ctg gag ttc cgc aaa gac tcg	672
Asp Ser Arg Ser Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser	
210 215 220	
agc tat gag ctg cag gtg cgg gca ggg ccc atg cct ggc tcc tcc tac	720
Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr	
225 230 235 240	
cag ggg acc tgg agt gaa tgg agt gac ccg gtc atc ttt cag acc cag	768
Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln	
245 250 255	
tca gag gag tta aag gaa ggc tgg aac cct cac ctg ctg ctt ctc ctc	816
Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu Leu Leu	
260 265 270	

ctg ctt gtc ata gtc ttc att cct gcc ttc tgg agc ctg aag acc cat	864
Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys Thr His	
275 280 285	
cca ttg tgg agg cta tgg aag aag ata tgg gcc gtc ccc agc cct gag	912
Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser Pro Glu	
290 295 300	
cgg ttc ttc atg ccc ctg tac aag ggc tgc agc gga gac ttc aag aaa	960
Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe Lys Lys	
305 310 315 320	
tgg gtg ggt gca ccc ttc act ggc tcc agc ctg gag ctg gga ccc tgg	1008
Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly Pro Trp	
325 330 335	
agc cca gag gtg ccc tcc acc ctg gag gtg tac agc tgc cac cca cca	1056
Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His Pro Pro	
340 345 350	
cgg agc ccg gcc aag agg ctg cag ctc acg gag cta caa gaa cca gca	1104
Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu Pro Ala	
355 360 365	
gag ctg gtg gag tct gac ggt gtg ccc aag ccc agc ttc tgg ccg aca	1152
Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp Pro Thr	
370 375 380	
gcc cag aac tcg ggg ggc tca gct tac agt gag gag agg gat cgg cca	1200
Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro	
385 390 395 400	
tac ggc ctg gtg tcc att gac aca gtg act gtg cta gat gca gag ggg	1248
Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala Glu Gly	
405 410 415	
cca tgc acc tgg ccc tgc agc tgt gag gat gac ggc tac cca gcc ctg	1296
Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Leu	
420 425 430	
gac ctg gat gct ggc ctg gag ccc agc cca ggc cta gag gac cca etc	1344
Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp Pro Leu	
435 440 445	

ttg gat gca ggg acc aca gtc ctg tcc tgt ggc tgt gtc tca gct ggc 1392  
 Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser Ala Gly  
 450 455 460

agc cct ggg cta gga ggg ccc ctg gga agc ctc ctg gac aga cta aag 1440  
 Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg Leu Lys  
 465 470 475 480

cca ccc ctt gca gat ggg gag gac tgg gct ggg gga ctg ccc tgg ggt 1488  
 Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro Trp Gly  
 485 490 495

ggc cgg tca cct gga ggg gtc tca gag agt gag gcg ggc tca ccc ctg 1536  
 Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser Pro Leu  
 500 505 510

gcc ggc ctg gat atg gac acg ttt gac agt ggc ttt gtg ggc tct gac 1584  
 Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly Ser Asp  
 515 520 525

tgc agc agc cct gtg gag tgt gac ttc acc agc ccc ggg gac gaa gga 1632  
 Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp Glu Gly  
 530 535 540

ccc ccc cgg agc tac ctc cgc cag tgg gtg gtc att cct ccg cca ctt 1680  
 Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro Pro Leu  
 545 550 555 560

tcg agc cct gga ccc cag gcc agc taa 1707  
 Ser Ser Pro Gly Pro Gln Ala Ser \*  
 565

<210> 65

<211> 568

<212> PRT

<213> homo sapiens

<400> 65

Met Pro Arg Gly Trp Ala Ala Pro Leu Leu Leu Leu Leu Gln Gly  
 1 5 10 15  
 Ala Leu Glu Gly Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro  
 20 25 30



Thr Lys Ala Ser Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp  
 35 40 45  
 Leu Val Cys Tyr Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu  
 50 55 60  
 Met Trp Asn Leu His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser  
 65 70 75 80  
 Asn Asn Thr Gly Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln  
 85 90 95  
 Asp Gln Tyr Glu Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His  
 100 105 110  
 Arg Ser Ala His Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp  
 115 120 125  
 Val Phe His Phe Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp  
 130 135 140  
 Gln Ser Gly Asn Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu  
 145 150 155 160  
 Ser Arg Gln Tyr Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala  
 165 170 175  
 Phe Tyr Met Leu Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn  
 180 185 190  
 Arg Gly Asp Pro Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val  
 195 200 205  
 Asp Ser Arg Ser Val Ser Leu Pro Leu Glu Phe Arg Lys Asp Ser  
 210 215 220  
 Ser Tyr Glu Leu Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr  
 225 230 235 240  
 Gln Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln  
 245 250 255  
 Ser Glu Glu Leu Lys Glu Gly Trp Asn Pro His Leu Leu Leu Leu Leu  
 260 265 270  
 Leu Leu Val Ile Val Phe Ile Pro Ala Phe Trp Ser Leu Lys Thr His  
 275 280 285  
 Pro Leu Trp Arg Leu Trp Lys Lys Ile Trp Ala Val Pro Ser Pro Glu  
 290 295 300  
 Arg Phe Phe Met Pro Leu Tyr Lys Gly Cys Ser Gly Asp Phe Lys Lys  
 305 310 315 320  
 Trp Val Gly Ala Pro Phe Thr Gly Ser Ser Leu Glu Leu Gly Pro Trp  
 325 330 335  
 Ser Pro Glu Val Pro Ser Thr Leu Glu Val Tyr Ser Cys His Pro Pro  
 340 345 350  
 Arg Ser Pro Ala Lys Arg Leu Gln Leu Thr Glu Leu Gln Glu Pro Ala  
 355 360 365

Glu Leu Val Glu Ser Asp Gly Val Pro Lys Pro Ser Phe Trp Pro Thr  
 370 375 380  
 Ala Gln Asn Ser Gly Gly Ser Ala Tyr Ser Glu Glu Arg Asp Arg Pro  
 385 390 395 400  
 Tyr Gly Leu Val Ser Ile Asp Thr Val Thr Val Leu Asp Ala Glu Gly  
 405 410 415  
 Pro Cys Thr Trp Pro Cys Ser Cys Glu Asp Asp Gly Tyr Pro Ala Leu  
 420 425 430  
 Asp Leu Asp Ala Gly Leu Glu Pro Ser Pro Gly Leu Glu Asp Pro Leu  
 435 440 445  
 Leu Asp Ala Gly Thr Thr Val Leu Ser Cys Gly Cys Val Ser Ala Gly  
 450 455 460  
 Ser Pro Gly Leu Gly Gly Pro Leu Gly Ser Leu Leu Asp Arg Leu Lys  
 465 470 475 480  
 Pro Pro Leu Ala Asp Gly Glu Asp Trp Ala Gly Gly Leu Pro Trp Gly  
 485 490 495  
 Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser Pro Leu  
 500 505 510  
 Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly Ser Asp  
 515 520 525  
 Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp Glu Gly  
 530 535 540  
 Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro Pro Leu  
 545 550 555 560  
 Ser Ser Pro Gly Pro Gln Ala Ser  
 565

&lt;210&gt; 66

&lt;211&gt; 741

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Degenerate polynucleotide sequence of SEQ ID NO:69

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(741)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 66

atggarmgna arytnrgyws nccnaarccn ccnccnacna argcnwsnyt nccnacngay 60  
 ccnccnggnt ggggntgycc ngayytngrn tgytayacng aytayytnca racngtnath 120

```

tgyathytn g aratgtggaa yytncaayccn wsnacnytna cnythacntg gathytnwsn 180
aayaayacng gntgytayat haargaymgn acnytngayy tnmgncarga ycartaygar 240
garytnaarg aygargcnac nwsntgywsn ytncaymgnw sngcncayaa ygcnacncay 300
gcnacntaya cntgycayat ggaygtntty cayttyatgg cngaygayat httysngtn 360
aayathacng aycarwsngg naaytaywsn cargartgyg gnwsnttyt nytnngcngar 420
wsnmgncart ayaayathws ntggmgwnsn gaytaygarg ayccngcntt ytayatgytn 480
aarggnaary tncartayga rytncartay mgnaymgng gngayccntg ggcngtnwsn 540
ccnmghmgna arytnathws ngtngaywsn mgnwsngtnw snytnytncc nytngartty 600
mgnayargayw snwsntayga rytncargtn mngcngggnc cnatgccngg nwsnwsntay 660
carggnacnt ggwsngartg gwsngayccn gtnathttyc aracncarws ngargarytn 720
aargarggnt ggaayccnca y 741

```

&lt;210&gt; 67

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; WXXW motif

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(4)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 67

Trp Xaa Xaa Trp

1

&lt;210&gt; 68

&lt;211&gt; 741

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(741)

&lt;400&gt; 68

atg gag agg aag ctc tgc agt ccc aag cca ccc ccc acc aag gcc tct 48

Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro Thr Lys Ala Ser

1

5

10

15

ctc ccc act gac cct cca ggc tgg ggc tgc ccc gac ctc gtc tgc tac 96

57

Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr	
20 25 30	
acc gat tac ctc cag acg gtc atc tgc atc ctg gaa atg tgg aac ctc	144
Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu	
35 40 45	
cac ccc agc acg ctc acc ctt acc tgg ata ctt tct aat aat act ggg	192
His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser Asn Asn Thr Gly	
50 55 60	
tgc tat atc aag gac aga aca ctg gac ctc agg caa gac cag tat gaa	240
Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln Asp Gln Tyr Glu	
65 70 75 80	
gag ctg aag gac gag gcc acc tcc tgc agc ctc cac agg tcg gcc cac	288
Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His	
85 90 95	
aat gcc acg cat gcc acc tac acc tgc cac atg gat gta ttc cac ttc	336
Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe	
100 105 110	
atg gcc gac gac att ttc agt gtc aac atc aca gac cag tct ggc aac	384
Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn	
115 120 125	
tac tcc cag gag tgt ggc agc ttt ctc ctg gct gag agc aga cag tat	432
Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu Ser Arg Gln Tyr	
130 135 140	
aat atc tcc tgg cgc tca gat tac gaa gac cct gcc ttc tac atg ctg	480
Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu	
145 150 155 160	
aag ggc aag ctt cag tat gag ctg cag tac agg aac cgg gga gac ccc	528
Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro	
165 170 175	
tgg gct gtg agt ccg agg aga aag ctg atc tca gtg gac tca aga agt	576
Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp Ser Arg Ser	
180 185 190	

gtc tcc ctc ctc ccc ctg gag ttc cgc aaa gac tcg agc tat gag ctg 624  
Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu  
195 200 205

cag gtg cgg gca ggg ccc atg cct ggc tcc tcc tac cag ggg acc tgg 672  
Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp  
210 215 220

agt gaa tgg agt gac ccg gtc atc ttt cag acc cag tca gag gag tta 720  
Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser Glu Glu Leu  
225 230 235 240

aag gaa ggc tgg aac cct cac 741  
Lys Glu,Gly Trp Asn Pro His  
245

<210> 69

<211> 247

<212> PRT

<213> Homo sapiens

<400> 69

Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro Thr Lys Ala Ser  
1 5 10 15

Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr  
20 25 30

Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu  
35 40 45

His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser Asn Asn Thr Gly  
50 55 60

Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln Asp Gln Tyr Glu  
65 70 75 80

Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His  
85 90 95 .

Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe  
100 105 110

Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn  
115 120 125

Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu Ser Arg Gln Tyr  
130 135 140

Asn Ile Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu  
145                      150                      155                      160

Lys Gly Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro  
                             165                            170                            175  
 Trp Ala Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp Ser Arg Ser  
                             180                            185                            190  
 Val Ser Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu  
                             195                            200                            205  
 Gln Val Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp  
                             210                            215                            220  
 Ser Glu Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser Glu Glu Leu  
 225                            230                            235                            240  
 Lys Glu Gly Trp Asn Pro His  
                             245

&lt;210&gt; 70

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Domain linker motif; \*PAPP motif

&lt;400&gt; 70

Pro Ala Pro Pro

1

&lt;210&gt; 71

&lt;211&gt; 261

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Representative variant soluble receptor with  
domain linker

&lt;221&gt; VARIANT

&lt;222&gt; (1)...(261)

&lt;223&gt; Xaa = Any Amino Acid

&lt;400&gt; 71

Met Glu Arg Lys Leu Cys Ser Pro Lys Pro Pro Pro Thr Lys Ala Ser

1

5

10

15

Leu Pro Thr Asp Pro Pro Gly Trp Gly Cys Pro Asp Leu Val Cys Tyr  
                   20                  25                  30  
 Thr Asp Tyr Leu Gln Thr Val Ile Cys Ile Leu Glu Met Trp Asn Leu  
                   35                  40                  45  
 His Pro Ser Thr Leu Thr Leu Thr Trp Ile Leu Ser Asn Asn Thr Gly  
                   50                  55                  60  
 Cys Tyr Ile Lys Asp Arg Thr Leu Asp Leu Arg Gln Asp Gln Tyr Glu  
 65                                  70                                  75                                  80  
 Glu Leu Lys Asp Glu Ala Thr Ser Cys Ser Leu His Arg Ser Ala His  
                                   85                                  90                                  95  
 Asn Ala Thr His Ala Thr Tyr Thr Cys His Met Asp Val Phe His Phe  
                                   100                                  105                                  110  
 Met Ala Asp Asp Ile Phe Ser Val Asn Ile Thr Asp Gln Ser Gly Asn  
                                   115                                  120                                  125  
 Tyr Ser Gln Glu Cys Gly Ser Phe Leu Leu Ala Glu Ser Xaa Xaa Pro  
                                   130                                  135                                  140  
 Ala Pro Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Gln Tyr Asn Ile  
 145                                  150                                  155                                  160  
 Ser Trp Arg Ser Asp Tyr Glu Asp Pro Ala Phe Tyr Met Leu Lys Gly  
                                   165                                  170                                  175  
 Lys Leu Gln Tyr Glu Leu Gln Tyr Arg Asn Arg Gly Asp Pro Trp Ala  
                                   180                                  185                                  190  
 Val Ser Pro Arg Arg Lys Leu Ile Ser Val Asp Ser Arg Ser Val Ser  
                                   195                                  200                                  205  
 Leu Leu Pro Leu Glu Phe Arg Lys Asp Ser Ser Tyr Glu Leu Gln Val  
                                   210                                  215                                  220  
 Arg Ala Gly Pro Met Pro Gly Ser Ser Tyr Gln Gly Thr Trp Ser Glu  
 225                                  230                                  235                                  240  
 Trp Ser Asp Pro Val Ile Phe Gln Thr Gln Ser Glu Glu Leu Lys Glu  
                                   245                                  250                                  255  
 Gly Trp Asn Pro His  
                                   260

&lt;210&gt; 72

&lt;211&gt; 1461

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Mouse zalphall extracellular domain murine  
 immunoglobulin gamma 2a heavy chain Fc region  
 fusion protein (zalphallm-mG2a) Polynucleotide

&lt;221&gt; CDS

&lt;222&gt; (1)...(1461)

&lt;400&gt; 72

atg gat gca atg aag aga ggg ctc tgc tgt gtg ctg ctg ctg tgt ggc	48
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly	
1 5 10 15	
gcc gtc ttc gtt tcg ctc agc cag aaa atc cat gcc gag ttg aga cgc	96
Ala Val Phe Val Ser Leu Ser Gln Lys Ile His Ala Glu Leu Arg Arg	
20 25 30	
ttc cgg aga tgc ctg gac ctc act tgc tac act gac tac ctc tgg acc	144
Phe Arg Arg Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr	
35 40 45	
atc acc tgt gtc ctg gag aca cgg agc ccc aac ccc agc ata ctc agt	192
Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser	
50 55 60	
ctc acc tgg caa gat gaa tat gag gaa ctt cag gac caa gag acc ttc	240
Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe	
65 70 75 80	
tgc agc cta cac agg tct ggc cac aac acc aca cat ata tgg tac acg	288
Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr	
85 90 95	
tgc cat atg cgc ttg tct caa ttc ctg tcc gat gaa gtt ttc att gtc	336
Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val	
100 105 110	
aat gtg acg gac cag tct ggc aac aac tcc caa gag tgt ggc agc ttt	384
Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe	
115 120 125	
gtc ctg gct gag agc atc aaa cca gct ccc ccc ttg aac gtg act gtg	432
Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val	
130 135 140	
gcc ttc tca gga cgc tat gat atc tcc tgg gac tca gct tat gac gaa	480



Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu	
145 150 155 160	
ccc tcc aac tac gtg ctg agg ggc aag cta caa tat gag ctg cag tat	528
Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr	
165 170 175	
cgg aac ctc aga gac ccc tat gct gtg agg ccg gtg acc aag ctg atc	576
Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile	
180 185 190	
tca gtg gac tca aga aac gtc tct ctt ctc cct gaa gag ttc cac aaa	624
Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys	
195 200 205	
gat tct agc tac cag ctg cag gtg cgg gca gcg cct cag cca ggc act	672
Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr	
210 215 220	
tca ttc agg ggg acc tgg agt gag tgg agt gac ccc gtc atc ttt cag	720
Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln	
225 230 235 240	
acc cag gct ggg gag ccc gag gca ggc tgg gac cct cac gag ccc aga	768
Thr Gln Ala Gly Glu Pro Glu Ala Gly Trp Asp Pro His Glu Pro Arg	
245 250 255	
tct ccc aca atc aag ccc tgt cct cca tgc aaa tgc cca gca cct aac	816
Ser Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn	
260 265 270	
ctc ttg ggt gga cca tcc gtc ttc atc ttc cct cca aag atc aag gat	864
Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp	
275 280 285	
gta ctc atg atc tcc ctg agc ccc ata gtc aca tgt gtg gtg gtg gat	912
Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp	
290 295 300	
gtg agc gag gat gac cca gat gtc cag atc agc tgg ttt gtg aac aac	960
Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn	
305 310 315 320	

gtg gaa gta cac aca gct cag aca caa acc cat aga gag gat tac aac Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn 325 330 335	1008
agt act ctc cgg gtg gtc agt gcc ctc ccc atc cag cac cag gac tgg Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp 340 345 350	1056
atg agt ggc aag gag ttc aaa tgc aag gtc aac aac aaa gac ctc cca Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro 355 360 365	1104
gcg ccc atc gag aga acc atc tca aaa ccc aaa ggg tca gta aga gct Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala 370 375 380	1152
cca cag gta tat gtc ttg cct cca cca gaa gaa gag atg act aag aaa Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys 385 390 395 400	1200
cag gtc act ctg acc tgc atg gtc aca gac ttc atg cct gaa gac att Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile 405 410 415	1248
tac gtg gag tgg acc aac aac ggg aaa aca gag cta aac tac aag aac Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn 420 425 430	1296
act gaa cca gtc ctg gac tct gat ggt tct tac ttc atg tac agc aag Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys 435 440 445	1344
ctg aga gtg gaa aag aag aac tgg gtg gaa aga aat agc tac tcc tgt Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys 450 455 460	1392
tca gtg gtc cac gag ggt ctg cac aat cac cac acg act aag agc ttc Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe 465 470 475 480	1440
tcc cgg act ccg ggt aaa taa	1461

Ser Arg Thr Pro Gly Lys \*  
485

<210> 73  
<211> 486  
<212> PRT  
<213> Artificial Sequence

<400> 73

Met	Asp	Ala	Met	Lys	Arg	Gly	Leu	Cys	Cys	Val	Leu	Leu	Leu	Cys	Gly
1				5				10						15	
Ala	Val	Phe	Val	Ser	Leu	Ser	Gln	Lys	Ile	His	Ala	Glu	Leu	Arg	Arg
			20					25					30		
Phe	Arg	Arg	Cys	Leu	Asp	Leu	Thr	Cys	Tyr	Thr	Asp	Tyr	Leu	Trp	Thr
			35				40					45			
Ile	Thr	Cys	Val	Leu	Glu	Thr	Arg	Ser	Pro	Asn	Pro	Ser	Ile	Leu	Ser
			50			55					60				
Leu	Thr	Trp	Gln	Asp	Glu	Tyr	Glu	Glu	Leu	Gln	Asp	Gln	Glu	Thr	Phe
65				70					75					80	
Cys	Ser	Leu	His	Arg	Ser	Gly	His	Asn	Thr	Thr	His	Ile	Trp	Tyr	Thr
			85					90					95		
Cys	His	Met	Arg	Leu	Ser	Gln	Phe	Leu	Ser	Asp	Glu	Val	Phe	Ile	Val
			100					105					110		
Asn	Val	Thr	Asp	Gln	Ser	Gly	Asn	Asn	Ser	Gln	Glu	Cys	Gly	Ser	Phe
			115				120					125			
Val	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Leu	Asn	Val	Thr	Val
			130			135					140				
Ala	Phe	Ser	Gly	Arg	Tyr	Asp	Ile	Ser	Trp	Asp	Ser	Ala	Tyr	Asp	Glu
145				150					155					160	
Pro	Ser	Asn	Tyr	Val	Leu	Arg	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr
			165					170					175		
Arg	Asn	Leu	Arg	Asp	Pro	Tyr	Ala	Val	Arg	Pro	Val	Thr	Lys	Leu	Ile
			180				185					190			
Ser	Val	Asp	Ser	Arg	Asn	Val	Ser	Leu	Leu	Pro	Glu	Glu	Phe	His	Lys
			195			200					205				
Asp	Ser	Ser	Tyr	Gln	Leu	Gln	Val	Arg	Ala	Ala	Pro	Gln	Pro	Gly	Thr
			210			215				220					
Ser	Phe	Arg	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln
225				230					235					240	
Thr	Gln	Ala	Gly	Glu	Pro	Glu	Ala	Gly	Trp	Asp	Pro	His	Glu	Pro	Arg
			245					250					255		

65

Ser Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala Pro Asn  
                   260                  265                  270  
 Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile Lys Asp  
                   275                  280                  285  
 Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val Val Asp  
                   290                  295                  300  
 Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn Asn  
 305                  310                  315                  320  
 Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr Asn  
                   325                  330                  335  
 Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln Asp Trp  
                   340                  345                  350  
 Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp Leu Pro  
                   355                  360                  365  
 Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val Arg Ala  
                   370                  375                  380  
 Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr Lys Lys  
 385                  390                  395                  400  
 Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu Asp Ile  
                   405                  410                  415  
 Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys Asn  
                   420                  425                  430  
 Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser Lys  
                   435                  440                  445  
 Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser Cys  
                   450                  455                  460  
 Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys Ser Phe  
 465                  470                  475                  480  
 Ser Arg Thr Pro Gly Lys  
                   485

&lt;210&gt; 74

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC26644

&lt;400&gt; 74

ggggtcgacg gccggccacc atg

23

66

&lt;210&gt; 75

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC26641

&lt;400&gt; 75

caagtgaggt ccaggcatct ccggaagcgt ctcaa

35

&lt;210&gt; 76

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC26642

&lt;400&gt; 76

ttgagacgct tccggagatg cctggacctc acttg

35

&lt;210&gt; 77

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC26662

&lt;400&gt; 77

tgtgggagat ctgggctcgt gaggggtccca gcctgc

36

&lt;210&gt; 78

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotide primer ZC26643

&lt;400&gt; 78

gagcccagat ctcccacaat caagccctgt

30

67

<210> 79  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide primer ZC26645

<400> 79  
 aaacgcggcc gcggatccgg c 21

<210> 80  
 <211> 35  
 <212> PRT  
 <213> Homo sapeins

<400> 80  
 Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly  
 1 5 10 15  
 Ala Val Phe Val Ser Leu Ser Gln Glu Ile His Ala Glu Leu Arg Arg  
 20 25 30  
 Phe Arg Arg  
 35

<210> 81  
 <211> 966  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (1)...(966)

<400> 81  
 ggg ggc ggg ggc gcc gcg cct acg gaa act cag cca cct gtg aca aat 48  
 Gly Gly Gly Gly Ala Ala Pro Thr Glu Thr Gln Pro Pro Val Thr Asn  
 1 5 10 15  
 ttg agt gtc tct gtt gaa aac ctc tgc aca gta ata tgg aca tgg aat 96  
 Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val Ile Trp Thr Trp Asn  
 20 25 30

cca ccc gag gga gcc agc tca aat tgt agt cta tgg tat ttt agt cat	144
Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu Trp Tyr Phe Ser His	
35 40 45	
ttt ggc gac aaa caa gat aag aaa ata gct ccg gaa act cgt cgt tca	192
Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro Glu Thr Arg Arg Ser	
50 55 60	
ata gaa gta ccc ctg aat gag agg att tgt ctg caa gtg ggg tcc cag	240
Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu Gln Val Gly Ser Gln	
65 70 75 80	
tgt agc acc aat gag agt gag aag cct agc att ttg gtt gaa aaa tgc	288
Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile Leu Val Glu Lys Cys	
85 90 95	
atc tca ccc cca gaa ggt gat cct gag tct gct gtg act gag ctt caa	336
Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val Thr Glu Leu Gln	
100 105 110	
tgc att tgg cac aac ctg agc tac atg aag tgt tct tgg ctc cct gga	384
Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser Trp Leu Pro Gly	
115 120 125	
agg aat acc agt ccc gac act aac tat act ctc tac tat tgg cac aga	432
Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu Tyr Tyr Trp His Arg	
130 135 140	
agc ctg gaa aaa att cat caa tgt gaa aac atc ttt aga gaa ggc caa	480
Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe Arg Glu Gly Gln	
145 150 155 160	
tac ttt ggt tgt tcc ttt gat ctg acc aaa gtg aag gat tcc agt ttt	528
Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys Asp Ser Ser Phe	
165 170 175	
gaa caa cac agt gtc caa ata atg gtc aag gat aat gca gga aaa att	576
Glu Gln His Ser Val Gln Ile Met Val Lys Asp Asn Ala Gly Lys Ile	
180 185 190	
aaa cca tcc ttc aat ata gtg cct tta act tcc cgt gtg aaa cct gat	624
Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg Val Lys Pro Asp	
195 200 205	

cct cca cat att aaa aac ctc tcc ttc cac aat gat gac cta tat gtg 672  
 Pro Pro His Ile Lys Asn Leu Ser Phe His Asn Asp Asp Leu Tyr Val  
           210                          215                          220

caa tgg gag aat cca cag aat ttt att agc aga tgc cta ttt tat gaa 720  
 Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg Cys Leu Phe Tyr Glu  
           225                          230                          235                          240

gta gaa gtc aat aac agc caa act gag aca cat aat gtt ttc tac gtc 768  
 Val Glu Val Asn Asn Ser Gln Thr Glu Thr His Asn Val Phe Tyr Val  
                                   245                                  250                                  255

caa gag gct aaa tgt gag aat cca gaa ttt gag aga aat gtg gag aat 816  
 Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg Asn Val Glu Asn  
                                   260                                  265                                  270

aca tct tgt ttc atg gtc cct ggt gtt ctt cct gat act ttg aac aca 864  
 Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp Thr Leu Asn Thr  
                                   275                                  280                                  285

gtc aga ata aga gtc aaa aca aat aag tta tgc tat gag gat gac aaa 912  
 Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys Tyr Glu Asp Asp Lys  
           290                          295                          300

ctc tgg agt aat tgg agc caa gaa atg agt ata ggt aag aag cgc aat 960  
 Leu Trp Ser Asn Trp Ser Gln Glu Met Ser Ile Gly Lys Lys Arg Asn  
           305                          310                          315                          320

tcc aca 966  
 Ser Thr

<210> 82

<211> 322

<212> PRT

<213> Homo sapiens

<400> 82

Gly Gly Gly Gly Ala Ala Pro Thr Glu Thr Gln Pro Pro Val Thr Asn  
   1                  5                  10                  15  
 Leu Ser Val Ser Val Glu Asn Leu Cys Thr Val Ile Trp Thr Trp Asn  
                   20                  25                  30



Pro Pro Glu Gly Ala Ser Ser Asn Cys Ser Leu Trp Tyr Phe Ser His  
           35                          40                          45  
 Phe Gly Asp Lys Gln Asp Lys Lys Ile Ala Pro Glu Thr Arg Arg Ser  
       50                          55                          60  
 Ile Glu Val Pro Leu Asn Glu Arg Ile Cys Leu Gln Val Gly Ser Gln  
       65                          70                          75                          80  
 Cys Ser Thr Asn Glu Ser Glu Lys Pro Ser Ile Leu Val Glu Lys Cys  
                           85                          90                          95  
 Ile Ser Pro Pro Glu Gly Asp Pro Glu Ser Ala Val Thr Glu Leu Gln  
                           100                          105                          110  
 Cys Ile Trp His Asn Leu Ser Tyr Met Lys Cys Ser Trp Leu Pro Gly  
           115                          120                          125  
 Arg Asn Thr Ser Pro Asp Thr Asn Tyr Thr Leu Tyr Tyr Trp His Arg  
       130                          135                          140  
 Ser Leu Glu Lys Ile His Gln Cys Glu Asn Ile Phe Arg Glu Gly Gln  
       145                          150                          155                          160  
 Tyr Phe Gly Cys Ser Phe Asp Leu Thr Lys Val Lys Asp Ser Ser Phe  
                           165                          170                          175  
 Glu Gln His Ser Val Gln Ile Met Val Lys Asp Asn Ala Gly Lys Ile  
                           180                          185                          190  
 Lys Pro Ser Phe Asn Ile Val Pro Leu Thr Ser Arg Val Lys Pro Asp  
           195                          200                          205  
 Pro Pro His Ile Lys Asn Leu Ser Phe His Asn Asp Asp Leu Tyr Val  
       210                          215                          220  
 Gln Trp Glu Asn Pro Gln Asn Phe Ile Ser Arg Cys Leu Phe Tyr Glu  
       225                          230                          235                          240  
 Val Glu Val Asn Asn Ser Gln Thr Glu Thr His Asn Val Phe Tyr Val  
                           245                          250                          255  
 Gln Glu Ala Lys Cys Glu Asn Pro Glu Phe Glu Arg Asn Val Glu Asn  
           260                          265                          270  
 Thr Ser Cys Phe Met Val Pro Gly Val Leu Pro Asp Thr Leu Asn Thr  
           275                          280                          285  
 Val Arg Ile Arg Val Lys Thr Asn Lys Leu Cys Tyr Glu Asp Asp Lys  
       290                          295                          300  
 Leu Trp Ser Asn Trp Ser Gln Glu Met Ser Ile Gly Lys Lys Arg Asn  
       305                          310                          315                          320  
 Ser Thr

&lt;210&gt; 83

&lt;211&gt; 951

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(951)

&lt;400&gt; 83

gac acc gag ata aaa gtt aac cct cct cag gat ttt gag ata gtg gat	48
Asp Thr Glu Ile Lys Val Asn Pro Pro Gln Asp Phe Glu Ile Val Asp	
1 5 10 15	
ccc gga tac tta ggt tat ctc tat ttg caa tgg caa ccc cca ctg tct	96
Pro Gly Tyr Leu Gly Tyr Leu Tyr Leu Gln Trp Gln Pro Pro Leu Ser	
20 25 30	
ctg gat cat ttt aag gaa tgc aca gtg gaa tat gaa cta aaa tac cga	144
Leu Asp His Phe Lys Glu Cys Thr Val Glu Tyr Glu Leu Lys Tyr Arg	
35 40 45	
aac att ggt agt gaa aca tgg aag acc atc att act aag aat cta cat	192
Asn Ile Gly Ser Glu Thr Trp Lys Thr Ile Ile Thr Lys Asn Leu His	
50 55 60	
tac aaa gat ggg ttt gat ctt aac aag ggc att gaa gcg aag ata cac	240
Tyr Lys Asp Gly Phe Asp Leu Asn Lys Gly Ile Glu Ala Lys Ile His	
65 70 75 80	
acg ctt tta cca tgg caa tgc aca aat gga tca gaa gtt caa agt tcc	288
Thr Leu Leu Pro Trp Gln Cys Thr Asn Gly Ser Glu Val Gln Ser Ser	
85 90 95	
tgg gca gaa act act tat tgg ata tca cca caa gga att cca gaa act	336
Trp Ala Glu Thr Thr Tyr Trp Ile Ser Pro Gln Gly Ile Pro Glu Thr	
100 105 110	
aaa gtt cag gat atg gat tgc gta tat tac aat tgg caa tat tta ctc	384
Lys Val Gln Asp Met Asp Cys Val Tyr Tyr Asn Trp Gln Tyr Leu Leu	
115 120 125	
tgt tct tgg aaa cct ggc ata ggt gta ctt ctt gat acc aat tac aac	432
Cys Ser Trp Lys Pro Gly Ile Gly Val Leu Leu Asp Thr Asn Tyr Asn	
130 135 140	
ttg ttt tac tgg tat gag ggc ttg gat cat gca tta cag tgt gtt gat	480

Leu	Phe	Tyr	Trp	Tyr	Glu	Gly	Leu	Asp	His	Ala	Leu	Gln	Cys	Val	Asp	
145					150					155					160	
tac	atc	aag	gct	gat	gga	caa	aat	ata	gga	tgc	aga	ttt	ccc	tat	ttg	528
Tyr	Ile	Lys	Ala	Asp	Gly	Gln	Asn	Ile	Gly	Cys	Arg	Phe	Pro	Tyr	Leu	
				165					170					175		
gag	gca	tca	gac	tat	aaa	gat	ttc	tat	att	tgt	gtt	aat	gga	tca	tca	576
Glu	Ala	Ser	Asp	Tyr	Lys	Asp	Phe	Tyr	Ile	Cys	Val	Asn	Gly	Ser	Ser	
			180					185					190			
gag	aac	aag	cct	atc	aga	tcc	agt	tat	ttc	act	ttt	cag	ctt	caa	aat	624
Glu	Asn	Lys	Pro	Ile	Arg	Ser	Ser	Tyr	Phe	Thr	Phe	Gln	Leu	Gln	Asn	
		195					200					205				
ata	gtt	aaa	cct	ttg	ccg	cca	gtc	tat	ctt	act	ttt	act	cgg	gag	agt	672
Ile	Val	Lys	Pro	Leu	Pro	Pro	Val	Tyr	Leu	Thr	Phe	Thr	Arg	Glu	Ser	
	210					215					220					
tca	tgt	gaa	att	aag	ctg	aaa	tgg	agc	ata	cct	ttg	gga	cct	att	cca	720
Ser	Cys	Glu	Ile	Lys	Leu	Lys	Trp	Ser	Ile	Pro	Leu	Gly	Pro	Ile	Pro	
225					230					235					240	
gca	agg	tgt	ttt	gat	tat	gaa	att	gag	atc	aga	gaa	gat	gat	act	acc	768
Ala	Arg	Cys	Phe	Asp	Tyr	Glu	Ile	Glu	Ile	Arg	Glu	Asp	Asp	Thr	Thr	
			245						250					255		
ttg	gtg	act	gct	aca	gtt	gaa	aat	gaa	aca	tac	acc	ttg	aaa	aca	aca	816
Leu	Val	Thr	Ala	Thr	Val	Glu	Asn	Glu	Thr	Tyr	Thr	Leu	Lys	Thr	Thr	
			260					265					270			
aat	gaa	acc	cga	caa	tta	tgc	ttt	gta	gta	aga	agc	aaa	gtg	aat	att	864
Asn	Glu	Thr	Arg	Gln	Leu	Cys	Phe	Val	Val	Arg	Ser	Lys	Val	Asn	Ile	
		275					280					285				
tat	tgc	tca	gat	gac	gga	att	tgg	agt	gag	tgg	agt	gat	aaa	caa	tgc	912
Tyr	Cys	Ser	Asp	Asp	Gly	Ile	Trp	Ser	Glu	Trp	Ser	Asp	Lys	Gln	Cys	
		290				295					300					
tgg	gaa	ggt	gaa	gac	cta	tcg	aag	aaa	act	ttg	cta	cgt				951
Trp	Glu	Gly	Glu	Asp	Leu	Ser	Lys	Lys	Thr	Leu	Leu	Arg				
305					310					315						

<210> 84  
 <211> 317  
 <212> PRT  
 <213> Homo sapiens

<400> 84

```

Asp Thr Glu Ile Lys Val Asn Pro Pro Gln Asp Phe Glu Ile Val Asp
 1           5           10           15
Pro Gly Tyr Leu Gly Tyr Leu Tyr Leu Gln Trp Gln Pro Pro Leu Ser
      20           25           30
Leu Asp His Phe Lys Glu Cys Thr Val Glu Tyr Glu Leu Lys Tyr Arg
      35           40           45
Asn Ile Gly Ser Glu Thr Trp Lys Thr Ile Ile Thr Lys Asn Leu His
 50           55           60
Tyr Lys Asp Gly Phe Asp Leu Asn Lys Gly Ile Glu Ala Lys Ile His
 65           70           75           80
Thr Leu Leu Pro Trp Gln Cys Thr Asn Gly Ser Glu Val Gln Ser Ser
      85           90           95
Trp Ala Glu Thr Thr Tyr Trp Ile Ser Pro Gln Gly Ile Pro Glu Thr
      100          105          110
Lys Val Gln Asp Met Asp Cys Val Tyr Tyr Asn Trp Gln Tyr Leu Leu
      115          120          125
Cys Ser Trp Lys Pro Gly Ile Gly Val Leu Leu Asp Thr Asn Tyr Asn
      130          135          140
Leu Phe Tyr Trp Tyr Glu Gly Leu Asp His Ala Leu Gln Cys Val Asp
      145          150          155          160
Tyr Ile Lys Ala Asp Gly Gln Asn Ile Gly Cys Arg Phe Pro Tyr Leu
      165          170          175
Glu Ala Ser Asp Tyr Lys Asp Phe Tyr Ile Cys Val Asn Gly Ser Ser
      180          185          190
Glu Asn Lys Pro Ile Arg Ser Ser Tyr Phe Thr Phe Gln Leu Gln Asn
      195          200          205
Ile Val Lys Pro Leu Pro Pro Val Tyr Leu Thr Phe Thr Arg Glu Ser
      210          215          220
Ser Cys Glu Ile Lys Leu Lys Trp Ser Ile Pro Leu Gly Pro Ile Pro
      225          230          235          240
Ala Arg Cys Phe Asp Tyr Glu Ile Glu Ile Arg Glu Asp Asp Thr Thr
      245          250          255
Leu Val Thr Ala Thr Val Glu Asn Glu Thr Tyr Thr Leu Lys Thr Thr
      260          265          270
Asn Glu Thr Arg Gln Leu Cys Phe Val Val Arg Ser Lys Val Asn Ile
      275          280          285

```

Tyr Cys Ser Asp Asp Gly Ile Trp Ser Glu Trp Ser Asp Lys Gln Cys  
 290 295 300  
 Trp Glu Gly Glu Asp Leu Ser Lys Lys Thr Leu Leu Arg  
 305 310 315

<210> 85  
 <211> 519  
 <212> DNA  
 <213> Homo sapeins

<220>  
 <221> CDS  
 <222> (1)...(519)

<400> 85

atc acg tgc cct ccc ccc atg tcc gtg gaa cac gca gac atc tgg gtc 48  
 Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val  
 1 5 10 15

aag agc tac agc ttg tac tcc agg gag cgg tac att tgt aac tct ggt 96  
 Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly  
 20 25 30

ttc aag cgt aaa gcc ggc acg tcc agc ctg acg gag tgc gtg ttg aac 144  
 Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn  
 35 40 45

aag gcc acg aat gtc gcc cac tgg aca acc ccc agt ctc aaa tgc att 192  
 Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile  
 50 55 60

aga gac cct gcc ctg gtt cac caa agg cca gcg cca ccc tcc aca gta 240  
 Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val  
 65 70 75 80

acg acg gca ggg gtg acc cca cag cca gag agc ctc tcc cct tct gga 288  
 Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly  
 85 90 95

aaa gag ccc gca gct tca tct ccc agc tca aac aac aca gcg gcc aca 336  
 Lys Glu Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr  
 100 105 110

75

aca gca gct att gtc ccg ggc tcc cag ctg atg cct tca aaa tca cct 384  
 Thr Ala Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro  
 115 120 125

tcc aca gga acc aca gag ata agc agt cat gag tcc tcc cac ggc acc 432  
 Ser Thr Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr  
 130 135 140

ccc tct cag aca aca gcc aag aac tgg gaa ctc aca gca tcc gcc tcc 480  
 Pro Ser Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser  
 145 150 155 160

cac cag ccg cca ggt gtg tat cca cag ggc cac agc gac 519  
 His Gln Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp  
 165 170

&lt;210&gt; 86

&lt;211&gt; 173

&lt;212&gt; PRT

&lt;213&gt; Homo sapeins

&lt;400&gt; 86

Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp Ile Trp Val  
 1 5 10 15  
 Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys Asn Ser Gly  
 20 25 30  
 Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys Val Leu Asn  
 35 40 45  
 Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu Lys Cys Ile  
 50 55 60  
 Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro Ser Thr Val  
 65 70 75 80  
 Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser Pro Ser Gly  
 85 90 95  
 Lys Glu Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr Ala Ala Thr  
 100 105 110  
 Thr Ala Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser Lys Ser Pro  
 115 120 125  
 Ser Thr Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser His Gly Thr  
 130 135 140  
 Pro Ser Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala Ser Ala Ser  
 145 150 155 160

76

His Gln Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp

165

170

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number  
**WO 01/77171 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 15/12, 15/62, 5/10, C07K 14/715, 16/28, A61K 38/19
- (74) Agent: JOHNSON, Jennifer, K.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).
- (21) International Application Number: PCT/US01/10872
- (22) International Filing Date: 3 April 2001 (03.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/194,731 5 April 2000 (05.04.2000) US  
60/222,121 28 July 2000 (28.07.2000) US
- (71) Applicant: ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).
- (72) Inventors: SPRECHER, Cindy, A.: 8207 39th Avenue NE, Seattle, WA 98115 (US). NOVAK, Julia, E.: 10699 Battle Point Drive Northeast, Bainbridge Island, WA 98110 (US). WEST, James, W.: 7539 19th NE, Seattle, WA 98115 (US). PRESNELL, Scott, R.: 2902 N. Puget Sound Avenue, Tacoma, WA 98407 (US). HOLLY, Richard, D.: 12539 10th Avenue N.W., Seattle, WA 98177 (US). NELSON, Andrew, J.: 1829 Northeast 170th Street, Shoreline, WA 98155 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- (88) Date of publication of the international search report:  
16 May 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

(57) Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonist, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

WO 01/77171 A3





# INTERNATIONAL SEARCH REPORT

In tional Application No  
PCT/US 01/10872

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/62 C12N5/10 C07K14/715 C07K16/28  
A61K38/19

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PARRISH J ET AL: "CLONING EXPRESSION ANALYSIS, GENOMIC LOCALIZATION, AND FUNCTIONAL CHARACTERIZATION OF A NOVEL CLASS I CYTOKINE RECEPTOR EXPRESSED IN CELLS OF LYMPHOID ORIGIN" AMERICAN JOURNAL OF HUMAN GENETICS, UNIVERSITY OF CHICAGO PRESS, CHICAGO,, US, vol. 65, no. 4, 19 October 1999 (1999-10-19), page A378 XP000881702 ISSN: 0002-9297 the whole document ---	1-11, 20-34, 38-44,46
X	WO 00 17235 A (ZYMOGENETICS INC) 30 March 2000 (2000-03-30) the whole document --- -/--	1-11, 20-34, 38-43

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

4 January 2002

Date of mailing of the international search report

18/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/10872

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 08152 A (MASIAKOWSKI PIOTR J ;MORRIS JODI (US); REGENERON PHARMA (US); VALE) 17 February 2000 (2000-02-17) the whole document ---	1-11, 20-34, 38,40-43
P,X	EP 1 088 831 A (CHUGAI RES INST FOR MOLECULAR) 4 April 2001 (2001-04-04)  the whole document	1-11, 20-34, 38,40-42
X	& WO 99 67290 A (CHUGAI RES INST MOLECULAR MED ;MAEDA MASATSUGU (JP); NOMURA HITOSH) 29 December 1999 (1999-12-29) the whole document ---	
A	WO 95 33059 A (IMMUNEX CORP) 7 December 1995 (1995-12-07) claim 10 ---	
P,X	PARRISH-NOVAK JULIA ET AL: "Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function." NATURE (LONDON), vol. 408, no. 6808, 2 November 2000 (2000-11-02), pages 57-63, XP002186602 ISSN: 0028-0836 cited in the application the whole document ---	27
P,X	OZAKI KATSUTOSHI ET AL: "Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11439-11444, XP002186603 October 10, 2000 ISSN: 0027-8424 the whole document ---	20, 22-24, 27,30, 33,39-42
T	ASOA, H. ET AL.: "Cutting edge: common gamma-chain is an indispensable subunit of the IL-21 receptor complex." JOURNAL OF IMMUNOLOGY, vol. 167, no. 1, July 2001 (2001-07), pages 1-5, XP002186604 the whole document -----	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/10872

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0017235	A	30-03-2000	AU 6499899 A	10-04-2000
			BR 9913942 A	16-10-2001
			EP 1115862 A2	18-07-2001
			NO 20011460 A	23-05-2001
			WO 0017235 A2	30-03-2000
WO 0008152	A	17-02-2000	AU 5104799 A	28-02-2000
			WO 0008152 A1	17-02-2000
EP 1088831	A	04-04-2001	AU 4392299 A	10-01-2000
			EP 1088831 A1	04-04-2001
			WO 9967290 A1	29-12-1999
WO 9533059	A	07-12-1995	US 5783672 A	21-07-1998
			AU 694232 B2	16-07-1998
			AU 2601695 A	21-12-1995
			CA 2190371 A1	07-12-1995
			EP 0760857 A1	12-03-1997
			JP 10501131 T	03-02-1998
			US 5891997 A	06-04-1999
			US 6010886 A	04-01-2000
			US 5925740 A	20-07-1999
			WO 9533059 A2	07-12-1995